<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">7146091</PMID><DateCompleted><Year>1983</Year><Month>01</Month><Day>07</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0720-4280</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>4</Issue><PubDate><Year>1982</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Pharmacopsychiatria</Title><ISOAbbreviation>Pharmacopsychiatria</ISOAbbreviation></Journal><ArticleTitle>Trends in lithium treatment and research during the last decade.</ArticleTitle><Pagination><MedlinePgn>128-30</MedlinePgn></Pagination><Abstract><AbstractText>The first systematic study on lithium prophylaxis in 1967 was supplemented some years later by (I) a study involving multiple regression analysis with cycle length and interval length as dependent variables and lithium treatment as one of the predictor variables, and (II) a double-blind study of discontinuation design in which patients were allocated randomly to lithium or placebo. Both studies confirmed the conclusions of the original trial. Interest in lithium remains vivid as reflected in many publications each year and widespread clinical usage. Overuse and misuse presumably occur to some extent. In recent years lithium research has included examination of possible predictors of response to lithium and studies on the effect of long-term lithium treatment of the kidneys. Guidelines for safe and effective lithium treatment are discussed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schou</LastName><ForeName>M</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Pharmacopsychiatria</MedlineTA><NlmUniqueID>8103699</NlmUniqueID><ISSNLinking>0720-4280</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012106" MajorTopicYN="N">Research</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1982</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1982</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1982</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">7146091</ArticleId><ArticleId IdType="doi">10.1055/s-2007-1019524</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23043691</PMID><DateCompleted><Year>2013</Year><Month>04</Month><Day>18</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>7</Issue><PubDate><Year>2012</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>State-related alterations of gene expression in bipolar disorder: a systematic review.</ArticleTitle><Pagination><MedlinePgn>684-96</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/bdi.12005</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Alterations in gene expression in bipolar disorder have been found in numerous studies. It is unclear whether such alterations are related to specific mood states. As a biphasic disorder, mood state-related alterations in gene expression have the potential to point to markers of disease activity, and trait-related alterations might indicate vulnerability pathways. This review therefore evaluated the evidence for whether gene expression in bipolar disorder is state or trait related.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A systematic review, using the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guideline for reporting systematic reviews, based on comprehensive database searches for studies on gene expression in patients with bipolar disorder in specific mood states, was conducted. We searched Medline, Embase, PsycINFO, and The Cochrane Library, supplemented by manually searching reference lists from retrieved publications.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 17 studies were included, comprising 565 patients and 418 control individuals. Six studies evaluated intraindividual alterations in gene expression across mood states. Two of five studies found evidence of intraindividual alterations in gene expression between a depressed state and a euthymic state. No studies evaluated intraindividual differences in gene expression between a manic state and a euthymic state, while only one case study evaluated differences between a manic state and a depressed state, finding altered expression in seven genes. No study investigated intraindividual variations in gene expression between a euthymic state and multiple states of various polarities (depressive, manic, hypomanic). Intraindividual alterations in expression of the same genes were not investigated across studies. Only one gene (the brain-derived neurotrophic factor gene; BDNF) was investigated across multiple studies, showing no alteration between bipolar disorder patients and control individuals.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">There is evidence of some genes exhibiting state-related alterations in expression in bipolar disorder; however, this finding is limited by the lack of replication across studies. Further prospective studies are warranted, measuring gene expression in various affective phases, allowing for assessment of intraindividual differences.</AbstractText><CopyrightInformation>Â© 2012 John Wiley and Sons A/S.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Munkholm</LastName><ForeName>Klaus</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Psychiatric Center Copenhagen, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. klaus.munkholm@regionh.dk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vinberg</LastName><ForeName>Maj</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Berk</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Kessing</LastName><ForeName>Lars Vedel</ForeName><Initials>LV</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016456">Historical Article</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>10</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019208">Brain-Derived Neurotrophic Factor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019208" MajorTopicYN="N">Brain-Derived Neurotrophic Factor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049691" MajorTopicYN="N">History, Medieval</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015201" MajorTopicYN="N">Meta-Analysis as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>10</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>10</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23043691</ArticleId><ArticleId IdType="doi">10.1111/bdi.12005</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15065747</PMID><DateCompleted><Year>2004</Year><Month>08</Month><Day>10</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0706-7437</ISSN><JournalIssue CitedMedium="Print"><Volume>49</Volume><Issue>2</Issue><PubDate><Year>2004</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Canadian journal of psychiatry. Revue canadienne de psychiatrie</Title><ISOAbbreviation>Can J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Prevalence and incidence studies of mood disorders: a systematic review of the literature.</ArticleTitle><Pagination><MedlinePgn>124-38</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To present the results of a systematic review of literature published between January 1, 1980, and December 31, 2000, that reports findings on the prevalence and incidence of mood disorders in both general population and primary care settings.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">We conducted a literature search of epidemiologic studies of mood disorders, using Medline and HealthSTAR databases and canvassing English-language publications. Eligible publications were restricted to studies that examined subjects aged at least 15 years and over. We used a set of predetermined inclusion and exclusion criteria to identify relevant studies. We extracted and analyzed prevalence and incidence data for heterogeneity.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of general population studies, a total of 18 prevalence and 5 incidence studies met eligibility criteria. We found heterogeneity across 1-year and lifetime prevalence of major depressive disorder (MDD), dysthymic disorder and bipolar I disorder. The corresponding pooled rates for 1-year prevalence were 4.1 per 100, 2.0 per 100, and 0.72 per 100, respectively. For lifetime prevalence, the corresponding pooled rates were 6.7 per 100, 3.6 per 100, and 0. per 100, respectively. Significant variation was observed among 1-year incidence rates of MDD, with a correspond ing pooled rate of 2.9 per 100.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The prevalence of mood disorders reported in high-quality studies is generally lower than rates commonly reported in the general psychiatric literature. When controlled for common methodological confounds, variation in prevalence rates persists across studies and deserves continued study. Methodological variation among studies that have examined the prevalence of depression in primary health care services is so large that comparative analyses cannot be achieved.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Waraich</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Mental Health Evaluation and Community Consultation Unit, University of British Columbia, Vancouver. waraich@interchange.ubc.ca</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldner</LastName><ForeName>Elliot M</ForeName><Initials>EM</Initials></Author><Author ValidYN="Y"><LastName>Somers</LastName><ForeName>Julian M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Hsu</LastName><ForeName>Lorena</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Can J Psychiatry</MedlineTA><NlmUniqueID>7904187</NlmUniqueID><ISSNLinking>0706-7437</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Can J Psychiatry. 2005 Aug;50(9):569-70</RefSource><PMID Version="1">16262116</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003431" MajorTopicYN="N">Cross-Cultural Comparison</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019263" MajorTopicYN="N">Dysthymic Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>96</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>4</Month><Day>7</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>8</Month><Day>11</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>4</Month><Day>7</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15065747</ArticleId><ArticleId IdType="doi">10.1177/070674370404900208</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">27314813</PMID><DateCompleted><Year>2017</Year><Month>11</Month><Day>10</Day></DateCompleted><DateRevised><Year>2019</Year><Month>10</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>203</Volume><PubDate><Year>2016</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>An approach to revealing clinically relevant subgroups across the mood spectrum.</ArticleTitle><Pagination><MedlinePgn>265-274</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0165-0327(16)30477-3</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2016.06.019</ELocationID><Abstract><AbstractText Label="BACKGROUND">Individuals diagnosed with bipolar 1 disorder (BP1), bipolar 2 disorder (BP2), or major depressive disorder (MDD) experience varying levels of depressive and (hypo)manic symptoms. Clarifying symptom heterogeneity is meaningful, as even subthreshold symptoms may impact quality of life and treatment outcome. The MOODS Lifetime self-report instrument was designed to capture the full range of depressive and (hypo)manic characteristics.</AbstractText><AbstractText Label="METHODS">This study applied clustering methods to 347 currently depressed adults with MDD, BP2, or BP1 to reveal naturally occurring MOODS subgroups. Subgroups were then compared on baseline clinical and demographic characteristics and as well as depressive and (hypo)manic symptoms over twenty weeks of treatment.</AbstractText><AbstractText Label="RESULTS">Four subgroups were identified: (1) high depressive and (hypo)manic symptoms (N=77, 22%), (2) moderate depressive and (hypo)manic symptoms (N=115, 33%), (3) low depressive and moderate (hypo)manic symptoms (N=82, 24%), and (4) low depressive and (hypo)manic symptoms (N=73, 21%). Individuals in the low depressive/moderate (hypo)manic subgroup had poorer quality of life and greater depressive symptoms over the course of treatment. Individuals in the high and moderate severity subgroups had greater substance use, longer duration of illness, and greater (hypo)manic symptoms throughout treatment. Treatment outcomes were primarily driven by individuals diagnosed with MDD.</AbstractText><AbstractText Label="LIMITATIONS">The sample was drawn from three randomized clinical trials. Validation is required for this exploratory study.</AbstractText><AbstractText Label="CONCLUSIONS">After validation, these subgroups may inform classification and personalized treatment beyond categorical diagnosis.</AbstractText><CopyrightInformation>Copyright Â© 2016 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wallace</LastName><ForeName>Meredith L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, United States; Department of Statistics, University of Pittsburgh, Pittsburgh, PA, United States. Electronic address: lotzmj@upmc.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simsek</LastName><ForeName>Burcin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Statistics, University of Pittsburgh, Pittsburgh, PA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kupfer</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swartz</LastName><ForeName>Holly A</ForeName><Initials>HA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fagiolini</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine, University of Siena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frank</LastName><ForeName>Ellen</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K01 MH096944</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 MH030915</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH065376</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH084831</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>06</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="N">Affect</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Bipolar disorder</Keyword><Keyword MajorTopicYN="Y">Cluster</Keyword><Keyword MajorTopicYN="Y">Dimensional construct</Keyword><Keyword MajorTopicYN="Y">Major depressive disorder</Keyword><Keyword MajorTopicYN="Y">Mood severity</Keyword><Keyword MajorTopicYN="Y">Subtype</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>03</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>05</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>06</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>6</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>6</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>11</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27314813</ArticleId><ArticleId IdType="pmc">PMC5066164</ArticleId><ArticleId IdType="pii">S0165-0327(16)30477-3</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2016.06.019</ArticleId><ArticleId IdType="mid">NIHMS796128</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bipolar Disord. 2007 Aug;9(5):462-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17680916</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2014 Sep;166:330-3</Citation><ArticleIdList><ArticleId IdType="pubmed">25012449</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacol Bull. 1993;29(2):321-6</Citation><ArticleIdList><ArticleId IdType="pubmed">8290681</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Serv. 2009 Jul;60(7):888-97</Citation><ArticleIdList><ArticleId IdType="pubmed">19564218</ArticleId></ArticleIdList></Reference><Reference><Citation>World Psychiatry. 2016 Feb;15(1):26-31</Citation><ArticleIdList><ArticleId IdType="pubmed">26833601</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2000 Sep;61(9):630-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11030482</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2014 Apr;171(4):395-7</Citation><ArticleIdList><ArticleId IdType="pubmed">24687194</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2004 Jul;161(7):1264-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15229060</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1978 Nov;133:429-35</Citation><ArticleIdList><ArticleId IdType="pubmed">728692</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Epidemiol. 2014 Aug;67(8):850-7</Citation><ArticleIdList><ArticleId IdType="pubmed">24831050</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2011 Jan;16(1):2-4</Citation><ArticleIdList><ArticleId IdType="pubmed">20351715</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2005;7 Suppl 4:4-12</Citation><ArticleIdList><ArticleId IdType="pubmed">15948762</ArticleId></ArticleIdList></Reference><Reference><Citation>World Psychiatry. 2016 Feb;15(1):38-9</Citation><ArticleIdList><ArticleId IdType="pubmed">26833606</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2011 Jan;41(1):151-62</Citation><ArticleIdList><ArticleId IdType="pubmed">20380782</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1999 Aug;54(3):319-28</Citation><ArticleIdList><ArticleId IdType="pubmed">10467978</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2009 Jun;11(4):382-90</Citation><ArticleIdList><ArticleId IdType="pubmed">19500091</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1997 Jul;36(7):980-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9204677</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2015 Aug 15;182:70-5</Citation><ArticleIdList><ArticleId IdType="pubmed">25978716</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Pract. 2001 Sep;7(5):287-97</Citation><ArticleIdList><ArticleId IdType="pubmed">15990539</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1989 Sep;155:294-304</Citation><ArticleIdList><ArticleId IdType="pubmed">2692760</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1999 Jan-Mar;52(1-3):135-44</Citation><ArticleIdList><ArticleId IdType="pubmed">10357026</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62</Citation><ArticleIdList><ArticleId IdType="pubmed">14399272</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Clin North Am. 2002 Dec;25(4):699-712, v</Citation><ArticleIdList><ArticleId IdType="pubmed">12462856</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">2380163</PMID><DateCompleted><Year>1990</Year><Month>09</Month><Day>11</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>51</Volume><Issue>8</Issue><PubDate><Year>1990</Year><Month>Aug</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Lithium-induced worsening of wintertime depression in a bipolar patient.</ArticleTitle><Pagination><MedlinePgn>347-8</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dilsaver</LastName><ForeName>S C</ForeName><Initials>SC</Initials></Author><Author ValidYN="Y"><LastName>DelMedico</LastName><ForeName>V J</ForeName><Initials>VJ</Initials></Author><Author ValidYN="Y"><LastName>Quadri</LastName><ForeName>A B</ForeName><Initials>AB</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006970" MajorTopicYN="N">Disorders of Excessive Somnolence</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012621" MajorTopicYN="Y">Seasons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012890" MajorTopicYN="N">Sleep</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1990</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1990</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1990</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2380163</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">1449384</PMID><DateCompleted><Year>1992</Year><Month>12</Month><Day>30</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-990X</ISSN><JournalIssue CitedMedium="Print"><Volume>49</Volume><Issue>12</Issue><PubDate><Year>1992</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Archives of general psychiatry</Title><ISOAbbreviation>Arch Gen Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Schizophrenics show spatial working memory deficits.</ArticleTitle><Pagination><MedlinePgn>975-82</MedlinePgn></Pagination><Abstract><AbstractText>The present study demonstrates that schizophrenics are impaired on spatial delayed-response tasks, analogous to those that have been used to assess the working memory function of the dorsolateral prefrontal cortex in rhesus monkeys. Schizophrenic patients and two control groups, normal subjects and bipolar psychiatric patients, were tested on the oculomotor version of the memory task, a haptic version of the same task, and two control tasks: a sensory task that did not require working memory and a digit span test. The schizophrenic patients showed marked deficits relative to the two control groups in both the oculomotor and haptic delayed-response tasks. They were not, however, impaired on the digit span test, which taps verbal working memory as well as voluntary attention, and on the sensory control task, in which their responses were guided by external cues rather than by spatial working memory. These findings provide direct evidence that schizophrenics suffer a loss in representational processing and that this deficit is modality independent. These data on spatial working memory add to the growing evidence for involvement of the dorsolateral prefrontal cortex in schizophrenic disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Park</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychology, Harvard University, Cambridge, MA 02138.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holzman</LastName><ForeName>P S</ForeName><Initials>PS</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 31154</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 MH44866</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH31340</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Gen Psychiatry</MedlineTA><NlmUniqueID>0372435</NlmUniqueID><ISSNLinking>0003-990X</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005133" MajorTopicYN="N">Eye Movements</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005625" MajorTopicYN="N">Frontal Lobe</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008253" MajorTopicYN="N">Macaca mulatta</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="Y">Memory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="Y">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011597" MajorTopicYN="N">Psychomotor Performance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011930" MajorTopicYN="N">Reaction Time</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="Y">Schizophrenic Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014110" MajorTopicYN="N">Touch</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014796" MajorTopicYN="N">Visual Perception</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014888" MajorTopicYN="N">Wechsler Scales</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1992</Year><Month>12</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1992</Year><Month>12</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1992</Year><Month>12</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1449384</ArticleId><ArticleId IdType="doi">10.1001/archpsyc.1992.01820120063009</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24447331</PMID><DateCompleted><Year>2015</Year><Month>02</Month><Day>21</Day></DateCompleted><DateRevised><Year>2014</Year><Month>07</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1440-1819</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>7</Issue><PubDate><Year>2014</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Psychiatry and clinical neurosciences</Title><ISOAbbreviation>Psychiatry Clin Neurosci</ISOAbbreviation></Journal><ArticleTitle>Mitochondrial DNA variation and increased oxidative damage in euthymic patients with bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>551-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/pcn.12163</ELocationID><Abstract><AbstractText Label="AIM" NlmCategory="OBJECTIVE">The aim of this study was to compare alterations of mitochondrial DNA (mtDNA) copy number, single nucleotide polymorphisms, and oxidative damage of mtDNA in clinically stable patients with bipolar I disorder (BD).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Patients meeting DSM-IV diagnostic criteria for BD were recruited from the psychiatric outpatient clinic at Changhua Christian Hospital, Taiwan. They were clinically stable and their medications had not changed for at least the preceding 2 months. Exclusion criteria were substance-induced psychotic disorder, eating disorder, anxiety disorder or illicit substance abuse. Comparison subjects did not have any history of major psychiatric disorders and they were non-smokers. By analyzing peripheral blood leukocytes, copy number, single nucleotide polymorphisms and oxidative damage of mtDNA were compared between the two groups.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The median age of the subjects was 38 years and 41.5 years in the comparison and BD groups, respectively. The leukocyte mtDNA copy number of the BD group was significantly lower than that of the comparison group (Pâ&lt;â0.001). BD patients had significantly higher mitochondrial oxidative damage than the comparison group (6.1 vs 3.9, Pâ&lt;â0.001). After generalized linear model adjusting with age, sex, smoking, family history, and psychotropic use, mtDNA copy number was still significantly lower in the BD group (Pâ&lt;â0.001). MtDNA oxidative damage was positively correlated with age (Pâ=â0.034), although mtDNA oxidative damage was similar between these two groups.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Possible involvement of oxidative stress and mitochondria in the pathophysiology of BD needs more large-scale studies. It is important that psychiatrists retain a high level of suspicion for mitochondrial dysfunction in patients with bipolar disorder.</AbstractText><CopyrightInformation>Â© 2014 The Authors. Psychiatry and Clinical Neurosciences Â© 2014 Japanese Society of Psychiatry and Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Cheng-Chen</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Changhua Christian Hospital, Changhua, Taiwan; The Institute of Medicine, Chungshan Medical University, Taichung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jou</LastName><ForeName>Shaw-Hwa</ForeName><Initials>SH</Initials></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Ta-Tsung</ForeName><Initials>TT</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Chin-San</ForeName><Initials>CS</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>03</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Psychiatry Clin Neurosci</MedlineTA><NlmUniqueID>9513551</NlmUniqueID><ISSNLinking>1323-1316</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004272">DNA, Mitochondrial</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056915" MajorTopicYN="Y">DNA Copy Number Variations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004272" MajorTopicYN="Y">DNA, Mitochondrial</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">bipolar disorder</Keyword><Keyword MajorTopicYN="N">mitochondria</Keyword><Keyword MajorTopicYN="N">oxidative damage</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>08</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>01</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>01</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>1</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>1</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>2</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24447331</ArticleId><ArticleId IdType="doi">10.1111/pcn.12163</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18801648</PMID><DateCompleted><Year>2009</Year><Month>01</Month><Day>08</Day></DateCompleted><DateRevised><Year>2015</Year><Month>08</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0165-1781</ISSN><JournalIssue CitedMedium="Print"><Volume>164</Volume><Issue>1</Issue><PubDate><Year>2008</Year><Month>Oct</Month><Day>30</Day></PubDate></JournalIssue><Title>Psychiatry research</Title><ISOAbbreviation>Psychiatry Res</ISOAbbreviation></Journal><ArticleTitle>Interregional cerebral metabolic associativity during a continuous performance task (Part II) : differential alterations in bipolar and unipolar disorders.</ArticleTitle><Pagination><MedlinePgn>30-47</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.pscychresns.2007.12.016</ELocationID><Abstract><AbstractText>Unipolar and bipolar disorders have often been reported to exhibit abnormal regional brain activity in prefrontal cortex and paralimbic structures compared with healthy controls. We sought to ascertain how regions postulated to be abnormal in bipolar and unipolar disorders were functionally connected to the rest of the brain, and how this associativity differed from healthy controls. Thirty patients with bipolar disorder (BPs), 34 patients with unipolar disorder (UPs), and 66 healthy volunteers (Willis, M.W., Benson, B.E., Ketter, T.A., Kimbrell, T.A., George, M.S., Speer, A.M., Herscovitch, P., Post, R.M., 2008. Interregional cerebral metabolic associativity during a continuous performance task in healthy adults. Psychiatry Research: Neuroimaging 164 (1)) were imaged using F-18-fluorodeoxyglucose and positron emission tomography (FDG-PET) while performing an auditory continuous performance task (CPT). Five bilateral regions of interest (ROIs), namely dorsolateral prefrontal cortex (DLPFC), insula, inferior parietal cortex (INFP), thalamus and cerebellum, were correlated with normalized cerebral metabolism in the rest of the brain while covarying out Hamilton Depression Rating Scale Scores. In bipolar patients compared with controls, metabolism in the left DLPFC and INFP, and bilateral thalamus and insula had more positive and fewer negative metabolic correlations with other brain regions. In contrast, compared with controls, unipolar patients had fewer significant correlative relationships, either positive or negative. In common, bipolar and unipolar patients lacked the normal inverse relationships between the DLPFC and cerebellum, as well as relationships between the primary ROIs and other limbic regions (medial prefrontal cortex, anterior cingulate, and temporal lobes) compared with controls. Associations of DLPFC and INFP with other brain areas were different in each hemisphere in patients and controls. Bipolar patients exhibited exaggerated positive coherence of activity throughout the brain, while unipolar patients showed a paucity of normal interrelationships compared with controls. These abnormal patterns of metabolic associativity suggest marked interregional neuronal dysregulation in bipolar and unipolar illness exists beyond that of mere absolute regional differences from control levels, and provides rationale for using acute and long-term therapies that may re-establish and maintain normal associativity in these devastating illnesses.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Benson</LastName><ForeName>Brenda E</ForeName><Initials>BE</Initials><AffiliationInfo><Affiliation>Mood and Anxiety Disorders Program, NIMH, NIH, Bethesda, MD 20892, United States. bbenson@helix.nih.gov</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Willis</LastName><ForeName>Mark W</ForeName><Initials>MW</Initials></Author><Author ValidYN="Y"><LastName>Ketter</LastName><ForeName>Terence A</ForeName><Initials>TA</Initials></Author><Author ValidYN="Y"><LastName>Speer</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Kimbrell</LastName><ForeName>Tim A</ForeName><Initials>TA</Initials></Author><Author ValidYN="Y"><LastName>George</LastName><ForeName>Mark S</ForeName><Initials>MS</Initials></Author><Author ValidYN="Y"><LastName>Herscovitch</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Post</LastName><ForeName>Robert M</ForeName><Initials>RM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>09</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Psychiatry Res</MedlineTA><NlmUniqueID>7911385</NlmUniqueID><ISSNLinking>0165-1781</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017397" MajorTopicYN="N">Prefrontal Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year><Month>07</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2007</Year><Month>10</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>12</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>9</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>1</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>9</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18801648</ArticleId><ArticleId IdType="pii">S0925-4927(07)00254-5</ArticleId><ArticleId IdType="doi">10.1016/j.pscychresns.2007.12.016</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22417535</PMID><DateCompleted><Year>2015</Year><Month>03</Month><Day>31</Day></DateCompleted><DateRevised><Year>2014</Year><Month>07</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1469-8978</ISSN><JournalIssue CitedMedium="Internet"><Volume>44</Volume><Issue>7</Issue><PubDate><Year>2014</Year><Month>May</Month></PubDate></JournalIssue><Title>Psychological medicine</Title><ISOAbbreviation>Psychol Med</ISOAbbreviation></Journal><ArticleTitle>Proposed DSM-5 mixed features are associated with greater likelihood of remission in out-patients with major depressive disorder.</ArticleTitle><Pagination><MedlinePgn>1361-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1017/S0033291712000281</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Draft DSM-5 criteria for a mixed major depressive episode have been proposed, but their predictive validity has not yet been established. We hypothesized that such symptoms would be associated with poorer antidepressant treatment outcomes.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">We examined outcomes among individuals with major depressive disorder participating in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study, an effectiveness study conducted at primary and specialty care centers in the USA. Mixed features were derived from the six self-report items of the mania subscale of the Psychiatric Diagnosis Screening Questionnaire. Primary analyses examined the association between the presence of at least two of these in the 6 months before study entry, and remission across up to four sequential treatment trials, as well as adverse outcomes.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 2397 subjects with a major depressive episode of at least 6 months' duration, 449 (18.7%) reported at least two mixed symptoms. The presence of such symptoms was associated with a greater likelihood of remission across up to four sequential treatments, which persisted after adjustment for potential confounding clinical and demographic variables (adjusted hazard ratio 1.16, 95% confidence interval 1.03-1.28). Two individual items, expansive mood and cheerfulness, were strongly associated with a greater likelihood of remission.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Proposed DSM-5 mixed state features were associated with a greater rather than a lesser likelihood of remission. While unexpected, this result suggests the potential utility of further investigation of depressive mixed states in major depression.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Perlis</LastName><ForeName>R H</ForeName><Initials>RH</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cusin</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fava</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH086026</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 MH-90003</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>03</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Psychol Med</MedlineTA><NlmUniqueID>1254142</NlmUniqueID><ISSNLinking>0033-2917</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0DHU5B8D6V</RegistryNumber><NameOfSubstance UI="D015283">Citalopram</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015283" MajorTopicYN="N">Citalopram</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="Y">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010045" MajorTopicYN="N">Outpatients</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012074" MajorTopicYN="Y">Remission Induction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>3</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>3</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>4</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22417535</ArticleId><ArticleId IdType="pii">S0033291712000281</ArticleId><ArticleId IdType="doi">10.1017/S0033291712000281</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">23418688</PMID><DateCompleted><Year>2013</Year><Month>04</Month><Day>11</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1326-5377</ISSN><JournalIssue CitedMedium="Internet"><Volume>198</Volume><Issue>3</Issue><PubDate><Year>2013</Year><Month>Feb</Month><Day>18</Day></PubDate></JournalIssue><Title>The Medical journal of Australia</Title><ISOAbbreviation>Med J Aust</ISOAbbreviation></Journal><ArticleTitle>Treatment of bipolar depression.</ArticleTitle><Pagination><MedlinePgn>139</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Berk</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Dodd</LastName><ForeName>Seetal</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Berk</LastName><ForeName>Lesley</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Med J Aust</MedlineTA><NlmUniqueID>0400714</NlmUniqueID><ISSNLinking>0025-729X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Med J Aust. 2013 Feb 18;198(3):138-9</RefSource><PMID Version="1">23418687</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>11</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>01</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>2</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>2</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>4</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23418688</ArticleId><ArticleId IdType="pii">10.5694/mja12.11740</ArticleId><ArticleId IdType="doi">10.5694/mja12.11740</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15555695</PMID><DateCompleted><Year>2005</Year><Month>04</Month><Day>04</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-0327</ISSN><JournalIssue CitedMedium="Print"><Volume>82</Volume><Issue>3</Issue><PubDate><Year>2004</Year><Month>Nov</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Suicide attempts: differences between unipolar and bipolar patients and among groups with different lethality risk.</ArticleTitle><Pagination><MedlinePgn>437-42</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The present naturalistic study aimed to distinguish between suicide attempts (SAs) of bipolar and unipolar patients, and among SAs characterized by different lethality risk.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The records of 2395 consecutive admissions to our psychiatric intensive care unit (PICU) were assessed for presence of suicide attempt (SA). Cases of SA were rated for symptom severity with the brief psychiatric rating scale (BPRS), the scale for the assessment of positive symptoms (SAPS), the scale for the assessment of negative symptoms (SANS), the mini mental state examination (MMSE), the global assessment of functioning scale (GAF) and the clinical global impression (CGI). An original questionnaire was administered to explore clinical aspects related with suicidal behavior.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 2395 admissions, 80 (3.3%) had attempted suicide. Fifty-three cases (66.2%) suffered from a mood episode, including 22 (27.5%) with unipolar depression and 31 (38.7%) with bipolar depression (types I and II combined) or mixed state, while 27 (33.8%) cases received other diagnoses. Forty-eight (60%) cases had attempted suicide prior to the index episode. Ten cases (12.5%) had a relative who attempted or committed suicide. Thirty-nine cases (48.7%) described their SA as impulsive. Twenty cases (25.0%) reported alcohol ingestion before SA. In comparison with women, men used more violent methods. Cases characterized by a non-lethal risk SA had higher BPRS psychotic cluster and SAPS scores than cases with either low or high lethal risk SA. Bipolar cases were over-represented in the high lethality risk group. BPRS anxiety-depressive cluster score was higher in unipolar than in bipolar cases.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">The sample may not be representative of all patients with SA. The questionnaire has not been standardized for use in psychiatric populations.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The higher proportion of high lethal risk SA in bipolar cases suggests that the risk of completed suicide is higher in bipolar disorder than in unipolar depression. The risk of lethality in SA was not associated with the intensity of symptoms of anxiety and depression.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Raja</LastName><ForeName>Michele</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Servizio Psichiatrico di Diagnosi e Cura, Dipartimento di Salute Mentale, Ospedale Santo Spirito, Via Prisciano 26, 00136 Rome, Italy. michele.raja@fastwebnet.it</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Azzoni</LastName><ForeName>Antonella</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013405" MajorTopicYN="N">Suicide</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013406" MajorTopicYN="N">Suicide, Attempted</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2003</Year><Month>09</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2004</Year><Month>02</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2004</Year><Month>02</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>11</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>4</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>11</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15555695</ArticleId><ArticleId IdType="pii">S0165032704000746</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2004.02.001</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15465587</PMID><DateCompleted><Year>2005</Year><Month>02</Month><Day>07</Day></DateCompleted><DateRevised><Year>2009</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-0327</ISSN><JournalIssue CitedMedium="Print"><Volume>82</Volume><Issue>1</Issue><PubDate><Year>2004</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Styles of adaptation in autoimmune thyroiditis and bipolar disorder: a pilot study.</ArticleTitle><Pagination><MedlinePgn>135-8</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">A growing body of evidence suggests that styles of adaptation, assessed with the Serial Color-Word Test (S-CWT, a 5-trials Stroop task), are able to differentiate several mental and psychosomatic disorders. Recent findings have confirmed a very high rate of cases of autoimmune thyroiditis (so called Hashimoto disease) among bipolar patients, suggesting an etio-pathogenetic relatedness between the two ailments. Based on the latter relatedness, it was hypothesized that the same styles of adaptation, which are known to differentiate bipolar and control subjects are also characteristic of patients with autoimmune thyroiditis.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Three groups (autoimmune thyroiditis, fully remitted bipolar I, and nonclinical) of 40 women, matched on age and schooling, were administered the S-CWT. The following variables were considered: (a) early discontinuity (i.e. the summed nonlinear change of the first three trials), (b) late discontinuity (i.e. the summed nonlinear change of the last two trials), (c) across-trials discontinuity (i.e. the nonlinear change of the five measures of nonlinear change).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The thyroiditis group had (1) higher values of early discontinuity (P=0.006) and of late discontinuity (P=0.004) compared with nonclinical controls, (2) lower values of early discontinuity (P=0.005) and of across-trials discontinuity (P=0.008) compared with the bipolar group.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">The study did not include men patients and lacked a quantification of affective symptoms among clinical and nonclinical participants.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">A discontinuous style of adaptation is more marked among remitted bipolar than among thyroiditis patients, and more marked among the latter ones than among nonclinical controls, thus delineating a sort of adaptive continuum.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rubino</LastName><ForeName>I Alex</ForeName><Initials>IA</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Psychiatric Clinic, University of Rome-Tor Vergata, Via Col della Porretta 13/A, I-00141 Rome, Italy. i.rubino@med.uniroma2.it &lt;i.rubino@med.uniroma2.it&gt;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salvadore</LastName><ForeName>Giacomo</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Siracusano</LastName><ForeName>Alberto</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Fidotti</LastName><ForeName>Enrico</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Zuppi</LastName><ForeName>Paolo</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000223" MajorTopicYN="Y">Adaptation, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013967" MajorTopicYN="N">Thyroiditis, Autoimmune</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2003</Year><Month>01</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2003</Year><Month>09</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2003</Year><Month>09</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>10</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>2</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>10</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15465587</ArticleId><ArticleId IdType="pii">S0165032703002337</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2003.09.007</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17542383</PMID><DateCompleted><Year>2007</Year><Month>07</Month><Day>16</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0706-7437</ISSN><JournalIssue CitedMedium="Print"><Volume>52</Volume><Issue>5</Issue><PubDate><Year>2007</Year><Month>May</Month></PubDate></JournalIssue><Title>Canadian journal of psychiatry. Revue canadienne de psychiatrie</Title><ISOAbbreviation>Can J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Comorbidity with ADHD decreases response to pharmacotherapy in children and adolescents with acute mania: evidence from a metaanalysis.</ArticleTitle><Pagination><MedlinePgn>323-8</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To assess whether comorbid attention-deficit hyperactivity disorder (ADHD) influences response to treatment in young patients with acute mania.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a metaanalysis of 5 open trials of 100, 35, 41, 60, and 37 children and adolescents. The pooled group included 273 children and adolescents with bipolar disorder (BD), divided into 2 subgroups: those with (n = 132), and those without (n = 141), ADHD comorbidity.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">There was a moderate and significant reduction in relative risk (RR) favouring treatment response in children and adolescents with BD but without ADHD comorbidity (RR 0.822; 95% CI, 0.69 to 0.97; P = 0.021). The negative effect of ADHD comorbidity on treatment response was more significant in studies including adolescents only or subjects with BD I only.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These findings suggest that children and adolescents with BD and ADHD tend to be less responsive to drugs used in treatment of acute mania.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Consoli</LastName><ForeName>AngÃ¨le</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Child and Adolescent Psychiatry, AP-HP, HÃ´pital PitiÃ©-SalpÃ©triÃ¨re, UniversitÃ© Pierre et Marie Curie, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bouzamondo</LastName><ForeName>Anissa</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>GuilÃ©</LastName><ForeName>Jean-Marc</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Lechat</LastName><ForeName>Philippe</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>David</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Can J Psychiatry</MedlineTA><NlmUniqueID>7904187</NlmUniqueID><ISSNLinking>0706-7437</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011619">Psychotropic Drugs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001289" MajorTopicYN="N">Attention Deficit Disorder with Hyperactivity</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011619" MajorTopicYN="N">Psychotropic Drugs</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>6</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>7</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>6</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17542383</ArticleId><ArticleId IdType="doi">10.1177/070674370705200507</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16910379</PMID><DateCompleted><Year>2006</Year><Month>09</Month><Day>22</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0333-7308</ISSN><JournalIssue CitedMedium="Print"><Volume>43</Volume><Issue>1</Issue><PubDate><Year>2006</Year></PubDate></JournalIssue><Title>The Israel journal of psychiatry and related sciences</Title><ISOAbbreviation>Isr J Psychiatry Relat Sci</ISOAbbreviation></Journal><ArticleTitle>The comorbidity of anxiety disorders in bipolar I patients: prevalence and clinical correlates.</ArticleTitle><Pagination><MedlinePgn>10-5</MedlinePgn></Pagination><Abstract><AbstractText>The purpose of this study was to determine the prevalence of lifetime anxiety disorders in bipolar I patients in Sanliurfa, Turkey, and to assess the association between comorbidity and several demographic and clinical variables. Seventy bipolar I patients in remission were assessed by means of the Structured Clinical Interview for DSM-IV axis I Disorders-Clinician Version (SCID-I-CV), Anxiety Disorder Module in order to detect lifetime comorbid anxiety disorders. Nineteen (27.1%) bipolar I patients were diagnosed with at least one lifetime comorbid anxiety disorder. The most common anxiety disorders in this sample were obsessive compulsive disorder (12.8%) and specific phobia (12.8%), followed by panic disorder (5.7%). Anxiety disorder comorbidity appears to be associated with greater number of hospitalizations, psychotic symptoms and suicide attempts in patients with bipolar I disorder. As comorbidity has a clear impact on the course of bipolar patients, special attention to this issue should be paid when interviewing bipolar patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Altindag</LastName><ForeName>Abdurrahman</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Harran University Faculty of Medicine, Department of Psychiatry, Sanliurfa, Turkey. aaltindag@yahoo.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yanik</LastName><ForeName>Medaim</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Nebioglu</LastName><ForeName>Melike</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Israel</Country><MedlineTA>Isr J Psychiatry Relat Sci</MedlineTA><NlmUniqueID>8108287</NlmUniqueID><ISSNLinking>0333-7308</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001008" MajorTopicYN="N">Anxiety Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="Y">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007557" MajorTopicYN="N" Type="Geographic">Israel</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="Y">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>8</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>9</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>8</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16910379</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24240495</PMID><DateCompleted><Year>2014</Year><Month>02</Month><Day>04</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1422-4917</ISSN><JournalIssue CitedMedium="Print"><Volume>41</Volume><Issue>6</Issue><PubDate><Year>2013</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie</Title><ISOAbbreviation>Z Kinder Jugendpsychiatr Psychother</ISOAbbreviation></Journal><ArticleTitle>Severe affective and behavioral dysregulation in youths is associated with a proinflammatory state.</ArticleTitle><Pagination><MedlinePgn>393-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1024/1422-4917/a000255</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">A heritable behavioral phenotype, the so-called Dysregulation Profile (DP), characterized by extreme scores on the syndrome scales Anxious/Depressed (A/D), Attention Problems (AP), and Aggressive Behavior (AGG), has been identified on the Child Behavior Checklist (CBCL). It characterizes children with severe affective and behavioral dysregulation. The present study examined possible alterations of the inflammatory system in CBCL-DP using a clinical sample of n = 133 children and adolescents.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Participants with the CBCL-DP scoring â¥ 2.5 SDs above average constituted the CBCL-DP subgroup (n = 51). Those with CBCL-DP scores of 1 SD or less above average were regarded as controls (n = 82). Groups were compared in terms of serum levels of C-reactive protein (CRP) and albumin.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Participants showing the CBCL-DP exhibited increased CRP and decreased albumin levels compared to controls. CRP was correlated with AGG, AP, and the CBCL-DP total score. A negative correlation was observed between albumin and AGG, AP, the CBCL-DP score, and A/D. These associations could not be attributed to differences in age, sex, weight, socioeconomic status, global functioning, or duration of illness.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This is the first study to demonstrate associations between the CBCL-DP and a proinflammatory state. Limitations include the lack of a healthy control group, the use of a single measurement of inflammatory markers, and the lack of follow-up data. Future research should address whether inflammatory diathesis in these children confers increased susceptibility to later development of cardiovascular disease and other medical morbidities.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Holtmann</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Ruhr-University Bochum, LWL-University Hospital for Child and Adolescent Psychiatry, &lt;location&gt;Hamm, Germany&lt;/location&gt; Department of Child and Adolescent Psychiatry and Psychotherapy, Goethe-University, &lt;location&gt;Frankfurt/Main, Germany&lt;/location&gt;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poustka</LastName><ForeName>Luise</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Zepf</LastName><ForeName>Florian D</ForeName><Initials>FD</Initials></Author><Author ValidYN="Y"><LastName>Banaschewski</LastName><ForeName>Tobias</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Priller</LastName><ForeName>Josef</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>BÃ¶lte</LastName><ForeName>Sven</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Legenbauer</LastName><ForeName>Tanja</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Z Kinder Jugendpsychiatr Psychother</MedlineTA><NlmUniqueID>9801717</NlmUniqueID><ISSNLinking>1422-4917</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018836">Inflammation Mediators</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012709">Serum Albumin</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-41-4</RegistryNumber><NameOfSubstance UI="D002097">C-Reactive Protein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000374" MajorTopicYN="N">Aggression</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001289" MajorTopicYN="N">Attention Deficit Disorder with Hyperactivity</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002097" MajorTopicYN="N">C-Reactive Protein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002653" MajorTopicYN="N">Child Behavior Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018836" MajorTopicYN="N">Inflammation Mediators</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007508" MajorTopicYN="N">Irritable Mood</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012016" MajorTopicYN="N">Reference Values</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012709" MajorTopicYN="N">Serum Albumin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="ger"><AbstractText>Fragestellung: Ein erblicher VerhaltensphÃ¤notyp, das sog. Dysregulations-Profil (DP), gekennzeichnet durch extreme Werte auf den Syndromskalen Ãngstlich/Depressiv (A/D), Aufmerksamkeitsprobleme (AP) und aggressives Verhalten (AGG) wurde mittels der Child Behavior Checklist (CBCL) identifiziert. Er erfasst Kinder mit schwerer affektiver und verhaltensbezogener Dysregulation. Die vorliegende Studie untersucht VerÃ¤nderungen des EntzÃ¼ndungssystems bei Patienten mit CBCL-DP an einer klinischen Stichprobe von n = 133 Kindern und Jugendlichen. Methodik: Patienten mit einem CBCL-DP-Wert = 2.5 SD Ã¼ber der Norm bildeten die CBCL-DP-Untergruppe (n = 51). Patienten mit CBCL-DP-Werten mit hÃ¶chstens 1 SD Ã¼ber dem Durchschnitt galten als Kontrollgruppe (n = 82). Beide Gruppen wurden im Hinblick auf die Serumspiegel von C-reaktivem Protein (CRP) und Albumin verglichen. Ergebnisse: Die CBCL-DP-Gruppe zeigte ein erhÃ¶htes CRP und verringertes Albumin. CRP war positiv mit AGG, AP und dem CBCL-DP-Gesamtwert korreliert. Eine negative Korrelation wurde zwischen Albumin und AGG, AP, dem CBCL-DP-Wert und A/D beobachtet. Die ZusammenhÃ¤nge konnten nicht durch Alter, Geschlecht, Gewicht, sozio-Ã¶konomischen Status, globales Funktionsniveau oder die Dauer der Erkrankung erklÃ¤rt werden. Schlussfolgerungen: Dies ist die erste Studie, die ZusammenhÃ¤nge zwischen dem CBCL-Dysregulations-Profil und einem proinflammatorischen Zustand beschreibt. EinschrÃ¤nkungen betreffen das Fehlen einer gesunden Kontrollgruppe, eine einzige Messung der EntzÃ¼ndungsmarker und das Fehlen von Follow-up-Daten. KÃ¼nftige Studien sollten untersuchen, ob VerÃ¤nderungen im EntzÃ¼ndungssystem bei diesen Kindern mit einer erhÃ¶hten AnfÃ¤lligkeit fÃ¼r die Entwicklung von Herz-Kreislauf-Erkrankungen und anderen medizinische AuffÃ¤lligkeiten einhergehen.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CRP</Keyword><Keyword MajorTopicYN="N">Child Behavior Checklist (CBCL)</Keyword><Keyword MajorTopicYN="N">EntzÃ¼ndung</Keyword><Keyword MajorTopicYN="N">Reizbarkeit</Keyword><Keyword MajorTopicYN="N">bipolar disorder</Keyword><Keyword MajorTopicYN="N">bipolare StÃ¶rung</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword><Keyword MajorTopicYN="N">irritability</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>11</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>11</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>2</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24240495</ArticleId><ArticleId IdType="pii">170G676855T32601</ArticleId><ArticleId IdType="doi">10.1024/1422-4917/a000255</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17240456</PMID><DateCompleted><Year>2007</Year><Month>08</Month><Day>17</Day></DateCompleted><DateRevised><Year>2009</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0165-0327</ISSN><JournalIssue CitedMedium="Print"><Volume>101</Volume><Issue>1-3</Issue><PubDate><Year>2007</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Towards a reconceptualization of mixed states, based on an emotional-reactivity dimensional model.</ArticleTitle><Pagination><MedlinePgn>35-41</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">DSM-IV criteria for mixed states may be too restrictive and may actually exclude patients who do not meet the full criteria for a manic and depressive state. Using this DSM-IV definition, many patients who are considered depressed may have mixed features, which can explain why some bipolar depressive states can worsen with antidepressants and can be improved by mood stabilizers or atypical antipsychotics. A dimensional approach not exclusively focused on the tonality of affect would help to define a broader entity of mixed states. The aim of this study was to apply a dimensional model to bipolar episodes and to assess the overlap between the groups defined using this model and using categorical diagnosis.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">We assessed 139 DSM-IV acutely ill bipolar I patients with MAThyS (Multidimensional Assessment of Thymic States by Henry et al. in press), a scale that assesses five quantitative dimensions exploring excitatory and inhibition processes, and that is not focused on tonality of mood but on emotional reactivity. We studied the relationship between clusters defined by statistical analyses and DSM-IV bipolar mood states.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">This study showed the existence of three clusters. Cluster 1 was characterized by an inhibition in all dimensions and corresponded to the depressive cluster (more than 90% of patients met the criteria for DSM-IV Major Depressive Episode (MDE)). Cluster 2 showed a general excitation and was mainly DSM-IV manic or hypomanic patients (90%). Cluster 3 (Mixed) was more complex and the diagnosis included MDE (56%) in most of the cases associated with manic or hypomanic symptoms, mixed states (18%) defined by DSM-IV criteria, and manic or hypomanic states (25%). Emotional reactivity was relevant to distinguish Cluster 1 (Depressive), exhibiting emotional hypo-reactivity, from Cluster 2 (Manic) and 3 (Mixed), characterized by emotional hyper-reactivity. Sadness was reported equally in all three clusters.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">A dimensional approach using the concept of emotional reactivity seems appropriate to define a broad mixed state entity in patients who would be diagnosed with MDE according to DSM-IV. Further studies are needed to test the relevance of this model in therapeutic strategies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Henry</LastName><ForeName>Chantal</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>HÃ´pital Charles Perrens, BÃ¢timent Lescure, 121 rue de la BÃ©chade, 33076 Bordeaux Cedex, France. chenry@perrens.aquisante.fr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M'BaÃ¯lara</LastName><ForeName>Katia</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Desage</LastName><ForeName>Alain</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Gard</LastName><ForeName>SÃ©bastien</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Misdrahi</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Vieta</LastName><ForeName>Eduard</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>01</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="N">Affect</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001143" MajorTopicYN="N">Arousal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016000" MajorTopicYN="N">Cluster Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010552" MajorTopicYN="N">Personality Assessment</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012931" MajorTopicYN="N">Social Environment</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year><Month>10</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>10</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>1</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>8</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>1</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17240456</ArticleId><ArticleId IdType="pii">S0165-0327(06)00464-2</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2006.10.027</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">2027422</PMID><DateCompleted><Year>1991</Year><Month>06</Month><Day>12</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-2804</ISSN><JournalIssue CitedMedium="Print"><Volume>62</Volume><Issue>1</Issue><PubDate><Year>1991</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Der Nervenarzt</Title><ISOAbbreviation>Nervenarzt</ISOAbbreviation></Journal><ArticleTitle>[Neuroleptic malignant syndrome with clozapine monotherapy and benign hyperthermia after resolving neuroleptic malignant syndrome with clozapine. Two case reports].</ArticleTitle><Pagination><MedlinePgn>55-7</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vetter</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Abteilung Psychiatrie, Zentrum Nervenheilkunde, Klinikum der CAU Kiel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Proppe</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Hoppe-Seyler</LastName><ForeName>S</ForeName><Initials>S</Initials></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Neuroleptisches malignes Syndrom (NMS) unter Clozapinmonotherapie und benigne Hyperthermie bei abklingendem NMS unter Clozapin. Zwei Kasuistiken.</VernacularTitle></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Nervenarzt</MedlineTA><NlmUniqueID>0400773</NlmUniqueID><ISSNLinking>0028-2804</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>J60AR2IKIC</RegistryNumber><NameOfSubstance UI="D003024">Clozapine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003024" MajorTopicYN="N">Clozapine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008305" MajorTopicYN="N">Malignant Hyperthermia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009459" MajorTopicYN="N">Neuroleptic Malignant Syndrome</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009460" MajorTopicYN="N">Neurologic Examination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010259" MajorTopicYN="N">Paranoid Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013375" MajorTopicYN="N">Substance Withdrawal Syndrome</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1991</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1991</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1991</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2027422</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">32521570</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>26</Day></DateCompleted><DateRevised><Year>2021</Year><Month>09</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>2</Issue><PubDate><Year>2021</Year><Month>03</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Altered frontal cortex functioning in emotion regulation and hopelessness in bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>152-164</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/bdi.12954</ELocationID><Abstract><AbstractText Label="OBJECTIVES">Emotion regulation difficulties precipitate and exacerbate acute mood symptoms in individuals with bipolar disorder (BD), and contribute to suicidal behavior. However, few studies have examined regional brain responses in explicit emotion regulation during acute BD mood states, or hopelessness, a major suicide risk factor. We assessed brain responses during explicit emotion regulation, and their relationship with hopelessness, in acutely symptomatic and euthymic individuals with BD.</AbstractText><AbstractText Label="METHODS">Functional MRI data were obtained from individuals with BD who were either in acute negative (BD-A; nÂ =Â 24) or euthymic (BD-E; nÂ =Â 24) mood states, and from healthy volunteers (HV; nÂ =Â 55), while participants performed a paradigm that instructed them to downregulate their responses to fearful (EmReg-Fear) and happy (EmReg-Happy) facial stimuli. Emotion regulation-related differences in brain responses during negative and euthymic BD states, as well as their associations with negative affective symptoms (hopelessness and depression), were examined.</AbstractText><AbstractText Label="RESULTS">Decreased responses were observed in ventral and dorsal frontal regions, including medial orbitofrontal (mOFC) and dorsal anterior cingulate cortices, during EmReg-Fear across symptomatic and euthymic states in participants with BD relative to HVs. The lowest responses were observed in the BD-A group. Across BD participants, negative associations were observed between mOFC responses and hopelessness, particularly due to loss of motivation. Differences were not significant during EmReg-Happy.</AbstractText><AbstractText Label="CONCLUSIONS">Lesser emotion regulation-related ventral and dorsal frontal engagement in BD could represent a trait abnormality that worsens during acute negative states. The reduced mOFC engagement in BD during explicit regulation of negative emotions may contribute to hopelessness particularly in the context of diminished motivation.</AbstractText><CopyrightInformation>Â© 2020 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sankar</LastName><ForeName>Anjali</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-7517-9776</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Purves</LastName><ForeName>Kirstin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Social, Genetic Developmental Psychiatry Centre, Institute of Psychiatry, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colic</LastName><ForeName>Lejla</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cox Lippard</LastName><ForeName>Elizabeth T</ForeName><Initials>ET</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, CT, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Dell Medical School, University of Texas, Austin, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Millard</LastName><ForeName>Hun</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Child Study Center, Yale School of Medicine, New Haven, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Siyan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spencer</LastName><ForeName>Linda</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Fei</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pittman</LastName><ForeName>Brian</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Constable</LastName><ForeName>R Todd</ForeName><Initials>RT</Initials><AffiliationInfo><Affiliation>Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gross</LastName><ForeName>James J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Department of Psychology, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blumberg</LastName><ForeName>Hilary P</ForeName><Initials>HP</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, CT, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Child Study Center, Yale School of Medicine, New Haven, CT, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH113230</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 DA022975</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001863</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC1 MH088366</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 MH014276</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000142</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH069747</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH070902</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000080103" MajorTopicYN="Y">Emotional Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004644" MajorTopicYN="N">Emotions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005625" MajorTopicYN="N">Frontal Lobe</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">bipolar disorder</Keyword><Keyword MajorTopicYN="Y">emotions</Keyword><Keyword MajorTopicYN="Y">fMRI</Keyword><Keyword MajorTopicYN="Y">frontal</Keyword><Keyword MajorTopicYN="Y">functional magnetic resonance imaging</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>03</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32521570</ArticleId><ArticleId IdType="doi">10.1111/bdi.12954</ArticleId><ArticleId IdType="pmc">PMC7790437</ArticleId><ArticleId IdType="mid">NIHMS1655674</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Clin Psychol. 2006 Jan;62(1):123-46</Citation><ArticleIdList><ArticleId IdType="pubmed">16287149</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2005 Feb 1;57(3):210-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15691521</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1978 Nov;133:429-35</Citation><ArticleIdList><ArticleId IdType="pubmed">728692</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2013 Jan 15;73(2):136-43</Citation><ArticleIdList><ArticleId IdType="pubmed">22871393</ArticleId></ArticleIdList></Reference><Reference><Citation>Suicide Life Threat Behav. 2012 Feb;42(1):1-10</Citation><ArticleIdList><ArticleId IdType="pubmed">22320192</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1997 Jul;36(7):980-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9204677</ArticleId></ArticleIdList></Reference><Reference><Citation>Cogn Emot. 2013;27(1):63-84</Citation><ArticleIdList><ArticleId IdType="pubmed">22775344</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurophysiol. 1959 Jul;22(4):451-7</Citation><ArticleIdList><ArticleId IdType="pubmed">13673296</ArticleId></ArticleIdList></Reference><Reference><Citation>J Comp Neurol. 2008 Feb 1;506(4):659-93</Citation><ArticleIdList><ArticleId IdType="pubmed">18067141</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2012 Jun;14(4):340-55</Citation><ArticleIdList><ArticleId IdType="pubmed">22631619</ArticleId></ArticleIdList></Reference><Reference><Citation>J Consult Clin Psychol. 1974 Dec;42(6):861-5</Citation><ArticleIdList><ArticleId IdType="pubmed">4436473</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2008 Sep;13(9):829, 833-57</Citation><ArticleIdList><ArticleId IdType="pubmed">18574483</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2012 Mar 31;201(3):196-205</Citation><ArticleIdList><ArticleId IdType="pubmed">22510433</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Behav Neurosci. 2019 Jul 11;13:149</Citation><ArticleIdList><ArticleId IdType="pubmed">31354443</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Biobehav Rev. 2014 Sep;45:202-11</Citation><ArticleIdList><ArticleId IdType="pubmed">24984244</ArticleId></ArticleIdList></Reference><Reference><Citation>Cogn Emot. 2011 Apr;25(3):400-12</Citation><ArticleIdList><ArticleId IdType="pubmed">21432682</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2014 Feb 15;87:345-55</Citation><ArticleIdList><ArticleId IdType="pubmed">24220041</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2017 Jul 1;174(7):667-675</Citation><ArticleIdList><ArticleId IdType="pubmed">28135845</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2015;45(12):2521-31</Citation><ArticleIdList><ArticleId IdType="pubmed">25997918</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2000 Dec 1;48(11):1045-52</Citation><ArticleIdList><ArticleId IdType="pubmed">11094137</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Cogn Sci. 2005 May;9(5):242-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15866151</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2012 Jun;14(4):313-25</Citation><ArticleIdList><ArticleId IdType="pubmed">22631617</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2012 Jul;42(7):1417-28</Citation><ArticleIdList><ArticleId IdType="pubmed">22099606</ArticleId></ArticleIdList></Reference><Reference><Citation>Cereb Cortex. 2014 Nov;24(11):2981-90</Citation><ArticleIdList><ArticleId IdType="pubmed">23765157</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Psychiatry. 2015 Jul;72(7):687-96</Citation><ArticleIdList><ArticleId IdType="pubmed">25945779</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2011 Oct;124(4):307-16</Citation><ArticleIdList><ArticleId IdType="pubmed">21644938</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2013 Jan 15;73(2):127-35</Citation><ArticleIdList><ArticleId IdType="pubmed">22858151</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2011 Dec;135(1-3):305-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21783257</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2009 May 1;45(4):1212-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19349235</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2015 Aug;17(5):461-70</Citation><ArticleIdList><ArticleId IdType="pubmed">25771686</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2018 May;20(3):238-247</Citation><ArticleIdList><ArticleId IdType="pubmed">29441653</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1990 Feb;147(2):190-5</Citation><ArticleIdList><ArticleId IdType="pubmed">2278535</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2011 Sep 1;58(1):275-85</Citation><ArticleIdList><ArticleId IdType="pubmed">21669291</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1999 Dec;156(12):1986-8</Citation><ArticleIdList><ArticleId IdType="pubmed">10588416</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2005 Sep;187:221-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16135858</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2020 Feb;50(3):413-421</Citation><ArticleIdList><ArticleId IdType="pubmed">30773147</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2001 Jan 15;21(2):700-12</Citation><ArticleIdList><ArticleId IdType="pubmed">11160449</ArticleId></ArticleIdList></Reference><Reference><Citation>Aust N Z J Psychiatry. 2018 Oct;52(10):962-971</Citation><ArticleIdList><ArticleId IdType="pubmed">29232968</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1973 Apr;130(4):455-9</Citation><ArticleIdList><ArticleId IdType="pubmed">4691303</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2003 Jul;19(3):1233-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12880848</ArticleId></ArticleIdList></Reference><Reference><Citation>Soc Cogn Affect Neurosci. 2017 Oct 1;12(10):1545-1557</Citation><ArticleIdList><ArticleId IdType="pubmed">28981910</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2009 Aug 15;168(3):242-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19564050</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2012 Aug 15;62(2):782-90</Citation><ArticleIdList><ArticleId IdType="pubmed">21979382</ArticleId></ArticleIdList></Reference><Reference><Citation>Transl Psychiatry. 2012 Mar 13;2:e90</Citation><ArticleIdList><ArticleId IdType="pubmed">22832855</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62</Citation><ArticleIdList><ArticleId IdType="pubmed">14399272</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2006 Jan 1;59(1):31-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16112653</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2019 Mar 1;246:480-485</Citation><ArticleIdList><ArticleId IdType="pubmed">30599372</ArticleId></ArticleIdList></Reference><Reference><Citation>Transl Psychiatry. 2015 Jan 20;5:e497</Citation><ArticleIdList><ArticleId IdType="pubmed">25603413</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Suicide Res. 2009;13(3):230-46</Citation><ArticleIdList><ArticleId IdType="pubmed">19590997</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2009 Sep 1;66(5):516-21</Citation><ArticleIdList><ArticleId IdType="pubmed">19427632</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurosci. 2009 Jan;10(1):59-70</Citation><ArticleIdList><ArticleId IdType="pubmed">19096369</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2018 Jul;234:231-238</Citation><ArticleIdList><ArticleId IdType="pubmed">29547816</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2014 Aug;171(8):829-43</Citation><ArticleIdList><ArticleId IdType="pubmed">24626773</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2007 Apr;164(4):638-46</Citation><ArticleIdList><ArticleId IdType="pubmed">17403978</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerebellum. 2009 Mar;8(1):28-34</Citation><ArticleIdList><ArticleId IdType="pubmed">18855096</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatry Neurosci. 2009 Nov;34(6):418-32</Citation><ArticleIdList><ArticleId IdType="pubmed">19949718</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2013 Aug;15(5):559-74</Citation><ArticleIdList><ArticleId IdType="pubmed">23848394</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Cogn Sci. 2012 Mar;16(3):147-56</Citation><ArticleIdList><ArticleId IdType="pubmed">22310704</ArticleId></ArticleIdList></Reference><Reference><Citation>Soc Cogn Affect Neurosci. 2013 Dec;8(8):911-7</Citation><ArticleIdList><ArticleId IdType="pubmed">22933520</ArticleId></ArticleIdList></Reference><Reference><Citation>Suicide Life Threat Behav. 2006 Aug;36(4):443-54</Citation><ArticleIdList><ArticleId IdType="pubmed">16978098</ArticleId></ArticleIdList></Reference><Reference><Citation>Soc Cogn Affect Neurosci. 2017 Apr 1;12(4):569-585</Citation><ArticleIdList><ArticleId IdType="pubmed">27998996</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 1995 Jul 28;57(2):169-80</Citation><ArticleIdList><ArticleId IdType="pubmed">7480383</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2009 Jun;48(6):636-642</Citation><ArticleIdList><ArticleId IdType="pubmed">19454919</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Biobehav Rev. 2009 Sep;33(8):1198-203</Citation><ArticleIdList><ArticleId IdType="pubmed">19538989</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2010 Jun 30;182(3):207-10</Citation><ArticleIdList><ArticleId IdType="pubmed">20493671</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurocytol. 2002 Mar-Jun;31(3-5):373-85</Citation><ArticleIdList><ArticleId IdType="pubmed">12815254</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2012 Jun;14(4):432-41</Citation><ArticleIdList><ArticleId IdType="pubmed">22524493</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Psychiatry. 2016 Apr;34:56-63</Citation><ArticleIdList><ArticleId IdType="pubmed">26945530</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17064428</PMID><DateCompleted><Year>2007</Year><Month>03</Month><Day>22</Day></DateCompleted><DateRevised><Year>2007</Year><Month>12</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0954-5794</ISSN><JournalIssue CitedMedium="Print"><Volume>18</Volume><Issue>4</Issue><PubDate><Year>2006</Year><Season>Fall</Season></PubDate></JournalIssue><Title>Development and psychopathology</Title><ISOAbbreviation>Dev Psychopathol</ISOAbbreviation></Journal><ArticleTitle>Controlled study of switching from attention-deficit/hyperactivity disorder to a prepubertal and early adolescent bipolar I disorder phenotype during 6-year prospective follow-up: rate, risk, and predictors.</ArticleTitle><Pagination><MedlinePgn>1037-53</MedlinePgn></Pagination><Abstract><AbstractText>Rate, risk, and predictors of switching from attention-deficit/hyperactivity disorder (ADHD) to a prepubertal and early adolescent bipolar I disorder phenotype (PEA-BP-I) were examined in a blindly rated, controlled, prospective 6-year follow-up that included assessments at 2-year intervals. Subjects were outpatients obtained by consecutive new case ascertainment. There were 81 subjects who were 9.7 +/- 2.0 years. Subjects had DSM-IV ADHD (hyperactive or combined subtypes); a Children's Global Assessment Scale (CGAS) score of &lt; or =60, consistent with moderate-severe impairment; and no BP or major depressive disorder (MDD) diagnoses. PEA-BP-I was defined as DSM-IV BP I (manic or mixed phase), with cardinal symptoms (elation and/or grandiosity), to avoid diagnosing mania by symptoms that overlapped with those of ADHD, and by a CGAS score of &lt; or =60. Morbid risk of switching to PEA-BP-I was 28.5%. Significant predictors of switching in a multivariate Cox model were more severe baseline CGAS, paternal recurrent MDD, and less stimulant use. BP I in first-degree relatives, antidepressants, psychosocial measures, and life events were not predictive.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tillman</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University, St. Louis, MO 63110-1093, USA. gellerb@beckermail.wustl.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geller</LastName><ForeName>Barbara</ForeName><Initials>B</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH-53063</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH-57451</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dev Psychopathol</MedlineTA><NlmUniqueID>8910645</NlmUniqueID><ISSNLinking>0954-5794</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000697">Central Nervous System Stimulants</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001289" MajorTopicYN="N">Attention Deficit Disorder with Hyperactivity</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000697" MajorTopicYN="N">Central Nervous System Stimulants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009679" MajorTopicYN="N">Nuclear Family</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010045" MajorTopicYN="N">Outpatients</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011627" MajorTopicYN="N">Puberty</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012919" MajorTopicYN="N">Social Behavior</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>10</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>3</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>10</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17064428</ArticleId><ArticleId IdType="pii">S0954579406060512</ArticleId><ArticleId IdType="doi">10.1017/S0954579406060512</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">24912456</PMID><DateCompleted><Year>2015</Year><Month>09</Month><Day>02</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-244X</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><PubDate><Year>2014</Year><Month>Jun</Month><Day>09</Day></PubDate></JournalIssue><Title>BMC psychiatry</Title><ISOAbbreviation>BMC Psychiatry</ISOAbbreviation></Journal><ArticleTitle>The addition of STEPPS in the treatment of patients with bipolar disorder and comorbid borderline personality features: a protocol for a randomized controlled trial.</ArticleTitle><Pagination><MedlinePgn>172</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/1471-244X-14-172</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Bipolar disorder (BD) and borderline personality disorder (BPD) both are severe and chronic psychiatric disorders. Both disorders have overlapping symptoms, and current research shows that the presence of a BPD has an adverse effect on the course of BD. The limited research available shows an unfavorable illness course, a worse prognosis and response to medication, longer treatment duration, more frequent psychiatric admissions, higher drop-out, increased risk of substance abuse, increased risk of suicide, and more impairment of social and occupational functioning. However, there is no research available on the effect of specific psychotherapeutic treatment for this patients.</AbstractText><AbstractText Label="METHODS/DESIGN" NlmCategory="METHODS">This paper presents the protocol of a RCT to investigate the presence of borderline personality features in patients treated for BD (study part 1) and the effectiveness of STEPPS (Systems Training for Emotional Predictability and Problem Solving) added to treatment as usual (TAU) for BD compared to TAU in patients with BD and comorbid borderline personality features (study part 2). STEPPS is a validated and effective intervention for BPD. The study population consists of patients treated for BD at specialized outpatient clinics for BD in the Netherlands. At first the prevalence of comorbid borderline personality features in outpatients with BD is investigated. Inclusion criteria for study part 2 is defined as having three or more of the DSM-IV-TR diagnostic criteria of BPD, including impulsivity and anger bursts. Primary outcomes will be the frequency and severity of manic and depressive recurrences as well as severity, course and burden of borderline personality features. Secondary outcomes will be quality of life, utilizing mental healthcare and psychopathologic symptoms not primarily related to BD or BPD. Assessment will be at baseline, at the end of the intervention, and at 12 and 18 months follow-up.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">This will be the first randomized controlled trial of a specific intervention in patients with BD and comorbid BPD or borderline personality features. There are no recommendations in the guideline of treatment of bipolar disorders for patients with this complex comorbidity. We expect that a combined treatment aimed at mood disorder and emotion regulation will improve treatment outcomes for these patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Riemann</LastName><ForeName>Georg</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Saxion University of Applied Science, Deventer, The Netherlands. g.riemann@saxion.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weisscher</LastName><ForeName>Nadine</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Goossens</LastName><ForeName>Peter J J</ForeName><Initials>PJ</Initials></Author><Author ValidYN="Y"><LastName>Draijer</LastName><ForeName>Nel</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Apenhorst-Hol</LastName><ForeName>Marjolein</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Kupka</LastName><ForeName>Ralph W</ForeName><Initials>RW</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>06</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Psychiatry</MedlineTA><NlmUniqueID>100968559</NlmUniqueID><ISSNLinking>1471-244X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001883" MajorTopicYN="N">Borderline Personality Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004644" MajorTopicYN="N">Emotions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009426" MajorTopicYN="N">Netherlands</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010045" MajorTopicYN="N">Outpatients</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010343" MajorTopicYN="N">Patient Admission</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010551" MajorTopicYN="N">Personality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011340" MajorTopicYN="N">Problem Solving</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011615" MajorTopicYN="N">Psychotherapy, Group</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019966" MajorTopicYN="N">Substance-Related Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>05</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>05</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>6</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>6</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>9</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24912456</ArticleId><ArticleId IdType="pii">1471-244X-14-172</ArticleId><ArticleId IdType="doi">10.1186/1471-244X-14-172</ArticleId><ArticleId IdType="pmc">PMC4065586</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Psychiatry Res. 1986 May;18(1):65-87</Citation><ArticleIdList><ArticleId IdType="pubmed">3737788</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 1998 May;28(3):551-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9626712</ArticleId></ArticleIdList></Reference><Reference><Citation>Harv Rev Psychiatry. 2004 May-Jun;12(3):140-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15371068</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2005 Apr;7(2):192-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15762861</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2002 Aug;4(4):237-42</Citation><ArticleIdList><ArticleId IdType="pubmed">12190712</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 2007 Mar-Apr;48(2):145-54</Citation><ArticleIdList><ArticleId IdType="pubmed">17292705</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2007 Feb-Mar;9(1-2):25-37</Citation><ArticleIdList><ArticleId IdType="pubmed">17391347</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2000 Feb;61(2):134-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10732661</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2002 May;63(5):442-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12019669</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2003 Apr;5(2):115-22</Citation><ArticleIdList><ArticleId IdType="pubmed">12680901</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2008 Nov;69(11):1794-803</Citation><ArticleIdList><ArticleId IdType="pubmed">19026249</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2004 Aug;6(4):294-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15225146</ArticleId></ArticleIdList></Reference><Reference><Citation>Health Serv Res. 2004 Aug;39(4 Pt 1):1005-26</Citation><ArticleIdList><ArticleId IdType="pubmed">15230939</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2004 Apr;79(1-3):297-303</Citation><ArticleIdList><ArticleId IdType="pubmed">15023511</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2008 Apr;165(4):468-78</Citation><ArticleIdList><ArticleId IdType="pubmed">18281407</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1978 Nov;133:429-35</Citation><ArticleIdList><ArticleId IdType="pubmed">728692</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2006 Feb;8(1):1-14</Citation><ArticleIdList><ArticleId IdType="pubmed">16411976</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Rep. 2004 Aug;95(1):121-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15460367</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 2012 Oct;53(7):952-61</Citation><ArticleIdList><ArticleId IdType="pubmed">22560773</ArticleId></ArticleIdList></Reference><Reference><Citation>J Consult Clin Psychol. 1993 Dec;61(6):1068-75</Citation><ArticleIdList><ArticleId IdType="pubmed">8113485</ArticleId></ArticleIdList></Reference><Reference><Citation>Tijdschr Psychiatr. 2007;49(6):393-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17614093</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2005 Mar;66(3):339-45</Citation><ArticleIdList><ArticleId IdType="pubmed">15766300</ArticleId></ArticleIdList></Reference><Reference><Citation>Tijdschr Psychiatr. 2009;51(5):291-301</Citation><ArticleIdList><ArticleId IdType="pubmed">19434566</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21683960</PMID><DateCompleted><Year>2012</Year><Month>03</Month><Day>06</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-1379</ISSN><JournalIssue CitedMedium="Internet"><Volume>45</Volume><Issue>10</Issue><PubDate><Year>2011</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of psychiatric research</Title><ISOAbbreviation>J Psychiatr Res</ISOAbbreviation></Journal><ArticleTitle>High level of persistence of pediatric bipolar-I disorder from childhood onto adolescent years: a four year prospective longitudinal follow-up study.</ArticleTitle><Pagination><MedlinePgn>1273-82</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jpsychires.2010.10.006</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To examine the longitudinal course of pediatric bipolar (BP)-I disorder in youth transitioning from childhood into adolescence.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a four year prospective follow-up study of 78 youth with BP-I disorder 6-17 years old at ascertainment followed up into adolescent years (13.4Â Â±Â 3.9 years). All subjects were comprehensively assessed with structured diagnostic interviews, neuropsychological testing, psychosocial, educational and treatment history assessments. BP disorder was considered persistent if subjects met full criteria for DSM-IV BP-I disorder at follow-up.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 78 BP-I participating youth subjects, 57 (73.1%), continued to meet full diagnostic criteria for BP-I Disorder. Of those with a non-persistent course, only 6.4% (nÂ =Â 5) were euthymic (i.e., syndromatic and symptomatic remission) at the 4-year follow-up and were not receiving pharmacotherapy for the disorder. The other non-persistent cases either continued to have subthreshold BP-I disorder (nÂ =Â 5, 6.4%), met full (nÂ =Â 3, 3.8%) or subthreshold (nÂ =Â 1, 1.3%) criteria for major depression, or were euthymic but were treated for the disorder (nÂ =Â 7, 9.0%). Full persistence was associated with higher rates of major depression and disruptive behavior disorders at the follow-up assessment and higher use of stimulant medicines at the baseline assessment. Non-Peristent BP-I was also characterized by high levels of dysfunction and morbidity.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This four year follow-up shows that the majority of BP-I disorder youth continue to experience persistent disorder into their mid and late adolescent years and its persistence is associated with high levels of morbidity and disability. Persistence of subsyndromal forms of bipolar disorder was also associated with dysfunction and morbidity.</AbstractText><CopyrightInformation>Copyright Â© 2010 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wozniak</LastName><ForeName>Janet</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Clinical and Research Program in Pediatric Psychopharmacology and Adult ADHD at Massachusetts General Hospital, Boston, MA 02114, United States. jwozniak@partners.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petty</LastName><ForeName>Carter R</ForeName><Initials>CR</Initials></Author><Author ValidYN="Y"><LastName>Schreck</LastName><ForeName>Meghan</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Moses</LastName><ForeName>Alana</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Faraone</LastName><ForeName>Stephen V</ForeName><Initials>SV</Initials></Author><Author ValidYN="Y"><LastName>Biederman</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH066237-04</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 MH001503-05</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5R01MH66237-5</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH066237-01A1</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH066237-02</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 MH001503-03</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH066237-05</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 MH001503-04</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH066237</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH066237-03</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>06</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Psychiatr Res</MedlineTA><NlmUniqueID>0376331</NlmUniqueID><ISSNLinking>0022-3956</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019958" MajorTopicYN="N">Attention Deficit and Disruptive Behavior Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>06</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2010</Year><Month>09</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>10</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>6</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>6</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21683960</ArticleId><ArticleId IdType="pii">S0022-3956(10)00290-6</ArticleId><ArticleId IdType="doi">10.1016/j.jpsychires.2010.10.006</ArticleId><ArticleId IdType="pmc">PMC3183254</ArticleId><ArticleId IdType="mid">NIHMS305918</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arch Gen Psychiatry. 2007 May;64(5):543-52</Citation><ArticleIdList><ArticleId IdType="pubmed">17485606</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2001 Feb;158(2):303-5</Citation><ArticleIdList><ArticleId IdType="pubmed">11156815</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2009 May;48(5):519-532</Citation><ArticleIdList><ArticleId IdType="pubmed">19325497</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2004 Aug;43(8):984-93</Citation><ArticleIdList><ArticleId IdType="pubmed">15266193</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2007 Oct;164(10):1547-56</Citation><ArticleIdList><ArticleId IdType="pubmed">17898346</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2002 Jun;159(6):927-33</Citation><ArticleIdList><ArticleId IdType="pubmed">12042179</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2009 Feb;166(2):164-72</Citation><ArticleIdList><ArticleId IdType="pubmed">19015231</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2005 Jun;44(6):565-73</Citation><ArticleIdList><ArticleId IdType="pubmed">15908839</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1998 Aug 15;44(4):260-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9715357</ArticleId></ArticleIdList></Reference><Reference><Citation>CNS Spectr. 2007 Sep;12(9):683-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17805214</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2007 Apr;99(1-3):19-25</Citation><ArticleIdList><ArticleId IdType="pubmed">17005256</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1995 Apr;34(4):454-63</Citation><ArticleIdList><ArticleId IdType="pubmed">7751259</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2005;66 Suppl 7:21-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16124838</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2007 Jul 15;62(2):158-67</Citation><ArticleIdList><ArticleId IdType="pubmed">17097071</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2006 Jul;163(7):1179-86</Citation><ArticleIdList><ArticleId IdType="pubmed">16816222</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2005 Aug 1;58(3):197-203</Citation><ArticleIdList><ArticleId IdType="pubmed">16084840</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2001 Aug;3(4):202-10</Citation><ArticleIdList><ArticleId IdType="pubmed">11552959</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2000 Apr 1;47(7):605-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10745052</ArticleId></ArticleIdList></Reference><Reference><Citation>CNS Spectr. 2005 Feb;10(2):141-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15685125</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2003 Jun 1;53(11):938-44</Citation><ArticleIdList><ArticleId IdType="pubmed">12788238</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychiatr Dis Treat. 2008 Feb;4(1):203-7</Citation><ArticleIdList><ArticleId IdType="pubmed">18728799</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2009 Jul;166(7):795-804</Citation><ArticleIdList><ArticleId IdType="pubmed">19448190</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1995 Jul;34(7):867-76</Citation><ArticleIdList><ArticleId IdType="pubmed">7649957</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2007 Jan;164(1):52-60</Citation><ArticleIdList><ArticleId IdType="pubmed">17202544</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2004 Aug;61(8):781-92</Citation><ArticleIdList><ArticleId IdType="pubmed">15289277</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2005 Jun;44(6):539-47</Citation><ArticleIdList><ArticleId IdType="pubmed">15908836</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2003 Mar;60(3):261-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12622659</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2005 Nov;39(6):611-22</Citation><ArticleIdList><ArticleId IdType="pubmed">16009376</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2005 Oct 1;58(7):583-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16197929</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1998 May;155(5):646-52</Citation><ArticleIdList><ArticleId IdType="pubmed">9585716</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2004 May;61(5):459-67</Citation><ArticleIdList><ArticleId IdType="pubmed">15123490</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2003 Jun 1;53(11):970-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12788242</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2004 Oct;82 Suppl 1:S103-11</Citation><ArticleIdList><ArticleId IdType="pubmed">15571784</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2004 Oct;82 Suppl 1:S17-23</Citation><ArticleIdList><ArticleId IdType="pubmed">15571786</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2006 Feb;63(2):175-83</Citation><ArticleIdList><ArticleId IdType="pubmed">16461861</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Adolesc Psychopharmacol. 2000 Fall;10(3):157-64</Citation><ArticleIdList><ArticleId IdType="pubmed">11052405</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1970 Jan;126(7):983-7</Citation><ArticleIdList><ArticleId IdType="pubmed">5409569</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2006 Oct;63(10):1130-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17015815</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2009 Jun;166(6):718-25</Citation><ArticleIdList><ArticleId IdType="pubmed">19448189</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Adolesc Psychopharmacol. 2003 Winter;13(4):449-51</Citation><ArticleIdList><ArticleId IdType="pubmed">14977457</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Adolesc Psychopharmacol. 2002 Spring;12(1):11-25</Citation><ArticleIdList><ArticleId IdType="pubmed">12014591</ArticleId></ArticleIdList></Reference><Reference><Citation>Harv Rev Psychiatry. 1995 Nov-Dec;3(4):227-30</Citation><ArticleIdList><ArticleId IdType="pubmed">9384951</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2002 Sep;63(9):807-11</Citation><ArticleIdList><ArticleId IdType="pubmed">12363122</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2006 Apr;163(4):716-23</Citation><ArticleIdList><ArticleId IdType="pubmed">16585449</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2008 Oct;65(10):1125-33</Citation><ArticleIdList><ArticleId IdType="pubmed">18838629</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">32997440</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>24</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2162-3279</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>12</Issue><PubDate><Year>2020</Year><Month>12</Month></PubDate></JournalIssue><Title>Brain and behavior</Title><ISOAbbreviation>Brain Behav</ISOAbbreviation></Journal><ArticleTitle>Preclinical atherosclerosis in adolescents with psychotic or bipolar disorders investigated with carotid high-frequency ultrasound.</ArticleTitle><Pagination><MedlinePgn>e01862</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/brb3.1862</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Early-onset psychosis (EOP) and bipolar disorder (EOBP) (at &lt;18Â years of age), are associated with an increased future risk of cardiovascular disease (CVD) and premature death. Yet it is unknown whether the arteries show visible signs of atherosclerosis in EOP and EOBP. This study investigated whether having EOP or EOBP was associated with detectable signs of preclinical atherosclerosis.</AbstractText><AbstractText Label="METHOD">By using 22Â MHz high-frequency ultrasound, different layers of the arterial wall of the left common carotid artery (LCCA) were assessed in 77 individuals with EOP (nÂ =Â 25), EOBP (nÂ =Â 22), and in age-matched healthy controls (nÂ =Â 30). Conventional CVD confounders were included in the analyses.</AbstractText><AbstractText Label="RESULTS">Adolescents with EOP and EOBP, compared to controls, had a significantly thicker LCCA intima thickness (0.132 vs. 0.095Â mm, pÂ &lt;Â .001) and intima/media ratio (0.24 vs. 0.17 pÂ &lt;Â .001). There was a nonsignificant intima difference between EOP and EOBP. Conventional CVD risk factors did not explain the association between EOP/EOBP and intima thickness. In the group of EOP/EOBP, there was a significant correlation between the dose of current antipsychotic medication and intima thickness; however, the correlation was attenuated to a nonsignificant level when adjusted for global function.</AbstractText><AbstractText Label="CONCLUSIONS">Adolescents with EOP or EOBP had an increased LCCA intima thickness, interpreted as a sign of preclinical atherosclerosis. Global function of the disorders was the strongest determinant of intima thickness. The findings, if replicated, might have implications for long-term treatment of EOP and EOBP in order to reduce a future risk of CVD.</AbstractText><CopyrightInformation>Â© 2020 The Authors. Brain and Behavior published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bohman</LastName><ForeName>Hannes</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-9726-6478</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Child and Adolescent Psychiatry, Uppsala University, Uppsala, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Science and Education SÃ¶dersjukhuset, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agartz</LastName><ForeName>Ingrid</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>NORMENT and K.G. Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatric Research, Diakonhjemmet Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mansouri</LastName><ForeName>Shiva</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Clinical Science and Education SÃ¶dersjukhuset, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naessen</LastName><ForeName>Tord</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lundberg</LastName><ForeName>Mathias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Clinical Science and Education SÃ¶dersjukhuset, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>SÃ¶derstrÃ¶mska-KÃ¶nigska Foundation</Agency><Country/></Grant><Grant><Agency>Svenska ForskningsrÃ¥det Formas</Agency><Country/></Grant><Grant><Agency>Svenska LÃ¤karesÃ¤llskapet</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>09</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Brain Behav</MedlineTA><NlmUniqueID>101570837</NlmUniqueID></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050197" MajorTopicYN="Y">Atherosclerosis</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002339" MajorTopicYN="N">Carotid Arteries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014463" MajorTopicYN="N">Ultrasonography</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">adolescents</Keyword><Keyword MajorTopicYN="Y">atherosclerosis</Keyword><Keyword MajorTopicYN="Y">bipolar disorder</Keyword><Keyword MajorTopicYN="Y">psychosis</Keyword><Keyword MajorTopicYN="Y">ultrasound</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>02</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>08</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>08</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>30</Day><Hour>12</Hour><Minute>19</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32997440</ArticleId><ArticleId IdType="doi">10.1002/brb3.1862</ArticleId><ArticleId IdType="pmc">PMC7749529</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World J Biol Psychiatry. 2010 Feb;11(1):71-5</Citation><ArticleIdList><ArticleId IdType="pubmed">19333836</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2006 May;45(5):550-560</Citation><ArticleIdList><ArticleId IdType="pubmed">16601399</ArticleId></ArticleIdList></Reference><Reference><Citation>Ultrasound Obstet Gynecol. 2014 Jun;43(6):675-80</Citation><ArticleIdList><ArticleId IdType="pubmed">24375803</ArticleId></ArticleIdList></Reference><Reference><Citation>Circulation. 2015 Sep 8;132(10):965-86</Citation><ArticleIdList><ArticleId IdType="pubmed">26260736</ArticleId></ArticleIdList></Reference><Reference><Citation>Hypertension. 2009 Nov;54(5):919-50</Citation><ArticleIdList><ArticleId IdType="pubmed">19729599</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardiol Rev. 2016 Mar-Apr;24(2):70-5</Citation><ArticleIdList><ArticleId IdType="pubmed">26825762</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2011 Mar;37(2):362-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19542527</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2017 Jan;179:57-63</Citation><ArticleIdList><ArticleId IdType="pubmed">27743650</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatr Cardiol. 2015 Jan;36(1):158-64</Citation><ArticleIdList><ArticleId IdType="pubmed">25096903</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2015 May;41(3):656-63</Citation><ArticleIdList><ArticleId IdType="pubmed">25422511</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2007 May;64(5):543-52</Citation><ArticleIdList><ArticleId IdType="pubmed">17485606</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nerv Ment Dis. 1997 Aug;185(8):491-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9284862</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Psychol Psychiatry. 2000 Jul;41(5):645-55</Citation><ArticleIdList><ArticleId IdType="pubmed">10946756</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2006 Jul;67(7):1034-41</Citation><ArticleIdList><ArticleId IdType="pubmed">16889445</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Cardiovasc Disord. 2014 Jan 21;14:9</Citation><ArticleIdList><ArticleId IdType="pubmed">24447603</ArticleId></ArticleIdList></Reference><Reference><Citation>Aust N Z J Psychiatry. 2001 Apr;35(2):196-202</Citation><ArticleIdList><ArticleId IdType="pubmed">11284901</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Behav. 2020 Dec;10(12):e01862</Citation><ArticleIdList><ArticleId IdType="pubmed">32997440</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Endocrinol. 2011 Oct 18;8(2):114-26</Citation><ArticleIdList><ArticleId IdType="pubmed">22009159</ArticleId></ArticleIdList></Reference><Reference><Citation>World Psychiatry. 2017 Jun;16(2):163-180</Citation><ArticleIdList><ArticleId IdType="pubmed">28498599</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleep. 2018 Jul 1;41(7):</Citation><ArticleIdList><ArticleId IdType="pubmed">29762755</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Schizophr Relat Psychoses. 2014 Jan;7(4):223-30</Citation><ArticleIdList><ArticleId IdType="pubmed">23428789</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Heart J. 2016 Aug 1;37(29):2315-2381</Citation><ArticleIdList><ArticleId IdType="pubmed">27222591</ArticleId></ArticleIdList></Reference><Reference><Citation>Metab Syndr Relat Disord. 2018 Apr;16(3):122-126</Citation><ArticleIdList><ArticleId IdType="pubmed">29412763</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2018 Apr 12;13(4):e0195687</Citation><ArticleIdList><ArticleId IdType="pubmed">29649252</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Public Health. 2018 Jun 15;18(1):742</Citation><ArticleIdList><ArticleId IdType="pubmed">29907101</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2013 May 21;346:f2539</Citation><ArticleIdList><ArticleId IdType="pubmed">23694688</ArticleId></ArticleIdList></Reference><Reference><Citation>Semin Arthritis Rheum. 2009 Apr;38(5):366-71</Citation><ArticleIdList><ArticleId IdType="pubmed">18336869</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacol Ther. 2010 Jan;125(1):169-79</Citation><ArticleIdList><ArticleId IdType="pubmed">19931306</ArticleId></ArticleIdList></Reference><Reference><Citation>Glob Heart. 2016 Sep;11(3):295-312.e3</Citation><ArticleIdList><ArticleId IdType="pubmed">27741977</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2000 Nov;157(11):1873-5</Citation><ArticleIdList><ArticleId IdType="pubmed">11058490</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Cardiol. 1991 Dec 15;68(17):1625-32</Citation><ArticleIdList><ArticleId IdType="pubmed">1746464</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Psychiatry. 2013 Mar;28(3):161-7</Citation><ArticleIdList><ArticleId IdType="pubmed">21964485</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Heart J. 2009 May;30(9):1046-56</Citation><ArticleIdList><ArticleId IdType="pubmed">19141562</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2009 Oct 28;302(16):1765-73</Citation><ArticleIdList><ArticleId IdType="pubmed">19861668</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Pediatr. 2015 Oct 16;15:161</Citation><ArticleIdList><ArticleId IdType="pubmed">26475608</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 1999 Jan 7;340(1):14-22</Citation><ArticleIdList><ArticleId IdType="pubmed">9878640</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2006;67 Suppl 9:25-30; discussion 36-42</Citation><ArticleIdList><ArticleId IdType="pubmed">16965186</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Psychiatry. 2009 May 16;9:24</Citation><ArticleIdList><ArticleId IdType="pubmed">19445700</ArticleId></ArticleIdList></Reference><Reference><Citation>Scand J Rheumatol. 2011;40(4):279-82</Citation><ArticleIdList><ArticleId IdType="pubmed">21469940</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Med Genet. 2005 Feb 11;6:7</Citation><ArticleIdList><ArticleId IdType="pubmed">15707482</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2011 Dec 30;190(2-3):372-4</Citation><ArticleIdList><ArticleId IdType="pubmed">21684015</ArticleId></ArticleIdList></Reference><Reference><Citation>Heart. 2014 Apr;100 Suppl 2:ii1-ii67</Citation><ArticleIdList><ArticleId IdType="pubmed">24667225</ArticleId></ArticleIdList></Reference><Reference><Citation>Transl Psychiatry. 2015 Aug 11;5:e616</Citation><ArticleIdList><ArticleId IdType="pubmed">26261884</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2014 Oct;159(1):176-81</Citation><ArticleIdList><ArticleId IdType="pubmed">25128454</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Prev Cardiol. 2017 Jan;24(1):103-110</Citation><ArticleIdList><ArticleId IdType="pubmed">27708071</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2019 Jun 18;45(4):773-783</Citation><ArticleIdList><ArticleId IdType="pubmed">30239900</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2009 Aug 22;374(9690):620-7</Citation><ArticleIdList><ArticleId IdType="pubmed">19595447</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23903341</PMID><DateCompleted><Year>2013</Year><Month>09</Month><Day>30</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1535-7228</ISSN><JournalIssue CitedMedium="Internet"><Volume>170</Volume><Issue>8</Issue><PubDate><Year>2013</Year><Month>Aug</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Clozapine-induced obsessive-compulsive symptoms in bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>930</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1176/appi.ajp.2013.13010144</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lemke</LastName><ForeName>Nicholas T</ForeName><Initials>NT</Initials></Author><Author ValidYN="Y"><LastName>Bustillo</LastName><ForeName>Juan R</ForeName><Initials>JR</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>UL1 TR000041</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003987">Dibenzothiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>2S3PL1B6UJ</RegistryNumber><NameOfSubstance UI="D000069348">Quetiapine Fumarate</NameOfSubstance></Chemical><Chemical><RegistryNumber>J60AR2IKIC</RegistryNumber><NameOfSubstance UI="D003024">Clozapine</NameOfSubstance></Chemical><Chemical><RegistryNumber>QUC7NX6WMB</RegistryNumber><NameOfSubstance UI="D020280">Sertraline</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003024" MajorTopicYN="N">Clozapine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003987" MajorTopicYN="N">Dibenzothiazepines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004351" MajorTopicYN="N">Drug Resistance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057915" MajorTopicYN="N">Drug Substitution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009771" MajorTopicYN="N">Obsessive-Compulsive Disorder</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069348" MajorTopicYN="N">Quetiapine Fumarate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020280" MajorTopicYN="N">Sertraline</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>10</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23903341</ArticleId><ArticleId IdType="pii">1722083</ArticleId><ArticleId IdType="doi">10.1176/appi.ajp.2013.13010144</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17845271</PMID><DateCompleted><Year>2007</Year><Month>12</Month><Day>19</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1398-5647</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>6</Issue><PubDate><Year>2007</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>The Bipolar Depression Rating Scale (BDRS): its development, validation and utility.</ArticleTitle><Pagination><MedlinePgn>571-9</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Unipolar and bipolar depression differ neurobiologically and in clinical presentation. Existing depression rating instruments, used in bipolar depression, fail to capture the necessary phenomenological nuances, as they are based on and skewed towards the characteristics of unipolar depression. Both clinically and in research there is a growing need for a new observer-rated scale that is specifically designed to assess bipolar depression.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">An instrument reflecting the characteristics of bipolar depression was drafted by the authors, and administered to 122 participants aged 18-65 (44 males and 78 females) with a diagnosis of DSM-IV bipolar disorder, who were currently experiencing symptoms of depression. The Bipolar Depression Rating Scale (BDRS) was administered together with the Hamilton Depression Rating Scale (HAM-D), Montgomery Asberg Depression Rating Scale (MADRS) and Young Mania Rating Scale (YMRS).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The BDRS has strong internal consistency (Cronbach's alpha = 0.917), and robust correlation coefficients with the MADRS (r = 0.906) and HAM-D (r = 0.744), and the mixed subscale correlated with the YMRS (r = 0.757). Exploratory factor analysis showed a three-factor solution gave the best account of the data. These factors corresponded to depression (somatic), depression (psychological) and mixed symptom clusters.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study provides evidence for the validity of the BDRS for the measurement of depression in bipolar disorder. These results suggest good internal validity, provisional evidence of inter-rater reliability and strong correlations with other depression rating scales.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Berk</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Barwon Health and the Geelong Clinic, Geelong; Department of Clinical and Biomedical Sciences, University of Melbourne; and Orygen Research Centre, Melbourne, Victoria, Australia. mikebe@barwonhealth.org.au</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malhi</LastName><ForeName>Gin S</ForeName><Initials>GS</Initials></Author><Author ValidYN="Y"><LastName>Cahill</LastName><ForeName>Catherine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Carman</LastName><ForeName>A Catherine</ForeName><Initials>AC</Initials></Author><Author ValidYN="Y"><LastName>Hadzi-Pavlovic</LastName><ForeName>Dusan</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Hawkins</LastName><ForeName>Mary T</ForeName><Initials>MT</Initials></Author><Author ValidYN="Y"><LastName>Tohen</LastName><ForeName>Mauricio</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Mitchell</LastName><ForeName>Philip B</ForeName><Initials>PB</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D023361">Validation Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005163" MajorTopicYN="N">Factor Analysis, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015588" MajorTopicYN="N">Observer Variation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="Y">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>9</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>12</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>9</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17845271</ArticleId><ArticleId IdType="pii">BDI536</ArticleId><ArticleId IdType="doi">10.1111/j.1399-5618.2007.00536.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23531096</PMID><DateCompleted><Year>2013</Year><Month>10</Month><Day>28</Day></DateCompleted><DateRevised><Year>2013</Year><Month>05</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>3</Issue><PubDate><Year>2013</Year><Month>May</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Incidence rates and risk factors of bipolar disorder in the general population: a population-based cohort study.</ArticleTitle><Pagination><MedlinePgn>306-13</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/bdi.12058</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To estimate the incidence rates (IRs) of bipolar I and bipolar II disorders in the general population according to sociodemographic population characteristics.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A cohort study (during the years 1996-2007) was conducted in a general practitioners research database with a longitudinal electronic record of 800000 patients throughout the Netherlands [the Integrated Primary Care Information (IPCI) database]. Cases of bipolar disorder were identified and classified by systematic review of medical records. Age- and gender-specific IRs were calculated per calendar year, degree of urbanization, and degree of deprivation.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The overall IR of bipolar disorder was 0.70/10000 person-years (PY) [95% confidence interval (CI): 0.57-0.83]; the IR of bipolar I disorder was 0.43/10000 PY (95% CI: 0.34-0.55) and the IR of bipolar II disorder was 0.19/10000 PY (95% CI: 0.13-0.27). Two peaks in the age at onset of the disorder were noticed: one in early adulthood (15-24 years; 0.68/10000 PY) and a larger peak in later life (45-54 years; 1.2/10000 PY). In bipolar II disorder, only one peak, in the 45-54 year age category (IR 0.42/10000 PY), was found. The IRs of bipolar disorder were significantly higher in deprived areas. Similar rates were found for men compared to women and in urban compared to rural areas. No association was found between the onset of first (hypo)manic episode and month or season of birth.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We found two peaks in the age at onset of bipolar disorder, one in early adulthood and one in later life, the former consisting mainly of bipolar I disorder subjects. The incidence of bipolar disorder is higher in deprived areas. The onset of bipolar disorder is not associated with gender, urbanization, or month or season of birth.</AbstractText><CopyrightInformation>Â© 2013 John Wiley and Sons A/S. Published by Blackwell Publishing Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kroon</LastName><ForeName>Jojanneke S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wohlfarth</LastName><ForeName>Tamar D</ForeName><Initials>TD</Initials></Author><Author ValidYN="Y"><LastName>Dieleman</LastName><ForeName>Jeanne</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Sutterland</LastName><ForeName>Arjen L</ForeName><Initials>AL</Initials></Author><Author ValidYN="Y"><LastName>Storosum</LastName><ForeName>Jitschak G</ForeName><Initials>JG</Initials></Author><Author ValidYN="Y"><LastName>Denys</LastName><ForeName>Damiaan</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>de Haan</LastName><ForeName>Lieuwe</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Sturkenboom</LastName><ForeName>Mirjam C J M</ForeName><Initials>MC</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>03</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018672" MajorTopicYN="N">Community Health Planning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009426" MajorTopicYN="N" Type="Geographic">Netherlands</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D036801" MajorTopicYN="N">Parturition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011610" MajorTopicYN="N">Psychosocial Deprivation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>03</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>10</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23531096</ArticleId><ArticleId IdType="doi">10.1111/bdi.12058</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">7315489</PMID><DateCompleted><Year>1982</Year><Month>02</Month><Day>22</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0001-690X</ISSN><JournalIssue CitedMedium="Print"><Volume>63</Volume><Issue>5</Issue><PubDate><Year>1981</Year><Month>May</Month></PubDate></JournalIssue><Title>Acta psychiatrica Scandinavica</Title><ISOAbbreviation>Acta Psychiatr Scand</ISOAbbreviation></Journal><ArticleTitle>Genetic independence of manic-depression and schizophrenia.</ArticleTitle><Pagination><MedlinePgn>444-52</MedlinePgn></Pagination><Abstract><AbstractText>Increasingly sophisticated twin and adoption research has demonstrated major genetic contributions to the etiology of manic-depression and schizophrenia. But studies disagree concerning whether the two are genetically related illnesses. This lack of consensus could be due to individual, regional, and temporal differences in the criteria used to diagnose the two conditions. This study is the first to employ the new DSM-III criteria. Schizophrenia was no more common in the 1,098 first-degree relatives of 100 male and 100 female manic-depressives than it is in the population at-large. This would appear to strengthen the view that manic-depression and schizophrenia are genetically unrelated diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Loranger</LastName><ForeName>A W</ForeName><Initials>AW</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Acta Psychiatr Scand</MedlineTA><NlmUniqueID>0370364</NlmUniqueID><ISSNLinking>0001-690X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000341" MajorTopicYN="N">Affective Disorders, Psychotic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1981</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1981</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1981</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">7315489</ArticleId><ArticleId IdType="doi">10.1111/j.1600-0447.1981.tb00694.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">1347479</PMID><DateCompleted><Year>1992</Year><Month>04</Month><Day>14</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0007-1250</ISSN><JournalIssue CitedMedium="Print"><Volume>160</Volume><PubDate><Year>1992</Year><Month>Jan</Month></PubDate></JournalIssue><Title>The British journal of psychiatry : the journal of mental science</Title><ISOAbbreviation>Br J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Tardive dyskinesia. Patients' lack of awareness of movement disorder.</ArticleTitle><Pagination><MedlinePgn>110-2</MedlinePgn></Pagination><Abstract><AbstractText>Of 113 patients in long-stay wards of a psychiatric hospital, 43 had TD. Twenty-six of the 39 patients who consented to take part in the study were unaware of abnormal involuntary movements. These patients scored significantly lower on a short test of cognitive function than patients who were aware of such movements. The diagnosis of schizophrenia, particularly the 'defect' state with cognitive deficit and negative symptoms, was found to be associated with lack of awareness of TD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Macpherson</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Northern General Psychiatric Unit, Northern General Hospital, Sheffield.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Collis</LastName><ForeName>R</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Psychiatry</MedlineTA><NlmUniqueID>0342367</NlmUniqueID><ISSNLinking>0007-1250</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001364" MajorTopicYN="Y">Awareness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004409" MajorTopicYN="N">Dyskinesia, Drug-Induced</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007326" MajorTopicYN="N">Institutionalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009460" MajorTopicYN="N">Neurologic Examination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="N">Schizophrenic Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012803" MajorTopicYN="Y">Sick Role</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1992</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1992</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1992</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1347479</ArticleId><ArticleId IdType="pii">S0007125000035054</ArticleId><ArticleId IdType="doi">10.1192/bjp.160.1.110</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">29216484</PMID><DateCompleted><Year>2018</Year><Month>11</Month><Day>05</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-7123</ISSN><JournalIssue CitedMedium="Internet"><Volume>260</Volume><PubDate><Year>2018</Year><Month>02</Month></PubDate></JournalIssue><Title>Psychiatry research</Title><ISOAbbreviation>Psychiatry Res</ISOAbbreviation></Journal><ArticleTitle>Beliefs about the causes of and treatments for depression and bipolar disorder among South Koreans.</ArticleTitle><Pagination><MedlinePgn>219-226</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0165-1781(17)31178-2</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.psychres.2017.11.050</ELocationID><Abstract><AbstractText>Public beliefs about psychiatric disorders are important for understanding help-seeking behaviours. We investigated factors that affect South Koreans' beliefs about the causes and treatment of depression and bipolar disorder. We recruited 654 participants aged 15-54 years using an online panel survey. Participants completed two questionnaires: 34 possible causes of and 33 possible treatments for depression and bipolar disorder. For both disorders, the questionnaires about causes revealed four factors: social-environmental, God/fate, heath/lifestyle, and biological; the questionnaires about treatments revealed five factors: self-help/stress management, physical treatment/health management, seeking mental health services, religious help, and resting. Causes of depression were more recognized as social-environmental, religious, and health/lifestyle compared to bipolar disorder. Participants expressed more beliefs in self-help/stress management, physical treatment/health management, seeking mental health services, and resting for depression, compared to bipolar disorder. Participants' beliefs about the causes of the disorders and their demographic and psychiatric characteristics were closely associated with beliefs about treatment validity. Participants' beliefs about the causes of depression and bipolar disorder significantly affected their beliefs about treatment. Therefore, strategies to improve mental health literacy should provide the aetiology of specific mental disorders. Further research using a representative community sample is needed to generalize our findings.</AbstractText><CopyrightInformation>Copyright Â© 2017 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Subin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Research Planning, Mental Health Research Institute, National Center for Mental Health, Seoul, South Korea. Electronic address: subin-21@hanmail.net.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jang</LastName><ForeName>Hyesue</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Research Planning, Mental Health Research Institute, National Center for Mental Health, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Furnham</LastName><ForeName>Adrian</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Research Department of Clinical, Educational and Health Psychology, University College London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeon</LastName><ForeName>Mina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychology and Human Development, University College London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Se Jin</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Department of Research Planning, Mental Health Research Institute, National Center for Mental Health, Seoul, South Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>11</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Psychiatry Res</MedlineTA><NlmUniqueID>7911385</NlmUniqueID><ISSNLinking>0165-1781</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000208" MajorTopicYN="Y">ethnology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000208" MajorTopicYN="Y">ethnology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000208" MajorTopicYN="Y">ethnology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007722" MajorTopicYN="N">Health Knowledge, Attitudes, Practice</DescriptorName><QualifierName UI="Q000208" MajorTopicYN="Y">ethnology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056910" MajorTopicYN="N">Republic of Korea</DescriptorName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Bipolar disorder</Keyword><Keyword MajorTopicYN="Y">Cause</Keyword><Keyword MajorTopicYN="Y">Depression</Keyword><Keyword MajorTopicYN="Y">Treatment</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>06</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>09</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>11</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>12</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>11</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>12</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29216484</ArticleId><ArticleId IdType="pii">S0165-1781(17)31178-2</ArticleId><ArticleId IdType="doi">10.1016/j.psychres.2017.11.050</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12369773</PMID><DateCompleted><Year>2003</Year><Month>02</Month><Day>25</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1018-8827</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>3</Issue><PubDate><Year>2002</Year><Month>Jun</Month></PubDate></JournalIssue><Title>European child &amp; adolescent psychiatry</Title><ISOAbbreviation>Eur Child Adolesc Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Cerebral palsy and juvenile-onset bipolar disorder. A preliminary report.</ArticleTitle><Pagination><MedlinePgn>134-7</MedlinePgn></Pagination><Abstract><AbstractText>Cerebral palsy refers to a heterogeneous group of congenital and early acquired brain disorders. Children with cerebral palsy and other brain disorders have an increased rate of psychiatric disorder. The pattern of disorder is not particularly distinctive and no specific association has been found. We report two cases of spastic diplegia of prematurity comorbid with juvenile onset bipolar disorder, which highlight some of the diagnostic difficulties in these cases. An interesting association between the periventricular leucomalacia as an aetiological factor in cerebral palsy and the white matter lesions seen on magnetic resonance imaging in cases of bipolar disorder is noted.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Craven</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Child and Adolescent Psychiatry, Brothers of Charity Southern Services, Lota, Glanmire, Cork, Republic of Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>James</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Murphy</LastName><ForeName>M</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Eur Child Adolesc Psychiatry</MedlineTA><NlmUniqueID>9212296</NlmUniqueID><ISSNLinking>1018-8827</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002547" MajorTopicYN="N">Cerebral Palsy</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007969" MajorTopicYN="N">Leukomalacia, Periventricular</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>10</Month><Day>9</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>2</Month><Day>26</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>10</Month><Day>9</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12369773</ArticleId><ArticleId IdType="doi">10.1007/s00787-002-0235-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32186664</PMID><DateCompleted><Year>2021</Year><Month>02</Month><Day>12</Day></DateCompleted><DateRevised><Year>2021</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6238</ISSN><JournalIssue CitedMedium="Internet"><Volume>77</Volume><Issue>8</Issue><PubDate><Year>2020</Year><Month>08</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA psychiatry</Title><ISOAbbreviation>JAMA Psychiatry</ISOAbbreviation></Journal><ArticleTitle>An Extended Swedish National Adoption Study of Bipolar Disorder Illness and Cross-Generational Familial Association With Schizophrenia and Major Depression.</ArticleTitle><Pagination><MedlinePgn>814-822</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamapsychiatry.2020.0223</ELocationID><Abstract><AbstractText Label="Importance">Information about how risk for bipolar disorder is transmitted across generations and how parental risk for bipolar disorder relates to their children's risk for schizophrenia and major depression is limited.</AbstractText><AbstractText Label="Objective">To evaluate the sources of parent-offspring transmission of bipolar disorder and its familial cross-generational association with schizophrenia and major depression.</AbstractText><AbstractText Label="Design, Setting, and Participants">Parents and offspring (born 1960-1990) from 4 family types were ascertained from Swedish national samples: intact (offspring, nâ=â2â¯175â¯259), not-lived-with biological father (nâ=â152â¯436), lived-with stepfather (nâ=â73 785), and adoptive (nâ=â15 624). Data analysis was conducted from October 28, 2019, to January 8, 2020.</AbstractText><AbstractText Label="Exposures">Three sources of parent-offspring resemblance: genes plus rearing, genes only, and rearing only.</AbstractText><AbstractText Label="Main Outcomes and Measures">Diagnosis of bipolar disorder, broad schizophrenia (ie, schizophrenia as a 3-level variable: unaffected, nonaffective psychosis, and schizophrenia) and major depression obtained from Swedish national registries. Parent-offspring resemblance was assessed primarily by tetrachoric correlation (ie, correlation of liability) and for key results, odds ratios (ORs) from logistic regression. Cross-generational associations of bipolar disorder with broad schizophrenia and major depression were assessed by their transmission from bipolar disorder in parents and transmission to bipolar disorder in offspring.</AbstractText><AbstractText Label="Results">The study population included 2â¯417â¯104 individuals of 4 family types (51.8% male and 48.2% female; median age, 41 [range, 25-60] years). For bipolar disorder to bipolar disorder transmission, tetrachoric correlations for 3 types of parent-offspring relationships were statistically homogeneous across family type and mothers and fathers for genes plus rearing (0.25; 95% CI, 0.24-0.26), genes only (0.22; 95% CI, 0.18-0.26), and rearing only (0.07; 95% CI, -0.01 to 0.15). Parallel ORs were 5.20 (95% CI, 4.91-5.50), 3.66 (95% CI, 2.97-4.51), and 1.63 (95% CI, 0.96-2.78). Best-estimate, cross-disorder tetrachoric correlations for 3 types of parent-offspring relationships for bipolar disorder and broad schizophrenia were 0.12 (95% CI, 0.11-0.13) for genes plus rearing, 0.12 (95% CI, 0.09-0.14) for genes only, and -0.03 (95% CI, -0.11 to 0.04) for rearing only, with parallel ORs of 1.95 (95% CI, 1.93-1.97), 2.04 (95% CI, 1.75-2.38), and 0.76 (95% CI, 0.43-1.35). For bipolar disorder and major depression, the parallel tetrachoric correlations were 0.09 (95% CI, 0.07-0.10) for genes plus rearing, 0.04 (95% CI, 0.01-0.07) for genes only, and 0.05 (95% CI, 0.01-0.08) for rearing only; parallel ORs were 1.53 (95% CI, 1.50-1.57), 1.23 (95% CI, 1.13-1.34), and 1.25 (95% CI, 1.09-1.42). Heritability for bipolar disorder was estimated at 0.44 (95% CI, 0.36-0.48). Genetic correlations were estimated at 0.572 (95% CI, 0.560-0.589) between bipolar disorder and broad schizophrenia and 0.302 (95% CI, 0.001-0.523) between bipolar disorder and major depression.</AbstractText><AbstractText Label="Conclusions and Relevance">The findings of this study suggest that genes are largely responsible for bipolar disorder transmission across generations, although modest rearing effects are also likely present. Cross-generational transmission between bipolar disorder and broad schizophrenia appears to be entirely genetic with a moderate genetic correlation; for bipolar disorder and major depression, transmission appears to result equally from genes and rearing with a modest genetic correlation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kendler</LastName><ForeName>Kenneth S</ForeName><Initials>KS</Initials><AffiliationInfo><Affiliation>Virginia Institute for Psychiatric and Behavioral Genetics, Virginia Commonwealth University, Richmond.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Virginia Commonwealth University, Richmond.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ohlsson</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Center for Primary Health Care Research, Lund University, MalmÃ¶, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sundquist</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Center for Primary Health Care Research, Lund University, MalmÃ¶, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Family Medicine and Community Health, Icahn School of Medicine at Mount Sinai, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sundquist</LastName><ForeName>Kristina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Center for Primary Health Care Research, Lund University, MalmÃ¶, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Family Medicine and Community Health, Icahn School of Medicine at Mount Sinai, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Community-Based Healthcare Research and Education, Department of Functional Pathology, School of Medicine, Shimane University, Matsue, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Psychiatry</MedlineTA><NlmUniqueID>101589550</NlmUniqueID><ISSNLinking>2168-622X</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000300" MajorTopicYN="N">Adoption</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002668" MajorTopicYN="Y">Child Rearing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059647" MajorTopicYN="Y">Gene-Environment Interaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="Y">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010290" MajorTopicYN="Y">Parents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013548" MajorTopicYN="N" Type="Geographic">Sweden</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>2</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32186664</ArticleId><ArticleId IdType="pii">2762983</ArticleId><ArticleId IdType="doi">10.1001/jamapsychiatry.2020.0223</ArticleId><ArticleId IdType="pmc">PMC7081154</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Psychol Bull. 2015 Jul;141(4):769-85</Citation><ArticleIdList><ArticleId IdType="pubmed">25961374</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Psychiatry. 2015 Mar;72(3):211-8</Citation><ArticleIdList><ArticleId IdType="pubmed">25565339</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 2013 Sep;45(9):984-94</Citation><ArticleIdList><ArticleId IdType="pubmed">23933821</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2011 Nov;168(11):1186-94</Citation><ArticleIdList><ArticleId IdType="pubmed">21676994</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Psychiatry. 2013 Jan;70(1):22-30</Citation><ArticleIdList><ArticleId IdType="pubmed">23147713</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1985 Aug;42(8):770-9</Citation><ArticleIdList><ArticleId IdType="pubmed">4015321</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Psychiatry Rep. 2002 Apr;4(2):130-3</Citation><ArticleIdList><ArticleId IdType="pubmed">11914174</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet C Semin Med Genet. 2003 Nov 15;123C(1):48-58</Citation><ArticleIdList><ArticleId IdType="pubmed">14601036</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2006 Oct;36(10):1417-25</Citation><ArticleIdList><ArticleId IdType="pubmed">16863597</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1982 Oct;39(10):1157-67</Citation><ArticleIdList><ArticleId IdType="pubmed">7125846</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2018 Nov 1;175(11):1137-1144</Citation><ArticleIdList><ArticleId IdType="pubmed">30021458</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Bull. 2002 May;128(3):490-529</Citation><ArticleIdList><ArticleId IdType="pubmed">12002699</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2011 Dec;124(6):447-53</Citation><ArticleIdList><ArticleId IdType="pubmed">21838734</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2020 Apr;25(4):914</Citation><ArticleIdList><ArticleId IdType="pubmed">31308466</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1981 May;38(5):535-9</Citation><ArticleIdList><ArticleId IdType="pubmed">7235854</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Hum Genet. 2012 Jun;20(6):668-74</Citation><ArticleIdList><ArticleId IdType="pubmed">22258521</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2003 May;60(5):497-502</Citation><ArticleIdList><ArticleId IdType="pubmed">12742871</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Psychiatry. 2017 Jun 30;17(1):235</Citation><ArticleIdList><ArticleId IdType="pubmed">28666429</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1977 Jul 28;268(5618):327-9</Citation><ArticleIdList><ArticleId IdType="pubmed">887159</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2000 Oct;157(10):1552-62</Citation><ArticleIdList><ArticleId IdType="pubmed">11007705</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Genet. 1995 May;25(3):217-32</Citation><ArticleIdList><ArticleId IdType="pubmed">7598665</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Psychiatry. 2018 Feb 1;75(2):194-200</Citation><ArticleIdList><ArticleId IdType="pubmed">29238796</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1993 Dec;50(12):952-60</Citation><ArticleIdList><ArticleId IdType="pubmed">8250681</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2015 Jun;172(6):553-60</Citation><ArticleIdList><ArticleId IdType="pubmed">25698436</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2009 Jan 17;373(9659):234-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19150704</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">14607396</PMID><DateCompleted><Year>2004</Year><Month>03</Month><Day>09</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-0327</ISSN><JournalIssue CitedMedium="Print"><Volume>77</Volume><Issue>2</Issue><PubDate><Year>2003</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Toward an integration of parent and clinician report on the Young Mania Rating Scale.</ArticleTitle><Pagination><MedlinePgn>179-90</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The Young Mania Rating Scale (YMRS) has validity in the assessment of mania in adults. The purpose of this study was to examine how the YMRS might optimally be used in the assessment of youths.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Children and adolescents between the ages of 5 and 17 years of age participated in this study. All youths were evaluated with the Schedule for Affective Disorders and Schizophrenia for School-Age Children (K-SADS). Based on the K-SADS results, subjects were then assigned to one of five groups: a bipolar I group, another bipolar spectrum group, a depressive disorders group, a disruptive behaviors disorders group, and a no diagnosis group. Guardians completed a version of the YMRS modified for parent reporting. Clinicians completed the YMRS on all participating youths.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Both parent and clinician ratings on the YMRS assigned patients (n=117) to the appropriate diagnostic group with 71-98% accuracy. Combining information from multiple informants did not significantly improve diagnostic group assignment.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">The same raters completed the clinician YMRS and the K-SADS interview involving the parent. Findings need replication in an independent sample with lower base rates of bipolar disorder, less rigorously trained and supervised raters, and using a prospective design to provide maximum generalizability of results. Current results should be interpreted as a 'best case' scenario.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These data suggest that the YMRS may be a useful adjunct in assessing the severity of mania in youths. Tentative cutting scores are proposed to maximize efficiency, sensitivity, and specificity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Youngstrom</LastName><ForeName>Eric A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry at Case Western Reserve University &amp; University Hospitals of Cleveland, Cleveland, OH, USA. eay@po.cwru.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gracious</LastName><ForeName>Barbara L</ForeName><Initials>BL</Initials></Author><Author ValidYN="Y"><LastName>Danielson</LastName><ForeName>Carla K</ForeName><Initials>CK</Initials></Author><Author ValidYN="Y"><LastName>Findling</LastName><ForeName>Robert L</ForeName><Initials>RL</Initials></Author><Author ValidYN="Y"><LastName>Calabrese</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000296" MajorTopicYN="Y">Adolescent Psychiatry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002665" MajorTopicYN="Y">Child Psychiatry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008609" MajorTopicYN="Y">Mental Status Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>11</Month><Day>11</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>3</Month><Day>10</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>11</Month><Day>11</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">14607396</ArticleId><ArticleId IdType="pii">S0165032702001088</ArticleId><ArticleId IdType="doi">10.1016/s0165-0327(02)00108-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24497226</PMID><DateCompleted><Year>2015</Year><Month>04</Month><Day>09</Day></DateCompleted><DateRevised><Year>2017</Year><Month>11</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1437-4331</ISSN><JournalIssue CitedMedium="Internet"><Volume>52</Volume><Issue>7</Issue><PubDate><Year>2014</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Clinical chemistry and laboratory medicine</Title><ISOAbbreviation>Clin Chem Lab Med</ISOAbbreviation></Journal><ArticleTitle>Peripheral blood lymphocytes from patients with bipolar disorder demonstrate apoptosis and differential regulation of advanced glycation end products and S100B.</ArticleTitle><Pagination><MedlinePgn>999-1007</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1515/cclm-2013-0978</ELocationID><ELocationID EIdType="pii" ValidYN="Y">/j/cclm.2014.52.issue-7/cclm-2013-0978/cclm-2013-0978.xml</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">This study addresses the expression of the glycosylated proteins known as advanced glycation end products (AGEs), the calcium binding protein S100B and the apoptotic parameters cytochome c and caspase-3 activity in peripheral lymphocyte cytosolic extracts from a sample of bipolar disorder (BD) patients and healthy (control) subjects.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Cross-sectional study of 35 patients with a clinical diagnosis of bipolar disease (10 euthymic, 12 depressed, 13 manic) and 10 healthy control subjects. Lymphocytes were used as a surrogate model in BD diagnosis and treatment. AGEs and S100B in lymphocyte cell extracts were measured by commercially available enzyme-linked immunosorbent assay.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">AGEs were lower in all BD patients compared to healthy subjects. Depressed patients had approximately two-fold higher S100B levels compared to healthy subjects. Manic and depressed BD patients had increased superoxide dismutase mRNA levels. Apoptosis as measured by BAX/Bcl2 ratio, cytochrome c release, caspase-3 activity was increased in manic and depressed patients compared to healthy subjects. In the depressed patients, S100B levels correlated with cytochrome c release.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In conclusion, our study shows decreased AGEs and increased S100B levels and caspase down-stream apoptosis in peripheral lymphocytes of BD patients that may underlie disease etiopathogenesis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Moutsatsou</LastName><ForeName>Paraskevi</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Tsoporis</LastName><ForeName>James N</ForeName><Initials>JN</Initials></Author><Author ValidYN="Y"><LastName>Salpeas</LastName><ForeName>Vasileios</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Bei</LastName><ForeName>Ekaterini</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Alevizos</LastName><ForeName>Basel</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Anagnostara</LastName><ForeName>Chrysoula</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Izhar</LastName><ForeName>Shehla</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Proteau</LastName><ForeName>Gerald</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Rizos</LastName><ForeName>Emmanouil</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Hatziagelaki</LastName><ForeName>Erifili</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Toumpoulis</LastName><ForeName>Ioannis K</ForeName><Initials>IK</Initials></Author><Author ValidYN="Y"><LastName>Rizos</LastName><ForeName>Ioannis K</ForeName><Initials>IK</Initials></Author><Author ValidYN="Y"><LastName>Parker</LastName><ForeName>Thomas G</ForeName><Initials>TG</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Clin Chem Lab Med</MedlineTA><NlmUniqueID>9806306</NlmUniqueID><ISSNLinking>1434-6621</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017127">Glycation End Products, Advanced</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064568">S100 Calcium Binding Protein beta Subunit</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C579160">S100B protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="Y">Apoptosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017127" MajorTopicYN="N">Glycation End Products, Advanced</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008214" MajorTopicYN="N">Lymphocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064568" MajorTopicYN="N">S100 Calcium Binding Protein beta Subunit</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>11</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>01</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>2</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>2</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>4</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24497226</ArticleId><ArticleId IdType="doi">10.1515/cclm-2013-0978</ArticleId><ArticleId IdType="pii">/j/cclm-ahead-of-print/cclm-2013-0978/cclm-2013-0978.xml</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">3871311</PMID><DateCompleted><Year>1985</Year><Month>01</Month><Day>29</Day></DateCompleted><DateRevised><Year>2007</Year><Month>11</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>142</Volume><Issue>1</Issue><PubDate><Year>1985</Year><Month>Jan</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Depression in borderline personality disorder: lifetime prevalence at interview and longitudinal course of symptoms.</ArticleTitle><Pagination><MedlinePgn>15-21</MedlinePgn></Pagination><Abstract><AbstractText>The author compared a group of patients with borderline personality disorder with groups of subjects with antisocial personality and bipolar II illness. The lifetime prevalence at interview of DSM-III major depression was high in all groups. Chronic depression demonstrated a specific relationship to borderline psychopathology. Prospectively, borderline psychopathology predicted high levels of depressive and anxiety symptoms. This relationship was reversed for depressive symptoms in patients with antisocial personality disorder, suggesting that when borderline and antisocial personality disorders occur together, some features may arise that differentiate patients with both disorders from those with either disorder alone.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Perry</LastName><ForeName>J C</ForeName><Initials>JC</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH-34123</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000987" MajorTopicYN="N">Antisocial Personality Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001008" MajorTopicYN="N">Anxiety Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001883" MajorTopicYN="N">Borderline Personality Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010554" MajorTopicYN="N">Personality Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1985</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1985</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1985</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">3871311</ArticleId><ArticleId IdType="doi">10.1176/ajp.142.1.15</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19345708</PMID><DateCompleted><Year>2010</Year><Month>03</Month><Day>12</Day></DateCompleted><DateRevised><Year>2009</Year><Month>07</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-4216</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>5</Issue><PubDate><Year>2009</Year><Month>Aug</Month><Day>01</Day></PubDate></JournalIssue><Title>Progress in neuro-psychopharmacology &amp; biological psychiatry</Title><ISOAbbreviation>Prog Neuropsychopharmacol Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Gustatory and olfactory function in patients with unipolar and bipolar depression.</ArticleTitle><Pagination><MedlinePgn>827-34</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.pnpbp.2009.03.030</ELocationID><Abstract><AbstractText>Although the crucial distinction between unipolar depressive disorder and bipolar disorder is the presence of mania (or hypomania) in the course of the latter, significant differences between unipolar and bipolar depression have also been found in clinical studies. The primary aim of the present investigation was to assess pleasantness/unpleasantness ratings of chemosensory stimuli in depressed patients, including subjects with unipolar and bipolar depression. Sensory aspects (thresholds and identification abilities) of gustatory and olfactory function were also assessed. There were no major differences between a depression group, as a whole, and healthy controls in terms of gustatory and olfactory thresholds and identification abilities. Similarly, pleasantness ratings of various gustatory and olfactory stimuli did not differ between the control and depression group. Gustatory and olfactory thresholds and identification abilities did not differ between individuals with unipolar and bipolar depression. Bipolar patients tended to rate less gustatory stimuli as unpleasant and more olfactory stimuli as pleasant compared to unipolar patients. The present results suggest that: i) depression is not associated with any major deficit in sensory aspects of gustatory and olfactory function or altered hedonic ratings of chemosensory stimuli; ii) hedonic responses to chemosensory stimuli tend to be increased in bipolar as compared to unipolar depressed patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Swiecicki</LastName><ForeName>Lukasz</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Psychiatry II, Institute of Psychiatry and Neurology, Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zatorski</LastName><ForeName>Pawel</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Bzinkowska</LastName><ForeName>Dorota</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Sienkiewicz-Jarosz</LastName><ForeName>Halina</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Szyndler</LastName><ForeName>Janusz</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Scinska</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>04</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Prog Neuropsychopharmacol Biol Psychiatry</MedlineTA><NlmUniqueID>8211617</NlmUniqueID><ISSNLinking>0278-5846</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012903" MajorTopicYN="N">Smell</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013649" MajorTopicYN="N">Taste</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013652" MajorTopicYN="N">Taste Threshold</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>02</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2009</Year><Month>03</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>03</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>4</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>4</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>3</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19345708</ArticleId><ArticleId IdType="pii">S0278-5846(09)00100-6</ArticleId><ArticleId IdType="doi">10.1016/j.pnpbp.2009.03.030</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22143953</PMID><DateCompleted><Year>2015</Year><Month>05</Month><Day>11</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1300-2163</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>4</Issue><PubDate><Year>2011</Year><Season>Winter</Season></PubDate></JournalIssue><Title>Turk psikiyatri dergisi = Turkish journal of psychiatry</Title><ISOAbbreviation>Turk Psikiyatri Derg</ISOAbbreviation></Journal><ArticleTitle>Aripiprazole augmentation treatment in treatment resistant bipolar depression: two patient reports.</ArticleTitle><Pagination><MedlinePgn>269-72</MedlinePgn></Pagination><Abstract><AbstractText>It is known that in patients with bipolar disorder, depressive episodes last longer than mixed or manic/hypomanic episodes and there are reports detailing the difficulties confronted in its treatment. The concept of treatment resistant depression in bipolar disorder has not been as well described as that in treatment resistant unipolar depression. Here we present two patients with treatment resistant bipolar depression. The first patient in our study is a 51 year old woman whose diagnoses were bipolar disorder, depressive episode and multiple sclerosis (in remission with interferon treatment) at the time of augmentation with aripiprazole. The second patient is a 43 year old woman with bipolar disorder, depressive disorder without any comorbid illness at the time of augmentation with aripiprazole. Aripiprazole was administered variably between 20-30mg/daily based on tolerability and efficacy. In both cases, depression was assessed using the Hamilton Depression Rating scale (HDRS). Both patients responded to aripiprazole augmentation treatment. The effect of aripiprazole on bipolar depression needs to be further evaluated in double blind controlled studies. However, augmentation with aripiprazole in bipolar patients may be a future routine treatment for treatment resistant bipolar depression.    In this report, treatment of refractory bipolar depression and the efficacy of aripiprazole augmentation treatment in bipolar depression are discussed through two patients in depressive episode who remitted with aripiprazole augmentation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>KaradaÄ</LastName><ForeName>Figen</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Maltepe University Medical Faculty, Psychiatry Department, Ä°stanbul. fkaradag@tnn.net</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Devran</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Unal</LastName><ForeName>Feyza</ForeName><Initials>F</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Turkey</Country><MedlineTA>Turk Psikiyatri Derg</MedlineTA><NlmUniqueID>9425936</NlmUniqueID><ISSNLinking>1300-2163</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015363">Quinolones</NameOfSubstance></Chemical><Chemical><RegistryNumber>82VFR53I78</RegistryNumber><NameOfSubstance UI="D000068180">Aripiprazole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068180" MajorTopicYN="N">Aripiprazole</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061218" MajorTopicYN="N">Depressive Disorder, Treatment-Resistant</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015363" MajorTopicYN="N">Quinolones</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>12</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>12</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>5</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22143953</ArticleId><ArticleId IdType="pii">825</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">6798028</PMID><DateCompleted><Year>1982</Year><Month>03</Month><Day>26</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>43</Volume><Issue>1</Issue><PubDate><Year>1982</Year><Month>Jan</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>The thyrotropin releasing hormone stimulation test: a review.</ArticleTitle><Pagination><MedlinePgn>4-6</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sternbach</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Gerner</LastName><ForeName>R H</ForeName><Initials>RH</Initials></Author><Author ValidYN="Y"><LastName>Gwirtsman</LastName><ForeName>H E</ForeName><Initials>HE</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>5Y5F15120W</RegistryNumber><NameOfSubstance UI="D013973">Thyrotropin-Releasing Hormone</NameOfSubstance></Chemical><Chemical><RegistryNumber>9002-71-5</RegistryNumber><NameOfSubstance UI="D013972">Thyrotropin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013972" MajorTopicYN="N">Thyrotropin</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013973" MajorTopicYN="Y">Thyrotropin-Releasing Hormone</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1982</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1982</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1982</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">6798028</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22041535</PMID><DateCompleted><Year>2012</Year><Month>01</Month><Day>26</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0165-1781</ISSN><JournalIssue CitedMedium="Print"><Volume>194</Volume><Issue>3</Issue><PubDate><Year>2011</Year><Month>Dec</Month><Day>30</Day></PubDate></JournalIssue><Title>Psychiatry research</Title><ISOAbbreviation>Psychiatry Res</ISOAbbreviation></Journal><ArticleTitle>Lateral ventricle volume and psychotic features in adolescents and adults with bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>400-402</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0925-4927(11)00245-9</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.pscychresns.2011.07.005</ELocationID><Abstract><AbstractText>This magnetic resonance imaging study demonstrates increased lateral ventricle volume (LVV) in adolescents and adults with bipolar disorder (BD) with psychotic symptoms, but not without psychosis, compared to healthy adolescents and adults. This suggests LVV is a morphologic feature associated with psychosis in BD, present by adolescence.</AbstractText><CopyrightInformation>Published by Elsevier Ireland Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Edmiston</LastName><ForeName>Erin E</ForeName><Initials>EE</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Fei</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA; Department of Psychiatry, Veterans Affairs, West Haven, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalmar</LastName><ForeName>Jessica H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Womer</LastName><ForeName>Fay Y</ForeName><Initials>FY</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chepenik</LastName><ForeName>Lara G</ForeName><Initials>LG</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA; Department of Psychiatry, Veterans Affairs, West Haven, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pittman</LastName><ForeName>Brian</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gueorguieva</LastName><ForeName>Ralitza</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA; Department of Epidemiology and Public Health, Yale School of Medicine, New Haven, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hur</LastName><ForeName>Esther</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spencer</LastName><ForeName>Linda</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Staib</LastName><ForeName>Lawrence H</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>Department of Diagnostic Radiology, Yale School of Medicine, New Haven, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Constable</LastName><ForeName>R Todd</ForeName><Initials>RT</Initials><AffiliationInfo><Affiliation>Department of Diagnostic Radiology, Yale School of Medicine, New Haven, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fulbright</LastName><ForeName>Robert K</ForeName><Initials>RK</Initials><AffiliationInfo><Affiliation>Department of Diagnostic Radiology, Yale School of Medicine, New Haven, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Papademetris</LastName><ForeName>Xenophon</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Diagnostic Radiology, Yale School of Medicine, New Haven, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blumberg</LastName><ForeName>Hilary P</ForeName><Initials>HP</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA; Department of Diagnostic Radiology, Yale School of Medicine, New Haven, CT, USA; Department of Child Study Center, Yale School of Medicine, New Haven, CT, USA; Department of Psychiatry, Veterans Affairs, West Haven, CT, USA. Electronic address: hilary.blumberg@yale.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K01 MH086621</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 EB006494</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH069747-01A1</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH070902-01A1</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R25 MH071240</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 MH014276</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH069747</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH070902</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>10</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Psychiatry Res</MedlineTA><NlmUniqueID>7911385</NlmUniqueID><ISSNLinking>0165-1781</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020547" MajorTopicYN="N">Lateral Ventricles</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>10</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>06</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>07</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>1</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22041535</ArticleId><ArticleId IdType="pii">S0925-4927(11)00245-9</ArticleId><ArticleId IdType="doi">10.1016/j.pscychresns.2011.07.005</ArticleId><ArticleId IdType="pmc">PMC3225709</ArticleId><ArticleId IdType="mid">NIHMS314620</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1997 Jul;36(7):980-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9204677</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1976 Oct 30;2(7992):924-6</Citation><ArticleIdList><ArticleId IdType="pubmed">62160</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2006 Mar;163(3):478-87</Citation><ArticleIdList><ArticleId IdType="pubmed">16513870</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1990 Jul;147(7):893-900</Citation><ArticleIdList><ArticleId IdType="pubmed">2356874</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2002 Nov;159(11):1841-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12411217</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2009 Nov;11(7):753-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19839998</ArticleId></ArticleIdList></Reference><Reference><Citation>World J Biol Psychiatry. 2010 Oct;11(7):873-87</Citation><ArticleIdList><ArticleId IdType="pubmed">20545464</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2009 Mar 15;65(6):535-40</Citation><ArticleIdList><ArticleId IdType="pubmed">19058791</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2009 Jun;48(6):636-642</Citation><ArticleIdList><ArticleId IdType="pubmed">19454919</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2001 Nov-Dec;35(6):313-22</Citation><ArticleIdList><ArticleId IdType="pubmed">11684138</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2008 Sep;65(9):1017-32</Citation><ArticleIdList><ArticleId IdType="pubmed">18762588</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychiatry Neuropsychol Behav Neurol. 2001 Oct-Dec;14(4):227-32</Citation><ArticleIdList><ArticleId IdType="pubmed">11725216</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2007 Oct 1;31(7):1514-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17706335</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2005 Mar 15;57(6):633-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15780850</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2000 Jan;157(1):16-25</Citation><ArticleIdList><ArticleId IdType="pubmed">10618008</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">29931798</PMID><DateCompleted><Year>2019</Year><Month>07</Month><Day>25</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>1</Issue><PubDate><Year>2019</Year><Month>02</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>A randomized controlled trial of MoodSwings 2.0: An internet-based self-management program for bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>28-39</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/bdi.12669</ELocationID><Abstract><AbstractText Label="OBJECTIVES">MoodSwings 2.0 is an online self-guided intervention for bipolar disorder that includes educational modules, interactive tools, and discussion forums. The primary aim of the study was to determine if participation in MoodSwings 2.0 would result in decreased symptoms of depression and mania compared to the control condition. Secondary aims were to identify improvements in core depression symptoms, quality of life, medication adherence, functioning, and time to relapse.</AbstractText><AbstractText Label="METHODS">This was a three-arm randomized controlled trial that compared two intervention arms against a peer support control group (forum). A total of 304 adults aged 21 to 65 years with a diagnosis of bipolar disorder were assigned to a forum-only control group (Group 1; nÂ =Â 102), a forum plus modules treatment group (Group 2; nÂ =Â 102), or a forum, modules, and tools treatment group (Group 3; nÂ =Â 100), in addition to usual care.</AbstractText><AbstractText Label="RESULTS">There was a significant intervention impact showing improvement on the primary outcome of depression for Group 2 compared to Group 1 (PÂ =Â .05) with effect sizes (Cohen's d) ranging from 0.17 to 0.43. There was also a significant intervention impact showing improvement on the secondary outcome of core depression for Group 2 (PÂ =Â .02) and Group 3 (PÂ =Â .05), but worse physical functioning for Group 3 (PÂ =Â .01), compared to Group 1.</AbstractText><AbstractText Label="CONCLUSIONS">This study provides evidence of the efficacy of internet-based psychoeducation interventions for bipolar disorder in reducing depressive symptoms. Further investigation is needed to assess effectiveness in a public program.</AbstractText><CopyrightInformation>Â© 2018 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gliddon</LastName><ForeName>Emma</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-5897-820X</Identifier><AffiliationInfo><Affiliation>IMPACT Strategic Research Centre, Barwon Health, Deakin University, Geelong, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University of Melbourne, Parkville, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cosgrove</LastName><ForeName>Victoria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Bipolar and Depression Research Program, VA Palo Alto Health Care System, Palo Alto, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berk</LastName><ForeName>Lesley</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-3677-7503</Identifier><AffiliationInfo><Affiliation>IMPACT Strategic Research Centre, Barwon Health, Deakin University, Geelong, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University of Melbourne, Parkville, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Population Health, University of Melbourne, Parkville, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lauder</LastName><ForeName>Sue</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-3461-1312</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, University of Melbourne, Parkville, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Health, School of Health Sciences and Psychology, Federation University Australia, Ballarat, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohebbi</LastName><ForeName>Mohammadreza</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>IMPACT Strategic Research Centre, Barwon Health, Deakin University, Geelong, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Deakin Biostatistics Unit, Deakin University, Geelong, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grimm</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Bipolar and Depression Research Program, VA Palo Alto Health Care System, Palo Alto, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Systems Psychology Lab, Georgia Institute of Technology, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dodd</LastName><ForeName>Seetal</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-7918-4636</Identifier><AffiliationInfo><Affiliation>IMPACT Strategic Research Centre, Barwon Health, Deakin University, Geelong, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University of Melbourne, Parkville, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Orygen, the National Centre of Excellence in Youth Mental Health, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coulson</LastName><ForeName>Carolyn</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>IMPACT Strategic Research Centre, Barwon Health, Deakin University, Geelong, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University of Melbourne, Parkville, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raju</LastName><ForeName>Karishma</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Bipolar and Depression Research Program, VA Palo Alto Health Care System, Palo Alto, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suppes</LastName><ForeName>Trisha</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Bipolar and Depression Research Program, VA Palo Alto Health Care System, Palo Alto, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berk</LastName><ForeName>Michael</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-5554-6946</Identifier><AffiliationInfo><Affiliation>IMPACT Strategic Research Centre, Barwon Health, Deakin University, Geelong, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University of Melbourne, Parkville, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Orygen, the National Centre of Excellence in Youth Mental Health, Melbourne, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Florey Institute for Neuroscience and Mental Health, Parkville, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT02106078</AccessionNumber><AccessionNumber>NCT02118623</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>1R34MH091284</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1R34MH091384</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>06</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="AssociatedDataset"><RefSource>Bipolar Disord. 2019 Feb;21(1):86-87</RefSource><PMID Version="1">30387928</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020407" MajorTopicYN="Y">Internet</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055118" MajorTopicYN="N">Medication Adherence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073278" MajorTopicYN="N">Self-Management</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016037" MajorTopicYN="N">Single-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017216" MajorTopicYN="N">Telemedicine</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">bipolar disorder</Keyword><Keyword MajorTopicYN="Y">clinical trial</Keyword><Keyword MajorTopicYN="Y">internet</Keyword><Keyword MajorTopicYN="Y">psychotherapy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>6</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>7</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>6</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29931798</ArticleId><ArticleId IdType="doi">10.1111/bdi.12669</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30905170</PMID><DateCompleted><Year>2020</Year><Month>01</Month><Day>02</Day></DateCompleted><DateRevised><Year>2020</Year><Month>01</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1461-7021</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>3</Issue><PubDate><Year>2019</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Clinical child psychology and psychiatry</Title><ISOAbbreviation>Clin Child Psychol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>The geography of a controversial diagnosis: A bibliographic analysis of published academic perspectives on 'paediatric bipolar disorder'.</ArticleTitle><Pagination><MedlinePgn>529-545</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/1359104519836700</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">The hypothesis that bipolar disorder presents before puberty with atypical mania has proved to be controversial. Published academic perspectives on the validity of Paediatric Bipolar Disorder (PBD) appear to vary between the United States and the rest of the world.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We examined the perspectives of articles citing four seminal articles. The citing articles were grouped as either supportive or non-supportive of the PBD hypothesis, and the perspectives of the articles by US authors were compared with those by non-US authors.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">There were 787 citing articles commenting on PBD, mostly published in US-based journals. Most authors were affiliated with several US institutions. Among the 624 articles with US authorship, the majority (83%) supported PBD. Of the 163 articles by non-US authors, most (60%) supported the traditional view that bipolar disorders are rare before mid-adolescence. Published academic perspectives in favour of the PBD hypothesis are mostly concentrated in several US institutions.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">There is majority support for PBD among citing articles from the United States, whereas the traditional perspective predominates in articles from most other countries.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Parry</LastName><ForeName>Peter</ForeName><Initials>P</Initials><Identifier Source="ORCID">https://orcid.org/0000-0003-1086-0138</Identifier><AffiliationInfo><Affiliation>1 School of Clinical Medicine - Children's Health Queensland Clinical Unit, University of Queensland, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>2 College of Medicine and Public Health, Flinders University, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Allison</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>2 College of Medicine and Public Health, Flinders University, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bastiampillai</LastName><ForeName>Tarun</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>2 College of Medicine and Public Health, Flinders University, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>3 Mind and Brain Theme, South Australian Health and Medical Research Institute, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>03</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Clin Child Psychol Psychiatry</MedlineTA><NlmUniqueID>9604507</NlmUniqueID><ISSNLinking>1359-1045</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015706" MajorTopicYN="N">Bibliometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bipolar disorder</Keyword><Keyword MajorTopicYN="N">bibliometric analysis</Keyword><Keyword MajorTopicYN="N">child psychiatry</Keyword><Keyword MajorTopicYN="N">early medical intervention</Keyword><Keyword MajorTopicYN="N">irritable mood</Keyword><Keyword MajorTopicYN="N">nosology</Keyword><Keyword MajorTopicYN="N">paediatrics</Keyword><Keyword MajorTopicYN="N">psychiatric diagnosis</Keyword><Keyword MajorTopicYN="N">transcultural psychiatry</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>3</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>1</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>3</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30905170</ArticleId><ArticleId IdType="doi">10.1177/1359104519836700</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19754460</PMID><DateCompleted><Year>2009</Year><Month>12</Month><Day>01</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1470-8752</ISSN><JournalIssue CitedMedium="Internet"><Volume>37</Volume><Issue>Pt 5</Issue><PubDate><Year>2009</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Biochemical Society transactions</Title><ISOAbbreviation>Biochem Soc Trans</ISOAbbreviation></Journal><ArticleTitle>Cellular consequences of inositol depletion.</ArticleTitle><Pagination><MedlinePgn>1099-103</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1042/BST0371099</ELocationID><Abstract><AbstractText>The inositol-depletion hypothesis was suggested to explain the therapeutic mechanism of mood-stabilizing drugs. Focus was previously on the phosphatidylinositol signalling pathway and on the regulatory roles of Ins(3,4,5)P(3) and DAG (diacylglycerol). Recent findings indicate that inositol and inositol-containing molecules, including phosphoinositides and inositol phosphates, have signalling and regulatory roles in many cellular processes. This suggests that depleting inositol may lead to perturbation of a wide range of cellular functions, at least some of which may be associated with bipolar disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Deranieh</LastName><ForeName>Rania M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Department of Biological Sciences, Wayne State University, Detroit, MI 48202, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greenberg</LastName><ForeName>Miriam L</ForeName><Initials>ML</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 DK081367</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DK081367</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Biochem Soc Trans</MedlineTA><NlmUniqueID>7506897</NlmUniqueID><ISSNLinking>0300-5127</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004075">Diglycerides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007295">Inositol Phosphates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018020">Lithium Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010716">Phosphatidylinositols</NameOfSubstance></Chemical><Chemical><RegistryNumber>4L6452S749</RegistryNumber><NameOfSubstance UI="D007294">Inositol</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.26</RegistryNumber><NameOfSubstance UI="D038362">Glycogen Synthase Kinase 3</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004075" MajorTopicYN="N">Diglycerides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D038362" MajorTopicYN="N">Glycogen Synthase Kinase 3</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007294" MajorTopicYN="N">Inositol</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007295" MajorTopicYN="N">Inositol Phosphates</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018020" MajorTopicYN="N">Lithium Compounds</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010716" MajorTopicYN="N">Phosphatidylinositols</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>58</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>9</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>9</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19754460</ArticleId><ArticleId IdType="pii">BST0371099</ArticleId><ArticleId IdType="doi">10.1042/BST0371099</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33765445</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>11</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>109</Volume><Issue>9</Issue><PubDate><Year>2021</Year><Month>05</Month><Day>05</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Akt-mTOR hypoactivity in bipolar disorder gives rise to cognitive impairments associated with altered neuronal structure and function.</ArticleTitle><Pagination><MedlinePgn>1479-1496.e6</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(21)00156-2</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2021.03.008</ELocationID><Abstract><AbstractText>The Akt family of kinases exerts many of its cellular effects via the activation of the mammalian target of rapamycin (mTOR) kinase through a series of intermediary proteins. Multiple lines of evidence have identified Akt-family kinases as candidate schizophrenia and bipolar disorder genes. Although dysfunction of the prefrontal cortex (PFC) is a key feature of both schizophrenia and bipolar disorder, no studies have comprehensively assessed potential alterations in Akt-mTOR pathway activity in the PFC of either disorder. Here, we examined the activity and expression profile of key proteins in the Akt-mTOR pathway in bipolar disorder and schizophrenia homogenates from two different PFC subregions. Our findings identify reduced Akt-mTOR PFC signaling in a subset of bipolar disorder subjects. Using a reverse-translational approach, we demonstrated that Akt hypofunction in the PFC is sufficient to give rise to key cognitive phenotypes that are paralleled by alterations in synaptic connectivity and function.</AbstractText><CopyrightInformation>Copyright Â© 2021 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vanderplow</LastName><ForeName>Amanda M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Comparative Biosciences, University of Wisconsin-Madison, Madison, WI 53706, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eagle</LastName><ForeName>Andrew L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Department of Physiology, Michigan State University, East Lansing, MI 48824, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kermath</LastName><ForeName>Bailey A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Department of Comparative Biosciences, University of Wisconsin-Madison, Madison, WI 53706, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bjornson</LastName><ForeName>Kathryn J</ForeName><Initials>KJ</Initials><AffiliationInfo><Affiliation>Department of Comparative Biosciences, University of Wisconsin-Madison, Madison, WI 53706, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robison</LastName><ForeName>Alfred J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Physiology, Michigan State University, East Lansing, MI 48824, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cahill</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Department of Comparative Biosciences, University of Wisconsin-Madison, Madison, WI 53706, USA. Electronic address: michael.cahill@wisc.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH111604</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 MH125227</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>03</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 2.7.1.1</RegistryNumber><NameOfSubstance UI="C546842">MTOR protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.1.1</RegistryNumber><NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017397" MajorTopicYN="N">Prefrontal Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">akt</Keyword><Keyword MajorTopicYN="Y">autophagy</Keyword><Keyword MajorTopicYN="Y">bipolar disorder</Keyword><Keyword MajorTopicYN="Y">cognition</Keyword><Keyword MajorTopicYN="Y">dendritic spine</Keyword><Keyword MajorTopicYN="Y">mTOR</Keyword><Keyword MajorTopicYN="Y">memory</Keyword><Keyword MajorTopicYN="Y">prefrontal cortex</Keyword><Keyword MajorTopicYN="Y">synapse</Keyword><Keyword MajorTopicYN="Y">ulk1</Keyword></KeywordList><CoiStatement>Declaration of interests The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>09</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>01</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>03</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>05</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>3</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>25</Day><Hour>20</Hour><Minute>9</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33765445</ArticleId><ArticleId IdType="pii">S0896-6273(21)00156-2</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2021.03.008</ArticleId><ArticleId IdType="pmc">PMC8105282</ArticleId><ArticleId IdType="mid">NIHMS1683471</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hippocampus. 2016 May;26(5):633-45</Citation><ArticleIdList><ArticleId IdType="pubmed">26501829</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2007 May;64(5):543-52</Citation><ArticleIdList><ArticleId IdType="pubmed">17485606</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neuropsychopharmacol. 2017 Aug 1;20(8):670-680</Citation><ArticleIdList><ArticleId IdType="pubmed">28498954</ArticleId></ArticleIdList></Reference><Reference><Citation>FEBS Lett. 2013 Dec 11;587(24):3928-34</Citation><ArticleIdList><ArticleId IdType="pubmed">24211447</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2008 Dec 10;28(50):13428-34</Citation><ArticleIdList><ArticleId IdType="pubmed">19074016</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2014 Sep 3;83(5):1131-43</Citation><ArticleIdList><ArticleId IdType="pubmed">25155956</ArticleId></ArticleIdList></Reference><Reference><Citation>FEBS Lett. 1997 Jun 23;410(1):78-82</Citation><ArticleIdList><ArticleId IdType="pubmed">9247127</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2005 Sep 15;58(6):446-50</Citation><ArticleIdList><ArticleId IdType="pubmed">16026766</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cell Sci. 2003 Apr 1;116(Pt 7):1175-86</Citation><ArticleIdList><ArticleId IdType="pubmed">12615961</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 2013 Oct;45(10):1150-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23974872</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2014 May;16(3):289-99</Citation><ArticleIdList><ArticleId IdType="pubmed">24119150</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2007 Feb-Mar;9(1-2):103-13</Citation><ArticleIdList><ArticleId IdType="pubmed">17391354</ArticleId></ArticleIdList></Reference><Reference><Citation>Learn Mem. 2007 Nov 14;14(11):758-70</Citation><ArticleIdList><ArticleId IdType="pubmed">18007019</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet B Neuropsychiatr Genet. 2015 Dec;168(8):649-59</Citation><ArticleIdList><ArticleId IdType="pubmed">26198764</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Biobehav Rev. 2002 Jan;26(1):91-104</Citation><ArticleIdList><ArticleId IdType="pubmed">11835987</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2018 Jun;23(6):1474-1486</Citation><ArticleIdList><ArticleId IdType="pubmed">28555077</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Mol Cell Biol. 2010 Jan;11(1):9-22</Citation><ArticleIdList><ArticleId IdType="pubmed">20027184</ArticleId></ArticleIdList></Reference><Reference><Citation>Learn Mem. 2008 Feb 19;15(3):97-105</Citation><ArticleIdList><ArticleId IdType="pubmed">18285468</ArticleId></ArticleIdList></Reference><Reference><Citation>Adv Biol Regul. 2019 May;72:51-62</Citation><ArticleIdList><ArticleId IdType="pubmed">31010692</ArticleId></ArticleIdList></Reference><Reference><Citation>Epidemiol Rev. 2008;30:67-76</Citation><ArticleIdList><ArticleId IdType="pubmed">18480098</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2010 Apr 30;182(1):22-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20227857</ArticleId></ArticleIdList></Reference><Reference><Citation>Hippocampus. 2013 May;23(5):352-66</Citation><ArticleIdList><ArticleId IdType="pubmed">23389958</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Cell Biol. 2011 Feb;13(2):132-41</Citation><ArticleIdList><ArticleId IdType="pubmed">21258367</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet B Neuropsychiatr Genet. 2006 Jun 5;141B(4):383-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16583435</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Biosci. 2020 Apr 1;10:54</Citation><ArticleIdList><ArticleId IdType="pubmed">32266056</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell Biol. 2009 Aug;29(15):4308-24</Citation><ArticleIdList><ArticleId IdType="pubmed">19487463</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 2003 Jul-Aug;44(4):263-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12923703</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Behav Neurosci. 2018 Apr 25;12:79</Citation><ArticleIdList><ArticleId IdType="pubmed">29755331</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2009 Jul 14;106(28):11606-11</Citation><ArticleIdList><ArticleId IdType="pubmed">19564600</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2004 Dec;9(12):1091-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15241432</ArticleId></ArticleIdList></Reference><Reference><Citation>Cereb Cortex. 2020 Jan 10;30(1):59-71</Citation><ArticleIdList><ArticleId IdType="pubmed">31220216</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Gen Psychiatry. 2015 Dec 01;14:42</Citation><ArticleIdList><ArticleId IdType="pubmed">26628905</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem J. 2012 Jan 1;441(1):1-21</Citation><ArticleIdList><ArticleId IdType="pubmed">22168436</ArticleId></ArticleIdList></Reference><Reference><Citation>Ther Adv Psychopharmacol. 2018 Apr 26;8(9):251-269</Citation><ArticleIdList><ArticleId IdType="pubmed">30181867</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 1994 Feb;89(2):135-41</Citation><ArticleIdList><ArticleId IdType="pubmed">8178665</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2012 Mar;135(1-3):8-14</Citation><ArticleIdList><ArticleId IdType="pubmed">22277669</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2017 Apr;56(4):286-296</Citation><ArticleIdList><ArticleId IdType="pubmed">28335872</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2014 Jul 24;511(7510):421-7</Citation><ArticleIdList><ArticleId IdType="pubmed">25056061</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2007 Mar 14;27(11):2948-57</Citation><ArticleIdList><ArticleId IdType="pubmed">17360918</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2020 Jul 10;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32651478</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2019 Sep;49(12):2036-2048</Citation><ArticleIdList><ArticleId IdType="pubmed">30303059</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2016 Jun 29;36(26):6926-36</Citation><ArticleIdList><ArticleId IdType="pubmed">27358451</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2017 Feb;20(2):242-250</Citation><ArticleIdList><ArticleId IdType="pubmed">28067902</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2013 Oct 2;33(40):15716-25</Citation><ArticleIdList><ArticleId IdType="pubmed">24089480</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 1997 Dec 12;272(50):31515-24</Citation><ArticleIdList><ArticleId IdType="pubmed">9395488</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Cell Biol. 2018 Aug;28(8):646-661</Citation><ArticleIdList><ArticleId IdType="pubmed">29731196</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2004 Jun;6(3):224-32</Citation><ArticleIdList><ArticleId IdType="pubmed">15117401</ArticleId></ArticleIdList></Reference><Reference><Citation>Amino Acids. 2010 Jan;38(1):223-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19145465</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2004 Feb;161(2):262-70</Citation><ArticleIdList><ArticleId IdType="pubmed">14754775</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2009 Oct 30;169(3):220-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19758705</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Mol Neurosci. 2016 Jan 05;8:78</Citation><ArticleIdList><ArticleId IdType="pubmed">26778955</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychiatr Dis Treat. 2015 Dec 17;11:3111-25</Citation><ArticleIdList><ArticleId IdType="pubmed">26719696</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2010 Feb;121(1-2):156-60</Citation><ArticleIdList><ArticleId IdType="pubmed">19505727</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand Suppl. 2007;(434):17-26</Citation><ArticleIdList><ArticleId IdType="pubmed">17688459</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2015 Feb;18(2):199-209</Citation><ArticleIdList><ArticleId IdType="pubmed">25599223</ArticleId></ArticleIdList></Reference><Reference><Citation>Essays Biochem. 2017 Dec 12;61(6):585-596</Citation><ArticleIdList><ArticleId IdType="pubmed">29233870</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Psychiatry. 2015 Aug 12;15:193</Citation><ArticleIdList><ArticleId IdType="pubmed">26263900</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2018 Feb;20(1):18-26</Citation><ArticleIdList><ArticleId IdType="pubmed">28833984</ArticleId></ArticleIdList></Reference><Reference><Citation>Cold Spring Harb Perspect Biol. 2012 Sep 01;4(9):a011189</Citation><ArticleIdList><ArticleId IdType="pubmed">22952397</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Dis Primers. 2015 Nov 12;1:15067</Citation><ArticleIdList><ArticleId IdType="pubmed">27189524</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 2018 Mar;50(3):381-389</Citation><ArticleIdList><ArticleId IdType="pubmed">29483656</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 2017 Nov;49(11):1576-1583</Citation><ArticleIdList><ArticleId IdType="pubmed">28991256</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Protoc Neurosci. 2015 Oct 01;73:4.37.1-4.37.31</Citation><ArticleIdList><ArticleId IdType="pubmed">26426386</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2005 Jul 15;280(28):26089-93</Citation><ArticleIdList><ArticleId IdType="pubmed">15905173</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 2018 Aug;50(8):1112-1121</Citation><ArticleIdList><ArticleId IdType="pubmed">30038396</ArticleId></ArticleIdList></Reference><Reference><Citation>Genes Brain Behav. 2010 Jul;9(5):503-11</Citation><ArticleIdList><ArticleId IdType="pubmed">20214684</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2010 Jan 15;67(2):117-24</Citation><ArticleIdList><ArticleId IdType="pubmed">19819426</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 2019 Feb;51(2):245-257</Citation><ArticleIdList><ArticleId IdType="pubmed">30643258</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 2019 May;51(5):793-803</Citation><ArticleIdList><ArticleId IdType="pubmed">31043756</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2005 Jul 8;280(27):25485-90</Citation><ArticleIdList><ArticleId IdType="pubmed">15899889</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2019 Jun 18;45(4):824-834</Citation><ArticleIdList><ArticleId IdType="pubmed">30285260</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Cell Biol. 2015 Sep;25(9):545-55</Citation><ArticleIdList><ArticleId IdType="pubmed">26159692</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Brain. 2014 Aug 28;7:61</Citation><ArticleIdList><ArticleId IdType="pubmed">25159295</ArticleId></ArticleIdList></Reference><Reference><Citation>Genes Brain Behav. 2004 Oct;3(5):287-302</Citation><ArticleIdList><ArticleId IdType="pubmed">15344922</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2017 Apr 6;169(2):361-371</Citation><ArticleIdList><ArticleId IdType="pubmed">28388417</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2007 Jan;10(1):93-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17143271</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cell Sci. 2009 Oct 15;122(Pt 20):3589-94</Citation><ArticleIdList><ArticleId IdType="pubmed">19812304</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2017 Nov;222:169-176</Citation><ArticleIdList><ArticleId IdType="pubmed">28709024</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Neurosci. 2010 Feb;33(2):67-75</Citation><ArticleIdList><ArticleId IdType="pubmed">19963289</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2004 Jul;34(5):823-32</Citation><ArticleIdList><ArticleId IdType="pubmed">15500303</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2004 Jun;6(3):233-44</Citation><ArticleIdList><ArticleId IdType="pubmed">15117402</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2007 Apr-Jun;41(3-4):265-72</Citation><ArticleIdList><ArticleId IdType="pubmed">16762369</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2008 Aug;165(8):1006-14</Citation><ArticleIdList><ArticleId IdType="pubmed">18519527</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychobiology. 2013;68(2):63-70</Citation><ArticleIdList><ArticleId IdType="pubmed">23881005</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Genet. 2018 Oct 24;9:470</Citation><ArticleIdList><ArticleId IdType="pubmed">30459806</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2016 Jun 1;90(5):969-83</Citation><ArticleIdList><ArticleId IdType="pubmed">27181059</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Psychiatry Rep. 2000 Aug;2(4):286-90</Citation><ArticleIdList><ArticleId IdType="pubmed">11122970</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2006 Jul;93(1-3):105-15</Citation><ArticleIdList><ArticleId IdType="pubmed">16677713</ArticleId></ArticleIdList></Reference><Reference><Citation>EMBO J. 1995 Nov 1;14(21):5279-87</Citation><ArticleIdList><ArticleId IdType="pubmed">7489717</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Brain Res. 2003 Nov 30;146(1-2):3-17</Citation><ArticleIdList><ArticleId IdType="pubmed">14643455</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1998 Feb 17;95(4):1432-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9465032</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2005 Nov 18;123(4):569-80</Citation><ArticleIdList><ArticleId IdType="pubmed">16286006</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Psychiatry. 2014 Dec 1;71(12):1323-31</Citation><ArticleIdList><ArticleId IdType="pubmed">25271938</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2018 Jun 14;173(7):1705-1715.e16</Citation><ArticleIdList><ArticleId IdType="pubmed">29906448</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Brain Res. 2013 Aug 1;250:91-101</Citation><ArticleIdList><ArticleId IdType="pubmed">23664821</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2017 May 30;114(22):E4462-E4471</Citation><ArticleIdList><ArticleId IdType="pubmed">28500272</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2006 Jan 15;59(2):138-46</Citation><ArticleIdList><ArticleId IdType="pubmed">16169530</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2013 Sep;128(3):149-62</Citation><ArticleIdList><ArticleId IdType="pubmed">23617548</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2010 Oct;126(1-2):55-60</Citation><ArticleIdList><ArticleId IdType="pubmed">20457470</ArticleId></ArticleIdList></Reference><Reference><Citation>Biotechniques. 2005 Sep;39(3):381-91</Citation><ArticleIdList><ArticleId IdType="pubmed">16206910</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2002 Jun 21;277(25):23065-75</Citation><ArticleIdList><ArticleId IdType="pubmed">11940578</ArticleId></ArticleIdList></Reference><Reference><Citation>Genes Dev. 1999 Jun 1;13(11):1422-37</Citation><ArticleIdList><ArticleId IdType="pubmed">10364159</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Genet. 2010 Jun;20(3):118-22</Citation><ArticleIdList><ArticleId IdType="pubmed">20421846</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Biol Int. 2014;2014:686984</Citation><ArticleIdList><ArticleId IdType="pubmed">25505994</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2016 Feb 3;89(3):566-82</Citation><ArticleIdList><ArticleId IdType="pubmed">26844834</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2018 Mar 21;97(6):1253-1260.e7</Citation><ArticleIdList><ArticleId IdType="pubmed">29503190</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">1819248</PMID><DateCompleted><Year>1991</Year><Month>10</Month><Day>01</Day></DateCompleted><DateRevised><Year>2004</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0033-3182</ISSN><JournalIssue CitedMedium="Print"><Volume>32</Volume><Issue>3</Issue><PubDate><Year>1991</Year><Season>Summer</Season></PubDate></JournalIssue><Title>Psychosomatics</Title><ISOAbbreviation>Psychosomatics</ISOAbbreviation></Journal><ArticleTitle>Mania and paranoid psychosis in AIDS.</ArticleTitle><Pagination><MedlinePgn>362</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>el-Mallakh</LastName><ForeName>R S</ForeName><Initials>RS</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Psychosomatics</MedlineTA><NlmUniqueID>0376506</NlmUniqueID><ISSNLinking>0033-3182</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CitationSubset>X</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Psychosomatics. 1992 Winter;33(1):118-9</RefSource><PMID Version="1">1539096</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D015526" MajorTopicYN="N">AIDS Dementia Complex</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010259" MajorTopicYN="N">Paranoid Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1991</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1991</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1991</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1819248</ArticleId><ArticleId IdType="pii">S0033-3182(91)72081-1</ArticleId><ArticleId IdType="doi">10.1016/S0033-3182(91)72081-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">6731658</PMID><DateCompleted><Year>1984</Year><Month>06</Month><Day>25</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-9548</ISSN><JournalIssue CitedMedium="Print"><Volume>44</Volume><Issue>1</Issue><PubDate><Year>1984</Year><Season>Spring</Season></PubDate></JournalIssue><Title>American journal of psychoanalysis</Title><ISOAbbreviation>Am J Psychoanal</ISOAbbreviation></Journal><ArticleTitle>Pathological attachments and their relationship to affective disorders in adult life.</ArticleTitle><Pagination><MedlinePgn>33-49, 51-7</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kestenbaum</LastName><ForeName>C J</ForeName><Initials>CJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Am J Psychoanal</MedlineTA><NlmUniqueID>0372630</NlmUniqueID><ISSNLinking>0002-9548</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004777" MajorTopicYN="N">Environment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005149" MajorTopicYN="N">Facial Expression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009034" MajorTopicYN="N">Mother-Child Relations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009769" MajorTopicYN="Y">Object Attachment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011037" MajorTopicYN="N">Poetry as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011582" MajorTopicYN="N">Psychological Theory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1984</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1984</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1984</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">6731658</ArticleId><ArticleId IdType="doi">10.1007/BF01255418</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">79077</PMID><DateCompleted><Year>1978</Year><Month>09</Month><Day>15</Day></DateCompleted><DateRevised><Year>2019</Year><Month>06</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0140-6736</ISSN><JournalIssue CitedMedium="Print"><Volume>2</Volume><Issue>8083</Issue><PubDate><Year>1978</Year><Month>Jul</Month><Day>29</Day></PubDate></JournalIssue><Title>Lancet (London, England)</Title><ISOAbbreviation>Lancet</ISOAbbreviation></Journal><ArticleTitle>Vasopressin in affective illness.</ArticleTitle><Pagination><MedlinePgn>273</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>de Wied</LastName><ForeName>D</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet</MedlineTA><NlmUniqueID>2985213R</NlmUniqueID><ISSNLinking>0140-6736</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>11000-17-2</RegistryNumber><NameOfSubstance UI="D014667">Vasopressins</NameOfSubstance></Chemical><Chemical><RegistryNumber>ENR1LLB0FP</RegistryNumber><NameOfSubstance UI="D003894">Deamino Arginine Vasopressin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003894" MajorTopicYN="N">Deamino Arginine Vasopressin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014667" MajorTopicYN="N">Vasopressins</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1978</Year><Month>7</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1978</Year><Month>7</Month><Day>29</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1978</Year><Month>7</Month><Day>29</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">79077</ArticleId><ArticleId IdType="pii">S0140-6736(78)91794-4</ArticleId><ArticleId IdType="doi">10.1016/s0140-6736(78)91794-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20392298</PMID><DateCompleted><Year>2011</Year><Month>01</Month><Day>25</Day></DateCompleted><DateRevised><Year>2016</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1469-5111</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>5</Issue><PubDate><Year>2010</Year><Month>Jun</Month></PubDate></JournalIssue><Title>The international journal of neuropsychopharmacology</Title><ISOAbbreviation>Int J Neuropsychopharmacol</ISOAbbreviation></Journal><ArticleTitle>Excellent lithium responders have normal cognitive functions and plasma BDNF levels.</ArticleTitle><Pagination><MedlinePgn>617-22</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1017/S1461145710000404</ELocationID><Abstract><AbstractText>In bipolar patients, neuropsychological and biochemical disturbances persist into the remission period. Excellent lithium responders (ELRs) comprise around one third of lithium-treated patients and have total remission of recurrences on lithium monotherapy. The objective of the study was to assess the performance on neuropsychological tests and to measure brain-derived neurotrophic factor (BDNF) plasma levels in ELRs compared to patients where the effect of lithium was not optimal, and with matched healthy control subjects. The study was performed with 60 patients on prophylactic lithium treatment, 13 of whom were ELRs, and with 60 matched healthy controls. Neuropsychological tests from the CANTAB battery measuring spatial working memory and sustained attention were used. ELRs performed better on all neuropsychological tests, and had higher plasma BDNF levels than the remaining lithium patients but not different from those of healthy controls. ELRs may constitute a specific subgroup of bipolar patients in which long-term lithium administration can produce complete normality.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rybakowski</LastName><ForeName>Janusz K</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>Department of Adult Psychiatry, Poznan University of Medical Sciences, Poznan, Poland. rybakows@wlkp.top.pl</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suwalska</LastName><ForeName>Aleksandra</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>04</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Neuropsychopharmacol</MedlineTA><NlmUniqueID>9815893</NlmUniqueID><ISSNLinking>1461-1457</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019208">Brain-Derived Neurotrophic Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019208" MajorTopicYN="N">Brain-Derived Neurotrophic Factor</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="Y">Neuropsychological Tests</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>1</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20392298</ArticleId><ArticleId IdType="pii">S1461145710000404</ArticleId><ArticleId IdType="doi">10.1017/S1461145710000404</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">20271595</PMID><DateCompleted><Year>2010</Year><Month>03</Month><Day>18</Day></DateCompleted><DateRevised><Year>2020</Year><Month>10</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0369-1519</ISSN><JournalIssue CitedMedium="Print"><Volume>50</Volume><Issue>1-2</Issue><PubDate><MedlineDate>1947 Jan-Apr</MedlineDate></PubDate></JournalIssue><Title>Monatsschrift fur Psychiatrie und Neurologie</Title><ISOAbbreviation>Monatsschr Psychiatr Neurol</ISOAbbreviation></Journal><ArticleTitle>Psychology and Clinic of the Manic-Depressive Intermediate Area.</ArticleTitle><Pagination><MedlinePgn>99-102</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>HUTTER</LastName><ForeName>A</ForeName><Initials>A</Initials></Author></AuthorList><Language>dut</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Psychologie en cliniek van het manisch-depressieve tusschengebied.</VernacularTitle></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Monatsschr Psychiatr Neurol</MedlineTA><NlmUniqueID>18750490R</NlmUniqueID><ISSNLinking>0369-1519</ISSNLinking></MedlineJournalInfo><SupplMeshList><SupplMeshName Type="Disease" UI="C565111">Major Affective Disorder 1</SupplMeshName></SupplMeshList><CitationSubset>OM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="CLML">4713:1546g1</OtherID><KeywordList Owner="NLM"><Keyword MajorTopicYN="Y">MANIC DEPRESSIVE PSYCHOSIS/psychology</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>3</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>1947</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>7</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20271595</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30371048</PMID><DateCompleted><Year>2019</Year><Month>10</Month><Day>30</Day></DateCompleted><DateRevised><Year>2019</Year><Month>10</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1488-2434</ISSN><JournalIssue CitedMedium="Internet"><Volume>43</Volume><Issue>6</Issue><PubDate><Year>2018</Year><Month>11</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of psychiatry &amp; neuroscience : JPN</Title><ISOAbbreviation>J Psychiatry Neurosci</ISOAbbreviation></Journal><ArticleTitle>The perils of being too stable: mood regulation in bipolar disorder</ArticleTitle><Pagination><MedlinePgn>363-365</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1503/jpn.180183</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Ortiz</LastName><ForeName>Abigail</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>From the Department of Psychiatry, University of Toronto, Toronto, Ont., Canada (Ortiz); the Department of Psychiatry, Dalhousie University, Halifax, NS, Canada (Alda); and the National Institute of Mental Health, Klecany, Czech Republic(Alda).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Alda</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the Department of Psychiatry, University of Toronto, Toronto, Ont., Canada (Ortiz); the Department of Psychiatry, Dalhousie University, Halifax, NS, Canada (Alda); and the National Institute of Mental Health, Klecany, Czech Republic(Alda).</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>J Psychiatry Neurosci</MedlineTA><NlmUniqueID>9107859</NlmUniqueID><ISSNLinking>1180-4882</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="Y">Affect</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008959" MajorTopicYN="N">Models, Neurological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008962" MajorTopicYN="N">Models, Theoretical</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>10</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>10</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>10</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30371048</ArticleId><ArticleId IdType="pmc">PMC6203548</ArticleId><ArticleId IdType="doi">10.1503/jpn.180183</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Am J Physiol. 1994 Apr;266(4 Pt 2):H1643-56</Citation><ArticleIdList><ArticleId IdType="pubmed">8184944</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Clin Psychol. 2010;6:285-312</Citation><ArticleIdList><ArticleId IdType="pubmed">20192795</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2003 Jul;28 Suppl 1:S13-20</Citation><ArticleIdList><ArticleId IdType="pubmed">12827139</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann N Y Acad Sci. 2001 Dec;954:245-67</Citation><ArticleIdList><ArticleId IdType="pubmed">11797860</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Comput Neurosci. 2013 Aug 12;7:106</Citation><ArticleIdList><ArticleId IdType="pubmed">24009579</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Physiol. 2013 Jul 26;4:186</Citation><ArticleIdList><ArticleId IdType="pubmed">23898302</ArticleId></ArticleIdList></Reference><Reference><Citation>Depress Anxiety. 2014 Mar;31(3):196-206</Citation><ArticleIdList><ArticleId IdType="pubmed">24610817</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Ther. 2015 Nov-Dec;22(6):477-86</Citation><ArticleIdList><ArticleId IdType="pubmed">25383489</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2016 Nov 15;205:165-181</Citation><ArticleIdList><ArticleId IdType="pubmed">27449549</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2004 Mar;78(3):185-92</Citation><ArticleIdList><ArticleId IdType="pubmed">15013242</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1995 Nov;52(11):947-59</Citation><ArticleIdList><ArticleId IdType="pubmed">7487343</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neuropsychopharmacol. 2017 Aug 1;20(8):670-680</Citation><ArticleIdList><ArticleId IdType="pubmed">28498954</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2015 Mar;17(2):139-49</Citation><ArticleIdList><ArticleId IdType="pubmed">25118155</ArticleId></ArticleIdList></Reference><Reference><Citation>Comput Math Methods Med. 2013;2013:324325</Citation><ArticleIdList><ArticleId IdType="pubmed">23864905</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2011 Oct;124(4):307-16</Citation><ArticleIdList><ArticleId IdType="pubmed">21644938</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2003 Sep;160(9):1696-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12944349</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2006 Oct;8(5 Pt 1):424-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17042880</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2019 Jan 15;243:274-279</Citation><ArticleIdList><ArticleId IdType="pubmed">30248639</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2013 May 14;8(5):e63345</Citation><ArticleIdList><ArticleId IdType="pubmed">23691030</ArticleId></ArticleIdList></Reference><Reference><Citation>J R Soc Interface. 2015 Nov 6;12(112):null</Citation><ArticleIdList><ArticleId IdType="pubmed">26577592</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1995 Nov;52(11):960-4</Citation><ArticleIdList><ArticleId IdType="pubmed">7487344</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2006;67 Suppl 1:8-15</Citation><ArticleIdList><ArticleId IdType="pubmed">16426111</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Cybern. 2000 Oct;83(4):355-66</Citation><ArticleIdList><ArticleId IdType="pubmed">11039700</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2008 Apr;42(5):337-47</Citation><ArticleIdList><ArticleId IdType="pubmed">17336329</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19851701</PMID><DateCompleted><Year>2011</Year><Month>01</Month><Day>05</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1433-9285</ISSN><JournalIssue CitedMedium="Internet"><Volume>45</Volume><Issue>12</Issue><PubDate><Year>2010</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Social psychiatry and psychiatric epidemiology</Title><ISOAbbreviation>Soc Psychiatry Psychiatr Epidemiol</ISOAbbreviation></Journal><ArticleTitle>Profiles of disability among adults with bipolar spectrum disorders.</ArticleTitle><Pagination><MedlinePgn>1125-34</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00127-009-0153-y</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Heterogeneous groups of patients with a spectrum of service needs are commonplace in mental health settings. Although comprehensive assessments are available to measure variations in service needs, numerous challenges still exist when confronting this heterogeneity and many assessments used in clinic settings are lengthy and have not been demonstrated to be consistent over time.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The purpose of this study was to identify subgroups of persons with bipolar spectrum disorders, who have similar disability profiles, and to the extent to which the subgrouping is stable over time.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Participants were recruited from the Continuous Improvement for Veterans in Care-Mood Disorders. Eligible patients (N = 435) were those who received inpatient or outpatient treatment for bipolar disorder at a large urban VA mental health facility in Western Pennsylvania from July 2004 through July 2006. This was a naturalistic cohort study of patients with bipolar spectrum disorders. Baseline and 1-year follow-up data were collected using face-to-face interviews and recorded abstraction. The World Health Organization Disability Assessment Scale was the primary measure used to identify subgroups within this sample.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Using a classification strategy called latent profile analysis, this study identified three unique subgroups that showed significant differences in various clinical measures at baseline and follow-up. The largest and most consistent subgroup differences were observed in the current bipolar symptomatology.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The classification of functional status in the present study can aid clinicians in the identification of bipolar patients, with specific impairment profiles, who may need additional intervention. Future research is needed to understand whether specific interventions targeted at these subgroups can improve the quality of care for this high-need and at-risk population.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Perron</LastName><ForeName>Brian E</ForeName><Initials>BE</Initials><AffiliationInfo><Affiliation>University of Michigan, Ann Arbor, USA. beperron@umich.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bohnert</LastName><ForeName>Amy S B</ForeName><Initials>AS</Initials></Author><Author ValidYN="Y"><LastName>Vaughn</LastName><ForeName>Michael G</ForeName><Initials>MG</Initials></Author><Author ValidYN="Y"><LastName>Bauer</LastName><ForeName>Mark S</ForeName><Initials>MS</Initials></Author><Author ValidYN="Y"><LastName>Kilbourne</LastName><ForeName>Amy M</ForeName><Initials>AM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH 74509</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH 79994</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>10</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Soc Psychiatry Psychiatr Epidemiol</MedlineTA><NlmUniqueID>8804358</NlmUniqueID><ISSNLinking>0933-7954</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="N">Activities of Daily Living</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017281" MajorTopicYN="N">Cost of Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004185" MajorTopicYN="Y">Disability Evaluation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006301" MajorTopicYN="N">Health Services Needs and Demand</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008605" MajorTopicYN="N">Mental Health Services</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010414" MajorTopicYN="N" Type="Geographic">Pennsylvania</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014728" MajorTopicYN="N">Veterans</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>09</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>10</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>10</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>10</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>1</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19851701</ArticleId><ArticleId IdType="doi">10.1007/s00127-009-0153-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Psychol Med. 1999 Jul;29(4):869-78</Citation><ArticleIdList><ArticleId IdType="pubmed">10473314</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1995 Nov;152(11):1635-40</Citation><ArticleIdList><ArticleId IdType="pubmed">7485627</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2005 Feb;7(1):89-97</Citation><ArticleIdList><ArticleId IdType="pubmed">15654937</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pain Symptom Manage. 2006 Jan;31(1):85-95</Citation><ArticleIdList><ArticleId IdType="pubmed">16442485</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2006 May;63(5):500-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16651507</ArticleId></ArticleIdList></Reference><Reference><Citation>J Consult Clin Psychol. 2008 Feb;76(1):22-27</Citation><ArticleIdList><ArticleId IdType="pubmed">18229979</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2003 Jan;73(1-2):123-31</Citation><ArticleIdList><ArticleId IdType="pubmed">12507745</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosp Community Psychiatry. 1988 Jun;39(6):652-7</Citation><ArticleIdList><ArticleId IdType="pubmed">3402925</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2001 Aug;65(3):231-41</Citation><ArticleIdList><ArticleId IdType="pubmed">11511403</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2007 Jan;89(1-3):101-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17097273</ArticleId></ArticleIdList></Reference><Reference><Citation>Violence Vict. 2008;23(1):3-17</Citation><ArticleIdList><ArticleId IdType="pubmed">18396578</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 1986 Jun 13;255(22):3138-42</Citation><ArticleIdList><ArticleId IdType="pubmed">3702024</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Serv. 2008 May;59(5):483-5</Citation><ArticleIdList><ArticleId IdType="pubmed">18451002</ArticleId></ArticleIdList></Reference><Reference><Citation>Gen Hosp Psychiatry. 1997 Mar;19(2):98-111</Citation><ArticleIdList><ArticleId IdType="pubmed">9097064</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychosomatics. 2007 Sep-Oct;48(5):412-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17878500</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2000 Dec;2(4):340-6</Citation><ArticleIdList><ArticleId IdType="pubmed">11252648</ArticleId></ArticleIdList></Reference><Reference><Citation>J Stud Alcohol Drugs. 2008 May;69(3):449-53</Citation><ArticleIdList><ArticleId IdType="pubmed">18432388</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Offender Ther Comp Criminol. 2008 Aug;52(4):435-53</Citation><ArticleIdList><ArticleId IdType="pubmed">18025077</ArticleId></ArticleIdList></Reference><Reference><Citation>J Adolesc Health. 2008 Jun;42(6):549-54</Citation><ArticleIdList><ArticleId IdType="pubmed">18486863</ArticleId></ArticleIdList></Reference><Reference><Citation>Ment Health Serv Res. 2002 Dec;4(4):225-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12558008</ArticleId></ArticleIdList></Reference><Reference><Citation>Soc Psychiatry Psychiatr Epidemiol. 2009 Jul;44(7):523-31</Citation><ArticleIdList><ArticleId IdType="pubmed">19011718</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1998 May;155(5):646-52</Citation><ArticleIdList><ArticleId IdType="pubmed">9585716</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Serv. 2004 Jan;55(1):54-8</Citation><ArticleIdList><ArticleId IdType="pubmed">14699201</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 1994 Dec 14;272(22):1749-56</Citation><ArticleIdList><ArticleId IdType="pubmed">7966923</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1991 Sep;48(9):807-12</Citation><ArticleIdList><ArticleId IdType="pubmed">1929771</ArticleId></ArticleIdList></Reference><Reference><Citation>Adm Policy Ment Health. 2008 Jul;35(4):283-94</Citation><ArticleIdList><ArticleId IdType="pubmed">18512145</ArticleId></ArticleIdList></Reference><Reference><Citation>Soc Psychiatry Psychiatr Epidemiol. 1992 Mar;27(2):78-82</Citation><ArticleIdList><ArticleId IdType="pubmed">1594977</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1996 Jul 8;39(2):93-7</Citation><ArticleIdList><ArticleId IdType="pubmed">8827417</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1996 Aug 15;40(4):279-83</Citation><ArticleIdList><ArticleId IdType="pubmed">8871774</ArticleId></ArticleIdList></Reference><Reference><Citation>J Fam Pract. 2001 Apr;50(4):313-20</Citation><ArticleIdList><ArticleId IdType="pubmed">11300982</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2005 May;86(1):47-60</Citation><ArticleIdList><ArticleId IdType="pubmed">15820270</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 1998 Nov;4(11):1241-3</Citation><ArticleIdList><ArticleId IdType="pubmed">9809543</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Gen Pract. 2008 Jan;58(546):32-6</Citation><ArticleIdList><ArticleId IdType="pubmed">18186994</ArticleId></ArticleIdList></Reference><Reference><Citation>Soc Psychiatry Psychiatr Epidemiol. 2009 Jul;44(7):515-22</Citation><ArticleIdList><ArticleId IdType="pubmed">19011720</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gen Intern Med. 2001 Sep;16(9):606-13</Citation><ArticleIdList><ArticleId IdType="pubmed">11556941</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nerv Ment Dis. 2004 Jun;192(6):405-13</Citation><ArticleIdList><ArticleId IdType="pubmed">15167403</ArticleId></ArticleIdList></Reference><Reference><Citation>J Formos Med Assoc. 2008 Feb;107(2):119-28</Citation><ArticleIdList><ArticleId IdType="pubmed">18285244</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21188303</PMID><DateCompleted><Year>2011</Year><Month>04</Month><Day>04</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0327-6139</ISSN><JournalIssue CitedMedium="Print"><Volume>21</Volume><Issue>91</Issue><PubDate><MedlineDate>2010 May-Jun</MedlineDate></PubDate></JournalIssue><Title>Vertex (Buenos Aires, Argentina)</Title><ISOAbbreviation>Vertex</ISOAbbreviation></Journal><ArticleTitle>[Training in the detection of bipolar disorders for psychologists and primary health agents: a pilot study].</ArticleTitle><Pagination><MedlinePgn>250-9</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">At present, Bipolar Disorders are considered a real public health problem. There is an agreement that it is a priority to solve the existent flaws as regards the certainty of a correct and timely diagnosis of these disorders. This paper report the results of a pilot experience in workshops of training in the detection of Bipolar Disorders aimed at psychologists and primary health agents.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">A survey was carried out before and after the training sessions with the aim of measuring prior knowledge about bipolar disorders and thus evaluating the impact of the training workshops.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">227 people completed the surveys. The results showed a scarce knowledge about these disorders, even among those professionals who acknowledged having bipolar patients in treatment and who had interest in being trained. On the other hand, these surveys revealed significant changes in their knowledge of bipolar disorders.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This pilot experience suggests that with low cost events such as the organized workshops it would be possible to increase the ability of timely detection of bipolar disorders in the key agents of the health system. Reducing frequents delays and mistakes in the diagnosis of these disorders which would determine a significant reduction in their morbid impact.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Strejilevich</LastName><ForeName>Sergio AdriÃ¡n</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Programa de Trastornos Bipolares, Instituto de Neurociencias de la FundaciÃ³n Favaloro, Buenos Aires, Argentina. sstrejilevich@ffavaloro.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baamonde</LastName><ForeName>Mariana Urtueta</ForeName><Initials>MU</Initials></Author><Author ValidYN="Y"><LastName>Martino</LastName><ForeName>Diego Javier</ForeName><Initials>DJ</Initials></Author><Author ValidYN="Y"><LastName>Perinot</LastName><ForeName>Lila</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>MorÃ¡n</LastName><ForeName>MarÃ­a ScÃ¡pola</ForeName><Initials>MS</Initials></Author><Author ValidYN="Y"><LastName>Colom</LastName><ForeName>Francesc Victoriano</ForeName><Initials>FV</Initials></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D023362">Evaluation Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Entrenamiento en detecciÃ³n de trastornos bipolares para psicÃ³logos y mÃ©dicos generalistas: reporte de una experiencia piloto.</VernacularTitle></Article><MedlineJournalInfo><Country>Argentina</Country><MedlineTA>Vertex</MedlineTA><NlmUniqueID>9440528</NlmUniqueID><ISSNLinking>0327-6139</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003625" MajorTopicYN="N">Data Collection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058006" MajorTopicYN="Y">General Practice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011320" MajorTopicYN="Y">Primary Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011584" MajorTopicYN="Y">Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>12</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>12</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>4</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21188303</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15555709</PMID><DateCompleted><Year>2005</Year><Month>04</Month><Day>22</Day></DateCompleted><DateRevised><Year>2009</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-0327</ISSN><JournalIssue CitedMedium="Print"><Volume>83</Volume><Issue>2-3</Issue><PubDate><Year>2004</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Ethnic differences in first clinical presentation of bipolar disorder: results from an epidemiological study.</ArticleTitle><Pagination><MedlinePgn>161-8</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Although high incidence rates of mania have been described in some ethnic minority populations, little is known about any ethnic differences in the early clinical presentation of bipolar disorder.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">All cases of operationalised DSM-IV bipolar I disorder (BPI), first manic episode, within a defined epidemiological catchment area over a 35-year period, were identified; sociodemographic data, including ethnicity, and clinical information were then extracted. The proportion of African-Caribbean (n=52), African (n=33) and white European (n=149) cases who experienced a depressive episode before onset of mania and psychotic symptoms at first mania were compared.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">African-Caribbean and African groups were significantly less likely to have experienced a depressive episode before onset of first mania, at 13.5% and 6.1%, respectively, compared with 28.1% in the white European group. African-Caribbean and African groups also experienced more severe psychotic symptoms at first mania, but there were no differences in mood incongruent or first rank symptoms between ethnic groups.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Data pertaining to diagnosis and clinical symptoms were extracted by retrospective case note review.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Ethnic differences in clinical presentation of bipolar disorder may have implications for assessment and treatment of ethnic minority patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kennedy</LastName><ForeName>N</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Box 63, Section of General Psychiatry, Division of Psychological Medicine, Institute of Psychiatry, De Crespigny Park, London SE5 8AF, UK. nkennedy@stpatsmail.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boydell</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>van Os</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Murray</LastName><ForeName>R M</ForeName><Initials>RM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044383" MajorTopicYN="N">African Continental Ancestry Group</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000208" MajorTopicYN="Y">ethnology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003431" MajorTopicYN="N">Cross-Cultural Comparison</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044465" MajorTopicYN="N">European Continental Ancestry Group</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008131" MajorTopicYN="N" Type="Geographic">London</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2004</Year><Month>03</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2004</Year><Month>06</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2004</Year><Month>06</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>11</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>4</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>11</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15555709</ArticleId><ArticleId IdType="pii">S0165-0327(04)00206-X</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2004.06.006</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10982196</PMID><DateCompleted><Year>2000</Year><Month>09</Month><Day>14</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>61</Volume><Issue>8</Issue><PubDate><Year>2000</Year><Month>Aug</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Clinical factors associated with treatment noncompliance in euthymic bipolar patients.</ArticleTitle><Pagination><MedlinePgn>549-55</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Noncompliance with medication is a very common feature among bipolar patients. Rates of poor compliance may reach 64% for bipolar disorders, and noncompliance is the most frequent cause of recurrence. Knowledge of the clinical factors associated with noncompliance would enhance clinical management and the design of strategies to achieve a better outcome for bipolar patients. Although most patients withdraw from medication during maintenance treatment, compliance studies in euthymic bipolar samples are scarce.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Compliance treatment and its clinical correlates were assessed at the end of 2-year follow-up in 200 patients meeting Research Diagnostic Criteria for bipolar I or bipolar II disorder by means of compliance-focused interviews, measurements of plasma concentrations of mood stabilizers, and 2 structured interviews: the Schedule for Affective Disorders and Schizophrenia and the Structured Clinical Interview for DSM-III-R Axis II disorders. Well-compliant patients and poorly compliant patients were compared with respect to several clinical and treatment variables.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The rate of mildly and poorly compliant patients was close to 40%. Comorbidity with personality disorders was strongly associated with poor compliance. Poorly compliant patients had a higher number of previous hospitalizations, but reported fewer previous episodes. The type of treatment was not associated with compliance.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Clinical factors, especially comorbidity with personality disorders, are more relevant for treatment compliance than other issues such as the nature of pharmacologic treatment. Compliant patients may have a better outcome in terms of number of hospitalizations, but not necessarily with respect to the number of episodes. Bipolar patients, especially those with personality disorders, should be monitored for treatment compliance.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Colom</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Bipolar Disorders Program, Institut d'Investigacions BiomÃ©diques AgustÃ­ Pi Sunyer, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vieta</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>MartÃ­nez-ArÃ¡n</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Reinares</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Benabarre</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>GastÃ³</LastName><ForeName>C</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011619">Psychotropic Drugs</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000553" MajorTopicYN="N">Ambulatory Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010554" MajorTopicYN="N">Personality Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011619" MajorTopicYN="N">Psychotropic Drugs</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016312" MajorTopicYN="N">Treatment Refusal</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>9</Month><Day>12</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>9</Month><Day>19</Day><Hour>11</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>9</Month><Day>12</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10982196</ArticleId><ArticleId IdType="doi">10.4088/jcp.v61n0802</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20361912</PMID><DateCompleted><Year>2010</Year><Month>09</Month><Day>09</Day></DateCompleted><DateRevised><Year>2010</Year><Month>08</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1555-2101</ISSN><JournalIssue CitedMedium="Internet"><Volume>71</Volume><Issue>8</Issue><PubDate><Year>2010</Year><Month>Aug</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Why do clinicians maintain antidepressants in some patients with acute mania? Hints from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM), a large naturalistic study.</ArticleTitle><Pagination><MedlinePgn>1000-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4088/JCP.09m05026gre</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Antidepressants are supposed to be withdrawn during a manic episode. The aim of this study was to analyze the characteristics of manic patients who received antidepressants during a manic phase in a large, naturalistic study.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">The European Mania in Bipolar Longitudinal Evaluation of Medication was a 2-year prospective observational study of inpatients and outpatients with acute mania/mixed mania (DSM-IV or ICD-10 criteria) conducted in 14 European countries. Of 2,416 manic patients who continued into the maintenance phase of the study, 345 (14%) were taking an antidepressant and 2,071 (86%) were not taking an antidepressant at baseline, week 1, and/or week 2 postbaseline. Demographic and clinical variables were collected at baseline and each study visit up to 24 months. Outcome measures included the Clinical Global Impressions-Bipolar Disorder scale (CGI-BP overall, mania, and depression scores) at 12 weeks and 24 months, the 5-item Hamilton Depression Rating Scale (HDRS-5), and the Young Mania Rating Scale (YMRS) at 12 weeks only. The present study was conducted from December 2002 to June 2004.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">More antidepressant maintenance use was seen in patients with mixed episodes (P &lt; .001), rapid cyclers (P &lt; .02), patients with more previous depressive episodes (P &lt; .001), and patients with higher mean HDRS-5 score at baseline (P &lt; .001)-specifically patients with anxiety (P = .013). Patients in the antidepressant group had significantly higher CGI-BP depression scores (P &lt; .001) and a significantly higher rate of depression relapse (P &lt; .001) at both 12 weeks and 24 months.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Patients with mania receiving antidepressants are more likely to be outpatients with mixed episodes, anxiety, or rapid cycling and have a higher risk of depression relapse during follow-up.</AbstractText><CopyrightInformation>Copyright 2010 Physicians Postgraduate Press, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rosa</LastName><ForeName>Adriane R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Bipolar Disorders Program, Hospital Clinic, University of Barcelona, CIBERSAM, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cruz</LastName><ForeName>NÃ¹ria</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Franco</LastName><ForeName>Carolina</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Haro</LastName><ForeName>Josep Maria</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Bertsch</LastName><ForeName>Jordan</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Reed</LastName><ForeName>Catherine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Aarre</LastName><ForeName>Trond F</ForeName><Initials>TF</Initials></Author><Author ValidYN="Y"><LastName>Sanchez-Moreno</LastName><ForeName>Jose</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Vieta</LastName><ForeName>Eduard</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>03</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005060" MajorTopicYN="N" Type="Geographic">Europe</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D038801" MajorTopicYN="N">International Classification of Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>01</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>03</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>4</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>4</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>9</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20361912</ArticleId><ArticleId IdType="doi">10.4088/JCP.09m05026gre</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31468317</PMID><DateCompleted><Year>2020</Year><Month>04</Month><Day>13</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1179-1950</ISSN><JournalIssue CitedMedium="Internet"><Volume>79</Volume><Issue>15</Issue><PubDate><Year>2019</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Drugs</Title><ISOAbbreviation>Drugs</ISOAbbreviation></Journal><ArticleTitle>Dopamine Receptor Partial Agonists for the Treatment of Bipolar Disorder.</ArticleTitle><Pagination><MedlinePgn>1657-1677</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40265-019-01189-8</ELocationID><Abstract><AbstractText>Bipolar disorder is a chronic, disabling, and costly illness with frequent relapses and recurrences, high rates of co-morbid conditions, and poor adherence to treatment. Mood stabilizers and antipsychotics are the cornerstones of treatment. Dopamine receptor partial agonists are a novel class of antipsychotic agents with original pharmacodynamic properties. Among them, two have been approved by the US Food and Drug Administration for the treatment of bipolar disorder. Aripiprazole (oral formulation) has been approved as monotherapy for the treatment of manic/mixed episodes in adult and pediatric populations and for maintenance treatment in adults, and as adjunctive treatment to mood stabilizers, for the acute treatment of manic/mixed episodes and for maintenance in adults. An intramuscular formulation of aripiprazole has been approved for the treatment of agitation in mania and a long-acting injectable formulation has been approved as maintenance treatment. In the USA, cariprazine has been approved as monotherapy for the acute treatment of manic/mixed as well as bipolar depressive episodes. Brexpiprazole is not yet approved to treat bipolar disorder. The evidence supporting these indications is reviewed via an analysis of clinical registration trials as well as additional studies, on the basis of a systematic literature search. Further studies dealing with other aspects of bipolar illness are also presented. Aripiprazole and cariprazine are efficacious and generally well tolerated agents that have shown cost effectiveness, and may therefore enrich our therapeutic armamentarium for bipolar illness. Brexpiprazole, which displays an overall promising tolerability profile, deserves further efficacy studies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Azorin</LastName><ForeName>Jean-Michel</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Sainte Marguerite Hospital, 13009, Marseille, France. jazorin@ap-hm.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simon</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Aix Marseille Univ, INSERM, IRD, SESSTIM, HÃ´pital Sainte Marguerite, Service de Pharmacologie Clinique, CAP, Marseille, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Drugs</MedlineTA><NlmUniqueID>7600076</NlmUniqueID><ISSNLinking>0012-6667</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018491">Dopamine Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011954">Receptors, Dopamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>82VFR53I78</RegistryNumber><NameOfSubstance UI="D000068180">Aripiprazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>F6RJL8B278</RegistryNumber><NameOfSubstance UI="C533287">cariprazine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068180" MajorTopicYN="N">Aripiprazole</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018491" MajorTopicYN="N">Dopamine Agonists</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011954" MajorTopicYN="N">Receptors, Dopamine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014486" MajorTopicYN="N">United States Food and Drug Administration</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>8</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>8</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31468317</ArticleId><ArticleId IdType="doi">10.1007/s40265-019-01189-8</ArticleId><ArticleId IdType="pii">10.1007/s40265-019-01189-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arch Gen Psychiatry. 2007 May;64(5):543-52</Citation><ArticleIdList><ArticleId IdType="pubmed">17485606</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2015 Mar 15;174:296-302</Citation><ArticleIdList><ArticleId IdType="pubmed">25532076</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2009 Apr 21;70(5):756-64</Citation><ArticleIdList><ArticleId IdType="pubmed">19389329</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Bipolar Disord. 2018 Jun 10;6(1):14</Citation><ArticleIdList><ArticleId IdType="pubmed">29886522</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychopharmacol. 2006 Jul;20(4):536-46</Citation><ArticleIdList><ArticleId IdType="pubmed">16401666</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Psychiatry Clin Pract. 2012 Jun;16(2):121-31</Citation><ArticleIdList><ArticleId IdType="pubmed">22296512</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2018 Jan 15;226:239-244</Citation><ArticleIdList><ArticleId IdType="pubmed">29017067</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2017 Mar;78(3):324-331</Citation><ArticleIdList><ArticleId IdType="pubmed">28146613</ArticleId></ArticleIdList></Reference><Reference><Citation>Ther Adv Psychopharmacol. 2016 Feb;6(1):39-54</Citation><ArticleIdList><ArticleId IdType="pubmed">26913177</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychosoc Nurs Ment Health Serv. 2015 Apr;53(4):23-5</Citation><ArticleIdList><ArticleId IdType="pubmed">25856810</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Investig Drugs. 2010 Jul;11(7):823-32</Citation><ArticleIdList><ArticleId IdType="pubmed">20571978</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2014 Feb;171(2):169-77</Citation><ArticleIdList><ArticleId IdType="pubmed">24170221</ArticleId></ArticleIdList></Reference><Reference><Citation>CNS Drugs. 2015 Dec;29(12):975-83</Citation><ArticleIdList><ArticleId IdType="pubmed">26585875</ArticleId></ArticleIdList></Reference><Reference><Citation>Cureus. 2016 Apr 07;8(4):e562</Citation><ArticleIdList><ArticleId IdType="pubmed">27190727</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2010 Oct;35(11):2143-54</Citation><ArticleIdList><ArticleId IdType="pubmed">20668436</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychopharmacol. 2008 Feb;28(1):13-20</Citation><ArticleIdList><ArticleId IdType="pubmed">18204335</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2006 Apr;67(4):509-16</Citation><ArticleIdList><ArticleId IdType="pubmed">16669715</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Psychiatry. 2013 Sep;70(9):931-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23863861</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Neuropsychopharmacol. 2015 Nov;25(11):1882-91</Citation><ArticleIdList><ArticleId IdType="pubmed">26419293</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2016 Dec 13;113(50):E8178-E8186</Citation><ArticleIdList><ArticleId IdType="pubmed">27911814</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2018 Dec 1;241:425-432</Citation><ArticleIdList><ArticleId IdType="pubmed">30145513</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2017 Jan 1;81(1):78-85</Citation><ArticleIdList><ArticleId IdType="pubmed">27832841</ArticleId></ArticleIdList></Reference><Reference><Citation>J Comp Eff Res. 2018 Jul;7(7):637-650</Citation><ArticleIdList><ArticleId IdType="pubmed">29694244</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2019 Apr 15;249:315-318</Citation><ArticleIdList><ArticleId IdType="pubmed">30802696</ArticleId></ArticleIdList></Reference><Reference><Citation>Ther Drug Monit. 2014 Oct;36(5):651-5</Citation><ArticleIdList><ArticleId IdType="pubmed">24682161</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2011 Jan;128 Suppl 1:S21-8</Citation><ArticleIdList><ArticleId IdType="pubmed">21220077</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Clin Pharmacol. 2008 Dec;66(6):802-10</Citation><ArticleIdList><ArticleId IdType="pubmed">19032724</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 2015 Sep;232(18):3297-308</Citation><ArticleIdList><ArticleId IdType="pubmed">26231497</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharmacol Exp Ther. 2010 Apr;333(1):328-40</Citation><ArticleIdList><ArticleId IdType="pubmed">20093397</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2009 Jan;112(1-3):36-49</Citation><ArticleIdList><ArticleId IdType="pubmed">18835043</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Psychopharmacol. 2011 Dec;26(8):543-53</Citation><ArticleIdList><ArticleId IdType="pubmed">22134973</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2015 May;164(1-3):127-35</Citation><ArticleIdList><ArticleId IdType="pubmed">25682550</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2007 Oct;68(10):1480-91</Citation><ArticleIdList><ArticleId IdType="pubmed">17960961</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2003 Sep;160(9):1651-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12944341</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2005 May 25;293(20):2528-30</Citation><ArticleIdList><ArticleId IdType="pubmed">15914754</ArticleId></ArticleIdList></Reference><Reference><Citation>Recent Pat Endocr Metab Immune Drug Discov. 2014 Jan;8(1):30-7</Citation><ArticleIdList><ArticleId IdType="pubmed">24372345</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2015 Apr;76(4):398-405</Citation><ArticleIdList><ArticleId IdType="pubmed">25844756</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2012 Feb;136(3):258-66</Citation><ArticleIdList><ArticleId IdType="pubmed">22209190</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacol Res Perspect. 2015 Feb;3(1):e00073</Citation><ArticleIdList><ArticleId IdType="pubmed">25692006</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2009 Jan;194(1):40-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19118324</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2008 Apr;107(1-3):145-54</Citation><ArticleIdList><ArticleId IdType="pubmed">17904226</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2009 Dec;11(8):827-39</Citation><ArticleIdList><ArticleId IdType="pubmed">19922552</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2009 Oct;70(10):1441-51</Citation><ArticleIdList><ArticleId IdType="pubmed">19906348</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Opin Drug Saf. 2016 Oct;15(10):1329-47</Citation><ArticleIdList><ArticleId IdType="pubmed">27347638</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2016 Mar 1;173(3):271-81</Citation><ArticleIdList><ArticleId IdType="pubmed">26541814</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2018 Jan 15;226:45-51</Citation><ArticleIdList><ArticleId IdType="pubmed">28961441</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Rev Neurother. 2019 Apr;19(4):317-323</Citation><ArticleIdList><ArticleId IdType="pubmed">30753085</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Rev Neurother. 2015 Oct;15(10):1219-29</Citation><ArticleIdList><ArticleId IdType="pubmed">26402059</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2018 Nov;20 Suppl 2:25-36</Citation><ArticleIdList><ArticleId IdType="pubmed">30328222</ArticleId></ArticleIdList></Reference><Reference><Citation>CNS Spectr. 2016 Feb;21(1):1-6</Citation><ArticleIdList><ArticleId IdType="pubmed">26899451</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Pharmacol Sci. 2007 Aug;28(8):416-22</Citation><ArticleIdList><ArticleId IdType="pubmed">17644195</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychopharmacol. 2007 Apr;27(2):171-6</Citation><ArticleIdList><ArticleId IdType="pubmed">17414241</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Clin North Am. 2005 Jun;28(2):325-47</Citation><ArticleIdList><ArticleId IdType="pubmed">15826735</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 1990 Nov 21;264(19):2511-8</Citation><ArticleIdList><ArticleId IdType="pubmed">2232018</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2007 Aug;9(5):531-5</Citation><ArticleIdList><ArticleId IdType="pubmed">17680925</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Des Devel Ther. 2016 Jan 14;10:327-38</Citation><ArticleIdList><ArticleId IdType="pubmed">26834462</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Pharmacol Toxicol. 2009;49:327-47</Citation><ArticleIdList><ArticleId IdType="pubmed">18928402</ArticleId></ArticleIdList></Reference><Reference><Citation>Basic Clin Pharmacol Toxicol. 2007 Jan;100(1):4-22</Citation><ArticleIdList><ArticleId IdType="pubmed">17214606</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2013 Sep 5;150(2):181-91</Citation><ArticleIdList><ArticleId IdType="pubmed">23759420</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Opin Drug Metab Toxicol. 2013 Feb;9(2):193-206</Citation><ArticleIdList><ArticleId IdType="pubmed">23320989</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2012 Feb;14(1):41-53</Citation><ArticleIdList><ArticleId IdType="pubmed">22329471</ArticleId></ArticleIdList></Reference><Reference><Citation>World J Biol Psychiatry. 2014 Feb;15(2):113-21</Citation><ArticleIdList><ArticleId IdType="pubmed">22540407</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Pharmacokinet. 2018 Dec;57(12):1493-1528</Citation><ArticleIdList><ArticleId IdType="pubmed">29915922</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2011 Mar;129(1-3):79-83</Citation><ArticleIdList><ArticleId IdType="pubmed">20888048</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Pharmacol. 2018 Jan;58(1):74-80</Citation><ArticleIdList><ArticleId IdType="pubmed">28750151</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 2016 Oct;233(19-20):3503-12</Citation><ArticleIdList><ArticleId IdType="pubmed">27525990</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochrane Database Syst Rev. 2006 Jul 19;(3):CD004362</Citation><ArticleIdList><ArticleId IdType="pubmed">16856043</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Rep. 2018 Aug 21;8(1):12509</Citation><ArticleIdList><ArticleId IdType="pubmed">30131592</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Neuropsychopharmacol. 2010 Nov;20(11):776-83</Citation><ArticleIdList><ArticleId IdType="pubmed">20728318</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Pract Epidemiol Ment Health. 2009 Jan 23;5:3</Citation><ArticleIdList><ArticleId IdType="pubmed">19166608</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Opin Drug Metab Toxicol. 2014 May;10(5):721-46</Citation><ArticleIdList><ArticleId IdType="pubmed">24494611</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Clin Pract. 2015 Sep;69(9):978-97</Citation><ArticleIdList><ArticleId IdType="pubmed">26250067</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Pharm Des. 2016;22(33):5144-5162</Citation><ArticleIdList><ArticleId IdType="pubmed">27396597</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Neuropharmacol. 2012 May-Jun;35(3):97-102</Citation><ArticleIdList><ArticleId IdType="pubmed">22592508</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Clin Pract. 2015 Nov;69(11):1211-20</Citation><ArticleIdList><ArticleId IdType="pubmed">26477545</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatry Neurosci. 2000 Mar;25(2):161-6</Citation><ArticleIdList><ArticleId IdType="pubmed">10740989</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Psychopharmacol. 2010 Mar;25(2):126-32</Citation><ArticleIdList><ArticleId IdType="pubmed">20196183</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharmacol Exp Ther. 2014 Sep;350(3):589-604</Citation><ArticleIdList><ArticleId IdType="pubmed">24947465</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2016 Apr 1;173(4):400-7</Citation><ArticleIdList><ArticleId IdType="pubmed">26552942</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Neuropsychopharmacol. 2005 Aug;15(4):425-34</Citation><ArticleIdList><ArticleId IdType="pubmed">15935623</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Pharmacol Sci. 2017 Aug;38(8):717-732</Citation><ArticleIdList><ArticleId IdType="pubmed">28645833</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2015 Feb;17(1):63-75</Citation><ArticleIdList><ArticleId IdType="pubmed">25056368</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neuropsychopharmacol. 2017 Jan 1;20(1):11-21</Citation><ArticleIdList><ArticleId IdType="pubmed">27566723</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2006 Apr;67(4):626-37</Citation><ArticleIdList><ArticleId IdType="pubmed">16669728</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2003 Aug;28(8):1400-11</Citation><ArticleIdList><ArticleId IdType="pubmed">12784105</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2007 Sep;164(9):1411-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17728427</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2009 Jul 21;339:b2535</Citation><ArticleIdList><ArticleId IdType="pubmed">19622551</ArticleId></ArticleIdList></Reference><Reference><Citation>Ther Adv Psychopharmacol. 2017 Jan;7(1):29-41</Citation><ArticleIdList><ArticleId IdType="pubmed">28101322</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2011 Mar;13(2):133-44</Citation><ArticleIdList><ArticleId IdType="pubmed">21443567</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13656-61</Citation><ArticleIdList><ArticleId IdType="pubmed">18768802</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2012 Jan;73(1):57-63</Citation><ArticleIdList><ArticleId IdType="pubmed">22152402</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 2013 Mar;226(2):285-93</Citation><ArticleIdList><ArticleId IdType="pubmed">23138433</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2015 Mar;76(3):284-92</Citation><ArticleIdList><ArticleId IdType="pubmed">25562205</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2008 Oct;165(10):1316-25</Citation><ArticleIdList><ArticleId IdType="pubmed">18381903</ArticleId></ArticleIdList></Reference><Reference><Citation>Perspect Psychiatr Care. 2017 Jul;53(3):148-155</Citation><ArticleIdList><ArticleId IdType="pubmed">27059102</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Econ. 2009 Jun;12(2):104-13</Citation><ArticleIdList><ArticleId IdType="pubmed">19527195</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2011 Oct;133(3):361-70</Citation><ArticleIdList><ArticleId IdType="pubmed">21040979</ArticleId></ArticleIdList></Reference><Reference><Citation>Actas Esp Psiquiatr. 2014 Sep-Oct;42(5):242-9</Citation><ArticleIdList><ArticleId IdType="pubmed">25179096</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Clin Pract. 2008 May;62(5):679-87</Citation><ArticleIdList><ArticleId IdType="pubmed">18373615</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2016 Aug;18(5):440-50</Citation><ArticleIdList><ArticleId IdType="pubmed">27566286</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Commun. 2016 Feb 24;7:10842</Citation><ArticleIdList><ArticleId IdType="pubmed">26905976</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Pharmacokinet. 2009;48(11):689-723</Citation><ArticleIdList><ArticleId IdType="pubmed">19817501</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Med. 2011 May;8(5):e1000434</Citation><ArticleIdList><ArticleId IdType="pubmed">21559324</ArticleId></ArticleIdList></Reference><Reference><Citation>J Comp Eff Res. 2018 Jul;7(7):627-636</Citation><ArticleIdList><ArticleId IdType="pubmed">29694243</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2013 Mar;15(2):138-49</Citation><ArticleIdList><ArticleId IdType="pubmed">23437959</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Discov Today. 2018 Jan;23(1):12-16</Citation><ArticleIdList><ArticleId IdType="pubmed">28782685</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2005 Sep;187:235-42</Citation><ArticleIdList><ArticleId IdType="pubmed">16135860</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Med Res Opin. 2014 Aug;30(8):1629-41</Citation><ArticleIdList><ArticleId IdType="pubmed">24666104</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2019 Oct 1;257:600-606</Citation><ArticleIdList><ArticleId IdType="pubmed">31344528</ArticleId></ArticleIdList></Reference><Reference><Citation>CNS Spectr. 2013 Dec;18(6):285-8</Citation><ArticleIdList><ArticleId IdType="pubmed">24300463</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Med Res Opin. 2010 Jun;26(6):1485-96</Citation><ArticleIdList><ArticleId IdType="pubmed">20429835</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoeconomics. 2003;21(9):601-22</Citation><ArticleIdList><ArticleId IdType="pubmed">12807364</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12084427</PMID><DateCompleted><Year>2002</Year><Month>07</Month><Day>31</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0920-9964</ISSN><JournalIssue CitedMedium="Print"><Volume>56</Volume><Issue>1-2</Issue><PubDate><Year>2002</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>Schizophrenia research</Title><ISOAbbreviation>Schizophr Res</ISOAbbreviation></Journal><ArticleTitle>PANSS factors and scores in schizophrenic and bipolar disorders during an index acute episode: a further analysis of the cognitive component.</ArticleTitle><Pagination><MedlinePgn>129-36</MedlinePgn></Pagination><Abstract><AbstractText>To investigate the factor structure of psychotic symptoms, we compared the clinical characteristics of manic patients with those of schizophrenic patients evaluated with positive and negative syndrome scale (PANSS). The clinical symptoms of 148 bipolar patients and 86 schizophrenic patients hospitalized for an index psychotic episode were assessed. Schizophrenic patients showed more positive and cognitive symptoms than bipolars. The factor analysis of the two PANSS scores showed a three-factor solution with 'positive', 'negative' and 'mixed' depressive-activated factors for bipolars and 'positive', 'negative' and 'depressive' factors for schizophrenics. In both groups, the 'cognitive cluster' loaded on the first 'positive' factor while the 'lack of insight' (LOI) has a different meaning in the two groups, more related to the positive symptoms in the bipolar patients and more related to the negative symptoms in the schizophrenic patients. This finding suggests that LOI could be a non-unitary phenomenon in psychoses and it should be further explored to better elucidate differences in symptom structures between schizophrenic and bipolar disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Daneluzzo</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Clinical Psychology, Villa Serena Medical Center, Viale L. Petruzzi, 19, I-65013, CittÃ  S. Angelo, Pescara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arduini</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Rinaldi</LastName><ForeName>O</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Di Domenico</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Petruzzi</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Kalyvoka</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Rossi</LastName><ForeName>A</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Schizophr Res</MedlineTA><NlmUniqueID>8804207</NlmUniqueID><ISSNLinking>0920-9964</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001364" MajorTopicYN="Y">Awareness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="N">Delusions</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010343" MajorTopicYN="N">Patient Admission</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="Y">Schizophrenic Psychology</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>6</Month><Day>27</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>8</Month><Day>1</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>6</Month><Day>27</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12084427</ArticleId><ArticleId IdType="pii">S0920996401002778</ArticleId><ArticleId IdType="doi">10.1016/s0920-9964(01)00277-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15001816</PMID><DateCompleted><Year>2004</Year><Month>06</Month><Day>07</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1535-1084</ISSN><JournalIssue CitedMedium="Print"><Volume>5</Volume><Issue>1</Issue><PubDate><Year>2004</Year></PubDate></JournalIssue><Title>Neuromolecular medicine</Title><ISOAbbreviation>Neuromolecular Med</ISOAbbreviation></Journal><ArticleTitle>Bipolar disorder and schizophrenia: convergent molecular data.</ArticleTitle><Pagination><MedlinePgn>109-17</MedlinePgn></Pagination><Abstract><AbstractText>Bipolar disorder (BPD) and schizophrenia (SZ) may have some common susceptibility genes, despite that current nosology separates them into nonoverlapping categories. The evidence for shared genetic factors includes epidemiologic characteristics, family studies, and overlap in confirmed linkages of BPD and/or SZ. Review of these data indicates that there are five genomic regions that may represent shared genetic susceptibility of BPD and SZ. As the genes underlying these confirmed linkages are identified, the current nosology must be changed to reflect the new knowledge concerning the shared etiologies of BPD and SZ.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Berrettini</LastName><ForeName>Wade</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Center for Neurobiology and Behavior, University of Pennsylvania, PA, USA. wadeb@mail.med.upenn.edu</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuromolecular Med</MedlineTA><NlmUniqueID>101135365</NlmUniqueID><ISSNLinking>1535-1084</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001923" MajorTopicYN="N">Brain Chemistry</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008040" MajorTopicYN="N">Genetic Linkage</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016678" MajorTopicYN="N">Genome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>76</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2003</Year><Month>10</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2003</Year><Month>10</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>3</Month><Day>6</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>6</Month><Day>21</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>3</Month><Day>6</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15001816</ArticleId><ArticleId IdType="pii">NMM:5:1:109</ArticleId><ArticleId IdType="doi">10.1385/NMM:5:1:109</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Genet Epidemiol. 1997;14(6):665-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9433560</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1975 May;126:449-56</Citation><ArticleIdList><ArticleId IdType="pubmed">1079150</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 2003 Jul;73(1):34-48</Citation><ArticleIdList><ArticleId IdType="pubmed">12802786</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet. 1999 Aug 20;88(4):411-5</Citation><ArticleIdList><ArticleId IdType="pubmed">10402510</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 2002 Dec;71(6):1296-302</Citation><ArticleIdList><ArticleId IdType="pubmed">12402217</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nerv Ment Dis. 1994 Aug;182(8):476-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8040660</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet. 1997 Apr 18;74(2):121-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9129709</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet. 1998 Jul 10;81(4):290-5</Citation><ArticleIdList><ArticleId IdType="pubmed">9674973</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2002 Dec;72(3):243-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12450641</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2002;7(2):189-200</Citation><ArticleIdList><ArticleId IdType="pubmed">11840312</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1996 Dec;153(12):1541-7</Citation><ArticleIdList><ArticleId IdType="pubmed">8942449</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet. 1998 Jul 10;81(4):296-301</Citation><ArticleIdList><ArticleId IdType="pubmed">9674974</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 1999 Jan;4(1):76-84</Citation><ArticleIdList><ArticleId IdType="pubmed">10089014</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 2003 Jul;73(1):17-33</Citation><ArticleIdList><ArticleId IdType="pubmed">12802787</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 1995 Nov;11(3):321-4</Citation><ArticleIdList><ArticleId IdType="pubmed">7581457</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2001 Jun 5;98(12):6917-22</Citation><ArticleIdList><ArticleId IdType="pubmed">11381111</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 2000 Oct;26(2):163-75</Citation><ArticleIdList><ArticleId IdType="pubmed">11017071</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2003 Jan;73(1-2):133-46</Citation><ArticleIdList><ArticleId IdType="pubmed">12507746</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1993 Dec;50(12):952-60</Citation><ArticleIdList><ArticleId IdType="pubmed">8250681</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1977 Sep;34(9):1074-83</Citation><ArticleIdList><ArticleId IdType="pubmed">302694</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2003 Jul;8(7):706-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12874607</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2001 Mar;6(2):202-10</Citation><ArticleIdList><ArticleId IdType="pubmed">11317223</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1982 Oct;39(10):1157-67</Citation><ArticleIdList><ArticleId IdType="pubmed">7125846</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet. 1996 Nov 22;67(6):580-94</Citation><ArticleIdList><ArticleId IdType="pubmed">8950417</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 1998 Oct;63(4):1139-52</Citation><ArticleIdList><ArticleId IdType="pubmed">9758604</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2001 Aug;158(8):1258-64</Citation><ArticleIdList><ArticleId IdType="pubmed">11481160</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 2003 Jul;73(1):49-62</Citation><ArticleIdList><ArticleId IdType="pubmed">12802785</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):16859-64</Citation><ArticleIdList><ArticleId IdType="pubmed">12477929</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1991 May;148(5):612-6</Citation><ArticleIdList><ArticleId IdType="pubmed">2018162</ArticleId></ArticleIdList></Reference><Reference><Citation>Physiol Genomics. 2000 Nov 09;4(1):83-91</Citation><ArticleIdList><ArticleId IdType="pubmed">11074017</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2001 Jan 16;98(2):585-90</Citation><ArticleIdList><ArticleId IdType="pubmed">11149935</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet. 1994 Mar 15;54(1):36-43</Citation><ArticleIdList><ArticleId IdType="pubmed">8178837</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1993 Nov;50(11):871-83</Citation><ArticleIdList><ArticleId IdType="pubmed">8215813</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1984 Jan;41(1):13-21</Citation><ArticleIdList><ArticleId IdType="pubmed">6691780</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2000 Nov;5(6):638-49</Citation><ArticleIdList><ArticleId IdType="pubmed">11126394</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 2002 Sep;71(3):565-74</Citation><ArticleIdList><ArticleId IdType="pubmed">12119601</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 2003 Jan;72(1):83-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12478479</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1988 Apr;45(4):323-7</Citation><ArticleIdList><ArticleId IdType="pubmed">3355319</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 1999 Oct;65(4):1096-103</Citation><ArticleIdList><ArticleId IdType="pubmed">10486329</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 1982 Apr;65(4):253-62</Citation><ArticleIdList><ArticleId IdType="pubmed">7080847</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 1997 Apr;60(4):851-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9106531</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 2003 May;72(5):1131-40</Citation><ArticleIdList><ArticleId IdType="pubmed">12647258</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet. 2000 Feb 7;96(1):18-23</Citation><ArticleIdList><ArticleId IdType="pubmed">10686547</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1982 Feb;139(2):209-12</Citation><ArticleIdList><ArticleId IdType="pubmed">7055292</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet B Neuropsychiatr Genet. 2003 Jan 1;116B(1):90-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12497621</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2002 Oct 1;57(2-3):259-66</Citation><ArticleIdList><ArticleId IdType="pubmed">12223257</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1974 Jul;31(1):73-7</Citation><ArticleIdList><ArticleId IdType="pubmed">4835987</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet. 2000 Dec 4;96(6):836-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11121192</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1999 May 11;96(10):5604-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10318931</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2003 Jan;73(1-2):1-5</Citation><ArticleIdList><ArticleId IdType="pubmed">12507732</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1988 Apr;45(4):328-36</Citation><ArticleIdList><ArticleId IdType="pubmed">3355320</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 2001 Oct;29(2):223-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11586304</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2004 Jan;9(1):87-92; image 5</Citation><ArticleIdList><ArticleId IdType="pubmed">14699445</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 1995 Dec;57(6):1384-94</Citation><ArticleIdList><ArticleId IdType="pubmed">8533768</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2002;7(4):405-11</Citation><ArticleIdList><ArticleId IdType="pubmed">11986984</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 2002 Oct;71(4):877-92</Citation><ArticleIdList><ArticleId IdType="pubmed">12145742</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1985 Apr;142(4):447-55</Citation><ArticleIdList><ArticleId IdType="pubmed">3976917</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1995 May;52(5):367-73</Citation><ArticleIdList><ArticleId IdType="pubmed">7726717</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2000 May;61(5):329-34</Citation><ArticleIdList><ArticleId IdType="pubmed">10847306</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2001 May 31;411(6837):599-603</Citation><ArticleIdList><ArticleId IdType="pubmed">11385576</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1994 Jun 21;91(13):5918-21</Citation><ArticleIdList><ArticleId IdType="pubmed">8016089</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 2002 Aug;71(2):337-48</Citation><ArticleIdList><ArticleId IdType="pubmed">12098102</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 1995 Nov;11(3):241-7</Citation><ArticleIdList><ArticleId IdType="pubmed">7581446</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet. 1996 Feb 16;67(1):40-5</Citation><ArticleIdList><ArticleId IdType="pubmed">8678112</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 1998 Sep;20(1):70-3</Citation><ArticleIdList><ArticleId IdType="pubmed">9731535</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13675-80</Citation><ArticleIdList><ArticleId IdType="pubmed">12364586</ArticleId></ArticleIdList></Reference><Reference><Citation>Genet Epidemiol. 1997;14(6):563-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9433543</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2003 Jan;60(1):82-91</Citation><ArticleIdList><ArticleId IdType="pubmed">12511175</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet. 1997 May 31;74(3):238-46</Citation><ArticleIdList><ArticleId IdType="pubmed">9184305</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1999 Aug;156(8):1164-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10450255</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">25779034</PMID><DateCompleted><Year>2015</Year><Month>10</Month><Day>16</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-7123</ISSN><JournalIssue CitedMedium="Internet"><Volume>232</Volume><Issue>2</Issue><PubDate><Year>2015</Year><Month>May</Month><Day>30</Day></PubDate></JournalIssue><Title>Psychiatry research</Title><ISOAbbreviation>Psychiatry Res</ISOAbbreviation></Journal><ArticleTitle>Widespread white matter tract aberrations in youth with familial risk for bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>184-92</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.pscychresns.2015.02.007</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0925-4927(15)00056-6</ELocationID><Abstract><AbstractText>Few studies have examined multiple measures of white matter (WM) differences in youth with familial risk for bipolar disorder (FR-BD). To investigate WM in the FR-BD group, we used three measures of WM structure and two methods of analysis. We used fractional anisotropy (FA), axial diffusivity (AD), and radial diffusivity (RD) to analyze diffusion tensor imaging (DTI) findings in 25 youth with familial risk for bipolar disorder, defined as having both a parent with BD and mood dysregulation, and 16 sex-, age-, and IQ-matched healthy controls. We conducted a whole brain voxelwise analysis using tract based spatial statistics (TBSS). Subsequently, we conducted a complementary atlas-based, region-of-interest analysis using Diffeomap to confirm results seen in TBSS. When TBSS was used, significant widespread between-group differences were found showing increased FA, increased AD, and decreased RD in the FR-BD group in the bilateral uncinate fasciculus, cingulum, cingulate, superior fronto-occipital fasciculus (SFOF), superior longitudinal fasciculus (SLF), inferior longitudinal fasciculus, and corpus callosum. Atlas-based analysis confirmed significant between-group differences, with increased FA and decreased RD in the FR-BD group in the SLF, cingulum, and SFOF. We found significant widespread WM tract aberrations in youth with familial risk for BD using two complementary methods of DTI analysis. </AbstractText><CopyrightInformation>Copyright Â© 2015 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Roybal</LastName><ForeName>Donna J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Division of Child and Adolescent Psychiatry, Department of Psychiatry and Behavioral Sciences, School of Medicine(,) Stanford University, Stanford, CA, USA. Electronic address: roybal@uthscsa.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barnea-Goraly</LastName><ForeName>Naama</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Center for Interdisciplinary Brain Sciences Research, Department of Psychiatry, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kelley</LastName><ForeName>Ryan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Center for Interdisciplinary Brain Sciences Research, Department of Psychiatry, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bararpour</LastName><ForeName>Layla</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Center for Interdisciplinary Brain Sciences Research, Department of Psychiatry, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Howe</LastName><ForeName>Meghan E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Division of Child and Adolescent Psychiatry, Department of Psychiatry and Behavioral Sciences, School of Medicine(,) Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reiss</LastName><ForeName>Allan L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Center for Interdisciplinary Brain Sciences Research, Department of Psychiatry, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Kiki D</ForeName><Initials>KD</Initials><AffiliationInfo><Affiliation>Division of Child and Adolescent Psychiatry, Department of Psychiatry and Behavioral Sciences, School of Medicine(,) Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH077047</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01MH077047-01A1</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1TR001085</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001085</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 MH019908</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>02</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Psychiatry Res</MedlineTA><NlmUniqueID>7911385</NlmUniqueID><ISSNLinking>0165-1781</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056324" MajorTopicYN="N">Diffusion Tensor Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009415" MajorTopicYN="N">Nerve Net</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066127" MajorTopicYN="N">White Matter</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Atlas-based analysis</Keyword><Keyword MajorTopicYN="N">Diffeomap</Keyword><Keyword MajorTopicYN="N">Diffusion tensor imaging</Keyword><Keyword MajorTopicYN="N">Neuroimaging</Keyword><Keyword MajorTopicYN="N">Pediatric</Keyword><Keyword MajorTopicYN="N">Tract-based spatial statistics</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>05</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>11</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>02</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>3</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>3</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>10</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25779034</ArticleId><ArticleId IdType="pii">S0925-4927(15)00056-6</ArticleId><ArticleId IdType="doi">10.1016/j.pscychresns.2015.02.007</ArticleId><ArticleId IdType="pmc">PMC6147249</ArticleId><ArticleId IdType="mid">NIHMS945240</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bipolar Disord. 2007 Dec;9(8):799-809</Citation><ArticleIdList><ArticleId IdType="pubmed">18076529</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2003 Jun 1;53(11):970-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12788242</ArticleId></ArticleIdList></Reference><Reference><Citation>Dev Psychopathol. 2006 Fall;18(4):1037-53</Citation><ArticleIdList><ArticleId IdType="pubmed">17064428</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2009 Apr 1;65(7):586-93</Citation><ArticleIdList><ArticleId IdType="pubmed">19027102</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2010 Dec;49(12):1260-8</Citation><ArticleIdList><ArticleId IdType="pubmed">21093775</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2010 Aug 15;52(2):415-28</Citation><ArticleIdList><ArticleId IdType="pubmed">20420929</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2005 Jan;10(1):105-16</Citation><ArticleIdList><ArticleId IdType="pubmed">15340357</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2009 Aug 1;66(3):238-44</Citation><ArticleIdList><ArticleId IdType="pubmed">19389661</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2011 Oct;50(10):1001-16.e3</Citation><ArticleIdList><ArticleId IdType="pubmed">21961775</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2005 Sep 30;309(5744):2226-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16195465</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2005 Apr 1;57(7):733-42</Citation><ArticleIdList><ArticleId IdType="pubmed">15820230</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2008 Jun;10(4):460-8</Citation><ArticleIdList><ArticleId IdType="pubmed">18452442</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2012 Dec 5;32(49):17612-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23223284</ArticleId></ArticleIdList></Reference><Reference><Citation>Magn Reson Med. 2009 May;61(5):1255-60</Citation><ArticleIdList><ArticleId IdType="pubmed">19253405</ArticleId></ArticleIdList></Reference><Reference><Citation>Cereb Cortex. 2010 Mar;20(3):534-48</Citation><ArticleIdList><ArticleId IdType="pubmed">19520764</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2011 Aug 15;70(4):350-6</Citation><ArticleIdList><ArticleId IdType="pubmed">21429475</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2009 Jan;166(1):18-24</Citation><ArticleIdList><ArticleId IdType="pubmed">19122014</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2007 Nov;103(1-3):29-42</Citation><ArticleIdList><ArticleId IdType="pubmed">17328959</ArticleId></ArticleIdList></Reference><Reference><Citation>Environ Res. 1999 May;80(4):348-54</Citation><ArticleIdList><ArticleId IdType="pubmed">10330308</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2008 Mar;165(3):313-20</Citation><ArticleIdList><ArticleId IdType="pubmed">18245175</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2009 Jul;166(7):795-804</Citation><ArticleIdList><ArticleId IdType="pubmed">19448190</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2008 Apr 1;40(2):570-582</Citation><ArticleIdList><ArticleId IdType="pubmed">18255316</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2013 Aug 15;150(1):70-6</Citation><ArticleIdList><ArticleId IdType="pubmed">23477846</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2010 Oct 1;52(4):1289-301</Citation><ArticleIdList><ArticleId IdType="pubmed">20570617</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2011 Feb;13(1):16-27</Citation><ArticleIdList><ArticleId IdType="pubmed">21320249</ArticleId></ArticleIdList></Reference><Reference><Citation>J Comput Assist Tomogr. 1998 Jan-Feb;22(1):139-52</Citation><ArticleIdList><ArticleId IdType="pubmed">9448779</ArticleId></ArticleIdList></Reference><Reference><Citation>J Magn Reson B. 1996 Jun;111(3):209-19</Citation><ArticleIdList><ArticleId IdType="pubmed">8661285</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2013 Nov;170(11):1317-25</Citation><ArticleIdList><ArticleId IdType="pubmed">24185242</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2003 Jul-Aug;37(4):297-303</Citation><ArticleIdList><ArticleId IdType="pubmed">12765852</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2008 Aug;193(2):126-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18669996</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2009 Jun;46(2):486-99</Citation><ArticleIdList><ArticleId IdType="pubmed">19385016</ArticleId></ArticleIdList></Reference><Reference><Citation>Biophys J. 2005 Nov;89(5):2927-38</Citation><ArticleIdList><ArticleId IdType="pubmed">16100258</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1978 Nov;133:429-35</Citation><ArticleIdList><ArticleId IdType="pubmed">728692</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Psychiatry. 1984 Mar;23(2):191-7</Citation><ArticleIdList><ArticleId IdType="pubmed">6715741</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2006 Feb;163(2):240-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16449477</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2006 Oct;63(10):1139-48</Citation><ArticleIdList><ArticleId IdType="pubmed">17015816</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Neuroinform. 2011 Oct 14;5:23</Citation><ArticleIdList><ArticleId IdType="pubmed">22016733</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2008 Sep;65(9):1041-52</Citation><ArticleIdList><ArticleId IdType="pubmed">18762590</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2012 Jun;14(4):375-410</Citation><ArticleIdList><ArticleId IdType="pubmed">22631621</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2007 Feb;46(2):197-204</Citation><ArticleIdList><ArticleId IdType="pubmed">17242623</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1993 Jul;28(3):143-53</Citation><ArticleIdList><ArticleId IdType="pubmed">8408977</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2012 Sep;14(6):597-606</Citation><ArticleIdList><ArticleId IdType="pubmed">22882719</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2004 Oct;82 Suppl 1:S35-43</Citation><ArticleIdList><ArticleId IdType="pubmed">15571788</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2001 Apr;40(4):450-5</Citation><ArticleIdList><ArticleId IdType="pubmed">11314571</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2010 Dec;49(12):1249-59, 1259.e1</Citation><ArticleIdList><ArticleId IdType="pubmed">21093774</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage Clin. 2013 Apr 05;2:558-68</Citation><ArticleIdList><ArticleId IdType="pubmed">24179807</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2007 Nov;12(11):1001-10</Citation><ArticleIdList><ArticleId IdType="pubmed">17471288</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1997 Jul;36(7):980-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9204677</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2006 Jul 15;31(4):1487-505</Citation><ArticleIdList><ArticleId IdType="pubmed">16624579</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2004 May 1;55(9):875-81</Citation><ArticleIdList><ArticleId IdType="pubmed">15110730</ArticleId></ArticleIdList></Reference><Reference><Citation>Isr J Psychiatry Relat Sci. 2012;49(1):28-43</Citation><ArticleIdList><ArticleId IdType="pubmed">22652927</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2000 Apr;39(4):453-60</Citation><ArticleIdList><ArticleId IdType="pubmed">10761347</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychologia. 2008 Mar 7;46(4):927-34</Citation><ArticleIdList><ArticleId IdType="pubmed">18093622</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Brain Mapp. 2002 Jan;15(1):1-25</Citation><ArticleIdList><ArticleId IdType="pubmed">11747097</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2009 Jun;48(6):636-42</Citation><ArticleIdList><ArticleId IdType="pubmed">19454919</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Imaging Behav. 2013 Jun;7(2):129-39</Citation><ArticleIdList><ArticleId IdType="pubmed">23070746</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Psychol Psychiatry. 2010 Apr;51(4):459-71</Citation><ArticleIdList><ArticleId IdType="pubmed">20085607</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2009 Aug 15;47(2):618-27</Citation><ArticleIdList><ArticleId IdType="pubmed">19398016</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2004 Jun;6(3):197-203</Citation><ArticleIdList><ArticleId IdType="pubmed">15117398</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2008 Oct 15;64(8):730-3</Citation><ArticleIdList><ArticleId IdType="pubmed">18620337</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2009 Jun;194(6):527-34</Citation><ArticleIdList><ArticleId IdType="pubmed">19478293</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2003 Aug;5(4):243-56</Citation><ArticleIdList><ArticleId IdType="pubmed">12895202</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2012 Jun;169(6):642-9</Citation><ArticleIdList><ArticleId IdType="pubmed">22535257</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2006 Feb;163(2):322-4</Citation><ArticleIdList><ArticleId IdType="pubmed">16449490</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Integr Neurosci. 2013 Mar 11;7:9</Citation><ArticleIdList><ArticleId IdType="pubmed">23483798</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9685-90</Citation><ArticleIdList><ArticleId IdType="pubmed">15980148</ArticleId></ArticleIdList></Reference><Reference><Citation>Cereb Cortex. 2005 Dec;15(12):1848-54</Citation><ArticleIdList><ArticleId IdType="pubmed">15758200</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2008 Apr;33(5):976-84</Citation><ArticleIdList><ArticleId IdType="pubmed">17581532</ArticleId></ArticleIdList></Reference><Reference><Citation>NMR Biomed. 2002 Nov-Dec;15(7-8):435-55</Citation><ArticleIdList><ArticleId IdType="pubmed">12489094</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2002 Dec;72(3):209-26</Citation><ArticleIdList><ArticleId IdType="pubmed">12450638</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatr Neurol. 2011 May;44(5):389-93</Citation><ArticleIdList><ArticleId IdType="pubmed">21481751</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2009 May;34(6):1590-600</Citation><ArticleIdList><ArticleId IdType="pubmed">19145224</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2002 Nov;17(3):1429-36</Citation><ArticleIdList><ArticleId IdType="pubmed">12414282</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2009 Jan;48(1):79-86</Citation><ArticleIdList><ArticleId IdType="pubmed">19050654</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2005 Dec;30(12):2225-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15988474</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2009 Feb;11(1):11-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19133962</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2013 Apr 30;206(2-3):223-31</Citation><ArticleIdList><ArticleId IdType="pubmed">23218918</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2007 Oct 31;27(44):11960-5</Citation><ArticleIdList><ArticleId IdType="pubmed">17978036</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2012 Mar 30;36(2):231-8</Citation><ArticleIdList><ArticleId IdType="pubmed">22119745</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2014 Jul;44(10):2139-50</Citation><ArticleIdList><ArticleId IdType="pubmed">24280191</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Adolesc Psychopharmacol. 2002 Spring;12(1):11-25</Citation><ArticleIdList><ArticleId IdType="pubmed">12014591</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2006 Feb;63(2):175-83</Citation><ArticleIdList><ArticleId IdType="pubmed">16461861</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15968808</PMID><DateCompleted><Year>2005</Year><Month>06</Month><Day>23</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0013-9580</ISSN><JournalIssue CitedMedium="Print"><Volume>46 Suppl 4</Volume><PubDate><Year>2005</Year></PubDate></JournalIssue><Title>Epilepsia</Title><ISOAbbreviation>Epilepsia</ISOAbbreviation></Journal><ArticleTitle>Antiepileptic drugs in mood-disordered patients.</ArticleTitle><Pagination><MedlinePgn>38-44</MedlinePgn></Pagination><Abstract><AbstractText>Bipolar disorder is a common, recurrent, often severe mental disorder that, without adequate treatment, is associated with high rates of morbidity and mortality. We review the evidence on the efficacy of a spectrum of antiepileptic drugs (AED) in bipolar disorder. Most studies have been carried out with carbamazepine (CBZ), valproate (VPA), and lamotrigine (LTG). All three of these AEDs have been shown to be of value in the management of patients with bipolar illnesses. VPA and CBZ seem to exert stronger antimanic effects and, to a lesser degree, acute antidepressant efficacy. LTG seems to be effective against depression and mania, with a more robust activity against depression. No firm evidence supports a role for vigabatrin, tiagabine, topiramate, or levetiracetam in these disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gajwani</LastName><ForeName>Prashant</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>NIMH Bipolar Research Center, Case Western Reserve University School of Medicine, Mood Disorders Program, University Hospitals of Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Forsthoff</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Muzina</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Amann</LastName><ForeName>Benedikt</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Keming</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Elhaj</LastName><ForeName>Omar</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Calabrese</LastName><ForeName>Joseph R</ForeName><Initials>JR</Initials></Author><Author ValidYN="Y"><LastName>Grunze</LastName><ForeName>Heinz</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Epilepsia</MedlineTA><NlmUniqueID>2983306R</NlmUniqueID><ISSNLinking>0013-9580</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014227">Triazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C476610">oxcarbamazepine</NameOfSubstance></Chemical><Chemical><RegistryNumber>33CM23913M</RegistryNumber><NameOfSubstance UI="D002220">Carbamazepine</NameOfSubstance></Chemical><Chemical><RegistryNumber>614OI1Z5WI</RegistryNumber><NameOfSubstance UI="D014635">Valproic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>U3H27498KS</RegistryNumber><NameOfSubstance UI="D000077213">Lamotrigine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002220" MajorTopicYN="N">Carbamazepine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077213" MajorTopicYN="N">Lamotrigine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014227" MajorTopicYN="N">Triazines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014635" MajorTopicYN="N">Valproic Acid</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>52</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>6</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>6</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>6</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15968808</ArticleId><ArticleId IdType="doi">10.1111/j.1528-1167.2005.463008.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">3714911</PMID><DateCompleted><Year>1986</Year><Month>06</Month><Day>27</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-1781</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><Issue>4</Issue><PubDate><Year>1986</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Psychiatry research</Title><ISOAbbreviation>Psychiatry Res</ISOAbbreviation></Journal><ArticleTitle>Weight change in depression.</ArticleTitle><Pagination><MedlinePgn>275-83</MedlinePgn></Pagination><Abstract><AbstractText>This report describes the weight changes of 109 outpatients during the course of a depressive illness and relates these changes to several potential predictors: age, gender, diagnosis, and scores on the Hamilton Rating Scale for Depression (HRSD), the Beck Depression Inventory, and the three factors on the Eating Questionnaire. Weight changes ranged from -33 to +50 pounds, with 40% of the patients reporting weight gain, 30% weight loss, and 30% no change in weight. Weight loss occurred more rapidly than did weight gain. The disinhibition factor of the Eating Questionnaire was significantly correlated with weight change during depression and, on a stepwise discriminant function analysis, differentiated weight-gaining from weight-losing patients at a high level of statistical significance. Severity of depression also differentiated weight-gaining from weight-losing patients in the discriminant function analysis, but only on the HRSD and at a level of more modest statistical significance.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Weissenburger</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Rush</LastName><ForeName>A J</ForeName><Initials>AJ</Initials></Author><Author ValidYN="Y"><LastName>Giles</LastName><ForeName>D E</ForeName><Initials>DE</Initials></Author><Author ValidYN="Y"><LastName>Stunkard</LastName><ForeName>A J</ForeName><Initials>AJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH-28459</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Psychiatry Res</MedlineTA><NlmUniqueID>7911385</NlmUniqueID><ISSNLinking>0165-1781</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001835" MajorTopicYN="Y">Body Weight</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005247" MajorTopicYN="N">Feeding Behavior</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1986</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1986</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1986</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">3714911</ArticleId><ArticleId IdType="pii">0165-1781(86)90075-2</ArticleId><ArticleId IdType="doi">10.1016/0165-1781(86)90075-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12950704</PMID><DateCompleted><Year>2004</Year><Month>01</Month><Day>12</Day></DateCompleted><DateRevised><Year>2004</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1323-1316</ISSN><JournalIssue CitedMedium="Print"><Volume>57</Volume><Issue>5</Issue><PubDate><Year>2003</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Psychiatry and clinical neurosciences</Title><ISOAbbreviation>Psychiatry Clin Neurosci</ISOAbbreviation></Journal><ArticleTitle>Unipolar depression with bipolar family history: links with the bipolar spectrum.</ArticleTitle><Pagination><MedlinePgn>497-503</MedlinePgn></Pagination><Abstract><AbstractText>The aim of the present paper was to find if unipolar major depressive disorder (MDD) with bipolar family history could be included in the bipolar spectrum, by comparing it to unipolar MDD without bipolar family history, and to bipolar II disorder, on typical bipolar variables. A sample of 280 consecutive bipolar II outpatients, and a sample of 135 consecutive unipolar MDD outpatients, presenting for major depressive episode (MDE) treatment, were interviewed with the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders (4th edn). Hypomanic symptoms during the MDE were systematically assessed. Clinical variables used to validate the inclusion of unipolar MDD with bipolar family history in the bipolar spectrum were young age of onset, many MDE recurrences, atypical features, and depressive mixed state (DMX; an MDE plus &gt;2 concurrent hypomanic symptoms), following many previous studies reporting that these variables were typical features of bipolar disorders. Means were compared by t-test and frequencies by chi2 test (stata 7). Two-tailed P &lt; 0.05 was chosen. Unipolar MDD with bipolar family history was present in 20% of MDD patients. Comparisons among unipolar MDD with bipolar family history (UP+BPFH), unipolar MDD without bipolar family history (UP-BPFH), and bipolar II (BPII), found that UP+BPFH versus UP-BPFH had a significantly lower age, lower age of onset, fewer recurrences, and more DMX; that UP+BPFH versus BPII had no significant differences (apart from recurrences); and that UP-BPFH versus BPII had significantly different age, age of onset, recurrences, atypical features, and DMX. Findings suggest that UP+BPFH shows many bipolar signs, and that it could therefore be included in the bipolar spectrum. Unipolar MDD with bipolar family history had a clinically significant 20.0% frequency in the unipolar MDD sample, supporting the clinical usefulness of this depression subtype. The subtyping of MDD based on bipolar family history could have treatment implications.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Benazzi</LastName><ForeName>Franco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Outpatient Psychiatry Private Center, Ravenna and Forli (a University of California at San Diego Collaborating Center), Department of Psychiatry, National Mental Health Service, Forli, Italy.f.benazzi@fo.nettuno.it</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Psychiatry Clin Neurosci</MedlineTA><NlmUniqueID>9513551</NlmUniqueID><ISSNLinking>1323-1316</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007558" MajorTopicYN="N" Type="Geographic">Italy</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008487" MajorTopicYN="N">Medical History Taking</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>9</Month><Day>3</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>1</Month><Day>13</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>9</Month><Day>3</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12950704</ArticleId><ArticleId IdType="pii">1154</ArticleId><ArticleId IdType="doi">10.1046/j.1440-1819.2003.01154.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">29864615</PMID><DateCompleted><Year>2019</Year><Month>01</Month><Day>22</Day></DateCompleted><DateRevised><Year>2019</Year><Month>01</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-7123</ISSN><JournalIssue CitedMedium="Internet"><Volume>266</Volume><PubDate><Year>2018</Year><Month>08</Month></PubDate></JournalIssue><Title>Psychiatry research</Title><ISOAbbreviation>Psychiatry Res</ISOAbbreviation></Journal><ArticleTitle>Subtle behavioural responses during negative emotion reactivity and down-regulation in bipolar disorder: A facial expression and eye-tracking study.</ArticleTitle><Pagination><MedlinePgn>152-159</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0165-1781(17)31491-9</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.psychres.2018.04.054</ELocationID><Abstract><AbstractText>Abnormal processing of emotional information and regulation are core trait-related features of bipolar disorder (BD) but evidence from behavioural studies is conflicting. This study aimed to investigate trait-related abnormalities in emotional reactivity and regulation in BD using novel sensitive behavioural measures including facial expressions and eye movements. Fifteen patients with BD in full or partial remission and 16 healthy controls (HCs) were given a computerised task in which they were instructed to 'react to' unpleasant and neutral pictures or 'dampen' their emotional response to aversive pictures. Participants rated their emotional response after each picture block, and eye-movements and facial expressions were recorded. Patients generally gazed less at unpleasant and neutral pictures during emotion processing and regulation. During emotional reactivity, patients exhibited stronger facial expressions to neutral pictures, a lack of facial expressions to unpleasant pictures, and more surprised facial expressions to both neutral and unpleasant pictures compared to HCs. The results point to subtle abnormalities in visual gaze patterns and facial displays of emotion between patients with BD during emotion processing and regulation. Aberrant eye-movements and facial displays could provide a more sensitive measure of emotional reactivity in BD than traditional behavioural measures, which could aid future diagnostic accuracy.</AbstractText><CopyrightInformation>Copyright Â© 2018. Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Broch-Due</LastName><ForeName>Ingrid</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>The Copenhagen Affective Disorder Research Center (CADIC), Psychiatric Center Copenhagen, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, Copenhagen 2100, and Department of Psychology, University of Copenhagen, Oester Farimagsgade 2A, Copenhagen 1353, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>KjÃ¦rstad</LastName><ForeName>Hanne Lie</ForeName><Initials>HL</Initials><AffiliationInfo><Affiliation>The Copenhagen Affective Disorder Research Center (CADIC), Psychiatric Center Copenhagen, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, Copenhagen 2100, and Department of Psychology, University of Copenhagen, Oester Farimagsgade 2A, Copenhagen 1353, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kessing</LastName><ForeName>Lars Vedel</ForeName><Initials>LV</Initials><AffiliationInfo><Affiliation>The Copenhagen Affective Disorder Research Center (CADIC), Psychiatric Center Copenhagen, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, Copenhagen 2100, and Department of Psychology, University of Copenhagen, Oester Farimagsgade 2A, Copenhagen 1353, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miskowiak</LastName><ForeName>Kamilla</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>The Copenhagen Affective Disorder Research Center (CADIC), Psychiatric Center Copenhagen, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, Copenhagen 2100, and Department of Psychology, University of Copenhagen, Oester Farimagsgade 2A, Copenhagen 1353, Denmark. Electronic address: Kamilla@miskowiak.dk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>05</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Psychiatry Res</MedlineTA><NlmUniqueID>7911385</NlmUniqueID><ISSNLinking>0165-1781</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004644" MajorTopicYN="N">Emotions</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005133" MajorTopicYN="N">Eye Movements</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005149" MajorTopicYN="Y">Facial Expression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010775" MajorTopicYN="N">Photic Stimulation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Emotion processing</Keyword><Keyword MajorTopicYN="Y">Emotion regulation</Keyword><Keyword MajorTopicYN="Y">Eye-tracking</Keyword><Keyword MajorTopicYN="Y">Facial expression</Keyword><Keyword MajorTopicYN="Y">Hot cognition</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>08</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>03</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>04</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>1</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29864615</ArticleId><ArticleId IdType="pii">S0165-1781(17)31491-9</ArticleId><ArticleId IdType="doi">10.1016/j.psychres.2018.04.054</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">2404001</PMID><DateCompleted><Year>1990</Year><Month>02</Month><Day>21</Day></DateCompleted><DateRevised><Year>2005</Year><Month>11</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>51 Suppl</Volume><PubDate><Year>1990</Year><Month>Jan</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Anxiety and mood disorders in medically ill patients.</ArticleTitle><Pagination><MedlinePgn>27-32</MedlinePgn></Pagination><Abstract><AbstractText>In medically ill patients, anxiety symptoms and mood alteration are common. Anxiety or mood alteration may be due to a reaction to the stress of illness, a preexisting psychiatric disorder, a manifestation of the medical condition, or an adverse effect of medication. Psychiatrists are frequently called upon to differentiate among these causes and to recommend treatment. This article reviews anxiety, depression, and mania, which are frequently associated with physical disease, and provides an approach to differential diagnosis and treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wise</LastName><ForeName>M G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Ochsner Clinic, New Orleans, LA 70121.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taylor</LastName><ForeName>S E</ForeName><Initials>SE</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001008" MajorTopicYN="N">Anxiety Disorders</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004194" MajorTopicYN="Y">Disease</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>34</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1990</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1990</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1990</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2404001</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30865288</PMID><DateCompleted><Year>2020</Year><Month>06</Month><Day>12</Day></DateCompleted><DateRevised><Year>2020</Year><Month>06</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1600-0447</ISSN><JournalIssue CitedMedium="Internet"><Volume>139</Volume><Issue>5</Issue><PubDate><Year>2019</Year><Month>05</Month></PubDate></JournalIssue><Title>Acta psychiatrica Scandinavica</Title><ISOAbbreviation>Acta Psychiatr Scand</ISOAbbreviation></Journal><ArticleTitle>The association between mixed symptoms, irritability and functioning measured using smartphones in bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>443-453</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/acps.13021</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To (i) validate patient-evaluated mixed symptoms and irritability measured using smartphones against clinical evaluations; (ii) investigate associations between mixed symptoms and irritability with stress, quality of life and functioning, respectively, in patients with bipolar disorder.</AbstractText><AbstractText Label="METHODS">A total of 84 patients with bipolar disorder used a smartphone-based system for daily evaluation of mixed symptoms and irritability for nine months. Clinically evaluated symptoms, stress, quality of life and clinically rated functioning were collected multiple times during follow-up.</AbstractText><AbstractText Label="RESULTS">Patients presented mild affective symptoms. Patient-reported mixed symptoms and irritability correlated with clinical evaluations. In analyses including confounding factors there was a statistically significant association between both mixed symptoms and irritability and stress (PÂ &lt;Â 0.0001) and between irritability and both quality of life and functioning (PÂ &lt;Â 0.0001) respectively. There was no association between mixed mood and both quality of life and functioning.</AbstractText><AbstractText Label="CONCLUSION">Mixed symptoms and irritability can be validly self-reported using smartphones in patients with bipolar disorder. Mixed symptoms and irritability are associated with increased stress even during full or partial remission. Irritability is associated with decreased quality of life and functioning. The findings emphasize the clinical importance of identifying inter-episodic symptoms including irritability pointing towards smartphones as a valid tool.</AbstractText><CopyrightInformation>Â© 2019 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Faurholt-Jepsen</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Copenhagen Affective Disorder Research Center (CADIC), Psychiatric Center Copenhagen, Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frost</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Monsenso ApS, Valby, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Christensen</LastName><ForeName>E M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Copenhagen Affective Disorder Research Center (CADIC), Psychiatric Center Copenhagen, Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bardram</LastName><ForeName>J E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Department of Applied Mathematics and Computer Science, The Technical University of Denmark, Lyngby, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vinberg</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Copenhagen Affective Disorder Research Center (CADIC), Psychiatric Center Copenhagen, Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kessing</LastName><ForeName>L V</ForeName><Initials>LV</Initials><AffiliationInfo><Affiliation>Copenhagen Affective Disorder Research Center (CADIC), Psychiatric Center Copenhagen, Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>The Mental Health Services in the Capital Region of Denmark including the Centre for Telemedicine in the Capital Region of Denmark, the EU 7th Frame Programme</Agency><Country>International</Country></Grant><Grant><Agency>IT University of Copenhagen</Agency><Country>International</Country></Grant><Grant><Agency>Tryg foundation</Agency><Country>International</Country></Grant><Grant><Agency>Lundbeck Foundation</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>03</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Acta Psychiatr Scand</MedlineTA><NlmUniqueID>0370364</NlmUniqueID><ISSNLinking>0001-690X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Acta Psychiatr Scand. 2019 Oct;140(4):293-294</RefSource><PMID Version="1">31535365</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="N">Affect</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000342" MajorTopicYN="N">Affective Symptoms</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003718" MajorTopicYN="N" Type="Geographic">Denmark</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007508" MajorTopicYN="N">Irritable Mood</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057566" MajorTopicYN="N">Self Report</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068997" MajorTopicYN="N">Smartphone</DescriptorName><QualifierName UI="Q000295" MajorTopicYN="Y">instrumentation</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013315" MajorTopicYN="N">Stress, Psychological</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">bipolar disorder</Keyword><Keyword MajorTopicYN="Y">irritability</Keyword><Keyword MajorTopicYN="Y">mixed symptoms</Keyword><Keyword MajorTopicYN="Y">smartphone</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>03</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>3</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>3</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30865288</ArticleId><ArticleId IdType="doi">10.1111/acps.13021</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">32279906</PMID><DateCompleted><Year>2020</Year><Month>11</Month><Day>10</Day></DateCompleted><DateRevised><Year>2020</Year><Month>11</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-2653</ISSN><JournalIssue CitedMedium="Internet"><Volume>78</Volume><PubDate><Year>2020</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia</Title><ISOAbbreviation>J Clin Neurosci</ISOAbbreviation></Journal><ArticleTitle>Association of MIF and MBL2 gene polymorphisms with attempted suicide in patients diagnosed with schizophrenia or bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>264-268</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0967-5868(20)30294-0</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jocn.2020.04.001</ELocationID><Abstract><AbstractText>The aim of this study to investigate the genetic polymorphisms in macrophage inhibitory factor (MIF) and mannose-binding lectin 2 (MBL2) gene in schizophrenia (SCZ) or bipolar disorder (BD) patients with attempted suicide by comparing with a non-attempted SCZ or BD patients and healthy controls. A sample of 108 patients with SCZ, 100 patients with BD and 100 healthy volunteers were included in the study. SCID-I was used to confirm the diagnosis according to DSM-IV-TR criteria. The patients were evaluated by data forms that included sociodemographic, suicidal behavior and symptom severity information. PCR-RFLP was used to determine MIF and MBL2 gene polymorphisms from DNA material. Our results demonstrated that the distributions of MBL2 genotype (AA, AB, BB), combined genotype (AA, AB/BB) and the allele frequencies (A, B) of attempted suicide patients in SCZ were significantly different from the non-attempted SCZ patients. The distributions of the MBL2 genotype of attempted suicide patients in SCZ were significantly different from the control group. The distributions of MIF genotype (GG, GC, CC), combined genotype (GG, GC/CC) and the allele frequencies (G, C) of attempted suicide patients in BD were significantly different from the non-attempted BD patients or control group. In summary MBL2 gene polymorphism may be associated with attempted suicide in SCZ and MIF gene polymorphism might be associated with attempted suicide in BD. However, further studies with other gene variants in different ethnic populations are needed to address the exact role of these polymorphisms in SCZ or BD.</AbstractText><CopyrightInformation>Copyright Â© 2020 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Aytac</LastName><ForeName>Hasan Mervan</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Psychiatry Unit, Malazgirt State Hospital, Mus, Turkey. Electronic address: hasanmervan.aytac@saglik.gov.tr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oyaci</LastName><ForeName>Yasemin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Medical Biology, Istanbul Faculty of Medicine, Istanbul University, Turkey. Electronic address: yaseminf@hotmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yazar</LastName><ForeName>Menekse Sila</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Bakirkoy Research and Training Hospital for Psychiatry, Neurology and Neurosurgery, Istanbul, Turkey. Electronic address: meneksesila@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Erol</LastName><ForeName>Ayse</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medical Biology, Istanbul Faculty of Medicine, Istanbul University, Turkey. Electronic address: bioayseerol@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pehlivan</LastName><ForeName>Sacide</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medical Biology, Istanbul Faculty of Medicine, Istanbul University, Turkey. Electronic address: sacide.pehlivan@istanbul.edu.tr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Scotland</Country><MedlineTA>J Clin Neurosci</MedlineTA><NlmUniqueID>9433352</NlmUniqueID><ISSNLinking>0967-5868</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C445619">MBL2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008263">Macrophage Migration-Inhibitory Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D037601">Mannose-Binding Lectin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 5.3.-</RegistryNumber><NameOfSubstance UI="D019746">Intramolecular Oxidoreductases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 5.3.2.1</RegistryNumber><NameOfSubstance UI="C515598">MIF protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019746" MajorTopicYN="N">Intramolecular Oxidoreductases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008263" MajorTopicYN="N">Macrophage Migration-Inhibitory Factors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D037601" MajorTopicYN="N">Mannose-Binding Lectin</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="N">Schizophrenic Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013406" MajorTopicYN="Y">Suicide, Attempted</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Attempted suicide</Keyword><Keyword MajorTopicYN="N">Bipolar disorder</Keyword><Keyword MajorTopicYN="N">Inflammation</Keyword><Keyword MajorTopicYN="N">MBL2</Keyword><Keyword MajorTopicYN="N">MIF</Keyword><Keyword MajorTopicYN="N">Schizophrenia</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>02</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>04</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>11</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32279906</ArticleId><ArticleId IdType="pii">S0967-5868(20)30294-0</ArticleId><ArticleId IdType="doi">10.1016/j.jocn.2020.04.001</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">7665540</PMID><DateCompleted><Year>1995</Year><Month>10</Month><Day>11</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>56</Volume><Issue>9</Issue><PubDate><Year>1995</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Clozapine in severe mood disorders.</ArticleTitle><Pagination><MedlinePgn>411-7</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">A growing literature suggests that the atypical antipsychotic agent clozapine may be effective in schizoaffective and psychotic mood disorders.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">To evaluate the efficacy and tolerability of clozapine in severe mood disorders, we reviewed published studies on clozapine in schizophrenia, bipolar disorder, schizoaffective disorder, major depression, and organic disorders with psychotic or major affective syndromes, identified through the MEDLINE data base.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Patients in manic or psychotic phases of schizoaffective or bipolar disorder were significantly more likely to respond to clozapine than patients with schizophrenia (p = .006) or severe depressive syndromes (unipolar, bipolar, and schizoaffective depression combined; p = .001). There was no significant difference in the side effect profile secondary to clozapine in patients with severe mood disorders compared to patients with schizophrenia.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Clozapine appears to be effective and well-tolerated in the short-term and maintenance treatment of severe or psychotic mood disorders, particularly in the manic-excited phases of schizoaffective and bipolar disorders, even in patients who have not responded well to conventional pharmacotherapies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zarate</LastName><ForeName>C A</ForeName><Initials>CA</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Bipolar and Psychotic Disorders Program, Mailman Research Center, McLean Hospital, Belmont, Mass 02178, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tohen</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Baldessarini</LastName><ForeName>R J</ForeName><Initials>RJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>J60AR2IKIC</RegistryNumber><NameOfSubstance UI="D003024">Clozapine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003024" MajorTopicYN="N">Clozapine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018849" MajorTopicYN="N">Controlled Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016239" MajorTopicYN="N">MEDLINE</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>59</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1995</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>3</Month><Day>28</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1995</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">7665540</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25937241</PMID><DateCompleted><Year>2016</Year><Month>05</Month><Day>06</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-7862</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>8</Issue><PubDate><Year>2015</Year><Month>Aug</Month></PubDate></JournalIssue><Title>European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology</Title><ISOAbbreviation>Eur Neuropsychopharmacol</ISOAbbreviation></Journal><ArticleTitle>Hyperprolactinemia and medications for bipolar disorder: systematic review of a neglected issue in clinical practice.</ArticleTitle><Pagination><MedlinePgn>1045-59</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.euroneuro.2015.04.007</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0924-977X(15)00107-8</ELocationID><Abstract><AbstractText>Drug-induced changes in serum prolactin (sPrl) levels constitute a relevant issue due to the potentially severe consequences on physical health of psychiatric patients such as sexual dysfunctions, osteoporosis and Prl-sensitive tumors. Several drugs have been associated to sPrl changes. Only antipsychotics have been extensively studied as sPrl-elevating agents in schizophrenia, but the extent to which bipolar disorder (BD) treatments affect sPrl levels is much less known. The objective of this systematic review is to summarize the evidence of the effects of drugs used in BD on Prl. This review followed the PRISMA statement. The MEDLINE/PubMed/Index Medicus, EMBASE, and Cochrane Library databases were systematically searched for articles in English appearing from any time to May 30, 2014. Twenty-six studies were included. These suggest that treatments for BD are less likely to be associated with Prl elevations, with valproate, quetiapine, lurasidone, mirtazapine, and bupropion reported not to change PRL levels significantly and lithium and aripiprazole to lower them in some studies. Taking into account the effects of the different classes of drugs on Prl may improve the care of BD patients requiring long-term pharmacotherapy. Based on the results of this review, lithium and valproate appear to be safer due to their low potential to elevate sPrL; among antipsychotics, quetiapine, lurasidone and aripiprazole appear to be similarly safe. </AbstractText><CopyrightInformation>Copyright Â© 2015 Elsevier B.V. and ECNP. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pacchiarotti</LastName><ForeName>Isabella</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Bipolar Disorders Unit, Institute of Neuroscience, Hospital ClÃ­nic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murru</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Bipolar Disorders Unit, Institute of Neuroscience, Hospital ClÃ­nic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kotzalidis</LastName><ForeName>Georgios D</ForeName><Initials>GD</Initials><AffiliationInfo><Affiliation>NESMOS Department (Neuroscience, Mental Health, and Sensory Organs), Sapienza University, School of Medicine and Psychology, Sant×³Andrea Hospital, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonnin</LastName><ForeName>C Mar</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Bipolar Disorders Unit, Institute of Neuroscience, Hospital ClÃ­nic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mazzarini</LastName><ForeName>Lorenzo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>NESMOS Department (Neuroscience, Mental Health, and Sensory Organs), Sapienza University, School of Medicine and Psychology, Sant×³Andrea Hospital, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colom</LastName><ForeName>Francesc</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Bipolar Disorders Unit, Institute of Neuroscience, Hospital ClÃ­nic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vieta</LastName><ForeName>Eduard</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Bipolar Disorders Unit, Institute of Neuroscience, Hospital ClÃ­nic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain. Electronic address: evieta@clinic.ub.es.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>04</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Eur Neuropsychopharmacol</MedlineTA><NlmUniqueID>9111390</NlmUniqueID><ISSNLinking>0924-977X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006966" MajorTopicYN="N">Hyperprolactinemia</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antidepressants</Keyword><Keyword MajorTopicYN="N">Antipsychotics</Keyword><Keyword MajorTopicYN="N">Bipolar disorder</Keyword><Keyword MajorTopicYN="N">Hyperprolactinemia</Keyword><Keyword MajorTopicYN="N">Mood stabilizers</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>09</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>03</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>04</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>5</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>5</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>5</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25937241</ArticleId><ArticleId IdType="pii">S0924-977X(15)00107-8</ArticleId><ArticleId IdType="doi">10.1016/j.euroneuro.2015.04.007</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15935234</PMID><DateCompleted><Year>2005</Year><Month>09</Month><Day>23</Day></DateCompleted><DateRevised><Year>2009</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-0327</ISSN><JournalIssue CitedMedium="Print"><Volume>86</Volume><Issue>2-3</Issue><PubDate><Year>2005</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Parental death and bipolar disorder: a robust association was found in early maternal suicide.</ArticleTitle><Pagination><MedlinePgn>151-9</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Previous studies have suggested that early parental death may be associated with the emergence of bipolar disorder in later life. However, it remains unknown whether this association applies specifically to parental death due to suicide or only to early parental death. The present study aimed to explore whether suicide as well as the non-suicidal death of father, mother, or siblings are associated with an increased risk for bipolar disorder, and whether the possible association is modified by the age at which the subject experiences such a death in the family.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The subjects were born in 1960 or later and were first admitted to or had first contact with Danish psychiatric facilities between 1981 and 1998 with a diagnosis of bipolar disorder, and fifty age-matched controls per case were extracted. The effects of the deaths of relatives were estimated by means of a conditional logistic regression analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 947 subjects with bipolar disorder and 47,350 controls, those having experienced the parental suicide were significantly associated with an increased risk for BPD (incidence rate ratios: 1.83 [95% confidence interval: 1.07 to 3.12] for paternal suicide, 3.44 [1.97 to 6.00] for maternal suicide), whereas the non-suicidal death of parents showed no such association. Those having experienced maternal suicide at some point before reaching 10 years of age were seven times as likely to develop bipolar disorder.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">The cohort members were followed until, but not exceeding, the age of 38.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Early parental, particularly maternal, suicide increases the risk for bipolar disorder in the offspring. Possible explanations include a family history of mental disorders as well as psychosocial factors.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tsuchiya</LastName><ForeName>Kenji J</ForeName><Initials>KJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurology, Hamamatsu University School of Medicine, Handayama 1, Hamamatsu 4313192, Japan. tsuchiya@zah.att.ne.jp</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agerbo</LastName><ForeName>Esben</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Mortensen</LastName><ForeName>Preben B</ForeName><Initials>PB</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001601" MajorTopicYN="Y">Bereavement</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002423" MajorTopicYN="Y">Cause of Death</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016241" MajorTopicYN="N">Child of Impaired Parents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003718" MajorTopicYN="N" Type="Geographic">Denmark</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005220" MajorTopicYN="N">Fathers</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009035" MajorTopicYN="N">Mothers</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010290" MajorTopicYN="Y">Parents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035781" MajorTopicYN="N">Siblings</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013405" MajorTopicYN="N">Suicide</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2004</Year><Month>06</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2005</Year><Month>01</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>6</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>9</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>6</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15935234</ArticleId><ArticleId IdType="pii">S0165-0327(05)00012-1</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2005.01.006</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17581446</PMID><DateCompleted><Year>2008</Year><Month>01</Month><Day>29</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0890-8567</ISSN><JournalIssue CitedMedium="Print"><Volume>46</Volume><Issue>7</Issue><PubDate><Year>2007</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Journal of the American Academy of Child and Adolescent Psychiatry</Title><ISOAbbreviation>J Am Acad Child Adolesc Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Dialectical behavior therapy for adolescents with bipolar disorder: a 1-year open trial.</ArticleTitle><Pagination><MedlinePgn>820-30</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To describe an adapted version of dialectical behavior therapy for adolescents with bipolar disorder.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">The dialectical behavior therapy intervention is delivered over 1 year and consists of two modalities: family skills training (conducted with individual family units) and individual therapy. The acute treatment period (6 months) includes 24 weekly sessions; sessions alternate between the two treatment modalities. Continuation treatment consists of 12 additional sessions tapering in frequency through 1 year. We conducted an open pilot trial of the treatment, designed as an adjunct to pharmacological management, to establish feasibility and acceptability of the treatment for this population. Participants included 10 patients (mean age 15.8 +/- 1.5 years, range 14-18) receiving treatment in an outpatient pediatric bipolar specialty clinic. Symptom severity and functioning were assessed quarterly by an independent evaluator. Consumer satisfaction was also assessed posttreatment.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Feasibility and acceptability of the intervention were high, with 9 of 10 patients completing treatment, 90% of scheduled sessions attended, and high treatment satisfaction ratings. Patients exhibited significant improvement from pre- to posttreatment in suicidality, nonsuicidal self-injurious behavior, emotional dysregulation, and depressive symptoms.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Dialectical behavior therapy may offer promise as an approach to the psychosocial treatment of adolescent bipolar disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Goldstein</LastName><ForeName>Tina R</ForeName><Initials>TR</Initials><AffiliationInfo><Affiliation>Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA. goldsteintr@upmc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Axelson</LastName><ForeName>David A</ForeName><Initials>DA</Initials></Author><Author ValidYN="Y"><LastName>Birmaher</LastName><ForeName>Boris</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Brent</LastName><ForeName>David A</ForeName><Initials>DA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH18951</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH66371</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 MH074581-01A2</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 MH066371</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 MH018951</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 MH074581</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Am Acad Child Adolesc Psychiatry</MedlineTA><NlmUniqueID>8704565</NlmUniqueID><ISSNLinking>0890-8567</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001521" MajorTopicYN="N">Behavior Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002985" MajorTopicYN="N">Clinical Protocols</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005196" MajorTopicYN="N">Family Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008370" MajorTopicYN="N">Manuals as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="N">Research Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>6</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>1</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>6</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17581446</ArticleId><ArticleId IdType="doi">10.1097/chi.0b013e31805c1613</ArticleId><ArticleId IdType="pii">S0890-8567(09)62170-5</ArticleId><ArticleId IdType="pmc">PMC2823290</ArticleId><ArticleId IdType="mid">NIHMS175483</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Child Adolesc Psychopharmacol. 2003 Winter;13(4):463-70</Citation><ArticleIdList><ArticleId IdType="pubmed">14977459</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2004 Mar;43(3):276-82</Citation><ArticleIdList><ArticleId IdType="pubmed">15076260</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2004 May;43(5):528-37</Citation><ArticleIdList><ArticleId IdType="pubmed">15100559</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann N Y Acad Sci. 2004 Jun;1021:1-22</Citation><ArticleIdList><ArticleId IdType="pubmed">15251869</ArticleId></ArticleIdList></Reference><Reference><Citation>Can J Psychiatry. 2004 Aug;49(8):551-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15453104</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Res Ther. 1983;21(4):335-40</Citation><ArticleIdList><ArticleId IdType="pubmed">6626104</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1985 Jul;42(7):696-702</Citation><ArticleIdList><ArticleId IdType="pubmed">4015311</ArticleId></ArticleIdList></Reference><Reference><Citation>J Consult Clin Psychol. 1986 Oct;54(5):724-5</Citation><ArticleIdList><ArticleId IdType="pubmed">3771893</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1989 Sep;28(5):723-8</Citation><ArticleIdList><ArticleId IdType="pubmed">2793800</ArticleId></ArticleIdList></Reference><Reference><Citation>J Autism Dev Disord. 1993 Jun;23(2):243-62</Citation><ArticleIdList><ArticleId IdType="pubmed">8331046</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1994 Dec;151(12):1771-6</Citation><ArticleIdList><ArticleId IdType="pubmed">7977884</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1995 Apr;34(4):454-63</Citation><ArticleIdList><ArticleId IdType="pubmed">7751259</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1995 Apr;34(4):464-71</Citation><ArticleIdList><ArticleId IdType="pubmed">7751260</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1995 Jun;34(6):724-31</Citation><ArticleIdList><ArticleId IdType="pubmed">7608045</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 1996 Dec 20;65(3):189-98</Citation><ArticleIdList><ArticleId IdType="pubmed">9029668</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1997 Jul;36(7):980-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9204677</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1997 Sep;36(9):1168-76</Citation><ArticleIdList><ArticleId IdType="pubmed">9291717</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1998 Jun;55(6):547-52</Citation><ArticleIdList><ArticleId IdType="pubmed">9633674</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2004 Oct;82 Suppl 1:S113-28</Citation><ArticleIdList><ArticleId IdType="pubmed">15571785</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2005 Mar;44(3):213-35</Citation><ArticleIdList><ArticleId IdType="pubmed">15725966</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Clin North Am. 2005 Jun;28(2):385-97</Citation><ArticleIdList><ArticleId IdType="pubmed">15826738</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2005 Sep;44(9):846-71</Citation><ArticleIdList><ArticleId IdType="pubmed">16113615</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Adolesc Psychopharmacol. 2005 Dec;15(6):913-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16379511</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2005 Dec;7(6):525-35</Citation><ArticleIdList><ArticleId IdType="pubmed">16403178</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2006 Feb;63(2):175-83</Citation><ArticleIdList><ArticleId IdType="pubmed">16461861</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2006 Aug;8(4):350-61</Citation><ArticleIdList><ArticleId IdType="pubmed">16879136</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2006 Oct;63(10):1130-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17015815</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2006 Oct;63(10):1139-48</Citation><ArticleIdList><ArticleId IdType="pubmed">17015816</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2001 Aug;3(4):202-10</Citation><ArticleIdList><ArticleId IdType="pubmed">11552959</ArticleId></ArticleIdList></Reference><Reference><Citation>Suicide Life Threat Behav. 2002 Summer;32(2):146-57</Citation><ArticleIdList><ArticleId IdType="pubmed">12079031</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2003 Jun 1;53(11):970-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12788242</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2003 Jun 1;53(11):1009-20</Citation><ArticleIdList><ArticleId IdType="pubmed">12788246</ArticleId></ArticleIdList></Reference><Reference><Citation>J Marital Fam Ther. 2003 Oct;29(4):491-504</Citation><ArticleIdList><ArticleId IdType="pubmed">14593691</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18302734</PMID><DateCompleted><Year>2008</Year><Month>04</Month><Day>10</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2458</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><PubDate><Year>2008</Year><Month>Feb</Month><Day>26</Day></PubDate></JournalIssue><Title>BMC public health</Title><ISOAbbreviation>BMC Public Health</ISOAbbreviation></Journal><ArticleTitle>Daylight saving time transitions and hospital treatments due to accidents or manic episodes.</ArticleTitle><Pagination><MedlinePgn>74</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/1471-2458-8-74</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Daylight saving time affects millions of people annually but its impacts are still widely unknown. Sleep deprivation and the change of circadian rhythm can trigger mental illness and cause higher accident rates. Transitions into and out of daylight saving time changes the circadian rhythm and may cause sleep deprivation. Thus it seems plausible that the prevalence of accidents and/or manic episodes may be higher after transition into and out of daylight saving time. The aim of this study was to explore the effects of transitions into and out of daylight saving time on the incidence of accidents and manic episodes in the Finnish population during the years of 1987 to 2003.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The nationwide data were derived from the Finnish Hospital Discharge Register. From the register we obtained the information about the hospital-treated accidents and manic episodes during two weeks before and two weeks after the transitions in 1987-2003.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The results were negative, as the transitions into or out of daylight saving time had no significant effect on the incidence of accidents or manic episodes.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">One-hour transitions do not increase the incidence of manic episodes or accidents which require hospital treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lahti</LastName><ForeName>Tuuli A</ForeName><Initials>TA</Initials><AffiliationInfo><Affiliation>Department of Mental Health and Alcohol Research, National Public Health Institute, Helsinki, Finland. tuuli.lahti@ktl.fi</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haukka</LastName><ForeName>Jari</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>LÃ¶nnqvist</LastName><ForeName>Jouko</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Partonen</LastName><ForeName>Timo</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>02</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Public Health</MedlineTA><NlmUniqueID>100968562</NlmUniqueID><ISSNLinking>1471-2458</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000059" MajorTopicYN="N">Accidents</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="Y">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002940" MajorTopicYN="Y">Circadian Rhythm</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004636" MajorTopicYN="N">Emergency Service, Hospital</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005387" MajorTopicYN="N">Finland</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D038801" MajorTopicYN="N">International Classification of Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015233" MajorTopicYN="N">Models, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012892" MajorTopicYN="N">Sleep Deprivation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013995" MajorTopicYN="Y">Time</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>06</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>02</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>2</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>4</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>2</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18302734</ArticleId><ArticleId IdType="pii">1471-2458-8-74</ArticleId><ArticleId IdType="doi">10.1186/1471-2458-8-74</ArticleId><ArticleId IdType="pmc">PMC2266740</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Minn Med. 2000 Aug;83(8):25-30</Citation><ArticleIdList><ArticleId IdType="pubmed">10974915</ArticleId></ArticleIdList></Reference><Reference><Citation>Ergonomics. 1980 Feb;23(2):167-78</Citation><ArticleIdList><ArticleId IdType="pubmed">7398616</ArticleId></ArticleIdList></Reference><Reference><Citation>Soc Psychiatry Psychiatr Epidemiol. 1998 May;33(5):211-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9604670</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Physiol. 2008 Feb 12;8:3</Citation><ArticleIdList><ArticleId IdType="pubmed">18269740</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 2006 Oct 9;406(3):174-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16930838</ArticleId></ArticleIdList></Reference><Reference><Citation>Aust N Z J Psychiatry. 1995 Sep;29(3):449-53</Citation><ArticleIdList><ArticleId IdType="pubmed">8573048</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Biol. 2007 Nov 20;17(22):1996-2000</Citation><ArticleIdList><ArticleId IdType="pubmed">17964164</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2004 Oct;161(10):1814-21</Citation><ArticleIdList><ArticleId IdType="pubmed">15465978</ArticleId></ArticleIdList></Reference><Reference><Citation>J Circadian Rhythms. 2006 Jan 19;4:1</Citation><ArticleIdList><ArticleId IdType="pubmed">16423282</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Public Health. 1995 Jan;85(1):92-5</Citation><ArticleIdList><ArticleId IdType="pubmed">7832269</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 2002 Jan-Feb;43(1):37-40</Citation><ArticleIdList><ArticleId IdType="pubmed">11788917</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 1996 Apr 4;334(14):924</Citation><ArticleIdList><ArticleId IdType="pubmed">8596592</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1980 Dec;2(4):239-47</Citation><ArticleIdList><ArticleId IdType="pubmed">6450783</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleep. 1995 Dec;18(10):908-11</Citation><ArticleIdList><ArticleId IdType="pubmed">8746400</ArticleId></ArticleIdList></Reference><Reference><Citation>Fed Proc. 1983 Aug;42(11):2809-14</Citation><ArticleIdList><ArticleId IdType="pubmed">6873309</ArticleId></ArticleIdList></Reference><Reference><Citation>Accid Anal Prev. 2004 May;36(3):351-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15003579</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Mol Cell Biol. 2005 Dec;6(12):965-71</Citation><ArticleIdList><ArticleId IdType="pubmed">16341082</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">33418281</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>21</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1876-2026</ISSN><JournalIssue CitedMedium="Internet"><Volume>56</Volume><PubDate><Year>2021</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Asian journal of psychiatry</Title><ISOAbbreviation>Asian J Psychiatr</ISOAbbreviation></Journal><ArticleTitle>Does CACNA1C rs1006737 genotype play a role in lithium treatment response in bipolar disorder patients?</ArticleTitle><Pagination><MedlinePgn>102525</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S1876-2018(20)30638-9</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ajp.2020.102525</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Paul</LastName><ForeName>Pradip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Molecular Genetics Laboratory, Department of Psychiatry, National Institute of Mental Health and Neuro Sciences (NIMHANS), Bangalore, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nadella</LastName><ForeName>Ravi Kumar</ForeName><Initials>RK</Initials><AffiliationInfo><Affiliation>Molecular Genetics Laboratory, Department of Psychiatry, National Institute of Mental Health and Neuro Sciences (NIMHANS), Bangalore, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Viswanath</LastName><ForeName>Biju</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Molecular Genetics Laboratory, Department of Psychiatry, National Institute of Mental Health and Neuro Sciences (NIMHANS), Bangalore, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reddy</LastName><ForeName>Y C Janardhan</ForeName><Initials>YCJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, National Institute of Mental Health and Neuro Sciences (NIMHANS), Bangalore, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jain</LastName><ForeName>Sanjeev</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Molecular Genetics Laboratory, Department of Psychiatry, National Institute of Mental Health and Neuro Sciences (NIMHANS), Bangalore, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Purushottam</LastName><ForeName>Meera</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Molecular Genetics Laboratory, Department of Psychiatry, National Institute of Mental Health and Neuro Sciences (NIMHANS), Bangalore, India. Electronic address: meera.purushottam@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>12</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Asian J Psychiatr</MedlineTA><NlmUniqueID>101517820</NlmUniqueID><ISSNLinking>1876-2018</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C079146">CACNA1C protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020746">Calcium Channels, L-Type</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020746" MajorTopicYN="N">Calcium Channels, L-Type</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="Y">Lithium</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>11</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>12</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>1</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>1</Month><Day>8</Day><Hour>20</Hour><Minute>16</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33418281</ArticleId><ArticleId IdType="pii">S1876-2018(20)30638-9</ArticleId><ArticleId IdType="doi">10.1016/j.ajp.2020.102525</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24243532</PMID><DateCompleted><Year>2014</Year><Month>05</Month><Day>05</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1535-1645</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>12</Issue><PubDate><Year>2013</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Current psychiatry reports</Title><ISOAbbreviation>Curr Psychiatry Rep</ISOAbbreviation></Journal><ArticleTitle>Toward clinically applicable biomarkers in bipolar disorder: focus on BDNF, inflammatory markers, and endothelial function.</ArticleTitle><Pagination><MedlinePgn>425</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11920-013-0425-9</ELocationID><Abstract><AbstractText>The importance of biomarkers to many branches of medicine is illustrated by their utility in diagnosis and monitoring treatment response and outcome. There is much enthusiasm in the field of mood disorders on the emergence of clinically relevant biomarkers with several potential targets. While there are generally accepted criteria to establish a biomarker, such approaches are premature for our field as we acquire evidence on the most relevant candidates. A number of components of the inflammatory pathway are supported by published data together with an increasing focus on brain-derived neurotrophic factor. These markers may have measurable impacts on endothelial function, which may be particularly amenable to study in clinical samples. The adolescent population is a key focus as identifying biomarkers before the onset of comorbid medical conditions and which may help direct early intervention seem especially promising. A systematic approach to biomarker development in mood disorders is clearly warranted. </AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Goldstein</LastName><ForeName>Benjamin I</ForeName><Initials>BI</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Toronto, Toronto, ON, Canada, benjamin.goldstein@sunnybrook.ca.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Young</LastName><ForeName>L Trevor</ForeName><Initials>LT</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH059929</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Psychiatry Rep</MedlineTA><NlmUniqueID>100888960</NlmUniqueID><ISSNLinking>1523-3812</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019208">Brain-Derived Neurotrophic Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018836">Inflammation Mediators</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019208" MajorTopicYN="N">Brain-Derived Neurotrophic Factor</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004730" MajorTopicYN="N">Endothelium, Vascular</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018836" MajorTopicYN="N">Inflammation Mediators</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>11</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>11</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>5</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24243532</ArticleId><ArticleId IdType="doi">10.1007/s11920-013-0425-9</ArticleId><ArticleId IdType="pmc">PMC3926699</ArticleId><ArticleId IdType="mid">NIHMS541105</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Neuroreport. 2007 Oct 8;18(15):1567-70</Citation><ArticleIdList><ArticleId IdType="pubmed">17885603</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2009 Aug;116(3):214-7</Citation><ArticleIdList><ArticleId IdType="pubmed">19251324</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neuropsychopharmacol. 2009 May;12(4):447-58</Citation><ArticleIdList><ArticleId IdType="pubmed">18771602</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2010 Oct;49(10):980-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20855043</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychother Psychosom. 2012;81(4):235-43</Citation><ArticleIdList><ArticleId IdType="pubmed">22584147</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2011 Aug;45(8):995-1004</Citation><ArticleIdList><ArticleId IdType="pubmed">21550050</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Cardiol. 2001 Jul 15;88(2):196-8, A7</Citation><ArticleIdList><ArticleId IdType="pubmed">11448425</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2013 Jul 1;74(1):15-25</Citation><ArticleIdList><ArticleId IdType="pubmed">23419545</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2009 Sep;11(6):657-62</Citation><ArticleIdList><ArticleId IdType="pubmed">19689508</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2009 Oct;43(15):1200-4</Citation><ArticleIdList><ArticleId IdType="pubmed">19501841</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychosom Med. 2009 Jul;71(6):598-606</Citation><ArticleIdList><ArticleId IdType="pubmed">19561163</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 1995 Mar-Apr;29(2):141-52</Citation><ArticleIdList><ArticleId IdType="pubmed">7666381</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pediatr Endocrinol Metab. 2007 Oct;20(10):1125-36</Citation><ArticleIdList><ArticleId IdType="pubmed">18051931</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2012 Nov;46(11):1511-4</Citation><ArticleIdList><ArticleId IdType="pubmed">22939945</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2008 Dec;69(12):1953-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19026266</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2013 Jan 10;144(1-2):16-27</Citation><ArticleIdList><ArticleId IdType="pubmed">22749156</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 2002 Aug 16;328(3):261-4</Citation><ArticleIdList><ArticleId IdType="pubmed">12147321</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2001 May;64(2-3):185-93</Citation><ArticleIdList><ArticleId IdType="pubmed">11313085</ArticleId></ArticleIdList></Reference><Reference><Citation>Aust N Z J Psychiatry. 2013 Apr;47(4):321-32</Citation><ArticleIdList><ArticleId IdType="pubmed">23411094</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Cardiol. 2005 Jun 22;102(1):169-71</Citation><ArticleIdList><ArticleId IdType="pubmed">15939120</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Coll Cardiol. 2006 Jul 4;48(1):170-5</Citation><ArticleIdList><ArticleId IdType="pubmed">16814663</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 1997 Apr 3;336(14):973-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9077376</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Cardiol. 2007 Apr 15;99(8):1134-6</Citation><ArticleIdList><ArticleId IdType="pubmed">17437742</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Heart J. 2008 May;29(9):1110-7</Citation><ArticleIdList><ArticleId IdType="pubmed">18400765</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2013 Sep;47(9):1119-33</Citation><ArticleIdList><ArticleId IdType="pubmed">23768870</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2006 Oct 15;60(8):889-91</Citation><ArticleIdList><ArticleId IdType="pubmed">16730331</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2007 Dec;104(1-3):91-5</Citation><ArticleIdList><ArticleId IdType="pubmed">17434599</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Psychopharmacol. 2008 Mar;23(2):87-94</Citation><ArticleIdList><ArticleId IdType="pubmed">18172906</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2009 May;14(5):523-31</Citation><ArticleIdList><ArticleId IdType="pubmed">18180758</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2009 Aug;70(8):1078-90</Citation><ArticleIdList><ArticleId IdType="pubmed">19497250</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2007 Sep;10(9):1089-93</Citation><ArticleIdList><ArticleId IdType="pubmed">17726474</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2007 Dec;41(12):979-90</Citation><ArticleIdList><ArticleId IdType="pubmed">17239400</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2001 Sep;58(9):844-50</Citation><ArticleIdList><ArticleId IdType="pubmed">11545667</ArticleId></ArticleIdList></Reference><Reference><Citation>Development. 2000 Nov;127(21):4531-40</Citation><ArticleIdList><ArticleId IdType="pubmed">11023857</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2006 Sep;86(1-3):321-2</Citation><ArticleIdList><ArticleId IdType="pubmed">16829047</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2007 Sep;9(6):596-602</Citation><ArticleIdList><ArticleId IdType="pubmed">17845274</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychosom Med. 2006 Jan-Feb;68(1):80-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16449415</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2008 Nov 20;359(21):2195-207</Citation><ArticleIdList><ArticleId IdType="pubmed">18997196</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2009 Nov 13;33(8):1366-71</Citation><ArticleIdList><ArticleId IdType="pubmed">19666076</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2008 Dec;69(12):1948-52</Citation><ArticleIdList><ArticleId IdType="pubmed">19203478</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2007 Jan 15;61(2):142-4</Citation><ArticleIdList><ArticleId IdType="pubmed">16893527</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2010 Nov;71(11):1518-25</Citation><ArticleIdList><ArticleId IdType="pubmed">20584522</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2006 Jun 15;59(12):1116-27</Citation><ArticleIdList><ArticleId IdType="pubmed">16631126</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2006 Feb;90(2-3):263-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16410025</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2007 Jun;46(6):687-700</Citation><ArticleIdList><ArticleId IdType="pubmed">17513981</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2013 Sep 03;8(9):e73520</Citation><ArticleIdList><ArticleId IdType="pubmed">24019926</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Invest. 2005 Mar;115(3):653-63</Citation><ArticleIdList><ArticleId IdType="pubmed">15765148</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2005 Jun;29(5):658-63</Citation><ArticleIdList><ArticleId IdType="pubmed">15905010</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2008 Apr;65(4):395-407</Citation><ArticleIdList><ArticleId IdType="pubmed">18391128</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2010 Apr;15(4):384-92</Citation><ArticleIdList><ArticleId IdType="pubmed">19488045</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardiovasc Drugs Ther. 2009 Oct;23(5):369-76</Citation><ArticleIdList><ArticleId IdType="pubmed">19636689</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2006 Jul;11(7):680-4</Citation><ArticleIdList><ArticleId IdType="pubmed">16491133</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychosom Med. 2010 Feb;72(2):122-7</Citation><ArticleIdList><ArticleId IdType="pubmed">20100885</ArticleId></ArticleIdList></Reference><Reference><Citation>Circulation. 2005 Oct 4;112(14):2114-20</Citation><ArticleIdList><ArticleId IdType="pubmed">16186425</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 2006 May 8;398(3):215-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16480819</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropharmacology. 1998 Dec;37(12):1553-61</Citation><ArticleIdList><ArticleId IdType="pubmed">9886678</ArticleId></ArticleIdList></Reference><Reference><Citation>Circulation. 2009 May 5;119(17):2408-16</Citation><ArticleIdList><ArticleId IdType="pubmed">19364974</ArticleId></ArticleIdList></Reference><Reference><Citation>Scand J Immunol. 2003 May;57(5):493-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12753507</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2007 Sep 1;62(5):530-5</Citation><ArticleIdList><ArticleId IdType="pubmed">17560556</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2004 Jul;65(7):940-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15291683</ArticleId></ArticleIdList></Reference><Reference><Citation>Hypertension. 2009 Nov;54(5):919-50</Citation><ArticleIdList><ArticleId IdType="pubmed">19729599</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychosom Med. 2010 Jan;72(1):20-6</Citation><ArticleIdList><ArticleId IdType="pubmed">19875632</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2009 Sep;43(14):1171-4</Citation><ArticleIdList><ArticleId IdType="pubmed">19473667</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1987 Nov-Dec;13(3):287-92</Citation><ArticleIdList><ArticleId IdType="pubmed">2960722</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2009 Jul;34(8):1904-13</Citation><ArticleIdList><ArticleId IdType="pubmed">19295510</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2004 Dec 30;129(3):267-72</Citation><ArticleIdList><ArticleId IdType="pubmed">15661320</ArticleId></ArticleIdList></Reference><Reference><Citation>FEBS Lett. 2000 Mar 24;470(2):113-7</Citation><ArticleIdList><ArticleId IdType="pubmed">10734218</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 2008 Mar 12;433(2):98-102</Citation><ArticleIdList><ArticleId IdType="pubmed">18242852</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci Res. 2006 Dec;84(8):1656-68</Citation><ArticleIdList><ArticleId IdType="pubmed">17061253</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2007 Jun;9 Suppl 1:128-35</Citation><ArticleIdList><ArticleId IdType="pubmed">17543031</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 2009 Mar 13;452(2):111-3</Citation><ArticleIdList><ArticleId IdType="pubmed">19383424</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 1999 Jul-Aug;33(4):335-40</Citation><ArticleIdList><ArticleId IdType="pubmed">10404471</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2009 Oct;70(10):1461-6</Citation><ArticleIdList><ArticleId IdType="pubmed">19744408</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2007 May 9;31(4):952-5</Citation><ArticleIdList><ArticleId IdType="pubmed">17391822</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychosom Med. 2011 Jul-Aug;73(6):456-61</Citation><ArticleIdList><ArticleId IdType="pubmed">21715299</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neuropsychopharmacol. 2011 Apr;14(3):347-53</Citation><ArticleIdList><ArticleId IdType="pubmed">20604989</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2000 Mar 16;342(11):763-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10717011</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuroimmunol. 2004 May;150(1-2):116-22</Citation><ArticleIdList><ArticleId IdType="pubmed">15081255</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Intern Med. 2009 Oct 6;151(7):483-95</Citation><ArticleIdList><ArticleId IdType="pubmed">19805771</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 2009 Dec 11;466(3):139-43</Citation><ArticleIdList><ArticleId IdType="pubmed">19786073</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2009 Apr;48(4):386-399</Citation><ArticleIdList><ArticleId IdType="pubmed">19252450</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2007 Nov;9(7):743-53</Citation><ArticleIdList><ArticleId IdType="pubmed">17988365</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Pathol. 1999 Oct;155(4):1183-93</Citation><ArticleIdList><ArticleId IdType="pubmed">10514401</ArticleId></ArticleIdList></Reference><Reference><Citation>J Natl Cancer Inst. 2001 Jul 18;93(14):1054-61</Citation><ArticleIdList><ArticleId IdType="pubmed">11459866</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2008 Sep;47(9):1077-85</Citation><ArticleIdList><ArticleId IdType="pubmed">18664999</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Arch Psychiatry Clin Neurosci. 2008 Aug;258(5):300-4</Citation><ArticleIdList><ArticleId IdType="pubmed">18297417</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Adolesc Psychopharmacol. 2011 Oct;21(5):479-84</Citation><ArticleIdList><ArticleId IdType="pubmed">22040193</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1999 Apr 15;45(8):989-94</Citation><ArticleIdList><ArticleId IdType="pubmed">10386181</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Cardiol. 2003 Oct 15;92(8):984-7</Citation><ArticleIdList><ArticleId IdType="pubmed">14556880</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Cardiovasc Med. 2007 May;17(4):140-3</Citation><ArticleIdList><ArticleId IdType="pubmed">17482097</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatrics. 2006 Oct;118(4):1683-91</Citation><ArticleIdList><ArticleId IdType="pubmed">17015562</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Rev Neurother. 2013 Jul;13(7):827-42</Citation><ArticleIdList><ArticleId IdType="pubmed">23898853</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2008 Feb;10(1):95-100</Citation><ArticleIdList><ArticleId IdType="pubmed">18199246</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2004 Sep;161(9):1698-700</Citation><ArticleIdList><ArticleId IdType="pubmed">15337662</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2000 Mar 23;342(12):836-43</Citation><ArticleIdList><ArticleId IdType="pubmed">10733371</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pept Sci. 2006 Aug;12(8):515-24</Citation><ArticleIdList><ArticleId IdType="pubmed">16680799</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2009 Sep;11(6):663-71</Citation><ArticleIdList><ArticleId IdType="pubmed">19689509</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2013 Sep 5;150(2):456-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23684514</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2012 Mar;137(1-3):151-5</Citation><ArticleIdList><ArticleId IdType="pubmed">22252095</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2011 Feb;168(2):114-6</Citation><ArticleIdList><ArticleId IdType="pubmed">21297044</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11941660</PMID><DateCompleted><Year>2002</Year><Month>04</Month><Day>26</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0012-7183</ISSN><JournalIssue CitedMedium="Print"><Volume>115</Volume><Issue>17</Issue><PubDate><Year>1999</Year></PubDate></JournalIssue><Title>Duodecim; laaketieteellinen aikakauskirja</Title><ISOAbbreviation>Duodecim</ISOAbbreviation></Journal><ArticleTitle>[The changing drug therapy of bipolar disorder].</ArticleTitle><Pagination><MedlinePgn>1911-7</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Leinonen</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>TAYS:n psykogeriatrian klinikka 33380 PitkÃ¤niemi. esa.leinonen@tays.fi</Affiliation></AffiliationInfo></Author></AuthorList><Language>fin</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Kaksisuuntaisen mielialahÃ¤iriÃ¶n muuttuva lÃ¤Ã¤kehoito.</VernacularTitle></Article><MedlineJournalInfo><Country>Finland</Country><MedlineTA>Duodecim</MedlineTA><NlmUniqueID>0373207</NlmUniqueID><ISSNLinking>0012-7183</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>12794-10-4</RegistryNumber><NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001569" MajorTopicYN="N">Benzodiazepines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011570" MajorTopicYN="N">Psychiatry</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>40</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>4</Month><Day>11</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>4</Month><Day>27</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>4</Month><Day>11</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11941660</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15934881</PMID><DateCompleted><Year>2006</Year><Month>04</Month><Day>14</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1744-7666</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>4</Issue><PubDate><Year>2005</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Expert opinion on pharmacotherapy</Title><ISOAbbreviation>Expert Opin Pharmacother</ISOAbbreviation></Journal><ArticleTitle>Prepubertal bipolar disorder: available pharmacological treatment options.</ArticleTitle><Pagination><MedlinePgn>547-60</MedlinePgn></Pagination><Abstract><AbstractText>Awareness of bipolar spectrum disorders in children is rapidly increasing, with a more precise definition of their clinical subtypes and early signs. Paediatric bipolar disorder can lead to an important impairment in scholastic, familial and social functioning, and to a higher risk for substance abuse and suicide. In the context of a multimodal approach, the core treatment of early-onset bipolar disorder is pharmacological. This review focuses on the empirical evidence for pharmacotherapy in paediatric bipolar disorder. Mood stabilizers, including lithium, and older and newer anticonvulsivants will be considered, in mono- or polypharmacy. Atypical antipsychotics will be considered in more severe and/or treatment-resistant manic or mixed episodes. Finally, the prophylaxis of intercritical phases and the management of specific challenging conditions, such as bipolar depression and attention deficit hyperactivity disorder, with bipolar comorbidity, will be reviewed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Masi</LastName><ForeName>Gabriele</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>IRCCS Stella Maris, Scientific Institute of Child Neurology and Psychiatry, Via dei Giacinti 2, 56018 Calambrone, Pisa, Italy. gabriele.masi@inpe.unipi.it</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Opin Pharmacother</MedlineTA><NlmUniqueID>100897346</NlmUniqueID><ISSNLinking>1465-6566</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011627" MajorTopicYN="N">Puberty</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>121</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>6</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>4</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>6</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15934881</ArticleId><ArticleId IdType="doi">10.1517/14656566.6.4.547</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10374652</PMID><DateCompleted><Year>1999</Year><Month>12</Month><Day>23</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0920-9964</ISSN><JournalIssue CitedMedium="Print"><Volume>37</Volume><Issue>2</Issue><PubDate><Year>1999</Year><Month>May</Month><Day>25</Day></PubDate></JournalIssue><Title>Schizophrenia research</Title><ISOAbbreviation>Schizophr Res</ISOAbbreviation></Journal><ArticleTitle>Meta-analysis of brain size in bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>177-81</MedlinePgn></Pagination><Abstract><AbstractText>A recent meta-analysis concluded that patients with schizophrenia have reduced cerebral volume, and this finding has been used to implicate neurodevelopmental events in the etiology of this disorder. Since bipolar-disorder patients and schizophrenia patients have some similar brain abnormalities, it was of interest to meta-analytically review the literature on brain size in bipolar disorder. Only seven studies met the inclusion/exclusion criteria for our meta-analysis, but none reported the brain size differences between the bipolar patients and the controls to be statistically significant. The composite effect size was a negligible 0.04 (95% CI: -0.17 to 0.25) and statistically not significantly different from 0.0 (no effect). Thus, it appears that bipolar disorder is not associated with the same cerebral volume reductions noted in schizophrenia. Implications for hypotheses regarding the etiology of the two disorders are discussed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hoge</LastName><ForeName>E A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>School of Medicine, Case Western Reserve University, University Hospitals of Cleveland, OH 44106-5000, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Friedman</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Schulz</LastName><ForeName>S C</ForeName><Initials>SC</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Schizophr Res</MedlineTA><NlmUniqueID>8804207</NlmUniqueID><ISSNLinking>0920-9964</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016239" MajorTopicYN="N">MEDLINE</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year><Month>6</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1999</Year><Month>6</Month><Day>22</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1999</Year><Month>6</Month><Day>22</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10374652</ArticleId><ArticleId IdType="pii">S0920-9964(98)00149-2</ArticleId><ArticleId IdType="doi">10.1016/s0920-9964(98)00149-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11302568</PMID><DateCompleted><Year>2001</Year><Month>08</Month><Day>09</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0176-3679</ISSN><JournalIssue CitedMedium="Print"><Volume>34</Volume><Issue>2</Issue><PubDate><Year>2001</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Pharmacopsychiatry</Title><ISOAbbreviation>Pharmacopsychiatry</ISOAbbreviation></Journal><ArticleTitle>Atypical antipsychotics in bipolar and schizoaffective disorders.</ArticleTitle><Pagination><MedlinePgn>80-1</MedlinePgn></Pagination><Abstract><AbstractText>No data are available comparing the relative efficacy of different atypical agents in patients with bipolar disorder. A chart review of bipolar and schizoaffective disorder patients who had received courses of at least two atypical agents (n = 33) in a community psychiatry system was conducted. No differences in rates of hospitalizations were found between individual atypical agents or between atypical agents as a class and conventional neuroleptics. However, a significant reduction in rates of emergency room visits was found with atypical agents compared to conventional neuroleptics, with a trend toward greater reduction with clozapine compared to other atypical antipsychotics. Larger prospective studies are needed to confirm these preliminary observations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>E S</ForeName><Initials>ES</Initials><AffiliationInfo><Affiliation>University of Texas Southwestern Medical Center at Dallas Department of Psychiatry, 75390-9070, USA. sherwood.brown@utsouthwestern.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>N R</ForeName><Initials>NR</Initials></Author><Author ValidYN="Y"><LastName>Carmody</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Mahadi</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Nejtek</LastName><ForeName>V A</ForeName><Initials>VA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Pharmacopsychiatry</MedlineTA><NlmUniqueID>8402938</NlmUniqueID><ISSNLinking>0176-3679</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004632" MajorTopicYN="N">Emergency Medical Services</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>4</Month><Day>17</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>8</Month><Day>10</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>4</Month><Day>17</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11302568</ArticleId><ArticleId IdType="doi">10.1055/s-2001-15179</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26799153</PMID><DateCompleted><Year>2017</Year><Month>09</Month><Day>22</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1469-7610</ISSN><JournalIssue CitedMedium="Internet"><Volume>57</Volume><Issue>6</Issue><PubDate><Year>2016</Year><Month>06</Month></PubDate></JournalIssue><Title>Journal of child psychology and psychiatry, and allied disciplines</Title><ISOAbbreviation>J Child Psychol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Actigraph measures discriminate pediatric bipolar disorder from attention-deficit/hyperactivity disorder and typically developing controls.</ArticleTitle><Pagination><MedlinePgn>706-16</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/jcpp.12520</ELocationID><Abstract><AbstractText Label="BACKGROUND">Distinguishing pediatric bipolar disorder (BD) from attention-deficit hyperactivity disorder (ADHD) can be challenging. Hyperactivity is a core feature of both disorders, but severely disturbed sleep and circadian dysregulation are more characteristic of BD, at least in adults. We tested the hypothesis that objective measures of activity, sleep, and circadian rhythms would help differentiate pediatric subjects with BD from ADHD and typically developing controls.</AbstractText><AbstractText Label="METHODS">Unmedicated youths (NÂ =Â 155, 97 males, age 5-18) were diagnosed using DSM-IV criteria with Kiddie-SADS PL/E. BD youths (nÂ =Â 48) were compared to typically developing controls (nÂ =Â 42) and children with ADHD (nÂ =Â 44) or ADHD plus comorbid depressive disorders (nÂ =Â 21). Three-to-five days of minute-to-minute belt-worn actigraph data (Ambulatory Monitoring Inc.), collected during the school week, were processed to yield 28 metrics per subject, and assessed for group differences with analysis of covariance. Cross-validated machine learning algorithms were used to determine the predictive accuracy of a four-parameter model, with measures reflecting sleep, hyperactivity, and circadian dysregulation, plus Indic's bipolar vulnerability index (VI).</AbstractText><AbstractText Label="RESULTS">There were prominent group differences in several activity measures, notably mean 5 lowest hours of activity, skewness of diurnal activity, relative circadian amplitude, and VI.Â A predictive support vector machine model discriminated bipolar from non-bipolar with mean accuracy of 83.1Â Â±Â 5.4%, ROC area of 0.781Â Â±Â 0.071, kappa of 0.587Â Â±Â 0.136, specificity of 91.7Â Â±Â 5.3%, and sensitivity of 64.4Â Â±Â 13.6%.</AbstractText><AbstractText Label="CONCLUSIONS">Objective measures of sleep, circadian rhythmicity, and hyperactivity were abnormal in BD. Wearable sensor technology may provide bio-behavioral markers that can help differentiate children with BD from ADHD and healthy controls.</AbstractText><CopyrightInformation>Â© 2016 Association for Child and Adolescent Mental Health.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Faedda</LastName><ForeName>Gianni L</ForeName><Initials>GL</Initials><AffiliationInfo><Affiliation>Mood Disorders Center 'Lucio Bini', New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Child and Adolescent Psychiatry, NYU Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ohashi</LastName><ForeName>Kyoko</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Developmental Biopsychiatry Research Program, McLean Hospital, 115 Mill Street, Belmont, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hernandez</LastName><ForeName>Mariely</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Mood Disorders Center 'Lucio Bini', New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McGreenery</LastName><ForeName>Cynthia E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Developmental Biopsychiatry Research Program, McLean Hospital, 115 Mill Street, Belmont, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grant</LastName><ForeName>Marie C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Mood Disorders Center 'Lucio Bini', New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baroni</LastName><ForeName>Argelinda</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Child and Adolescent Psychiatry, NYU Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Sleep Medicine, NYU Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Polcari</LastName><ForeName>Ann</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Developmental Biopsychiatry Research Program, McLean Hospital, 115 Mill Street, Belmont, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bouve School of Nursing, Northeastern University, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teicher</LastName><ForeName>Martin H</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Developmental Biopsychiatry Research Program, McLean Hospital, 115 Mill Street, Belmont, MA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>RC1 MH089743</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>01</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Child Psychol Psychiatry</MedlineTA><NlmUniqueID>0375361</NlmUniqueID><ISSNLinking>0021-9630</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D056044" MajorTopicYN="N">Actigraphy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D041923" MajorTopicYN="N">Adolescent Development</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001289" MajorTopicYN="N">Attention Deficit Disorder with Hyperactivity</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002657" MajorTopicYN="N">Child Development</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002940" MajorTopicYN="N">Circadian Rhythm</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060388" MajorTopicYN="N">Support Vector Machine</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">ADHD</Keyword><Keyword MajorTopicYN="Y">Actigraphy</Keyword><Keyword MajorTopicYN="Y">bipolar disorder</Keyword><Keyword MajorTopicYN="Y">child</Keyword><Keyword MajorTopicYN="Y">circadian rhythms</Keyword><Keyword MajorTopicYN="Y">sleep</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>12</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>1</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>1</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>9</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26799153</ArticleId><ArticleId IdType="doi">10.1111/jcpp.12520</ArticleId><ArticleId IdType="pmc">PMC4873411</ArticleId><ArticleId IdType="mid">NIHMS746586</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Pediatr Psychol. 2008 May;33(4):349-57</Citation><ArticleIdList><ArticleId IdType="pubmed">18192301</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2011 Oct;50(10):1001-16.e3</Citation><ArticleIdList><ArticleId IdType="pubmed">21961775</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleep. 1999 Feb 1;22(1):95-103</Citation><ArticleIdList><ArticleId IdType="pubmed">9989370</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleep. 2006 Feb;29(2):193-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16494087</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2013 Jan;170(1):59-70</Citation><ArticleIdList><ArticleId IdType="pubmed">23111466</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2011;6(5):e20650</Citation><ArticleIdList><ArticleId IdType="pubmed">21655197</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Psychiatry. 2012 Mar 20;3:22</Citation><ArticleIdList><ArticleId IdType="pubmed">22454624</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2009 Jul;166(7):795-804</Citation><ArticleIdList><ArticleId IdType="pubmed">19448190</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2003 Jan;73(1-2):133-46</Citation><ArticleIdList><ArticleId IdType="pubmed">12507746</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2004 Aug;6(4):305-13</Citation><ArticleIdList><ArticleId IdType="pubmed">15225148</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1993 Jul;32(4):760-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8340296</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2008 Mar;10(2):256-65</Citation><ArticleIdList><ArticleId IdType="pubmed">18271904</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2012 Dec;14(8):870-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23167935</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1974 Jun;30(6):765-8</Citation><ArticleIdList><ArticleId IdType="pubmed">4832184</ArticleId></ArticleIdList></Reference><Reference><Citation>Semin Pediatr Neurol. 2015 Jun;22(2):113-25</Citation><ArticleIdList><ArticleId IdType="pubmed">26072341</ArticleId></ArticleIdList></Reference><Reference><Citation>Harv Rev Psychiatry. 1995 Nov-Dec;3(4):171-95</Citation><ArticleIdList><ArticleId IdType="pubmed">9384947</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Biobehav Rev. 2014 Jul;44:183-94</Citation><ArticleIdList><ArticleId IdType="pubmed">23099283</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2009 Sep;48(9):894-908</Citation><ArticleIdList><ArticleId IdType="pubmed">19625983</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1983 Jun;40(6):681-7</Citation><ArticleIdList><ArticleId IdType="pubmed">6847335</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2005 Dec;7(6):483-96</Citation><ArticleIdList><ArticleId IdType="pubmed">16403174</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pediatr. 2007 May;150(5):485-90</Citation><ArticleIdList><ArticleId IdType="pubmed">17452221</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleep. 2005 Nov;28(11):1437-45</Citation><ArticleIdList><ArticleId IdType="pubmed">16335331</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2009 Jun;11(4):391-400</Citation><ArticleIdList><ArticleId IdType="pubmed">19500092</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1996 Oct;35(10):1384-93</Citation><ArticleIdList><ArticleId IdType="pubmed">8885593</ArticleId></ArticleIdList></Reference><Reference><Citation>Stat Med. 1990 Jul;9(7):811-8</Citation><ArticleIdList><ArticleId IdType="pubmed">2218183</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1997 Feb;36(2):188-95</Citation><ArticleIdList><ArticleId IdType="pubmed">9031571</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2008 Jun;108(3):199-206</Citation><ArticleIdList><ArticleId IdType="pubmed">18001840</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2011 Sep;72(9):1250-6</Citation><ArticleIdList><ArticleId IdType="pubmed">21672501</ArticleId></ArticleIdList></Reference><Reference><Citation>Comput Biomed Res. 1990 Jun;23(3):283-95</Citation><ArticleIdList><ArticleId IdType="pubmed">2350963</ArticleId></ArticleIdList></Reference><Reference><Citation>Hist Psychiatry. 2004 Jun;15(58 Pt 2):201-26</Citation><ArticleIdList><ArticleId IdType="pubmed">15272482</ArticleId></ArticleIdList></Reference><Reference><Citation>Harv Rev Psychiatry. 1995 May-Jun;3(1):18-35</Citation><ArticleIdList><ArticleId IdType="pubmed">9384925</ArticleId></ArticleIdList></Reference><Reference><Citation>Physiol Behav. 2001 Jan;72(1-2):21-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11239977</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2007 Feb;46(2):233-41</Citation><ArticleIdList><ArticleId IdType="pubmed">17242627</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1997 Feb;54(2):124-30</Citation><ArticleIdList><ArticleId IdType="pubmed">9040280</ArticleId></ArticleIdList></Reference><Reference><Citation>J Fam Psychol. 2007 Mar;21(1):114-23</Citation><ArticleIdList><ArticleId IdType="pubmed">17371116</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2007 May;64(5):543-52</Citation><ArticleIdList><ArticleId IdType="pubmed">17485606</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1980 Mar;37(3):257-63</Citation><ArticleIdList><ArticleId IdType="pubmed">7362415</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatrics. 1991 Apr;87(4):494-9</Citation><ArticleIdList><ArticleId IdType="pubmed">2011426</ArticleId></ArticleIdList></Reference><Reference><Citation>Chronobiol Int. 2005;22(3):559-70</Citation><ArticleIdList><ArticleId IdType="pubmed">16076654</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Med Surg. 1961;19:284-309</Citation><ArticleIdList><ArticleId IdType="pubmed">13903777</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Pediatr Adolesc Med. 2008 Apr;162(4):323-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18391140</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleep. 2001 May 1;24(3):303-12</Citation><ArticleIdList><ArticleId IdType="pubmed">11322713</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Adolesc Psychopharmacol. 2002 Spring;12(1):3-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12014593</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19906346</PMID><DateCompleted><Year>2009</Year><Month>11</Month><Day>23</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1555-2101</ISSN><JournalIssue CitedMedium="Internet"><Volume>70</Volume><Issue>10</Issue><PubDate><Year>2009</Year><Month>Oct</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Olanzapine/fluoxetine combination for the treatment of mixed depression in bipolar I disorder: a post hoc analysis.</ArticleTitle><Pagination><MedlinePgn>1424-31</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4088/JCP.08m04772gre</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Mixed depression (ie, co-occurrence of syndromal depression and subsyndromal mania/hypomania) is a common variant of bipolar depression. However, its treatment is much understudied. The aim of the study was to assess the efficacy of the antipsychotic and mood-stabilizing agent olanzapine and the efficacy of the combination of an antidepressant (fluoxetine) and olanzapine (olanzapine/fluoxetine combination; OFC) for the treatment of bipolar I mixed depression.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">We carried out a post hoc analysis of an 8-week, double-blind trial of adult bipolar I depression treated with placebo (n = 355), olanzapine (5-20 mg/d; n = 351), or OFC (olanzapine/fluoxetine doses: 6/25, 6/50, 12/50 mg/d; n = 82). Studying mixed depression was not a previous goal of the double-blind trial. Subjects in the trial were diagnosed according to DSM-IV and were randomly assigned to treatment during the period June 2000 to December 2001. Mixed depression was defined as the co-occurrence of a major depressive episode and &gt; or = 2 manic/hypomanic symptoms (ie, &gt; or = 2 Young Mania Rating Scale [YMRS] items scoring &gt; or = 2). Response was defined as a &gt; or = 50% reduction in Montgomery-Asberg Depression Rating Scale score and &lt; 2 concurrent manic/hypomanic symptoms. Switching to mania/hypomania was defined as a YMRS score &gt; or = 15.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Frequency of mixed depression was 45.1% in the OFC arm, 49.3% in the olanzapine arm, and 46.8% in the placebo arm (P = .705). The most frequent manic/ hypomanic symptoms of mixed depression were irritability, reduced need for sleep, talkativeness, and racing thoughts. Response rates in patients with nonmixed depression versus patients with mixed depression were the following: in the OFC arm, 48.9% versus 43.2% (OR = 1.24; 95% CI, 0.51-2.98); in the olanzapine arm, 39.9% versus 26.6% (OR = 1.84; 95% CI, 1.17-2.90); in the placebo arm, 27.5% versus 16.3% (OR = 1.94; 95% CI, 1.15-3.28). Response rates in the samples of patients with mixed depression were the following: OFC versus olanzapine, OR = 2.00 (95% CI, 0.96-4.19); OFC versus placebo, OR = 3.91 (95% CI, 1.80-8.49); olanzapine versus placebo, OR = 1.95 (95% CI, 1.14-3.34). It was found that no baseline manic/hypomanic symptom of mixed depression predicted treatment response. A higher number of baseline concurrent manic/hypomanic symptoms predicted a lower response rate in the olanzapine and placebo arms, but not in the OFC arm. The rates of switching were the following: in the OFC arm, 8.5%; in the olanzapine arm, 6.8%; and in the placebo arm, 7.9% (P = .808). The rates of dropouts in patients with mixed depression versus patients with nonmixed depression were not significantly different within any of the treatment arms. The rates of dropouts in the samples of patients with mixed depression were the following: in the OFC arm, 29.7%; in the olanzapine arm, 53.8%; and in the placebo arm, 59.6% (olanzapine vs OFC: OR = 2.66; 95% CI, 1.23-5.75; placebo vs OFC: OR = 3.48; 95% CI, 1.61-7.54; placebo vs olanzapine: OR = 1.30; 95% CI, 0.84-2.01).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Olanzapine/fluoxetine combination may be an effective treatment for bipolar I mixed depression. Statistically, the efficacy of OFC was not significantly different from that of olanzapine, but inspection of the 95% CI showed a trend in favor of a possible superiority of OFC. Supporting the study findings are the similar efficacy of OFC in bipolar mixed depression independent of the number of concurrent manic/hypomanic symptoms, a lower dropout rate, and a similarly low switching rate compared to olanzapine. Contrary to other current limited evidence, an antidepressant (fluoxetine) showed efficacy and did not worsen bipolar mixed depression if combined with a mood-stabilizing agent (olanzapine).</AbstractText><CopyrightInformation>Copyright 2009 Physicians Postgraduate Press, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Benazzi</LastName><ForeName>Franco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Hecker Psychiatry Research Center, Forli, Italy. FrancoBenazzi@FBenazzi.it</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berk</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Frye</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Wei</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Barraco</LastName><ForeName>Alessandra</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Tohen</LastName><ForeName>Mauricio</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018687">Antidepressive Agents, Second-Generation</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010919">Placebos</NameOfSubstance></Chemical><Chemical><RegistryNumber>01K63SUP8D</RegistryNumber><NameOfSubstance UI="D005473">Fluoxetine</NameOfSubstance></Chemical><Chemical><RegistryNumber>12794-10-4</RegistryNumber><NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical><Chemical><RegistryNumber>N7U69T4SZR</RegistryNumber><NameOfSubstance UI="D000077152">Olanzapine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018687" MajorTopicYN="N">Antidepressive Agents, Second-Generation</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001569" MajorTopicYN="N">Benzodiazepines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005473" MajorTopicYN="N">Fluoxetine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077152" MajorTopicYN="N">Olanzapine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010919" MajorTopicYN="N">Placebos</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>10</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>01</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>11</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>11</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19906346</ArticleId><ArticleId IdType="doi">10.4088/JCP.08m04772gre</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18774873</PMID><DateCompleted><Year>2009</Year><Month>01</Month><Day>06</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1083-4087</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>7</Issue><PubDate><Year>2008</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of managed care pharmacy : JMCP</Title><ISOAbbreviation>J Manag Care Pharm</ISOAbbreviation></Journal><ArticleTitle>Prevalence and humanistic impact of potential misdiagnosis of bipolar disorder among patients with major depressive disorder in a commercially insured population.</ArticleTitle><Pagination><MedlinePgn>631-42</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Patients with bipolar disorder typically present to physicians in the depressed rather than the manic or hypomanic phase of illness. Because the depressive episodes in bipolar disorder may be indistinguishable from those in major depressive disorder (MDD), misdiagnosis may occur.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To estimate from administrative claims data and a telephone survey the prevalence of potential misdiagnosis of bipolar disorder among patients with MDD and the humanistic (health-related quality of life [HRQOL] and disability) effects associated with misdiagnosis in a managed care setting.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Administrative claims data were used to identify patients with medical claims for MDD from a database of 9 million members of commercial health plans from 3 U.S. regions. The inclusion criteria were as follows: (a) adults aged 18 years or older; (b) at least 2 medical claims, including a primary or secondary diagnosis of MDD: ICD-9-CM codes 296.2x (MDD, single episode), 296.3x (MDD, recurrent episode), or 311 (depressive disorder, not classified elsewhere) during an identification period from January 1, 2000, through March 31, 2004 (study intake period); (c) at least 12 months of pre-index and 12 months of post-index plan eligibility; and (d) active enrollment through March 31, 2005. The index date was defined as the date of the first claim for MDD during the identification period. Patients with ICD-9-CM codes for bipolar disorder at any time throughout the study period (January 1, 2000, through March 31, 2005) were excluded from this cohort. This cohort was targeted for a telephone survey that was conducted from August 1 through October 30, 2006. From the telephone survey sampling frame of 5,777, a total of 1,360 interviews were completed for a response rate of 23.5%. Respondents were screened for potential bipolar disorder using the Mood Disorder Questionnaire (MDQ). The Medical Outcomes 12-Item Short Form Survey (SF-12), Version 2, a widely used and validated instrument that assesses health-related functioning, and the Sheehan Disability Scale (SDS), which measures depression-related disability, were administered to a convenience subsample of 112 survey respondents to collect HRQOL and disability information, respectively.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 1,360 adult patients aged 18 years or older with a diagnosis of MDD but without a medical claim for diagnosis of bipolar disorder, 94 (6.9%) screened positive for bipolar disorder on the MDQ. More patients with a positive screen for bipolar disorder reported lifetime histories of obsessive compulsive disorder (24.5% vs. 8.2%, P&lt;0.001), psychotic disorders or hallucinations (9.6% vs. 2.4%, P&lt;0.001), suicidal ideation (61.7% vs. 29.4%, P&lt;0.001), and drug abuse (34.0% vs. 11.1%, P&lt;0.001) than did patients with a negative screen for bipolar disorder. In the subgroup of patients who completed the SF-12 and SDS, patients with a positive screen for bipolar disorder (n=33) had lower scores (i.e., greater impairment) on the social functioning, role emotional, and overall mental component summary scales of the SF-12 than did patients with a negative screen for bipolar disorder (n=79, P&lt;0.001), but did not significantly differ on the physical component summary scale. Patients with a positive screen for bipolar disorder on the MDQ were more likely than patients who screened MDQ-negative to report severe depression-related impairment (scores of 7 and higher on the SDS scale) with work life (54.5% vs. 24.1%, respectively, P=0.002), social life (66.7% vs. 39.2%, P=0.008), and family life (66.7% vs. 34.2%, P=0.002) on the SDS.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In this study of patients carrying medical claims for a diagnosis of MDD in their administrative claims data, approximately 7% screened positive for bipolar disorder on a validated self-report assessment instrument. Patients with MDD who screened positive for bipolar disorder reported poorer HRQOL and disability scores than did patients with MDD who screened MDQ-negative. These findings may encourage interventions for appropriate screening, diagnosis, and management of potentially misdiagnosed bipolar disorder patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kamat</LastName><ForeName>Siddhesh A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>HealthCore, Wilmington, Delaware 19801, USA. skamat@healthcore.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rajagopalan</LastName><ForeName>Krithika</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Pethick</LastName><ForeName>Ned</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Willey</LastName><ForeName>Vincent</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Bullano</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Hassan</LastName><ForeName>Mariam</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Manag Care Pharm</MedlineTA><NlmUniqueID>9605854</NlmUniqueID><ISSNLinking>1083-4087</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017281" MajorTopicYN="N">Cost of Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003951" MajorTopicYN="N">Diagnostic Errors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007348" MajorTopicYN="N">Insurance, Health</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012959" MajorTopicYN="N">Socioeconomic Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>9</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>1</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>9</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18774873</ArticleId><ArticleId IdType="pii">2008(14)7: 631-642</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16009430</PMID><DateCompleted><Year>2005</Year><Month>12</Month><Day>15</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-0327</ISSN><JournalIssue CitedMedium="Print"><Volume>87</Volume><Issue>2-3</Issue><PubDate><Year>2005</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>The lifetime prevalence, health services utilization and risk of suicide of bipolar spectrum subjects, including subthreshold categories in the SÃ£o Paulo ECA study.</ArticleTitle><Pagination><MedlinePgn>231-41</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Identifying the bipolar (BP) spectrum, including the classic Bipolar I subtype (BP-I), Bipolar II (BP-II) and subthreshold bipolar disorders not meeting DSM-IV diagnostic criteria has raised growing interest, as these softer expressions of bipolar spectrum have been underdiagnosed in spite of clinical consequences.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Data are from the Sao Paulo Epidemiological Catchment Area Study (N=1464). Non-affective controls were compared to BP spectrum groups, based on DSM-IIIR and on the "clinical significance" criteria: Subsyndromal Hypomania (SSH) and Manic Symptoms (MS).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The lifetime prevalence of BP subgroups was 8.3% (N=122). All BP-I and -II and around 75% of SSH and MS subjects had a lifetime depressive syndrome. Compared to controls and MS subjects, BP-I, BP-II and SSH groups searched more medical help and mental health services. SSH group displayed higher rates of clinical significance than BP-I subjects, and suicidality was higher in BP groups compared to controls. Even the softer MS group had higher rate of suicide attempts than SSH subjects.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">This is a cross-sectional study and interviews were conducted by lay personnel. Replication in bigger community samples using a mood spectrum approach is necessary to confirm these findings. However, our findings were very similar to those obtained by other authors.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Softer expressions of BP disorders appear in 6.6% of this community sample and have serious clinical consequences, which supports the importance of including these categories in the BP spectrum.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Moreno</LastName><ForeName>Doris Hupfeld</ForeName><Initials>DH</Initials><AffiliationInfo><Affiliation>Mood Disorders Unit, Institute of Psychiatry, University of SÃ£o Paulo School of Medicine, Rua Capote Valente, 423-Conj 35, 05409-001 SÃ£o Paulo-SP, Brazil. dorismoreno@uol.com.br</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andrade</LastName><ForeName>Laura Helena</ForeName><Initials>LH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000124" MajorTopicYN="N">Achievement</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001938" MajorTopicYN="N" Type="Geographic">Brazil</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002391" MajorTopicYN="N">Catchment Area, Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003710" MajorTopicYN="N">Demography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008605" MajorTopicYN="N">Mental Health Services</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010342" MajorTopicYN="N">Patient Acceptance of Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013406" MajorTopicYN="N">Suicide, Attempted</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2004</Year><Month>11</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2005</Year><Month>04</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>7</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>12</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>7</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16009430</ArticleId><ArticleId IdType="pii">S0165-0327(05)00142-4</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2005.04.010</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23929355</PMID><DateCompleted><Year>2014</Year><Month>02</Month><Day>17</Day></DateCompleted><DateRevised><Year>2014</Year><Month>11</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1535-7228</ISSN><JournalIssue CitedMedium="Internet"><Volume>170</Volume><Issue>12</Issue><PubDate><Year>2013</Year><Month>Dec</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Assisting Social Security Disability Insurance beneficiaries with schizophrenia, bipolar disorder, or major depression in returning to work.</ArticleTitle><Pagination><MedlinePgn>1433-41</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1176/appi.ajp.2013.13020214</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">People with psychiatric impairments (primarily schizophrenia or a mood disorder) are the largest and fastest-growing group of Social Security Disability Insurance (SSDI) beneficiaries. The authors investigated whether evidence-based supported employment and mental health treatments can improve vocational and mental health recovery for this population.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Using a randomized controlled trial design, the authors tested a multifaceted intervention: team-based supported employment, systematic medication management, and other behavioral health services, along with elimination of barriers by providing complete health insurance coverage (with no out-of-pocket expenses) and suspending disability reviews. The control group received usual services. Paid employment was the primary outcome measure, and overall mental health and quality of life were secondary outcome measures.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Overall, 2,059 SSDI beneficiaries with schizophrenia, bipolar disorder, or depression in 23 cities participated in the 2-year intervention. The teams implemented the intervention package with acceptable fidelity. The intervention group experienced more paid employment (60.3% compared with 40.2%) and reported better mental health and quality of life than the control group.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Implementation of the complex intervention in routine mental health treatment settings was feasible, and the intervention was effective in assisting individuals disabled by schizophrenia or depression to return to work and improve their mental health and quality of life.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Drake</LastName><ForeName>Robert E</ForeName><Initials>RE</Initials></Author><Author ValidYN="Y"><LastName>Frey</LastName><ForeName>William</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Bond</LastName><ForeName>Gary R</ForeName><Initials>GR</Initials></Author><Author ValidYN="Y"><LastName>Goldman</LastName><ForeName>Howard H</ForeName><Initials>HH</Initials></Author><Author ValidYN="Y"><LastName>Salkever</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Moore</LastName><ForeName>Troy A</ForeName><Initials>TA</Initials></Author><Author ValidYN="Y"><LastName>Riley</LastName><ForeName>Jarnee</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Karakus</LastName><ForeName>Mustafa</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Milfort</LastName><ForeName>Roline</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Am J Psychiatry. 2013 Dec;170(12):1379-81</RefSource><PMID Version="1">24306332</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000534" MajorTopicYN="Y">rehabilitation</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000534" MajorTopicYN="Y">rehabilitation</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006233" MajorTopicYN="N">Disabled Persons</DescriptorName><QualifierName UI="Q000534" MajorTopicYN="N">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019468" MajorTopicYN="N">Disease Management</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016832" MajorTopicYN="N">Employment, Supported</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018868" MajorTopicYN="Y">Insurance, Disability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012050" MajorTopicYN="N">Rehabilitation, Vocational</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062707" MajorTopicYN="N">Return to Work</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000534" MajorTopicYN="Y">rehabilitation</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012943" MajorTopicYN="Y">Social Security</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>8</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>8</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>2</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23929355</ArticleId><ArticleId IdType="pii">1725890</ArticleId><ArticleId IdType="doi">10.1176/appi.ajp.2013.13020214</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18775569</PMID><DateCompleted><Year>2009</Year><Month>06</Month><Day>25</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>115</Volume><Issue>1-2</Issue><PubDate><Year>2009</Year><Month>May</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Lamotrigine in bipolar disorder: results of a mirror-image evaluation using the NIMH Lifechart-Methodology.</ArticleTitle><Pagination><MedlinePgn>241-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2008.07.020</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Lamotrigine (LTG) is characterized by prophylactic efficacy against bipolar depression (BPD). We evaluated retro- and prospectively the naturalistic treatment outcome with LTG analysing lifecharts of patients from the bipolar outpatient clinic.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Lifechart-data of 20 patients routinely treated with LTG for the first time were evaluated, comparing number and duration of manic, depressive and mixed episodes prior to LTG and after initiation of treatment (mirror-image evaluation). The mean prospective evaluation period based on the lifechart was 18.1 months. Also we compared the number and severity of "switches" from depression in mania. Additionally, CGI-BP, YMRS, IDS-C and GAF scores at the monthly visits were compared for time after LTG initiation.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We found no significant differences in the absolute number of manic, depressive and mixed episodes, respectively, before and after initiation of LTG. The number of "switches" did not differ significantly. A significant difference in duration of time patients suffered from a depressive state before and after initiation of LTG was observed in favour of LTG treatment (p=.006). A similar finding was observed for the time spent in mixed episodes (p&lt;.001). No significant difference was observed for scores of mood scales at the monthly visits (CGI-BP, YMRS, IDS-C, GAF).</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Generalizability of these results is limited due to the uncontrolled design and the issues in comparing prospective and retrospective data.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These data underline not only the antidepressant profile of LTG, but also the usefulness of the Lifechart-Methodology (LCM) in the evaluation of treatment outcome under routine conditions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Born</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Ludwig Maximilians-University, Nussbaumstr. 7, D-80336, Munich, Germany. christoph.born@med.uni-muenchen.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bernhard</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Dittmann</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>SeemÃ¼ller</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Grunze</LastName><ForeName>H</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>09</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014227">Triazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>U3H27498KS</RegistryNumber><NameOfSubstance UI="D000077213">Lamotrigine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="N">Affect</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N">Germany</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077213" MajorTopicYN="N">Lamotrigine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015993" MajorTopicYN="N">Life Tables</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055502" MajorTopicYN="N">Secondary Prevention</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014227" MajorTopicYN="N">Triazines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>12</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2008</Year><Month>07</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>07</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>9</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>6</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>9</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18775569</ArticleId><ArticleId IdType="pii">S0165-0327(08)00315-7</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2008.07.020</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31034683</PMID><DateCompleted><Year>2020</Year><Month>04</Month><Day>03</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1099-0879</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>5</Issue><PubDate><Year>2019</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Clinical psychology &amp; psychotherapy</Title><ISOAbbreviation>Clin Psychol Psychother</ISOAbbreviation></Journal><ArticleTitle>Measuring personal recovery in people with bipolar disorder and exploring its relationship with well-being and social role participation.</ArticleTitle><Pagination><MedlinePgn>540-549</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/cpp.2371</ELocationID><Abstract><AbstractText>The relevance of personal recovery receives increasing attention in mental health care and is also important for people with bipolar disorder (BD). There is a need for reliable and valid instruments measuring personal recovery. Therefore, the current study evaluated the psychometric properties of a Dutch translation of the Questionnaire about the Process of Recovery (QPR) in a sample of people with BD and explored the relationship with constructs of well-being, social role participation, and psychopathology. A cross-sectional survey study was conducted in which 102 people diagnosed with BD completed the QPR. Factor structure of the QPR was evaluated by conducting confirmatory factor analyses (CFA), and internal consistency was assessed by calculating reliability coefficients. Convergent validation measures assessed well-being, social role participation, and symptomatology. Incremental validity was determined by evaluating the ability of the QPR to explain variance in symptomatology above and beyond well-being. Findings of the CFA supported a unidimensional factor structure, and internal consistency estimates were excellent. Scores of the QPR showed strong correlations with convergent measures, but were only weakly associated with manic symptomatology. Moreover, personal recovery explained additional variance in symptoms of depression and anxiety above and beyond well-being, indicating incremental validity. The QPR appears to be a reliable and valid tool to assess personal recovery in people with BD. Our findings underline the importance of personal recovery in the context of treatment of BD. Personal recovery demonstrates a substantial overlap with well-being.</AbstractText><CopyrightInformation>Â© 2019 The Authors. Clinical Psychology &amp; Psychotherapy Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kraiss</LastName><ForeName>Jannis T</ForeName><Initials>JT</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-5342-3029</Identifier><AffiliationInfo><Affiliation>Centre for eHealth and Well-being Research, Department of Psychology, Health, and Technology, University of Twente, Enschede, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ten Klooster</LastName><ForeName>Peter M</ForeName><Initials>PM</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-2565-5439</Identifier><AffiliationInfo><Affiliation>Centre for eHealth and Well-being Research, Department of Psychology, Health, and Technology, University of Twente, Enschede, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chrispijn</LastName><ForeName>Melissa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Bipolar Disorders, Dimence Mental Health, Deventer, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stevens</LastName><ForeName>Anja W M M</ForeName><Initials>AWMM</Initials><AffiliationInfo><Affiliation>Center for Bipolar Disorders, Dimence Mental Health, Deventer, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kupka</LastName><ForeName>Ralph W</ForeName><Initials>RW</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-1662-7436</Identifier><AffiliationInfo><Affiliation>Amsterdam UMC, Vrije Universiteit, Psychiatry, Amsterdam Public Health research institute, Amsterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bohlmeijer</LastName><ForeName>Ernst T</ForeName><Initials>ET</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-7861-1245</Identifier><AffiliationInfo><Affiliation>Centre for eHealth and Well-being Research, Department of Psychology, Health, and Technology, University of Twente, Enschede, Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>06</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Clin Psychol Psychother</MedlineTA><NlmUniqueID>9416196</NlmUniqueID><ISSNLinking>1063-3995</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000534" MajorTopicYN="Y">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005163" MajorTopicYN="N">Factor Analysis, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073038" MajorTopicYN="Y">Mental Health Recovery</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012919" MajorTopicYN="Y">Social Behavior</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="Y">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">bipolar disorder</Keyword><Keyword MajorTopicYN="N">personal recovery</Keyword><Keyword MajorTopicYN="N">psychometric evaluation</Keyword><Keyword MajorTopicYN="N">social role participation</Keyword><Keyword MajorTopicYN="N">well-being</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>01</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>03</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>04</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>4</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>4</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31034683</ArticleId><ArticleId IdType="doi">10.1002/cpp.2371</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Altman, E., Hedeker, D., Peterson, J. L., &amp; Davis, J. M. (2001). A comparative evaluation of three self-rating scales for acute mania. Biological Psychiatry, 50(6), 468-471. https://doi.org/10.1016/S0006-3223(01)01065-4</Citation></Reference><Reference><Citation>Altman, E. G., Hedeker, D., Peterson, J. L., &amp; Davis, J. M. (1997). The Altman self-rating mania scale. Biological Psychiatry, 42(10), 948-955. https://doi.org/10.1016/S0006-3223(96)00548-3</Citation></Reference><Reference><Citation>Argentzell, E., Hultqvist, J., Neil, S., &amp; Eklund, M. (2017). Measuring personal recovery-psychometric properties of the Swedish questionnaire about the process of recovery (QPR-Swe). Nordic Journal of Psychiatry, 71(7), 529-535. https://doi.org/10.1080/08039488.2017.1346144</Citation></Reference><Reference><Citation>Bird, V., Leamy, M., Tew, J., Le Boutillier, C., Williams, J., &amp; Slade, M. (2014). Fit for purpose? Validation of a conceptual framework for personal recovery with current mental health consumers. Australian &amp; New Zealand Journal of Psychiatry, 48(7), 644-653. https://doi.org/10.1177/0004867413520046</Citation></Reference><Reference><Citation>Browne, M. W., &amp; Cudeck, R. (1992). Alternative ways of assessing model fit. Sociological Methods &amp; Research, 21(2), 230-258. https://doi.org/10.1177/0049124192021002005</Citation></Reference><Reference><Citation>Calabrese, J. R., Hirschfeld, R. M. A., Reed, M., Davies, M. A., Frye, M. A., Keck, P. E., â¦ Wagner, K. D. (2003). Impact of bipolar disorder on a U.S. community sample. The Journal of Clinical Psychiatry, 64(4), 425-432. https://doi.org/10.4088/JCP.v64n0412</Citation></Reference><Reference><Citation>Chien, W. T., &amp; Chan, Z. C. (2013). Chinese translation and validation of the questionnaire on the process of recovery in schizophrenia and other psychotic disorders. Research in Nursing &amp; Health, 36(4), 400-411. https://doi.org/10.1002/nur.21549</Citation></Reference><Reference><Citation>Cicchetti, D. V. (1994). Guidelines, criteria, and rules of thumb for evaluating normed and standardized assessment instruments in psychology. Psychological Assessment, 6(4), 284-290. https://doi.org/10.1037/1040-3590.6.4.284</Citation></Reference><Reference><Citation>Cook, K. F., Kallen, M. A., &amp; Amtmann, D. (2009). Having a fit: Impact of number of items and distribution of data on traditional criteria for assessing IRT's unidimensionality assumption. Quality of Life Research, 18(4), 447-460. https://doi.org/10.1007/s11136-009-9464-4</Citation></Reference><Reference><Citation>de Vos, J. A., LaMarre, A., Radstaak, M., Bijkerk, C. A., Bohlmeijer, E. T., &amp; Westerhof, G. J. (2017). Identifying fundamental criteria for eating disorder recovery: A systematic review and qualitative meta-analysis. Journal of Eating Disorders, 5(1), 34. https://doi.org/10.1186/s40337-017-0164-0</Citation></Reference><Reference><Citation>Dean, B. B., Gerner, D., &amp; Gerner, R. H. (2004). A systematic review evaluating health-related quality of life, work impairment, and healthcare costs and utilization in bipolar disorder. Current Medical Research and Opinion, 20(2), 139-154. https://doi.org/10.1185/030079903125002801</Citation></Reference><Reference><Citation>Dilsaver, S. C. (2011). An estimate of the minimum economic burden of bipolar I and II disorders in the United States: 2009. Journal of Affective Disorders, 129(1), 79-83. https://doi.org/10.1016/j.jad.2010.08.030</Citation></Reference><Reference><Citation>DiStefano, C., Liu, J., Jiang, N., &amp; Shi, D. (2018). Examination of the weighted root mean square residual: Evidence for trustworthiness? Structural Equation Modeling: A Multidisciplinary Journal, 25(3), 453-466. https://doi.org/10.1080/10705511.2017.1390394</Citation></Reference><Reference><Citation>Dunn, T. J., Baguley, T., &amp; Brunsden, V. (2014). From alpha to omega: A practical solution to the pervasive problem of internal consistency estimation. British Journal of Psychology, 105(3), 399-412. https://doi.org/10.1111/bjop.12046</Citation></Reference><Reference><Citation>Fagiolini, A., Forgione, R., Maccari, M., Cuomo, A., Morana, B., Dell'Osso, M. C., â¦ Rossi, A. (2013). Prevalence, chronicity, burden and borders of bipolar disorder. Journal of Affective Disorders, 148(2-3), 161-169. https://doi.org/10.1016/j.jad.2013.02.001</Citation></Reference><Reference><Citation>Fajutrao, L., Locklear, J., Priaulx, J., &amp; Heyes, A. (2009). A systematic review of the evidence of the burden of bipolar disorder in Europe. Clinical Practice and Epidemiology in Mental Health, 5, 3. https://doi.org/10.1186/1745-0179-5-3</Citation></Reference><Reference><Citation>Fava, G. A., Ruini, C., &amp; Belaise, C. (2007). The concept of recovery in major depression. Psychological Medicine, 37(3), 307-317. https://doi.org/10.1017/S0033291706008981</Citation></Reference><Reference><Citation>Flora, D. B., &amp; Curran, P. J. (2004). An empirical evaluation of alternative methods of estimation for confirmatory factor analysis with ordinal data. Psychological Methods, 9(4), 466-491. https://doi.org/10.1037/1082-989X.9.4.466</Citation></Reference><Reference><Citation>Floyd, F. J., &amp; Widaman, K. F. (1995). Factor analysis in the development and refinement of clinical assessment instruments. Psychological Assessment, 7(3), 286-299. https://doi.org/10.1037/1040-3590.7.3.286</Citation></Reference><Reference><Citation>Gordeev, V. S., Maksymowych, W. P., Evers, S. M., Ament, A., Schachna, L., &amp; Boonen, A. (2010). Role of contextual factors in health-related quality of life in ankylosing spondylitis. Annals of the Rheumatic Diseases, 69(1), 108-112. https://doi.org/10.1136/ard.2008.100164</Citation></Reference><Reference><Citation>Grande, I., Berk, M., Birmaher, B., &amp; Vieta, E. (2015). Bipolar disorder. The Lancet, 387(10027), 1561-1572. https://doi.org/10.1016/S0140-6736(15)00241-X</Citation></Reference><Reference><Citation>Hair, J. F., Black, W. C., Babin, B. J., Anderson, R. E., &amp; Tatham, R. L. (2009). Multivariate data analysis. New Jersey, NJ: Prentice Hall.</Citation></Reference><Reference><Citation>Hu, L.-t., &amp; Bentler, P. M. (1998). Fit indices in covariance structure modeling: Sensitivity to underparameterized model misspecification. Psychological Methods, 3(4), 424-453. https://doi.org/10.1037/1082-989X.3.4.424</Citation></Reference><Reference><Citation>Hu, L.-t., &amp; Bentler, P. M. (1999). Cutoff criteria for fit indexes in covariance structure analysis: Conventional criteria versus new alternatives. Structural Equation Modeling: A Multidisciplinary Journal, 6(1), 1-55.</Citation></Reference><Reference><Citation>Jaeger, M., &amp; Hoff, P. (2012). Recovery: Conceptual and ethical aspects. Current Opinion in Psychiatry, 25(6), 497-502. https://doi.org/10.1097/YCO.0b013e328359052f</Citation></Reference><Reference><Citation>Jones, S., Higginson, S., Murray, C., &amp; Morrison, A. P. (2010). Recovery experiences in bipolar disorder. Paper presented at the Britisch Association for Behavioural and Cognitive Psychotherapy Annual Conference, Manchester, UK.</Citation></Reference><Reference><Citation>Jones, S., Mulligan, L. D., Higginson, S., Dunn, G., &amp; Morrison, A. P. (2013). The bipolar recovery questionnaire: Psychometric properties of a quantitative measure of recovery experiences in bipolar disorder. Journal of Affective Disorders, 147(1), 34-43. https://doi.org/10.1016/j.jad.2012.10.003</Citation></Reference><Reference><Citation>Jones, S., Mulligan, L. D., Law, H., Dunn, G., Welford, M., Smith, G., &amp; Morrison, A. P. (2012). A randomised controlled trial of recovery focused CBT for individuals with early bipolar disorder. BMC Psychiatry, 12(1), 204. https://doi.org/10.1186/1471-244X-12-204</Citation></Reference><Reference><Citation>JÃ¶reskog, K. G. (1993). Testing structural equation models. Sage focus editions, 154, 294-294.</Citation></Reference><Reference><Citation>Kanehara, A., Kotake, R., Miyamoto, Y., Kumakura, Y., Morita, K., Ishiura, T., â¦ Kondo, S. (2017). The Japanese version of the questionnaire about the process of recovery: Development and validity and reliability testing. BMC Psychiatry, 17(1), 360. https://doi.org/10.1186/s12888-017-1520-y</Citation></Reference><Reference><Citation>Kelley, K. (2018). MBESS: The MBESS R Package Version 4.4.3. Retrieved July 30, 2018 from https://CRAN.R-project.org/package=MBESS</Citation></Reference><Reference><Citation>Keyes, C. L. (2005). Mental illness and/or mental health? Investigating axioms of the complete state model of health. Journal of Consulting and Clinical Psychology, 73(3), 539-548. https://doi.org/10.1037/0022-006x.73.3.539</Citation></Reference><Reference><Citation>Keyes, C. L., Dhingra, S. S., &amp; Simoes, E. J. (2010). Change in level of positive mental health as a predictor of future risk of mental illness. American Journal of Public Health, 100(12), 2366-2371. https://doi.org/10.2105/AJPH.2010.192245</Citation></Reference><Reference><Citation>Kline, R. B. (2015). Principles and practice of structural equation modelingGuilford publications.</Citation></Reference><Reference><Citation>Kupka, R., Knoppert, E., &amp; Nolen, W. (2008). Handboek bipolaire stoornissen. Utrecht: De Tijdstroom.</Citation></Reference><Reference><Citation>Lamers, S., Westerhof, G. J., Bohlmeijer, E. T., ten Klooster, P. M., &amp; Keyes, C. L. (2011). Evaluating the psychometric properties of the mental health continuum-short form (MHC-SF). Journal of Clinical Psychology, 67(1), 99-110. https://doi.org/10.1002/jclp.20741</Citation></Reference><Reference><Citation>Lamers, S. M. A., Westerhof, G. J., Glas, C. A. W., &amp; Bohlmeijer, E. T. (2015). The bidirectional relation between positive mental health and psychopathology in a longitudinal representative panel study. The Journal of Positive Psychology, 10(6), 553-560. https://doi.org/10.1080/17439760.2015.1015156</Citation></Reference><Reference><Citation>Law, H., Neil, S. T., Dunn, G., &amp; Morrison, A. P. (2014). Psychometric properties of the questionnaire about the process of recovery (QPR). Schizophrenia Research, 156(2-3), 184-189. https://doi.org/10.1016/j.schres.2014.04.011</Citation></Reference><Reference><Citation>Laxman, K. E., Lovibond, K. S., &amp; Hassan, M. K. (2008). Impact of bipolar disorder in employed populations. The American Journal of Managed Care, 14(11), 757-764.</Citation></Reference><Reference><Citation>Leamy, M., Bird, V., Le Boutillier, C., Williams, J., &amp; Slade, M. (2011). Conceptual framework for personal recovery in mental health: Systematic review and narrative synthesis. The British Journal of Psychiatry, 199(6), 445-452. https://doi.org/10.1192/bjp.bp.110.083733</Citation></Reference><Reference><Citation>Mead, S., &amp; Copeland, M. E. (2000). What recovery means to us: Consumers' perspectives. Community Mental Health Journal, 36(3), 315-328. https://doi.org/10.1023/A:1001917516869</Citation></Reference><Reference><Citation>Merikangas, K. R., Akiskal, H. S., Angst, J., Greenberg, P. E., Hirschfeld, R. M. A., Petukhova, M., &amp; Kessler, R. C. (2007). Lifetime and 12-month prevalence of bipolar spectrum disorder in the national comorbidity survey replication. Archives of General Psychiatry, 64(5), 543-552. https://doi.org/10.1001/archpsyc.64.5.543</Citation></Reference><Reference><Citation>Miller, S., Dell'Osso, B., &amp; Ketter, T. A. (2014). The prevalence and burden of bipolar depression. Journal of Affective Disorders, 169(Supplement 1), S3-S11. https://doi.org/10.1016/S0165-0327(14)70003-5</Citation></Reference><Reference><Citation>Moshagen, M., &amp; Musch, J. (2014). Sample size requirements of the robust weighted least squares estimator. Methodology, 10, 60-70. https://doi.org/10.1027/1614-2241/a000068</Citation></Reference><Reference><Citation>MuthÃ©n, L. K., &amp; MuthÃ©n, B. O. (2010). Mplus User's Guide (Sixth ed.). Los Angeles, CA: MuthÃ©n &amp; MuthÃ©n.</Citation></Reference><Reference><Citation>Neil, S. T., Kilbride, M., Pitt, L., Nothard, S., Welford, M., Sellwood, W., &amp; Morrison, A. P. (2009). The questionnaire about the process of recovery (QPR): A measurement tool developed in collaboration with service users. Psychosis, 1(2), 145-155. https://doi.org/10.1080/17522430902913450</Citation></Reference><Reference><Citation>Oude Voshaar, M., van Onna, M., van Genderen, S., van de Laar, M., van der Heijde, D., Heuft, L., â¦ Boonen, A. (2016). Development and validation of a short form of the social role participation questionnaire in patients with ankylosing spondylitis. The Journal of Rheumatology, 43(7), 1386-1392. https://doi.org/10.3899/jrheum.151013</Citation></Reference><Reference><Citation>Pitt, L., Kilbride, M., Nothard, S., Welford, M., &amp; Morrison, A. P. (2007). Researching recovery from psychosis: A user-led project. Psychiatric Bulletin, 31(2), 55-60. https://doi.org/10.1192/pb.bp.105.008532</Citation></Reference><Reference><Citation>R Core Team (2018). R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing.</Citation></Reference><Reference><Citation>Ryff, C. D. (2014). Self-realisation and meaning making in the face of adversity: A eudaimonic approach to human resilience. Journal of Psychology in Africa, 24(1), 1-12. https://doi.org/10.1080/14330237.2014.904098</Citation></Reference><Reference><Citation>Schotanus-Dijkstra, M., Pieterse, M. E., Drossaert, C. H., Westerhof, G. J., De Graaf, R., Ten Have, M., â¦ Bohlmeijer, E. T. (2016). What factors are associated with flourishing? Results from a large representative national sample. Journal of Happiness Studies, 17(4), 1351-1370. https://doi.org/10.1007/s10902-015-9647-3</Citation></Reference><Reference><Citation>Shanks, V., Williams, J., Leamy, M., Bird, V. J., Le Boutillier, C., &amp; Slade, M. (2013). Measures of personal recovery: A systematic review. Psychiatric Services, 64(10), 974-980. https://doi.org/10.1176/appi.ps.005012012</Citation></Reference><Reference><Citation>Slade, M. (2009). Personal recovery and mental illness: A guide for mental health professionals. New York: Cambridge University Press. https://doi.org/10.1017/CBO9780511581649</Citation></Reference><Reference><Citation>Slade, M. (2010). Mental illness and well-being: the central importance of positive psychology and recovery approaches. BMC Health Services Research, 10(1), 26. https://doi.org/10.1186/1472-6963-10-26</Citation></Reference><Reference><Citation>Spinhoven, P., Ormel, J., Sloekers, P., Kempen, G., Speckens, A., &amp; Van Hemert, A. (1997). A validation study of the Hospital Anxiety and Depression Scale (HADS) in different groups of Dutch subjects. Psychological Medicine, 27(2), 363-370. https://doi.org/10.1017/S0033291796004382</Citation></Reference><Reference><Citation>Watkins, D. (1989). The role of confirmatory factor analysis in cross-cultltral research. International Journal of Psychology, 24(6), 685-701. https://doi.org/10.1080/00207598908246806</Citation></Reference><Reference><Citation>Whitley, R., &amp; Drake, R. E. (2010). Recovery: A dimensional approach. Psychiatric Services, 61(12), 1248-1250. https://doi.org/10.1176/ps.2010.61.12.1248</Citation></Reference><Reference><Citation>Williams, J., Leamy, M., Pesola, F., Bird, V., Le Boutillier, C., &amp; Slade, M. (2015). Psychometric evaluation of the Questionnaire about the Process of Recovery (QPR). The British Journal of Psychiatry, 207(6), 551-555. https://doi.org/10.1192/bjp.bp.114.161695</Citation></Reference><Reference><Citation>Wood, A. M., &amp; Joseph, S. (2010). The absence of positive psychological (eudemonic) well-being as a risk factor for depression: A ten year cohort study. Journal of Affective Disorders, 122(3), 213-217. https://doi.org/10.1016/j.jad.2009.06.032</Citation></Reference><Reference><Citation>Wood, A. M., Maltby, J., Gillett, R., Linley, P. A., &amp; Joseph, S. (2008). The role of gratitude in the development of social support, stress, and depression: Two longitudinal studies. Journal of Research in Personality, 42(4), 854-871. https://doi.org/10.1016/j.jrp.2007.11.003</Citation></Reference><Reference><Citation>Yu, C.-Y. (2002). Evaluating cutoff criteria of model fit indices for latent variable models with binary and continuous outcomes. Los Angeles: University of California.</Citation></Reference><Reference><Citation>Zigmond, A. S., &amp; Snaith, R. P. (1983). The hospital anxiety and depression scale. Acta Psychiatrica Scandinavica, 67(6), 361-370. https://doi.org/10.1111/j.1600-0447.1983.tb09716.x</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26165112</PMID><DateCompleted><Year>2015</Year><Month>08</Month><Day>10</Day></DateCompleted><DateRevised><Year>2015</Year><Month>07</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0035-2640</ISSN><JournalIssue CitedMedium="Print"><Volume>65</Volume><Issue>5</Issue><PubDate><Year>2015</Year><Month>May</Month></PubDate></JournalIssue><Title>La Revue du praticien</Title><ISOAbbreviation>Rev Prat</ISOAbbreviation></Journal><ArticleTitle>[Bipolar depression, suicide and antidepressant prescriptions].</ArticleTitle><Pagination><MedlinePgn>686</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Borwell</LastName><ForeName>Baptiste</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Micoulaud-Franchi</LastName><ForeName>Jean-Arthur</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>LanÃ§on</LastName><ForeName>Christophe</ForeName><Initials>C</Initials></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>DÃ©pression bipolaire, suicide et prescription des antidÃ©presseurs.</VernacularTitle></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Rev Prat</MedlineTA><NlmUniqueID>0404334</NlmUniqueID><ISSNLinking>0035-2640</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011307" MajorTopicYN="N">Drug Prescriptions</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013405" MajorTopicYN="Y">Suicide</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>7</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>7</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26165112</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">22244027</PMID><DateCompleted><Year>2012</Year><Month>03</Month><Day>02</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1555-2101</ISSN><JournalIssue CitedMedium="Internet"><Volume>72</Volume><Issue>12</Issue><PubDate><Year>2011</Year><Month>Dec</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Antidepressant use and risk for suicide attempts in bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>1697; author reply 1697</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4088/JCP.11lr07372</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Goldberg</LastName><ForeName>Joseph F</ForeName><Initials>JF</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>J Clin Psychiatry. 2011 May;72(5):580-6</RefSource><PMID Version="1">21658345</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013405" MajorTopicYN="N">Suicide</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013406" MajorTopicYN="N">Suicide, Attempted</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>1</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>1</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22244027</ArticleId><ArticleId IdType="doi">10.4088/JCP.11lr07372</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21125506</PMID><DateCompleted><Year>2011</Year><Month>03</Month><Day>01</Day></DateCompleted><DateRevised><Year>2010</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1300-2163</ISSN><JournalIssue CitedMedium="Print"><Volume>21</Volume><Issue>4</Issue><PubDate><Year>2010</Year><Season>Winter</Season></PubDate></JournalIssue><Title>Turk psikiyatri dergisi = Turkish journal of psychiatry</Title><ISOAbbreviation>Turk Psikiyatri Derg</ISOAbbreviation></Journal><ArticleTitle>[The relationship between attachment style, and temperament, personality and bipolar symptoms: a controlled study on bipolar patients and their children].</ArticleTitle><Pagination><MedlinePgn>309-18</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This study aimed to identify the attachment style of bipolar patients and their children, and to investigate the relationship between attachment style, and temperament, personality characteristics, and clinical features of bipolar disorder.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">The study included 44 euthymic bipolar patients, 35 of their healthy children (&gt;16 years old), and 84 healthy controls (matched in terms of age, gender, and sociocultural background with the patients and their children). Diagnostic interviews were conducted using SCID-I, SCID-II, and SCID-NP. Bipolar symptoms were evaluated using SCIP-TURK. Temperament and attachment style were measured using TEMPS-A and AAS.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">More of the bipolar patients had an avoidant attachment style and more of their children had an anxious/ambivalent attachment style than did the healthy controls (p &lt; 0.001 and p &lt;&lt; 0.001). There was a negative correlation between insecure attachment and hyperthymic temperament (p = 0.008 and r = -0.623, and p = 0.049, r = -0.386). Insecure attachment style in the bipolar patients was predicted by borderline personality disorder, the severity of manic/depressive episodes, and depressive temperament. Insecure attachment in their children was predicted by anxious-avoidant and anxious-ambivalent attachment styles, the number of depressive episodes, irritable temperament (children), low-level social functioning, and a depression-mania-remission pattern.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">We observed a reciprocal relationship between insecure attachment style and mood disorders. This study shows that depressive temperament in bipolar patients and irritable temperament in their children predicted insecure attachment in both patients and their children.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>KÃ¶kÃ§Ã¼</LastName><ForeName>Filiz</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>fkokcu@adu.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kesebir</LastName><ForeName>Sermin</ForeName><Initials>S</Initials></Author></AuthorList><Language>tur</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Ä°ki UÃ§lu Olgular ve ÃocuklarÄ±nda BaÄlanma BiÃ§iminin MizaÃ§, KiÅilik ve Klinik Ãzellikler ile Ä°liÅkisi: Kontrollu Bir ÃaliÅma.</VernacularTitle></Article><MedlineJournalInfo><Country>Turkey</Country><MedlineTA>Turk Psikiyatri Derg</MedlineTA><NlmUniqueID>9425936</NlmUniqueID><ISSNLinking>1300-2163</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001007" MajorTopicYN="N">Anxiety</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001883" MajorTopicYN="N">Borderline Personality Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007407" MajorTopicYN="N">Interviews as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010287" MajorTopicYN="Y">Parent-Child Relations</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>12</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>12</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>3</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21125506</ArticleId><ArticleId IdType="pii">778</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20089313</PMID><DateCompleted><Year>2010</Year><Month>12</Month><Day>30</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>125</Volume><Issue>1-3</Issue><PubDate><Year>2010</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Clinical and psychosocial correlates of non-suicidal self-injury within a sample of children and adolescents with bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>89-97</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2009.12.029</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The purpose of this study is to examine the prevalence and correlates of non-suicidal self-injury (NSSI) among children and adolescents diagnosed with bipolar disorder (BP).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Four hundred-thirty two youth with a diagnosis of BP and their parents, including 193 children and 239 adolescents, completed a diagnostic interview and instruments to assess youth clinical and illness history, youth comorbidity, parental mood disorder, and psychosocial functioning.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Approximately 22% of children and 22% of adolescents reported NSSI during the course of their most recent mood episode. In a multivariate model controlling for global impairment, among children, a BPI or BPII diagnosis (versus BPNOS), psychosis, separation anxiety disorder, and greater severity of depressive symptoms were found to be associated with NSSI. Among adolescents, a mixed episode, a suicide attempt, greater severity of depressive symptoms, and poor psychosocial functioning were found to be associated with NSSI. Neither the presence of a youth comorbid disruptive behavior disorder nor a parental mood disorder was associated with NSSI.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">The primary limitations of this study include the use of a cross-sectional study design, lack of a control group, and limited generalizability of study results to non-clinical and ethnically diverse samples.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">NSSI is not uncommon among youth with BP, particularly those who present with BPI or BPII, psychosis, a mixed episode, suicidal behavior, severe depressive symptoms, separation anxiety, and/or poor psychosocial functioning. However, the relative importance of these factors in relation to NSSI may vary with age. Treatments for BP that are developmentally sensitive, examine the function of NSSI for each youth, and teach adaptive skills to address emotional and social needs, may prove to be most successful.</AbstractText><CopyrightInformation>2010 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Esposito-Smythers</LastName><ForeName>Christianne</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>George Mason University, Department of Psychology, 4400 University Drive, MSN 3F5, Fairfax, VA 22030, United States. cesposi1@gmu.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldstein</LastName><ForeName>Tina</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Birmaher</LastName><ForeName>Boris</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Goldstein</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Hunt</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Neal</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Axelson</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Strober</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Gill</LastName><ForeName>Mary Kay</ForeName><Initials>MK</Initials></Author><Author ValidYN="Y"><LastName>Hanley</LastName><ForeName>Andrea</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Keller</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH059691</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH059977-09</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH59691</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH59977</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH059929</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH059929-09</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH059977</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH59929</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH059691-09</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>01</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007406" MajorTopicYN="N">Interview, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016728" MajorTopicYN="N">Self-Injurious Behavior</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012917" MajorTopicYN="N">Social Adjustment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013406" MajorTopicYN="N">Suicide, Attempted</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>03</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2009</Year><Month>12</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>12</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>12</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20089313</ArticleId><ArticleId IdType="pii">S0165-0327(10)00008-X</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2009.12.029</ArticleId><ArticleId IdType="pmc">PMC2888943</ArticleId><ArticleId IdType="mid">NIHMS169309</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Am J Psychiatry. 1983 Jul;140(7):867-72</Citation><ArticleIdList><ArticleId IdType="pubmed">6859301</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2004 Dec;110(6):401-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15521823</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1991 Sep;30(5):735-9</Citation><ArticleIdList><ArticleId IdType="pubmed">1938787</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Suicide Res. 2007;11(2):129-47</Citation><ArticleIdList><ArticleId IdType="pubmed">17453692</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Child Adolesc Psychiatry. 2006 Jun;15(4):199-206</Citation><ArticleIdList><ArticleId IdType="pubmed">16604437</ArticleId></ArticleIdList></Reference><Reference><Citation>Suicide Life Threat Behav. 2003 Fall;33(3):277-87</Citation><ArticleIdList><ArticleId IdType="pubmed">14582838</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2007 Aug;37(8):1183-92</Citation><ArticleIdList><ArticleId IdType="pubmed">17349105</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1985 Jul;42(7):696-702</Citation><ArticleIdList><ArticleId IdType="pubmed">4015311</ArticleId></ArticleIdList></Reference><Reference><Citation>Bull Menninger Clin. 1993 Winter;57(1):41-68</Citation><ArticleIdList><ArticleId IdType="pubmed">8443617</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nerv Ment Dis. 2000 Dec;188(12):805-12</Citation><ArticleIdList><ArticleId IdType="pubmed">11191580</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2006 Aug;45(8):955-964</Citation><ArticleIdList><ArticleId IdType="pubmed">16865038</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Psychol Rev. 2008 Jul;28(6):969-81</Citation><ArticleIdList><ArticleId IdType="pubmed">18358579</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2006 Oct;63(10):1139-48</Citation><ArticleIdList><ArticleId IdType="pubmed">17015816</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1997 Jul;36(7):980-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9204677</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1987 Jun;44(6):540-8</Citation><ArticleIdList><ArticleId IdType="pubmed">3579500</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1995 Apr;34(4):454-63</Citation><ArticleIdList><ArticleId IdType="pubmed">7751259</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 2005 Feb;114(1):140-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15709820</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1997 May;36(5):610-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9136495</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nerv Ment Dis. 1998 May;186(5):259-68</Citation><ArticleIdList><ArticleId IdType="pubmed">9612442</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2000 Jul;57(7):675-82</Citation><ArticleIdList><ArticleId IdType="pubmed">10891038</ArticleId></ArticleIdList></Reference><Reference><Citation>Child Psychiatry Hum Dev. 1987 Winter;18(2):82-9</Citation><ArticleIdList><ArticleId IdType="pubmed">3436175</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Psychol Psychiatry. 1988 Jul;29(4):477-88</Citation><ArticleIdList><ArticleId IdType="pubmed">3215919</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2009 Jul;166(7):795-804</Citation><ArticleIdList><ArticleId IdType="pubmed">19448190</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2009 Apr;114(1-3):174-83</Citation><ArticleIdList><ArticleId IdType="pubmed">18715651</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 1989 Mar;79(3):283-9</Citation><ArticleIdList><ArticleId IdType="pubmed">2711856</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Pediatr Adolesc Med. 2007 Jul;161(7):641-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17606826</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 2002 Feb;111(1):198-202</Citation><ArticleIdList><ArticleId IdType="pubmed">11866174</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2009 Jul;48(7):730-739</Citation><ArticleIdList><ArticleId IdType="pubmed">19465878</ArticleId></ArticleIdList></Reference><Reference><Citation>Suicide Life Threat Behav. 2004 Spring;34(1):12-23</Citation><ArticleIdList><ArticleId IdType="pubmed">15106884</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2006 Feb;63(2):175-83</Citation><ArticleIdList><ArticleId IdType="pubmed">16461861</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1983 Nov;40(11):1228-31</Citation><ArticleIdList><ArticleId IdType="pubmed">6639293</ArticleId></ArticleIdList></Reference><Reference><Citation>J Consult Clin Psychol. 1994 Apr;62(2):366-74</Citation><ArticleIdList><ArticleId IdType="pubmed">8201075</ArticleId></ArticleIdList></Reference><Reference><Citation>J Consult Clin Psychol. 2004 Oct;72(5):885-90</Citation><ArticleIdList><ArticleId IdType="pubmed">15482046</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1998 Dec;155(12):1733-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9842784</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2006 Mar 30;141(3):305-14</Citation><ArticleIdList><ArticleId IdType="pubmed">16499973</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12359694</PMID><DateCompleted><Year>2002</Year><Month>10</Month><Day>23</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>159</Volume><Issue>10</Issue><PubDate><Year>2002</Year><Month>Oct</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Oxcarbazepine for mood disorders.</ArticleTitle><Pagination><MedlinePgn>1793</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nasr</LastName><ForeName>Suhayl</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>33CM23913M</RegistryNumber><NameOfSubstance UI="D002220">Carbamazepine</NameOfSubstance></Chemical><Chemical><RegistryNumber>VZI5B1W380</RegistryNumber><NameOfSubstance UI="D000078330">Oxcarbazepine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002220" MajorTopicYN="N">Carbamazepine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017579" MajorTopicYN="N">Domestic Violence</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000078330" MajorTopicYN="N">Oxcarbazepine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019966" MajorTopicYN="N">Substance-Related Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>10</Month><Day>3</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>10</Month><Day>31</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>10</Month><Day>3</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12359694</ArticleId><ArticleId IdType="doi">10.1176/appi.ajp.159.10.1793</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">4587067</PMID><DateCompleted><Year>1974</Year><Month>02</Month><Day>12</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-990X</ISSN><JournalIssue CitedMedium="Print"><Volume>30</Volume><Issue>1</Issue><PubDate><Year>1974</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Archives of general psychiatry</Title><ISOAbbreviation>Arch Gen Psychiatry</ISOAbbreviation></Journal><ArticleTitle>L-tryptophan in mania. Contribution to a permissive hypothesis of affective disorders.</ArticleTitle><Pagination><MedlinePgn>56-62</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Prange</LastName><ForeName>A J</ForeName><Initials>AJ</Initials><Suffix>Jr</Suffix></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>I C</ForeName><Initials>IC</Initials></Author><Author ValidYN="Y"><LastName>Lynn</LastName><ForeName>C W</ForeName><Initials>CW</Initials></Author><Author ValidYN="Y"><LastName>Alltop</LastName><ForeName>L B</ForeName><Initials>LB</Initials></Author><Author ValidYN="Y"><LastName>Stikeleather</LastName><ForeName>R A</ForeName><Initials>RA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D018848">Controlled Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Gen Psychiatry</MedlineTA><NlmUniqueID>0372435</NlmUniqueID><ISSNLinking>0003-990X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000588">Amines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002395">Catecholamines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007211">Indoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010919">Placebos</NameOfSubstance></Chemical><Chemical><RegistryNumber>8DUH1N11BX</RegistryNumber><NameOfSubstance UI="D014364">Tryptophan</NameOfSubstance></Chemical><Chemical><RegistryNumber>U42B7VYA4P</RegistryNumber><NameOfSubstance UI="D002746">Chlorpromazine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000342" MajorTopicYN="N">Affective Symptoms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000588" MajorTopicYN="N">Amines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002395" MajorTopicYN="N">Catecholamines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002746" MajorTopicYN="N">Chlorpromazine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004341" MajorTopicYN="N">Drug Evaluation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007211" MajorTopicYN="N">Indoles</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010919" MajorTopicYN="N">Placebos</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012075" MajorTopicYN="N">Remission, Spontaneous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014364" MajorTopicYN="N">Tryptophan</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1974</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>3</Month><Day>28</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1974</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">4587067</ArticleId><ArticleId IdType="doi">10.1001/archpsyc.1974.01760070040006</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11256681</PMID><DateCompleted><Year>2001</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1398-5647</ISSN><JournalIssue CitedMedium="Print"><Volume>2</Volume><Issue>3 Pt 1</Issue><PubDate><Year>2000</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>The mitochondrial hypothesis of bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>145-7</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hough</LastName><ForeName>C J</ForeName><Initials>CJ</Initials></Author><Author ValidYN="Y"><LastName>Chuang</LastName><ForeName>D M</ForeName><Initials>DM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016420">Comment</PublicationType><PublicationType UI="D016421">Editorial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004272">DNA, Mitochondrial</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016194">Receptors, N-Methyl-D-Aspartate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Bipolar Disord. 2000 Sep;2(3 Pt 1):180-90</RefSource><PMID Version="1">11256685</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004272" MajorTopicYN="N">DNA, Mitochondrial</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017354" MajorTopicYN="N">Point Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016194" MajorTopicYN="N">Receptors, N-Methyl-D-Aspartate</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>3</Month><Day>21</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>5</Month><Day>18</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>3</Month><Day>21</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11256681</ArticleId><ArticleId IdType="doi">10.1034/j.1399-5618.2000.020301.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">2951414</PMID><DateCompleted><Year>1987</Year><Month>05</Month><Day>15</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-0327</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>3</Issue><PubDate><MedlineDate>1986 Nov-Dec</MedlineDate></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>The effectiveness of lithium prophylaxis in bipolar and unipolar depressions and schizo-affective disorders.</ArticleTitle><Pagination><MedlinePgn>275-80</MedlinePgn></Pagination><Abstract><AbstractText>The effectiveness of lithium prophylaxis in bipolar affective disorders is generally supported in the literature. The effects in this group, as well as in unipolar depressions and schizo-affective disorders were studied, using an individual retrospective control method, and the Life Table method. Lithium prophylaxis resulted in a substantial decrease in the number of episodes and hospital admissions in bipolar and schizo-affective disorders. In addition, these two groups showed frequent relapses after termination of the prophylaxis. The number of episodes preceding the prophylaxis and the absence of unipolar depression are found to be predictors of effectiveness. The consequences of patient selection and of inconclusive diagnostic criteria are pointed out.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bouman</LastName><ForeName>T K</ForeName><Initials>TK</Initials></Author><Author ValidYN="Y"><LastName>Niemantsverdriet-van Kampen</LastName><ForeName>J G</ForeName><Initials>JG</Initials></Author><Author ValidYN="Y"><LastName>Ormel</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Slooff</LastName><ForeName>C J</ForeName><Initials>CJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1986</Year><Month>11</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1986</Year><Month>11</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1986</Year><Month>11</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2951414</ArticleId><ArticleId IdType="pii">0165-0327(86)90079-0</ArticleId><ArticleId IdType="doi">10.1016/0165-0327(86)90079-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29463875</PMID><DateCompleted><Year>2019</Year><Month>09</Month><Day>19</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>19</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>1</Issue><PubDate><Year>2018</Year><Month>02</Month><Day>20</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Proliferation and apoptosis of T lymphocytes in patients with bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>3327</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-018-21769-0</ELocationID><Abstract><AbstractText>The aim of the study was to evaluate proliferation capacity and susceptibility to apoptosis of T lymphocytes of patients with bipolar disorder (BD) and to investigate in vitro influence of two standard mood stabilizers: lithium and valproic acid on these parameters using flow cytometry. Our results show that T lymphocytes of BD patients, especially those treated with lithium, have reduced proliferation capacity compared to healthy people. In vitro studies showed that valproic acid reduces the number of cell divisions and percentages of proliferating cells regardless of health status but mainly in very high dose, while lithium has no significant influence on proliferation capacity of patients' T lymphocytes. Lymphocytes of BD patients are also more prone to apoptosis compared with healthy individuals which is related to high expression of Bax, a pro-apoptotic protein. In vitro lithium protected patients' lymphocytes from apoptosis proportionally to dose used. Valproic acid protected lymphocytes of patients from apoptosis mainly in therapeutic concentration. Our results show that mood stabilizers used to prevent relapses of the disease have anti-apoptotic effect on T lymphocytes of BD patients but they are not able to improve their proliferation capacity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pietruczuk</LastName><ForeName>Krzysztof</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Physiopathology, Medical University of Gdansk, Gdansk, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lisowska</LastName><ForeName>Katarzyna A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Department of Physiopathology, Medical University of Gdansk, Gdansk, Poland. katlis@gumed.edu.pl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grabowski</LastName><ForeName>Karol</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Clinic of Adult Psychiatry, Medical University of Gdansk, Gdansk, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Landowski</LastName><ForeName>Jerzy</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Clinic of Adult Psychiatry, Medical University of Gdansk, Gdansk, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Witkowski</LastName><ForeName>Jacek M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Physiopathology, Medical University of Gdansk, Gdansk, Poland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>02</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018020">Lithium Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>614OI1Z5WI</RegistryNumber><NameOfSubstance UI="D014635">Valproic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="Y">Apoptosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049109" MajorTopicYN="Y">Cell Proliferation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018020" MajorTopicYN="N">Lithium Compounds</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014635" MajorTopicYN="N">Valproic Acid</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>09</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>02</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>2</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>2</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29463875</ArticleId><ArticleId IdType="doi">10.1038/s41598-018-21769-0</ArticleId><ArticleId IdType="pii">10.1038/s41598-018-21769-0</ArticleId><ArticleId IdType="pmc">PMC5820246</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Chemother. 1997 Jun;9(3):219-26</Citation><ArticleIdList><ArticleId IdType="pubmed">9210006</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2002 Sep;71(1-3):205-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12167518</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2007 Dec;104(1-3):91-5</Citation><ArticleIdList><ArticleId IdType="pubmed">17434599</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer. 1980 Jan 1;45(1):91-7</Citation><ArticleIdList><ArticleId IdType="pubmed">7351009</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2008 May;108(1-2):43-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17904227</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Transplant. 2009;18(9):951-75</Citation><ArticleIdList><ArticleId IdType="pubmed">19523343</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Tissue Res. 2000 Jul;301(1):85-99</Citation><ArticleIdList><ArticleId IdType="pubmed">10928283</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Neuropsychiatry. 2016 Oct;2(3):115-123</Citation><ArticleIdList><ArticleId IdType="pubmed">27867936</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2016 Nov 15;205:73-80</Citation><ArticleIdList><ArticleId IdType="pubmed">27420134</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Lett. 2008 Sep 28;269(1):7-17</Citation><ArticleIdList><ArticleId IdType="pubmed">18462867</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Dis. 2010 Mar;37(3):596-603</Citation><ArticleIdList><ArticleId IdType="pubmed">19945534</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2009 Aug;116(3):214-7</Citation><ArticleIdList><ArticleId IdType="pubmed">19251324</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2001 May;64(2-3):185-93</Citation><ArticleIdList><ArticleId IdType="pubmed">11313085</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychol. 2006 Jan;62(1):123-46</Citation><ArticleIdList><ArticleId IdType="pubmed">16287149</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Toxicol (Phila). 2015 Jun;53(5):454-65</Citation><ArticleIdList><ArticleId IdType="pubmed">25950372</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Behav Immun. 2003 Feb;17 Suppl 1:S18-26</Citation><ArticleIdList><ArticleId IdType="pubmed">12615182</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Immunol Immunopathol. 1981 May;19(2):284-8</Citation><ArticleIdList><ArticleId IdType="pubmed">7226579</ArticleId></ArticleIdList></Reference><Reference><Citation>Tumori. 2000 Mar-Apr;86(2):149-52</Citation><ArticleIdList><ArticleId IdType="pubmed">10855853</ArticleId></ArticleIdList></Reference><Reference><Citation>Ther Drug Monit. 2013 Oct;35(5):643-8</Citation><ArticleIdList><ArticleId IdType="pubmed">23783169</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Hematol. 2007 Oct;35(10):1527-37</Citation><ArticleIdList><ArticleId IdType="pubmed">17697742</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacol Bull. 2007;40(4):99-115</Citation><ArticleIdList><ArticleId IdType="pubmed">18227781</ArticleId></ArticleIdList></Reference><Reference><Citation>J Chemother. 2000 Jun;12(3):252-7</Citation><ArticleIdList><ArticleId IdType="pubmed">10877522</ArticleId></ArticleIdList></Reference><Reference><Citation>Adv Clin Exp Med. 2015 Jan-Feb;24(1):55-62</Citation><ArticleIdList><ArticleId IdType="pubmed">25923087</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2014 Jul 30;217(3):226-32</Citation><ArticleIdList><ArticleId IdType="pubmed">24746391</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2014 Jan;152-154:474-7</Citation><ArticleIdList><ArticleId IdType="pubmed">24007785</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Protoc Cytom. 2008 Apr;Chapter 9:Unit9.25</Citation><ArticleIdList><ArticleId IdType="pubmed">18770652</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2003 Jan 15;53(2):157-65</Citation><ArticleIdList><ArticleId IdType="pubmed">12547472</ArticleId></ArticleIdList></Reference><Reference><Citation>Rev Psiquiatr Salud Ment. 2012 Apr-Jun;5(2):127-33</Citation><ArticleIdList><ArticleId IdType="pubmed">22854584</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2015 Sep;17(6):636-44</Citation><ArticleIdList><ArticleId IdType="pubmed">26257203</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychoneuroendocrinology. 2009 Sep;34(8):1162-75</Citation><ArticleIdList><ArticleId IdType="pubmed">19359101</ArticleId></ArticleIdList></Reference><Reference><Citation>CNS Spectr. 2016 Aug;21(4):318-23</Citation><ArticleIdList><ArticleId IdType="pubmed">27378177</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychopharmacol. 2009 Jun;23(4):346-88</Citation><ArticleIdList><ArticleId IdType="pubmed">19329543</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimmunomodulation. 2014;21(2-3):117-22</Citation><ArticleIdList><ArticleId IdType="pubmed">24557044</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18423667</PMID><DateCompleted><Year>2009</Year><Month>01</Month><Day>12</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-3956</ISSN><JournalIssue CitedMedium="Print"><Volume>43</Volume><Issue>1</Issue><PubDate><Year>2008</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Journal of psychiatric research</Title><ISOAbbreviation>J Psychiatr Res</ISOAbbreviation></Journal><ArticleTitle>Effectiveness of lamotrigine in bipolar disorder in a clinical setting.</ArticleTitle><Pagination><MedlinePgn>13-23</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jpsychires.2008.02.007</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To assess lamotrigine effectiveness in bipolar disorder (BD) patients in a clinical setting.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Open lamotrigine was naturalistically administered to outpatients at the Stanford University BD Clinic assessed with the Systematic Treatment Enhancement Program for BD (STEP-BD) Affective Disorders Evaluation, and monitored longitudinally with the STEP-BD Clinical Monitoring Form.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">One hundred and ninety-seven patients (64 BD I, 110 BD II, 21 BD NOS, 2 Schizoaffective Bipolar Type, mean+/-SD age 42.2+/-14.4 years, 62% female) had 200 trials of lamotrigine. Lamotrigine was combined with a mean of 2.1+/-1.5 other psychotropic medications, most often during euthymia or depressive symptoms. Mean lamotrigine duration was 434+/-444 days, and mean final dose was 236+/-132mg/day without valproate, and 169+/-137mg/day with valproate. Lamotrigine was discontinued in only 26.5% of trials at 255+/-242 days, most often due to inefficacy, and seldom due to adverse effects. In 31.5% of trials lamotrigine was continued 264+/-375 days with no subsequent psychotropic added. In 42.0% of trials lamotrigine was continued 674+/-479 days, but had subsequent psychotropic added at 146+/-150 days, most often for anxiety/insomnia and depressive symptoms. In 145 trials started at Stanford, lamotrigine primarily yielded relief of depressive symptoms or maintained euthymia. In 55 trials in which lamotrigine was started prior to Stanford, lamotrigine primarily maintained euthymia. Lamotrigine was generally well tolerated, with no serious rash, and only 3.5% discontinuing due to benign rash.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In a cohort of bipolar disorder outpatients commonly with comorbid conditions, and most often receiving complex combination therapy, lamotrigine had a low (26.5%, with an overall mean duration of treatment of 434 days) discontinuation rate, suggesting effectiveness in BD in a clinical setting.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ketter</LastName><ForeName>Terence A</ForeName><Initials>TA</Initials><AffiliationInfo><Affiliation>Stanford University School of Medicine, 401 Quarry Road, Room 2124, Stanford, CA, USA. tketter@stanford.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brooks</LastName><ForeName>John O</ForeName><Initials>JO</Initials></Author><Author ValidYN="Y"><LastName>Hoblyn</LastName><ForeName>Jennifer C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Champion</LastName><ForeName>Laurel M</ForeName><Initials>LM</Initials></Author><Author ValidYN="Y"><LastName>Nam</LastName><ForeName>Jennifer Y</ForeName><Initials>JY</Initials></Author><Author ValidYN="Y"><LastName>Culver</LastName><ForeName>Jenifer L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Marsh</LastName><ForeName>Wendy K</ForeName><Initials>WK</Initials></Author><Author ValidYN="Y"><LastName>Bonner</LastName><ForeName>Julie C</ForeName><Initials>JC</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Psychiatr Res</MedlineTA><NlmUniqueID>0376331</NlmUniqueID><ISSNLinking>0022-3956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011619">Psychotropic Drugs</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014227">Triazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>U3H27498KS</RegistryNumber><NameOfSubstance UI="D000077213">Lamotrigine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000553" MajorTopicYN="N">Ambulatory Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002985" MajorTopicYN="N">Clinical Protocols</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004351" MajorTopicYN="N">Drug Resistance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077213" MajorTopicYN="N">Lamotrigine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010352" MajorTopicYN="N">Patient Dropouts</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011619" MajorTopicYN="N">Psychotropic Drugs</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014227" MajorTopicYN="N">Triazines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>11</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2008</Year><Month>02</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>02</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>4</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>1</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>4</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18423667</ArticleId><ArticleId IdType="pii">S0022-3956(08)00053-8</ArticleId><ArticleId IdType="doi">10.1016/j.jpsychires.2008.02.007</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23945460</PMID><DateCompleted><Year>2013</Year><Month>11</Month><Day>01</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1555-2101</ISSN><JournalIssue CitedMedium="Internet"><Volume>74</Volume><Issue>7</Issue><PubDate><Year>2013</Year><Month>Jul</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Randomized controlled trial to assess reduction of cardiovascular disease risk in patients with bipolar disorder: the Self-Management Addressing Heart Risk Trial (SMAHRT).</ArticleTitle><Pagination><MedlinePgn>e655-62</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4088/JCP.12m08082</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Persons with bipolar disorder experience a disproportionate burden of medical conditions, notably cardiovascular disease (CVD), leading to impaired functioning and premature mortality. We hypothesized that the Life Goals Collaborative Care (LGCC) intervention, compared to enhanced usual care, would reduce CVD risk factors and improve physical and mental health outcomes in US Department of Veterans Affairs patients with bipolar disorder.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Patients with an ICD-9 diagnosis of bipolar disorder and â¥ 1 CVD risk factor (N = 118) enrolled in the Self-Management Addressing Heart Risk Trial, conducted April 2008-May 2010, were randomized to LGCC (n = 58) or enhanced usual care (n = 60). Life Goals Collaborative Care included 4 weekly self-management sessions followed by tailored contacts combining health behavior change strategies, medical care management, registry tracking, and provider guideline support. Enhanced usual care included quarterly wellness newsletters sent during a 12-month period in addition to standard treatment. Primary outcome measures included systolic and diastolic blood pressure, nonfasting total cholesterol, and physical health-related quality of life.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 180 eligible patients identified for study participation, 134 were enrolled (74%) and 118 completed outcomes assessments (mean age = 53 years, 17% female, 5% African American). Mixed effects analyses comparing changes in 24-month outcomes among patients in LGCC (n = 57) versus enhanced usual care (n = 59) groups revealed that patients receiving LGCC had reduced systolic (Î² = -3.1, P = .04) and diastolic blood pressure (Î² = -2.1, P = .04) as well as reduced manic symptoms (Î² = -23.9, P = .01). Life Goals Collaborative Care had no significant impact on other primary outcomes (total cholesterol and physical health-related quality of life).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Life Goals Collaborative Care, compared to enhanced usual care, may lead to reduced CVD risk factors, notably through decreased blood pressure, as well as reduced manic symptoms, in patients with bipolar disorder.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">ClinicalTrials.gov identifier: NCT00499096.</AbstractText><CopyrightInformation>Â© Copyright 2013 Physicians Postgraduate Press, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kilbourne</LastName><ForeName>Amy M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>VA Ann Arbor Center for Clinical Management Research and National Serious Mental Illness, Treatment Resource &amp; Evaluation Center, North Campus Research Complex, 2800 Plymouth Rd, Bldg 14, Ann Arbor, MI 48109-2800, USA. amykilbo@umich.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goodrich</LastName><ForeName>David E</ForeName><Initials>DE</Initials></Author><Author ValidYN="Y"><LastName>Lai</LastName><ForeName>Zongshan</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Post</LastName><ForeName>Edward P</ForeName><Initials>EP</Initials></Author><Author ValidYN="Y"><LastName>Schumacher</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Nord</LastName><ForeName>Kristina M</ForeName><Initials>KM</Initials></Author><Author ValidYN="Y"><LastName>Bramlet</LastName><ForeName>Margretta</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Chermack</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Bialy</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Bauer</LastName><ForeName>Mark S</ForeName><Initials>MS</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00499096</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>R34 MH074509</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R34MH74509</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D032763" MajorTopicYN="N">Behavior Control</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="Y">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003299" MajorTopicYN="N">Cooperative Behavior</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006304" MajorTopicYN="N">Health Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D038801" MajorTopicYN="N">International Classification of Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010347" MajorTopicYN="N">Patient Care Planning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D040242" MajorTopicYN="N">Risk Reduction Behavior</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012648" MajorTopicYN="Y">Self Care</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012944" MajorTopicYN="N">Social Support</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>08</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>11</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>8</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>8</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23945460</ArticleId><ArticleId IdType="doi">10.4088/JCP.12m08082</ArticleId><ArticleId IdType="pmc">PMC4154058</ArticleId><ArticleId IdType="mid">NIHMS620233</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Med Care. 1996 Mar;34(3):220-33</Citation><ArticleIdList><ArticleId IdType="pubmed">8628042</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Serv. 2006 Jul;57(7):927-36</Citation><ArticleIdList><ArticleId IdType="pubmed">16816276</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2007 Aug;9(5):443-52</Citation><ArticleIdList><ArticleId IdType="pubmed">17680914</ArticleId></ArticleIdList></Reference><Reference><Citation>Milbank Q. 1996;74(4):511-44</Citation><ArticleIdList><ArticleId IdType="pubmed">8941260</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes Care. 2004 Feb;27(2):596-601</Citation><ArticleIdList><ArticleId IdType="pubmed">14747245</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2010 Feb;167(2):151-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20008945</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2002 Dec;4(6):398-405</Citation><ArticleIdList><ArticleId IdType="pubmed">12519100</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2010 Dec 30;363(27):2611-20</Citation><ArticleIdList><ArticleId IdType="pubmed">21190455</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gen Intern Med. 2000 Jun;15(6):395-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10886474</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Obes (Lond). 2011 Aug;35(8):1114-23</Citation><ArticleIdList><ArticleId IdType="pubmed">21042323</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Serv. 2009 May;60(5):589</Citation><ArticleIdList><ArticleId IdType="pubmed">19411344</ArticleId></ArticleIdList></Reference><Reference><Citation>Circulation. 1998 May 12;97(18):1837-47</Citation><ArticleIdList><ArticleId IdType="pubmed">9603539</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychosom Med. 2009 Oct;71(8):894-900</Citation><ArticleIdList><ArticleId IdType="pubmed">19661187</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Serv. 2006 Jul;57(7):937-45</Citation><ArticleIdList><ArticleId IdType="pubmed">16816277</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2009 Aug;70(8):1078-90</Citation><ArticleIdList><ArticleId IdType="pubmed">19497250</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Serv. 2008 Jul;59(7):760-8</Citation><ArticleIdList><ArticleId IdType="pubmed">18586993</ArticleId></ArticleIdList></Reference><Reference><Citation>Contemp Clin Trials. 2012 Jul;33(4):666-78</Citation><ArticleIdList><ArticleId IdType="pubmed">22386799</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Serv. 2007 Jun;58(6):740</Citation><ArticleIdList><ArticleId IdType="pubmed">17535932</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Prax. 2001 Jul;28 Suppl 1:S7-11</Citation><ArticleIdList><ArticleId IdType="pubmed">11533901</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2005 May 25;293(20):2528-30</Citation><ArticleIdList><ArticleId IdType="pubmed">15914754</ArticleId></ArticleIdList></Reference><Reference><Citation>Prim Care Companion CNS Disord. 2011;13(1):</Citation><ArticleIdList><ArticleId IdType="pubmed">21731829</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2006 May;63(5):500-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16651507</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2008 Sep;10(6):672-83</Citation><ArticleIdList><ArticleId IdType="pubmed">18837861</ArticleId></ArticleIdList></Reference><Reference><Citation>Community Ment Health J. 2010 Dec;46(6):540-52</Citation><ArticleIdList><ArticleId IdType="pubmed">20012197</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Serv. 2009 Feb;60(2):147-56</Citation><ArticleIdList><ArticleId IdType="pubmed">19176408</ArticleId></ArticleIdList></Reference><Reference><Citation>Ment Health Serv Res. 2002 Dec;4(4):175-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12558001</ArticleId></ArticleIdList></Reference><Reference><Citation>Gen Hosp Psychiatry. 2010 Nov-Dec;32(6):636-43</Citation><ArticleIdList><ArticleId IdType="pubmed">21112457</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2003 Jan;73(1-2):123-31</Citation><ArticleIdList><ArticleId IdType="pubmed">12507745</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2002 Oct 16;288(15):1882-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12377087</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Clin Psychiatry. 2011 Feb;23(1):40-7</Citation><ArticleIdList><ArticleId IdType="pubmed">21318195</ArticleId></ArticleIdList></Reference><Reference><Citation>Gen Hosp Psychiatry. 2009 Nov-Dec;31(6):555-63</Citation><ArticleIdList><ArticleId IdType="pubmed">19892214</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2003 Oct;5(5):366-9</Citation><ArticleIdList><ArticleId IdType="pubmed">14525558</ArticleId></ArticleIdList></Reference><Reference><Citation>Adm Policy Ment Health. 2006 Jan;33(1):54-64</Citation><ArticleIdList><ArticleId IdType="pubmed">16215661</ArticleId></ArticleIdList></Reference><Reference><Citation>Health Aff (Millwood). 2006 May-Jun;25(3):659-69</Citation><ArticleIdList><ArticleId IdType="pubmed">16684729</ArticleId></ArticleIdList></Reference><Reference><Citation>J Fam Pract. 2001 Apr;50(4):313-20</Citation><ArticleIdList><ArticleId IdType="pubmed">11300982</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2012 Aug;169(8):790-804</Citation><ArticleIdList><ArticleId IdType="pubmed">22772364</ArticleId></ArticleIdList></Reference><Reference><Citation>Circulation. 2005 Oct 25;112(17):2735-52</Citation><ArticleIdList><ArticleId IdType="pubmed">16157765</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2002 Oct 9;288(14):1775-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12365965</ArticleId></ArticleIdList></Reference><Reference><Citation>Vital Health Stat 1. 1993 Aug;(31):1-412</Citation><ArticleIdList><ArticleId IdType="pubmed">8236861</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32169562</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>04</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-4216</ISSN><JournalIssue CitedMedium="Internet"><Volume>101</Volume><PubDate><Year>2020</Year><Month>07</Month><Day>13</Day></PubDate></JournalIssue><Title>Progress in neuro-psychopharmacology &amp; biological psychiatry</Title><ISOAbbreviation>Prog Neuropsychopharmacol Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>The role of CACNA1C gene and childhood trauma interaction on bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>109915</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0278-5846(19)31003-6</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.pnpbp.2020.109915</ELocationID><Abstract><AbstractText>Studies on gene x environment interaction (GxE) have provided vital information for uncovering the origins of complex diseases. When considering the etiology of bipolar disorder (BD), the role of such interactions is unknown. Here, we tested whether trauma during childhood could modify the effect of two polymorphisms in the CACNA1C gene (rs1006737 and rs4765913) in terms of susceptibility to BD. The study enrolled 878 Caucasian young adults in a cross-sectional population-based survey. BD diagnosis was performed using a clinical interview MINI 5.0, and trauma was assessed with the childhood trauma questionnaire (CTQ). Binary logistic regression models were employed to test the main effects of polymorphisms, haplotypes, and GxE interactions using sex as a confounder. We did not observe an association between the polymorphisms and diagnosis of BD. However, we noted that childhood trauma modified the effect of the rs4765913 polymorphism (pÂ =Â .018) and the AA haplotype (rs1006737 - rs4765913) (pÂ =Â .018) on BD susceptibility. A allele carriers of the rs4765913 polymorphism or the AA haplotype exposed to childhood trauma are more likely to develop BD compared to the individuals without a genetic risk. Thus, this study showed that the risk of developing BD in individuals exposed to childhood trauma was influenced by the individual's genetic background, varying according to the CACNA1C genotypes.</AbstractText><CopyrightInformation>Copyright Â© 2020 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bastos</LastName><ForeName>Clarissa Ribeiro</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>Laboratory of Clinical Neuroscience, Post-graduation Program in Health and Behavior, Catholic University of Pelotas, Pelotas, Rio Grande do Sul, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tovo-Rodrigues</LastName><ForeName>Luciana</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Postgraduate Program in Epidemiology, Federal University of Pelotas, Pelotas, Rio Grande do Sul, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ardais</LastName><ForeName>Ana Paula</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Laboratory of Clinical Neuroscience, Post-graduation Program in Health and Behavior, Catholic University of Pelotas, Pelotas, Rio Grande do Sul, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xavier</LastName><ForeName>Janaina</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Laboratory of Clinical Neuroscience, Post-graduation Program in Health and Behavior, Catholic University of Pelotas, Pelotas, Rio Grande do Sul, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salerno</LastName><ForeName>Pamela Silva VitÃ³ria</ForeName><Initials>PSV</Initials><AffiliationInfo><Affiliation>Laboratory of Clinical Neuroscience, Post-graduation Program in Health and Behavior, Catholic University of Pelotas, Pelotas, Rio Grande do Sul, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Camerini</LastName><ForeName>LaÃ­sa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Laboratory of Clinical Neuroscience, Post-graduation Program in Health and Behavior, Catholic University of Pelotas, Pelotas, Rio Grande do Sul, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jansen</LastName><ForeName>Karen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Laboratory of Clinical Neuroscience, Post-graduation Program in Health and Behavior, Catholic University of Pelotas, Pelotas, Rio Grande do Sul, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Mattos Souza</LastName><ForeName>Luciano Dias</ForeName><Initials>LD</Initials><AffiliationInfo><Affiliation>Laboratory of Clinical Neuroscience, Post-graduation Program in Health and Behavior, Catholic University of Pelotas, Pelotas, Rio Grande do Sul, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>da Silva</LastName><ForeName>Ricardo Azevedo</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Laboratory of Clinical Neuroscience, Post-graduation Program in Health and Behavior, Catholic University of Pelotas, Pelotas, Rio Grande do Sul, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lara</LastName><ForeName>Diogo Rizzato</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Biology, Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghisleni</LastName><ForeName>Gabriele</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Laboratory of Clinical Neuroscience, Post-graduation Program in Health and Behavior, Catholic University of Pelotas, Pelotas, Rio Grande do Sul, Brazil. Electronic address: gabriele.ghisleni@ucpel.edu.br.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>03</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Prog Neuropsychopharmacol Biol Psychiatry</MedlineTA><NlmUniqueID>8211617</NlmUniqueID><ISSNLinking>0278-5846</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C079146">CACNA1C protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020746">Calcium Channels, L-Type</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000076783" MajorTopicYN="N">Adverse Childhood Experiences</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001938" MajorTopicYN="N" Type="Geographic">Brazil</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020746" MajorTopicYN="N">Calcium Channels, L-Type</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Bipolar disorder</Keyword><Keyword MajorTopicYN="Y">Calcium channels L-type</Keyword><Keyword MajorTopicYN="Y">Childhood trauma</Keyword><Keyword MajorTopicYN="Y">Gene-environment interaction</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest All authors disclose no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>12</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>02</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>03</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32169562</ArticleId><ArticleId IdType="pii">S0278-5846(19)31003-6</ArticleId><ArticleId IdType="doi">10.1016/j.pnpbp.2020.109915</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">25771686</PMID><DateCompleted><Year>2016</Year><Month>03</Month><Day>09</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>5</Issue><PubDate><Year>2015</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Emotion regulation deficits in euthymic bipolar I versus bipolar II disorder: a functional and diffusion-tensor imaging study.</ArticleTitle><Pagination><MedlinePgn>461-70</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/bdi.12292</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Emotion regulation deficits are a core feature of bipolar disorder. However, their potential neurobiological underpinnings and existence beyond bipolar I disorder remain unexplored. Our main goal was to investigate whether both individuals with bipolar I and bipolar II disorder show deficits in emotion regulation during an attention control task, and to explore the neurophysiological underpinnings of this potential deficit.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Twenty healthy controls, 16 euthymic participants with bipolar I disorder, and 19 euthymic participants with bipolar II disorder completed psychometric and clinical assessments, a neuroimaging emotion regulation paradigm, and an anatomical diffusion-weighted scan. Groups were matched for age, gender, and verbal IQ.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">During the presence of emotional distracters, subjects with bipolar I disorder showed slowed reaction times to targets, and increased blood oxygenation level-dependent (BOLD) responses in the amygdala, accumbens, and dorsolateral prefrontal cortex, but not increased inverse functional connectivity between these prefrontal and subcortical areas, and altered white matter microstructure organization in the right uncinate fasciculus. Subjects with bipolar II disorder showed no altered reaction times, increased BOLD responses in the same brain areas, increased inverse functional connectivity between the prefrontal cortex and amygdala, and no abnormalities in white matter organization.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Participants with bipolar I disorder showed abnormalities in functional and anatomical connectivity between prefrontal cortices and subcortical structures in emotion regulation circuitry. However, these deficits did not extend to subjects with bipolar II disorder, suggesting fundamental differences in the pathophysiology of bipolar disorder subtypes.</AbstractText><CopyrightInformation>Â© 2015 The Authors. Bipolar Disorders Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Caseras</LastName><ForeName>Xavier</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>MRC Centre for Neuropsychiatric Genetics and Genomics, Institute of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience and Mental Health Research Institute, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murphy</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Neuroscience and Mental Health Research Institute, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiff University Brain Research Imaging Centre, School of Psychology, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lawrence</LastName><ForeName>Natalia S</ForeName><Initials>NS</Initials><AffiliationInfo><Affiliation>Mood Disorders Centre, School of Psychology, University of Exeter, Exeter, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fuentes-Claramonte</LastName><ForeName>Paola</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Departament de Psicologia BÃ sica, ClÃ­nica i Psicobiologia, School of Psychology, Universitat Jaume I de CastellÃ³, Castello, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watts</LastName><ForeName>Jessica</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>MRC Centre for Neuropsychiatric Genetics and Genomics, Institute of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience and Mental Health Research Institute, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Derek K</ForeName><Initials>DK</Initials><AffiliationInfo><Affiliation>Neuroscience and Mental Health Research Institute, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiff University Brain Research Imaging Centre, School of Psychology, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Phillips</LastName><ForeName>Mary L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>MRC Centre for Neuropsychiatric Genetics and Genomics, Institute of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience and Mental Health Research Institute, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mood and Brain Laboratory, Department of Psychiatry, University of Pittsburgh School of Medicine, Western Psychiatric Institute and Clinic, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>096646</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L010305/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>03</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000679" MajorTopicYN="N">Amygdala</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001288" MajorTopicYN="N">Attention</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056324" MajorTopicYN="N">Diffusion Tensor Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004644" MajorTopicYN="Y">Emotions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059907" MajorTopicYN="N">Functional Neuroimaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009714" MajorTopicYN="N">Nucleus Accumbens</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017397" MajorTopicYN="N">Prefrontal Cortex</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011930" MajorTopicYN="N">Reaction Time</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068356" MajorTopicYN="N">Self-Control</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066127" MajorTopicYN="N">White Matter</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">BOLD</Keyword><Keyword MajorTopicYN="N">DTI</Keyword><Keyword MajorTopicYN="N">bipolar disorder</Keyword><Keyword MajorTopicYN="N">emotion regulation</Keyword><Keyword MajorTopicYN="N">fMRI</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>10</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>12</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>3</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25771686</ArticleId><ArticleId IdType="doi">10.1111/bdi.12292</ArticleId><ArticleId IdType="pmc">PMC4672703</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Eur Psychiatry. 2015 Jan;30(1):82-8</Citation><ArticleIdList><ArticleId IdType="pubmed">24853295</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Soc Clin Psychol. 1967 Dec;6(4):278-96</Citation><ArticleIdList><ArticleId IdType="pubmed">6080235</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2007 Oct 15;62(8):917-24</Citation><ArticleIdList><ArticleId IdType="pubmed">17825802</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Brain Mapp. 2010 May;31(5):758-69</Citation><ArticleIdList><ArticleId IdType="pubmed">19957268</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2012 Jun;14(4):326-39</Citation><ArticleIdList><ArticleId IdType="pubmed">22631618</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Psychiatry. 2013;13:165</Citation><ArticleIdList><ArticleId IdType="pubmed">23758923</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2010 Dec;127(1-3):309-15</Citation><ArticleIdList><ArticleId IdType="pubmed">20598752</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Cogn Sci. 2005 May;9(5):242-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15866151</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2008 Mar;165(3):313-20</Citation><ArticleIdList><ArticleId IdType="pubmed">18245175</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2003 Sep 1;54(5):515-28</Citation><ArticleIdList><ArticleId IdType="pubmed">12946880</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Psychiatry. 2013 Aug 08;4:87</Citation><ArticleIdList><ArticleId IdType="pubmed">23964248</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2014 Feb;19(2):200-8</Citation><ArticleIdList><ArticleId IdType="pubmed">23358158</ArticleId></ArticleIdList></Reference><Reference><Citation>Transl Psychiatry. 2012;2:e90</Citation><ArticleIdList><ArticleId IdType="pubmed">22832855</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cogn Neurosci. 2007 May;19(5):776-98</Citation><ArticleIdList><ArticleId IdType="pubmed">17488204</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2013 May;170(5):533-41</Citation><ArticleIdList><ArticleId IdType="pubmed">23558337</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57</Citation><ArticleIdList><ArticleId IdType="pubmed">9881538</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1978 Nov;133:429-35</Citation><ArticleIdList><ArticleId IdType="pubmed">728692</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2012 Jan;42(1):29-40</Citation><ArticleIdList><ArticleId IdType="pubmed">21733287</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Clin Psychol. 1992 Sep;31 ( Pt 3):327-9</Citation><ArticleIdList><ArticleId IdType="pubmed">1393161</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2008 Sep;65(9):1041-52</Citation><ArticleIdList><ArticleId IdType="pubmed">18762590</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2013 Sep;128(3):149-62</Citation><ArticleIdList><ArticleId IdType="pubmed">23617548</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Psychol Psychiatry. 2012 Jul;53(7):775-81</Citation><ArticleIdList><ArticleId IdType="pubmed">22339488</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2012 Jun;14(4):375-410</Citation><ArticleIdList><ArticleId IdType="pubmed">22631621</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Image Anal. 2001 Jun;5(2):143-56</Citation><ArticleIdList><ArticleId IdType="pubmed">11516708</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2011 Jun;131(1-3):299-306</Citation><ArticleIdList><ArticleId IdType="pubmed">21236494</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2008 Mar;10(2):245-55</Citation><ArticleIdList><ArticleId IdType="pubmed">18271903</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2011 Aug;132(3):344-55</Citation><ArticleIdList><ArticleId IdType="pubmed">21470688</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Neuropsychopharmacol. 2012 Feb;22(2):100-13</Citation><ArticleIdList><ArticleId IdType="pubmed">21820878</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 1997 Oct;6(3):218-29</Citation><ArticleIdList><ArticleId IdType="pubmed">9344826</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2012 Jul;42(7):1417-28</Citation><ArticleIdList><ArticleId IdType="pubmed">22099606</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2013 Jan 15;73(2):127-35</Citation><ArticleIdList><ArticleId IdType="pubmed">22858151</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2008 Sep;13(9):829, 833-57</Citation><ArticleIdList><ArticleId IdType="pubmed">18574483</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2012 Mar 31;201(3):196-205</Citation><ArticleIdList><ArticleId IdType="pubmed">22510433</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2011 Jun;131(1-3):59-67</Citation><ArticleIdList><ArticleId IdType="pubmed">21195482</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2011 Mar;68(3):241-51</Citation><ArticleIdList><ArticleId IdType="pubmed">21383262</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 2009 May 29;456(1):44-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19429131</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2012 Aug;169(8):831-40</Citation><ArticleIdList><ArticleId IdType="pubmed">22773540</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2011 Sep;41(9):1791-803</Citation><ArticleIdList><ArticleId IdType="pubmed">21275085</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2011 Dec;50(12):1275-89.e2</Citation><ArticleIdList><ArticleId IdType="pubmed">22115148</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2009 Oct;14(10):946-53, 907</Citation><ArticleIdList><ArticleId IdType="pubmed">19506560</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2009 Feb;11(1):11-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19133962</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">29689499</PMID><DateCompleted><Year>2018</Year><Month>12</Month><Day>31</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-7123</ISSN><JournalIssue CitedMedium="Internet"><Volume>264</Volume><PubDate><Year>2018</Year><Month>06</Month></PubDate></JournalIssue><Title>Psychiatry research</Title><ISOAbbreviation>Psychiatry Res</ISOAbbreviation></Journal><ArticleTitle>Is 'subthreshold' bipolar II disorder more difficult to differentiate from borderline personality disorder than formal bipolar II disorder?</ArticleTitle><Pagination><MedlinePgn>416-420</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0165-1781(17)31327-6</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.psychres.2018.04.018</ELocationID><Abstract><AbstractText>Recent research indicates that borderline personality disorder (BPD) can be diagnostically differentiated from the bipolar disorders. However, no studies have attempted to differentiate participants with sub-threshold bipolar disorder or SubT BP (where hypomanic episodes last less than 4 days) from those with a BPD. In this study, participants were assigned a SubT BP, bipolar II disorder (BP II) or BPD diagnosis based on clinical assessment and DSM-IV criteria. Participants completed self-report measures and undertook a clinical interview which collected socio-demographic information, a mood history, family history, developmental history, treatment information, and assessed cognitive, emotional and behavioural functioning. Both bipolar groups, whether SubT BP or BP II, differed to the BPD group on a number of key variables (i.e. developmental trauma, depression correlates, borderline personality scores, self-harm and suicide attempts), and compared to each other, returned similar scores on nearly all key variables. Borderline risk scores resulted in comparable classification rates of 0.74 (for BPD vs BP II) and 0.82 (for BPD vs sub-threshold BP II). Study findings indicate that both SubT BP and BP II disorder can be differentiated from BPD on a set of refined clinical variables with comparable accuracy.</AbstractText><CopyrightInformation>Copyright Â© 2018 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bayes</LastName><ForeName>Adam</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>School of Psychiatry, University of New South Wales, Sydney, NSW, Australia; Black Dog Institute, Sydney, NSW, Australia. Electronic address: a.bayes@unsw.edu.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graham</LastName><ForeName>Rebecca K</ForeName><Initials>RK</Initials><AffiliationInfo><Affiliation>School of Psychiatry, University of New South Wales, Sydney, NSW, Australia; Black Dog Institute, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parker</LastName><ForeName>Gordon B</ForeName><Initials>GB</Initials><AffiliationInfo><Affiliation>School of Psychiatry, University of New South Wales, Sydney, NSW, Australia; Black Dog Institute, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCraw</LastName><ForeName>Stacey</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>School of Psychiatry, University of New South Wales, Sydney, NSW, Australia; Black Dog Institute, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>04</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Psychiatry Res</MedlineTA><NlmUniqueID>7911385</NlmUniqueID><ISSNLinking>0165-1781</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="N">Affect</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001883" MajorTopicYN="N">Borderline Personality Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003527" MajorTopicYN="N">Cyclothymic Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="Y">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004644" MajorTopicYN="N">Emotions</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057566" MajorTopicYN="N">Self Report</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016728" MajorTopicYN="N">Self-Injurious Behavior</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013406" MajorTopicYN="N">Suicide, Attempted</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Bipolar disorder</Keyword><Keyword MajorTopicYN="Y">Borderline personality disorder</Keyword><Keyword MajorTopicYN="Y">Diagnosis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>07</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>12</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>04</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>4</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>1</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>4</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29689499</ArticleId><ArticleId IdType="pii">S0165-1781(17)31327-6</ArticleId><ArticleId IdType="doi">10.1016/j.psychres.2018.04.018</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10507524</PMID><DateCompleted><Year>1999</Year><Month>12</Month><Day>23</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0920-9964</ISSN><JournalIssue CitedMedium="Print"><Volume>39</Volume><Issue>2</Issue><PubDate><Year>1999</Year><Month>Sep</Month><Day>29</Day></PubDate></JournalIssue><Title>Schizophrenia research</Title><ISOAbbreviation>Schizophr Res</ISOAbbreviation></Journal><ArticleTitle>Structural and functional brain changes in bipolar disorder: a selective review.</ArticleTitle><Pagination><MedlinePgn>133-40; discussion 162</MedlinePgn></Pagination><Abstract><AbstractText>The purpose of this paper is to provide a concise, selective review of the major issues and findings germane to structural and functional neuroimaging studies of bipolar affective disorder (BPD). In attempting to identify the brain changes associated with BPD, investigators have used neuroimaging techniques to focus on several interrelated questions. These are: What are the changes and where do they occur? Do their nature and location suggest a particular etiopathologic basis or have notable clinical correlates? With regard to specificity, are the changes unique to BPD, or do they overlap with those reported in other neuropsychiatric illnesses, especially schizophrenia? Do they occur in brain systems that normally play a role in modulating mood? Finally, how do the brain changes integrate with neurocognitive, neurogenetic, and neuropathologic data in the same patients? To date, these questions have been addressed only preliminarily. We outline some of the strategies used to pursue answers to these questions and review conclusions to date.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pearlson</LastName><ForeName>G D</ForeName><Initials>GD</Initials><AffiliationInfo><Affiliation>Psychiatry Neuroimaging, Johns Hopkins University, Baltimore, MD 21287, USA. godfr@jhmi.edu</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="N"><Grant><GrantID>MH 43326</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH 43775</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH 52886</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Schizophr Res</MedlineTA><NlmUniqueID>8804207</NlmUniqueID><ISSNLinking>0920-9964</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000342" MajorTopicYN="N">Affective Symptoms</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="Y">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001930" MajorTopicYN="N">Brain Injuries</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009434" MajorTopicYN="N">Neural Pathways</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>66</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year><Month>10</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1999</Year><Month>10</Month><Day>3</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1999</Year><Month>10</Month><Day>3</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10507524</ArticleId><ArticleId IdType="pii">S0920996499001127</ArticleId><ArticleId IdType="doi">10.1016/s0920-9964(99)00112-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20350583</PMID><DateCompleted><Year>2010</Year><Month>06</Month><Day>30</Day></DateCompleted><DateRevised><Year>2010</Year><Month>04</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-7972</ISSN><JournalIssue CitedMedium="Internet"><Volume>475</Volume><Issue>2</Issue><PubDate><Year>2010</Year><Month>May</Month><Day>14</Day></PubDate></JournalIssue><Title>Neuroscience letters</Title><ISOAbbreviation>Neurosci Lett</ISOAbbreviation></Journal><ArticleTitle>Increased plasma levels of brain-derived neurotrophic factor in patients with long-term bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>95-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neulet.2010.03.055</ELocationID><Abstract><AbstractText>Recent data indicate that neurotrophins may play a role in the physiopathology of bipolar disorder (BD) and may be useful as biomarkers of the disease. The aim of this study was to evaluate the plasma concentrations of brain-derived neurotrophic factor (BDNF) in BD patients, and to correlate their levels with clinical parameters. BDNF was measured in plasma from 53 BD type I subjects (34 during mania and 19 during euthymia) and 38 healthy controls by enzyme-linked immuno-sorbent assay (ELISA). Patients were assessed by a structured clinical interview (Mini-plus), Young mania and Hamilton depression rating scales. Plasma BDNF levels were significantly increased in patients with mania (P&lt;/=0.001) and euthymia (P&lt;/=0.001) when compared with controls, but did not correlate with any clinical parameters. BDNF concentration was higher in BD patients with 10 or more years of disease. BDNF plasma levels were increased in BD patients, mainly in those with a longer course of disease. In line with previous studies, it is conceivable that BDNF may play a role in the pathophysiology of BD.</AbstractText><CopyrightInformation>Copyright 2010 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Barbosa</LastName><ForeName>Izabela GuimarÃ£es</ForeName><Initials>IG</Initials><AffiliationInfo><Affiliation>Programa de NeurociÃªncias, Universidade Federal de Minas Gerais (UFMG), Avenida AntÃ´nio Carlos 6627, 31270-901 Campus Pampulha, Belo Horizonte, Minas Gerais, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huguet</LastName><ForeName>Rodrigo Barreto</ForeName><Initials>RB</Initials></Author><Author ValidYN="Y"><LastName>MendonÃ§a</LastName><ForeName>Vanessa Amaral</ForeName><Initials>VA</Initials></Author><Author ValidYN="Y"><LastName>Neves</LastName><ForeName>Fernando Silva</ForeName><Initials>FS</Initials></Author><Author ValidYN="Y"><LastName>Reis</LastName><ForeName>Helton JosÃ©</ForeName><Initials>HJ</Initials></Author><Author ValidYN="Y"><LastName>Bauer</LastName><ForeName>MoisÃ©s Evandro</ForeName><Initials>ME</Initials></Author><Author ValidYN="Y"><LastName>Janka</LastName><ForeName>ZoltÃ¡n</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>PalotÃ¡s</LastName><ForeName>AndrÃ¡s</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Teixeira</LastName><ForeName>AntÃ´nio LÃºcio</ForeName><Initials>AL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>03</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Neurosci Lett</MedlineTA><NlmUniqueID>7600130</NlmUniqueID><ISSNLinking>0304-3940</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019208">Brain-Derived Neurotrophic Factor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019208" MajorTopicYN="N">Brain-Derived Neurotrophic Factor</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>02</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2010</Year><Month>03</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>03</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>3</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>3</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>7</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20350583</ArticleId><ArticleId IdType="pii">S0304-3940(10)00364-2</ArticleId><ArticleId IdType="doi">10.1016/j.neulet.2010.03.055</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10929789</PMID><DateCompleted><Year>2000</Year><Month>12</Month><Day>01</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0010-440X</ISSN><JournalIssue CitedMedium="Print"><Volume>41</Volume><Issue>4</Issue><PubDate><MedlineDate>2000 Jul-Aug</MedlineDate></PubDate></JournalIssue><Title>Comprehensive psychiatry</Title><ISOAbbreviation>Compr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Qualitative differences in manic symptoms during mixed versus pure mania.</ArticleTitle><Pagination><MedlinePgn>237-41</MedlinePgn></Pagination><Abstract><AbstractText>Previous studies have compared demographic and clinical-outcome features of bipolar patients with mixed or pure mania. However, little is known about the potential differences in the nature and extent of manic symptoms in mania either with or without an accompanying depression. This study examined DSM-III-R manic symptoms in a cohort of 183 bipolar I inpatients hospitalized for mixed mania (diagnosed by broad or narrow criteria) or pure manic episodes. Inpatient charts were reviewed to determine the presence of individual affective symptoms. The results indicate that clinicians were more likely to diagnose a pure mania from the beginning to end of an episode than to diagnose a mixed mania from its beginning to end. Mixed-manic patients had significantly fewer manic symptoms than pure manic patients. Grandiosity, euphoria, pressured speech, and a decreased need for sleep were more prevalent during pure versus mixed mania. Grandiosity and a diminished need for sleep were especially notable during pure mania compared with mixed mania as defined by narrow criteria for mixed states. The observed differences in manic symptom profiles between mixed and pure mania may aid in the clinical assessment of dysphoric states among bipolar patients. The data also lend support to the use of broad diagnostic criteria for defining mixed mania as an entity phenomenologically distinct from pure mania.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Goldberg</LastName><ForeName>J F</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Weill Medical College of Cornell University, New York, NY USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garno</LastName><ForeName>J L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Portera</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Leon</LastName><ForeName>A C</ForeName><Initials>AC</Initials></Author><Author ValidYN="Y"><LastName>Kocsis</LastName><ForeName>J H</ForeName><Initials>JH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Compr Psychiatry</MedlineTA><NlmUniqueID>0372612</NlmUniqueID><ISSNLinking>0010-440X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>8</Month><Day>10</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>2</Month><Day>28</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>8</Month><Day>10</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10929789</ArticleId><ArticleId IdType="pii">S0010-440X(00)48800-0</ArticleId><ArticleId IdType="doi">10.1053/comp.2000.7427</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27570898</PMID><DateCompleted><Year>2017</Year><Month>05</Month><Day>22</Day></DateCompleted><DateRevised><Year>2017</Year><Month>12</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1539-736X</ISSN><JournalIssue CitedMedium="Internet"><Volume>204</Volume><Issue>9</Issue><PubDate><Year>2016</Year><Month>09</Month></PubDate></JournalIssue><Title>The Journal of nervous and mental disease</Title><ISOAbbreviation>J Nerv Ment Dis</ISOAbbreviation></Journal><ArticleTitle>The Functional Exercise Capacity Is Associated With Global Functioning in People With Bipolar Disorder.</ArticleTitle><Pagination><MedlinePgn>673-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/NMD.0000000000000580</ELocationID><Abstract><AbstractText>The aim of the current study was to determine whether the Global Assessment of Functioning (GAF) score is associated with the functional exercise capacity among in- and outpatients with bipolar disorder. Sixty-five (36â) persons with bipolar disorder performed a 6-minute walk test (6MWT) and were assessed with the GAF, Quick Inventory of Depressive Symptomatology Self Report (QIDS), and the International Physical Activity Questionnaire (IPAQ). The mean GAF-score was 55.0 Â± 15.0, whereas the mean distance achieved on the 6MWT was 615.6 Â± 118.6 m. There was a positive association between the GAF score and 6MWT score (r = 0.60, p &lt; 0.001). A backward regression analysis demonstrated that an inpatient status, illness duration (16.1 Â± 10.7 years), and the QIDS score (7.7 Â± 5.7) explained 72.4% of the GAF-score variance. The GAF, QIDS score, and age explained 74.1% of the 6MWT-score variance. Our results indicate that a bidirectional relationship is evident between the exercise capacity and global functioning among people with bipolar disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vancampfort</LastName><ForeName>Davy</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>*Department of Rehabilitation Sciences, KU Leuven-University of Leuven, Leuven; â KU Leuven University Psychiatric Center, KU Leuven-University of Leuven, Kortenberg, Belgium; â¡Physiotherapy Department, South London and Maudsley NHS Foundation Trust; Â§Health Service and Population Research Department, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK; â¥School of Public Health &amp; Charles Perkins Centre, University of Sydney, Sydney, Australia; and Â¶Butabika National Referral and Mental Health Hospital, Kampala, Uganda.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sienaert</LastName><ForeName>Pascal</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Wyckaert</LastName><ForeName>Sabine</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>De Hert</LastName><ForeName>Marc</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Stubbs</LastName><ForeName>Brendon</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Richards</LastName><ForeName>Justin</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Mugisha</LastName><ForeName>James</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Probst</LastName><ForeName>Michel</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Nerv Ment Dis</MedlineTA><NlmUniqueID>0375402</NlmUniqueID><ISSNLinking>0022-3018</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015444" MajorTopicYN="N">Exercise</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005080" MajorTopicYN="N">Exercise Test</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010809" MajorTopicYN="Y">Physical Fitness</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>8</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>8</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>5</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27570898</ArticleId><ArticleId IdType="doi">10.1097/NMD.0000000000000580</ArticleId><ArticleId IdType="pii">00005053-201609000-00006</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16469198</PMID><DateCompleted><Year>2006</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2017</Year><Month>09</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0033-2917</ISSN><JournalIssue CitedMedium="Print"><Volume>36</Volume><Issue>5</Issue><PubDate><Year>2006</Year><Month>May</Month></PubDate></JournalIssue><Title>Psychological medicine</Title><ISOAbbreviation>Psychol Med</ISOAbbreviation></Journal><ArticleTitle>Structural brain correlates of IQ changes in bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>609-18</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">There is increasing evidence that cognitive deficits are present in bipolar disorder (BP), but their neural correlates have not been fully explored. The aim of this study is to correlate structural brain abnormalities with cognitive performance in BP and to explore differences between clinical subtypes.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Thirty-six BP patients (13 men, 23 women) with a mean age of 39 years (range 21-63 years) underwent neuropsychological testing and imaging. Twenty-five patients had bipolar disorder I (BP I) and 11 had bipolar disorder II (BP II). Patients with co-morbid psychiatric diagnosis, drug and alcohol abuse or systemic illness were excluded. Correlations between cognitive performance and structural brain changes were explored using high-resolution anatomical imaging and magnetization transfer imaging (MTI).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In the whole BP group the difference between estimated pre-morbid IQ and current IQ was significantly correlated with left-sided reduction of the magnetization transfer ratio (MTR) in the superior temporal gyrus, uncus and para-hippocampal gyrus. In BP II patients the areas where these correlations were significant extended to the right superior and middle temporal gyri, cingulate gyrus, pre-cuneus and adjacent frontal and parietal white matter. The volume of superior temporal white matter was also correlated with IQ difference in this subgroup.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The study highlights the association between fronto-temporal abnormalities and decline in IQ in BP. The more extensive abnormalities present in BP II patients suggest that persistent depression, rather than mania, may be a key pathophysiological factor or that BP II represents a clinical phenotype with a higher risk of developing cognitive abnormalities.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bruno</LastName><ForeName>S D</ForeName><Initials>SD</Initials><AffiliationInfo><Affiliation>Institute of Neurology, University College London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Papadopoulou</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Cercignani</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Cipolotti</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Ron</LastName><ForeName>M A</ForeName><Initials>MA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>748</GrantID><Agency>Multiple Sclerosis Society</Agency><Country>United Kingdom</Country></Grant><Grant><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>02</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Psychol Med</MedlineTA><NlmUniqueID>1254142</NlmUniqueID><ISSNLinking>0033-2917</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007089" MajorTopicYN="N">Image Enhancement</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007360" MajorTopicYN="Y">Intelligence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="Y">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015999" MajorTopicYN="N">Multivariate Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012044" MajorTopicYN="N">Regression Analysis</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>2</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>9</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>2</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16469198</ArticleId><ArticleId IdType="pii">S0033291706007112</ArticleId><ArticleId IdType="doi">10.1017/S0033291706007112</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>